Page last updated: 2024-12-08

dabigatran

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dabigatran: A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dabigatran : An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-beta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID Source	ID
PubMed CID	216210
CHEMBL ID	48361
CHEBI ID	70752
SCHEMBL ID	3573
MeSH ID	M0553211

Synonyms (90)

Synonym
n-[(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1h-benzimidazol-5-yl)carbonyl]-n-pyridin-2-yl-beta-alanine
AB01274802-01
dabigatran
bibr-953
bibr-953zw
bibr 953 zw
chebi:70752 ,
bibr-953-zw
pradaxa (dabigatran)
CHEMBL48361 ,
3-({2-[(4-carbamimidoyl-phenylamino)-methyl]-1-methyl-1h-benzoimidazole-5-carbonyl}-pyridin-2-yl-amino)-propionic acid
bdbm50112086
AKOS005266720
3-[[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid
n-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1h-benzimidazol-5-yl)carbonyl)-n-2-pyridinyl-beta-alanine
D09707
dabigatran (usan/inn)
3-[[2-[[(4-carbamimidoylphenyl)amino]methyl]-1-methyl-benzimidazol-5-yl]carbonyl-pyridin-2-yl-amino]propanoic acid
A815190
3-[[[2-[(4-carbamimidoylanilino)methyl]-1-methyl-5-benzimidazolyl]-oxomethyl]-(2-pyridinyl)amino]propanoic acid
bibr 953 (dabigatran, pradaxa)
211914-51-1
BIBR 953 - DABIGATRAN - PRADAXA
bibr953
i0vm4m70gc ,
n-((2-((p-amidinoanilino)methyl)-1-methyl-5-benzimidazolyl)carbonyl)-n-2-pyridyl-beta-alanine
hsdb 8062
dabigatran [usan:inn:ban]
unii-i0vm4m70gc
beta-alanine, n-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1h-benzimidazol-5-yl)carbonyl)-n-2-pyridinyl-
bibr 953
3-(((2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-1h-benzimidazol-5-yl)carbonyl)(pyridin-2-yl)amino)propanoic acid
CS-1399
bibr 953,dabigatran, pradaxa
FT-0648482
NCGC00346575-01
PB38204
3-[[2-[[(4-carbamimidoylphenyl)amino]methyl]-1-methyl-benzoimidazole-5-carbonyl]-pyridin-2-yl-amino]propanoic acid
dabigatran [inn]
3-{[(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1h-benzimidazol-5-yl)carbonyl](pyridin-2-yl)amino}propanoic acid
dabigatran [usan]
dabigatran [mi]
dabigatran [who-dd]
dabigatran [mart.]
dabigatran [vandf]
n-((2-((p-amidinoanilino)methyl)-1-methyl-5-benzimidazolyl)carbonyl)-n-2-pyridyl-.beta.-alanine
.beta.-alanine, n-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1h-benzimidazol-5-yl)carbonyl)-n-2-pyridinyl-
EPITOPE ID:186729
S2196
gtpl6380
3-[[2-[[(4-carbamimidoylphenyl)amino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid
HY-10163
1-methyl-2-[(4-amidinophenyl)aminomethyl]benzimidazol-5-yl-carboxylic acid-n-(2-pyridyl)-n-(2-hydroxycarbonylethyl)amide
1-methyl-2-[n-(4-amidinophenyl)aminomethyl]benzimidazol-5-yl-carboxylic acid-n-(2-pyridyl)-n-(2-hydroxycarbonylethyl)amide
1-methyl-2-[n-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-n-(2-pyridyl)-n-(2-hydroxycarbonylethyl)-amide
YBSJFWOBGCMAKL-UHFFFAOYSA-N
beta-alanine, n-[[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1h-benzimidazol-5-yl]carbonyl]-n-2-pyridinyl-
AM81238
SCHEMBL3573
Q-102529
AC-25299
AB01274802_02
DTXSID50175419 ,
STL450902
C21556
3-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-n-(pyridin-2-yl)-1h-benzo[d]imidazole-5-carboxamido)propanoic acid
bibr 953zw
mfcd09837830
NCGC00346575-06
3-[1-(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1h-1,3-benzodiazol-5-yl)-n-(pyridin-2-yl)formamido]propanoic acid
bibr 953(dabigatran)
FT-0665441
BCP06664
Q419345
bibr 953 (dabigatran etexilate, pradaxa)
DB14726
AS-11488
b-alanine,n-[[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1h-benzimidazol-5-yl]carbonyl]-n-2-pyridinyl-
SB20292
2,6-bis[(r)-4-phenyloxazolin-2-yl]pyridine
3-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-n-(pyridin-2-yl)-1h-benzo[d]imidazole-5-carboxamido)propanoicacid
bibr 953; bibr 953zw; dabigatran; n-[[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1h-benzimidazol-5-yl]carbonyl]-n-2-pyridinyl-beta-alanine; n-[[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1h-benzimidazol-5-yl]carbonyl]-n-2-pyridinyl
EN300-7418742
D5902
dabigatran (mart.)
beta-alanine, n-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1- methyl-1h-benzimidazol-5-yl)carbonyl)-n-2-pyridinyl-
dtxcid4097910
3-[2-[[(4-carbamimidoylphenyl)amino]methyl]-1-methyl-n-(2-pyridyl)benzimidazole-5-carboxamido]propanoic acid
SY030371
Z2681891234

Research Excerpts

Overview

Dabigatran is a direct thrombin inhibitor approved for stroke prophylaxis in patients with non-valvular atrial fibrillation (NVAF) It is an anticoagulant with potential use during cardiopulmonary bypass in children and adults.

Excerpt	Reference	Relevance
"Dabigatran is a novel oral anticoagulant that directly inhibits free and fibrin-bound thrombins and exerts rapid and predictable anticoagulant effects. "	( Dabigatran Etexilate Induces Cytotoxicity in Rat Gastric Epithelial Cell Line via Mitochondrial Reactive Oxygen Species Production. Kurokawa, H; Matsui, H; Shigekawa, H; Taninaka, A, 2021)	3.51
"Dabigatran is a direct thrombin inhibitor approved for stroke prophylaxis in patients with non-valvular atrial fibrillation (NVAF). "	( Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of Long-term Anticoagulant Treatment Experience (RE-LATE) study. Chern, AKC; Choi, EK; Chutinet, A; Hanafy, DA; Jiampo, P; Lee, YS; Oh, YS; Trivedi, P; Zhai, D, 2021)	2.32
"Dabigatran is an anticoagulant with potential use during cardiopulmonary bypass in children and adults. "	( Delayed concentration effect models for dabigatran anticoagulation. Anderson, BJ; Eaton, MP; LeMoine, D; Nadtochiy, SM; Stefanos, T, 2022)	2.43
"Dabigatran is a direct thrombin inhibitor used to treat cardiac arrhythmias, and rates of non-adherence to dabigatran in Polish populations are high. "	( Evaluation of a pharmacist-led intervention to improve medication adherence in patients initiating dabigatran treatment: a comparison with standard pharmacy practice in Poland. Balcerzak, M; Cameron, JD; Hering, D; Jaguszewski, M; Konstanty, M; Merks, P; Religioni, U; Świeczkowski, D; Szymański, FM; Vaillancourt, R, 2022)	2.38
"Dabigatran is a direct oral anticoagulant used to prevent stroke and systemic embolism in patients with atrial fibrillation. "	( [Dabigatran Reversal: A Practical Approach]. Ricca Gonçalves, L; Robalo Nunes, A, 2022)	3.07
"Dabigatran etexilate is a suitable choice preoperatively to modify coagulation function and pain in patients with VMs."	( Dabigatran etexilate is efficacious in consumptive coagulopathy and pain associated with venous malformations. Chen, H; Gu, H; Hu, L; Lin, X; Liu, H; Xu, Z; Yang, X, 2023)	3.07
"Dabigatran etexilate is a direct oral anticoagulant (thrombin inhibitor) used for the prevention of stroke and systemic thromboembolic events in patients with permanent atrial fibrillation; prevention of venous thromboembolic events and deep veins thrombosis; treatment and prevention of pulmonary embolism. "	( Possible Interaction between Dabigatran and Ranolazine in Patients with Renal Failure. Damulevičienė, G; Galaunė, V; Gumbrevičius, G; Gumbrevičiūtė, M, 2019)	2.25
"Dabigatran is a novel oral anticoagulant molecule which is a direct thrombin (Factor IIa) inhibitor and is used for prevention of stroke and systemic embolism. "	( A Rare Case Report of Dabigatran Induced Oral Ulcers. Prabha, N; Singh, A; Yadav, H, 2020)	2.32
"Dabigatran is an anticoagulant medication that has been widely used to prevent strokes caused by atrial fibrillation, deep vein thrombosis, and pulmonary embolism. "	( Dabigatran-induced esophagitis: A case report. Dai, Y; Fu, Z; Lu, L; Zhou, Y, 2020)	3.44
"Dabigatran etexilate is a non-vitamin K antagonist oral anticoagulant (NOAC) that is used to prevent stroke and systemic embolism in adults with nonvalvular atrial fibrillation (NVAF) and one or more risk factors. "	( Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects. Duan, J; Harada, A; Li, H; Yamamura, N; Yang, L, 2020)	2.29
"Dabigatran is a direct oral anticoagulant (DOAC) used for the treatment of several thrombotic conditions. "	( Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran. Abad-Santos, F; Almenara, S; Koller, D; Mejía, G; Navares-Gómez, M; Ochoa, D; Román, M; Saiz-Rodríguez, M; Soria-Chacartegui, P; Zubiaur, P, 2020)	2.2
"Dabigatran is an orally active direct thrombin inhibitor, initially approved by FDA for the prophylaxis of stroke and systemic embolism in the setting of non-valvular atrial fibrillation (NVAF). "	( Dabigatran-induced chronic progressive immune hemolytic anemia: A case report. Gong, JH; Liu, GJ; Sun, ZQ; Zhou, F, 2020)	3.44
"Dabigatran is a direct thrombin inhibitor for which a reversal agent exists."	( High-Dose Dabigatran Is an Effective Anticoagulant for Simulated Cardiopulmonary Bypass Using Human Blood. Angona, RE; Baldzizhar, A; Eaton, MP; Feng, C; Jones-Smith, KL; Nadtochiy, SM; O'Leary, KE; Stefanos, T, 2021)	1.75
"Dabigatran is a direct thrombin inhibitor that is widely used to prevent the formation of thrombus formation. "	( Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms: A case report. Chen, W; Fu, J; Wu, T; Xia, X; Zhang, J, 2020)	2.23
"Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the limitations of standard of care in children with venous thromboembolism. "	( Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Albisetti, M; Bomgaars, L; Brandão, LR; Brueckmann, M; Chalmers, E; Gorbatikov, K; Gropper, S; Halton, J; Huang, F; Kreuzer, J; Luciani, M; Mitchell, LG; Nurmeev, I; Reilly, P; Sharathkumar, A; Simetzberger, M; Sun, Z; Svirin, P; Tartakovsky, I, 2021)	3.51
"Dabigatran (DAB) is a direct thrombin inhibitor used for preventing blood clots and emboli after orthopedic surgery. "	( Introduction of a thrombin sensor based on its interaction with dabigatran as an oral direct thrombin inhibitor. Ahmadi, E; Gholivand, MB; Paimard, G; Shahlaei, M; Shamsipur, M, 2021)	2.3
"Dabigatran is an orally administrated anticoagulant that directly inhibits thrombin. "	( Pitfalls in the assessment of disseminated intravascular coagulation in patients on dabigatran. Bousounis, A; Ho, WK; Hogan, C; Kanda, GS; Rodrigues, C, 2021)	2.29
"Dabigatran is a direct oral anticoagulant thrombin inhibitor approved for stroke prophylaxis in patients with non-valvular atrial fibrillation and prophylaxis or treatment of venous thromboembolism. "	( Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR). Kutner, S; Scaturo, N; Williams, B, 2021)	2.06
": Dabigatran is a direct oral anticoagulant drug exhibiting clinical benefits over vitamin K antagonists. "	( Rapid and well tolerated action of idarucizumab for antagonizing dabigatran in a patient needing urgent thrombolysis: a case report. DeGuidi, G; Facchinetti, R; Lippi, G; Pitoni, F; Ricci, G, 2017)	1.41
"Dabigatran is a direct thrombin inhibitor used to reduce the risk of stroke in patients with nonvalvular atrial fibrillation. "	( Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator. Bissig, D; Manjunath, R; Ng, KL; Richman, DP; Traylor, BR, 2017)	2.22
"Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab."	( Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report. He, J; Nordling, MM; Tireli, D; Wienecke, T, 2017)	1.43
"Dabigatran is a reversible direct inhibitor of thrombin that has not been studied in neonates using a sophisticated global assay, such as TEG."	( In-vitro assessment of the effect of dabigatran on thrombosis of adult and neonatal plasma: comparisons using thromboelastography and microscopic visualization of fibrin clot structure. Atkinson, HM; Berry, LR; Chan, AKC; Chan, HHW; Gantioqui, J; Nossair, FF, 2017)	1.45
"Dabigatran is an oral anticoagulant and a reversible inhibitor of thrombin. "	( Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner. Brandes, A; Nielsen, C; Nybo, M; Söderström, AC; Vinholt, PJ, 2017)	3.34
"Dabigatran is an oral, reversible and competitive thrombin inhibitor that has shown promising results."	( Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature. Cosenza, G; Davì, S; Di Franco, F; Fasullo, S; Giubilato, A; La Manna, N; Maringhini, G; Vetrano, G, 2018)	1.45
"Dabigatran is a direct thrombin inhibitor and a non-vitamin-K-antagonizing oral anticoagulant, approved for the prevention of stroke and systemic embolization in atrial fibrillation. "	( Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients. Brich, J; Geisen, U; Harloff, A; Heck, D; Hieber, M; Hollasch, H; Mächtel, M; Niesen, WD, 2018)	2.3
"Dabigatran etexilate is an oral anticoagulant recognized as noninferior to LMWH."	( Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada. Banica, A; Benoit, B; Delisle, J; Fernandes, JC; Laflamme, GY; Malo, M; Nguyen, H; Ranger, P; Senay, A; Trottier, M, 2018)	1.2
"Dabigatran is a direct thrombin inhibitor. "	( Dabigatran affects thrombin-dependent platelet aggregation after a week-long therapy. Ivankova, J; Mokan, M; Nehaj, F; Sokol, J; Stasko, J, 2018)	3.37
"Dabigatran is a once daily oral anticoagulant that is FDA approved for venous thromboembolism prophylaxis after orthopedic surgery, uses fixed dosing, and has an antidote."	( Dabigatran (Pradaxa) Is Safe for Extended Venous Thromboembolism Prophylaxis After Surgery for Pancreatic Cancer. Chabot, JA; Dwyer, FA; Jackson, TL; Kluger, MD; Morgan, JA; Rashid, MF; Schrope, BA, 2019)	2.68
"Dabigatran is an oral anticoagulant prescribed as an alternative to warfarin which has been associated with exfoliative esophagitis and esophageal ulcer. "	( Symptomatic exfoliative esophagitis induced by dabigatran. Cuadros Martínez, M; Froilán Torres, C; Gonzalo Bada, N, 2018)	2.18
"Dabigatran is a direct thrombin inhibitor that might be useful in the management of HIT."	( Dabigatran as a Treatment Option for Heparin-Induced Thrombocytopenia. Amouzegar, A; Basi, A; Emami, S; Farasatinasab, M; Mokhtari, M; Nasiripour, S; Saif, M, 2019)	2.68
"Dabigatran etexilate is a selective, specific, reversible direct thrombin inhibitor that has been approved in United States, European countries and in India for SPAF and primary venous thromboembolism prevention and treatment."	( Dabigatran - the First Approved DTI for SPAF. Hiremath, JS; Trailokya, A, 2018)	2.64
": Dabigatran is a direct thrombin inhibitor that was approved as an alternative to warfarin because it offers the benefit of predictable pharmacokinetic properties, favorable safety profile and ease of administration. "	( Probable drug-drug interaction between dabigatran and quinidine resulting in thrombin time rebound despite multiple idarucizumab doses. George, S; Lewis, V; Taburyanskaya, M, 2019)	1.5
"Dabigatran is a kind of oral anticoagulant and there was little review only about dabigatran and warfarin used in patients with atrial fibrillation. "	( Comparison of dabigatran and warfarin used in patients with non-valvular atrial fibrillation: Meta-analysis of random control trial. Chu, HM; Fang, RY; Fu, GH; Gao, F; Liu, J; Yu, YB, 2018)	2.28
"Dabigatran etexilate is a direct thrombin inhibitor that clinicians increasingly prescribe to prevent stroke in patients with non-valvular atrial fibrillation (NVAF). "	( Statins and the risk of bleeding in patients taking dabigatran. Chao, AC; Chen, CF; Chou, PS; Ho, BL; Hu, HH; Lin, RT; Lin, SF; Lin, YJ, 2019)	2.21
"Dabigatran is an oral anticoagulant used for atrial fibrillation and venous thromboembolism. "	( The effect of routine preoperative interruption of dabigatran therapy on coagulation parameters and dabigatran plasma levels in a mixed surgical population. Brett, CN; Brett, OF; Chin, PK, 2019)	2.21
"Dabigatran is a direct oral anticoagulant which is used as an alternative to the traditional vitamin K antagonists. "	( [Dabigatran-induced oesophagitis]. Bhalla, A; van der Voorn, MMPJA; Ykema, BLM, 2019)	2.87
"Dabigatran etexilate is a newly approved agent for prophylaxis of stroke in atrial fibrillation. "	( Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review. Dawson, J; Fearon, P; Marshall, S; Quinn, TJ, 2013)	2.08
"Dabigatran is an oral direct thrombin inhibitor (DTI) licensed for stroke prevention in atrial fibrillation and likely to be soon approved in Europe for treatment of venous thrombosis. "	( The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Alikhan, R; Baglin, T; Benson, G; Green, L; Keeling, D; Marshall, S; Patel, R; Pavord, S; Rayment, R; Rose, P; Tait, C, 2014)	2.07
"Dabigatran is an oral anticoagulant that inhibits thrombin but not vitamin K. "	( Dabigatran: life-threatening bleeding. , 2013)	3.28
"Dabigatran etexilate is a direct thrombin inhibitor and used widely as an anticoagulant for the prevention of stroke in patients with atrial fibrillation. "	( A specific antidote for dabigatran: functional and structural characterization. Canada, K; Litzenburger, T; Nar, H; Newsome, C; Park, J; Schiele, F; Sepulveda, E; van Ryn, J, 2013)	2.14
"Dabigatran etexilate is a pro-drug of the oral reversible direct thrombin inhibitor dabigatran that interacts with the active site in the catalytic domain of the thrombin molecule."	( Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects. Clemens, A; Friedman, J; Rathgen, K; Reilly, P; Ring, A; Stangier, J, 2013)	3.28
"Dabigatran is a reversible direct thrombin inhibitor recently approved for stroke prevention in patients with atrial fibrillation. "	( Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. Berger, R; Chase, M; Ganetsky, M; Salhanick, SD, 2013)	2.06
"Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered in South Africa (SA) to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation (AF). "	( Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. Bergh, M; Marais, CA; Miller-Jansön, H; Salie, F; Stander, MP, 2013)	2.15
"Dabigatran etexilate is an effective and safe anticoagulation therapy for AF ablation. "	( Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation. Higashiya, S; Hina, K; Hirohata, S; Kamikawa, S; Kawamura, H; Kusachi, S; Murakami, M; Murakami, T; Yamaji, H, 2013)	2.19
"Dabigatran is an oral direct thrombin inhibitor indicated for thromboembolism prophylaxis in patients with nonvalvular atrial fibrillation. "	( Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. Chen, BC; Dadzie, KA; Hoffman, RS; Nelson, LS; Sheth, NR; Smith, SW; Winchester, JF, 2013)	2.07
"Dabigatran etexilate is a novel oral direct thrombin inhibitor."	( Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation. Chevalier, J; de Pouvourville, G; Giroud, M, 2013)	1.36
"Dabigatran is an oral, direct, and competitive inhibitor of thrombin, which is administered to patients with non-valvular atrial fibrillation for prevention of stroke at a dose of 110 mg twice daily or 150 mg twice daily. "	( [Direct oral thrombin inhibitor, "dabigatran"]. Yasaka, M, 2013)	2.11
"Dabigatran is a direct thrombin inhibitor gaining popularity as a stroke prevention agent in patients with atrial fibrillation. "	( Traumatic intracranial hemorrhage in patients taking dabigatran: report of 3 cases and review of the literature. Abel, TJ; Greenlee, JD; Grossbach, A; Howard, MA; Jackson, AW; Viljoen, SV; Wassef, SN, 2013)	2.08
"Dabigatran is an oral direct thrombin inhibitor that is Food and Drug Administration-approved for prevention of stroke in patients with atrial fibrillation. "	( Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Hallows, KR; Henry, BL; Maw, TT; Nolin, TD; Pastor-Soler, NM; Singh, T; Unruh, ML, 2013)	2.13
"Dabigatran is an oral direct thrombin inhibitor that does not require routine laboratory monitoring. "	( The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Butler, J; Chunilal, S; Hapgood, G; Malan, E; Tran, H, 2013)	2.19
"Dabigatran is an oral direct thrombin inhibitor for which routine laboratory monitoring is currently not recommended. "	( Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Antovic, JP; Beck, O; Boija, EE; Eintrei, J; Hjemdahl, P; Malmström, RE; Norberg, EM; Onelöv, L; Pohanka, A; Rönquist-Nii, Y; Skeppholm, M; Söderblom, L, 2013)	2.07
"Dabigatran is a direct thrombin inhibitor approved to help prevent thrombotic events in patients with atrial fibrillation. "	( Dental management considerations for a patient taking dabigatran etexilate: a case report. Henry, RG; Miller, CS; Romond, KK, 2013)	2.08
"Dabigatran is an oral direct thrombin inhibitor widely used to prevent and treat various thromboembolic complications. "	( Dabigatran and kidney disease: a bad combination. Berns, JS; Chaknos, CM; Knauf, F; Perazella, MA, 2013)	3.28
"Dabigatran is a new anticoagulant in patients with nonvalvular AF."	( The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran. Hamasaki, S; Ichiki, H; Iriki, Y; Ishida, S; Maenosono, R; Miyata, M; Namino, F; Ninomiya, Y; Oketani, N; Okui, H; Tei, C, 2013)	1.32
"Dabigatran is a direct thrombin inhibitor and its role in patients with acute coronary syndrome is being explored."	( Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran. Doraiswamy, VA; Gesheff, MG; Gurbel, PA; Slepian, MJ; Tantry, US, 2013)	1.32
"Dabigatran is an oral direct thrombin inhibitor that has been shown to be an effective alternative to warfarin in patients with atrial fibrillation. "	( Dabigatran versus warfarin in patients with mechanical heart valves. Blatchford, J; Brueckmann, M; Connolly, SJ; Devenny, K; Eikelboom, JW; Friedman, J; Granger, CB; Guiver, K; Harper, R; Kappetein, AP; Khder, Y; Lobmeyer, MT; Maas, H; Mack, MJ; Simoons, ML; Van de Werf, F; Voigt, JU, 2013)	3.28
"Dabigatran is a relatively novel therapeutic option for patients with AF."	( Floating thrombus in the left upper pulmonary vein dissolved by dabigatran. Takeuchi, H, 2013)	1.35
"Dabigatran is a newer oral anticoagulant, indicated for chronic atrial fibrillation anticoagulation. "	( Emergency abdominal surgery in a patient anticoagulated with dabigatran. DeMuro, JP, 2013)	2.07
"Dabigatran is an oral thrombin inhibitor which has been approved for prevention of stroke or embolism in atrial fibrillation patients as an alternative to vitamin K antagonists. "	( Life-threatening epistaxis and red blood cell polyagglutination under dabigatran. Finsterer, J; Krutisch, G; Stöllberger, C, 2014)	2.08
"Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. "	( Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Holmes, DN; Hylek, EM; Kowey, PR; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013)	2.17
"Dabigatran is a novel oral anticoagulant for which a well-defined range of toxicity and proven antidote has not been established."	( Evaluation of dabigatran exposures reported to poison control centers. Conway, SE; Harrison, DL; Schaeffer, SE, 2014)	2.21
"Dabigatran is a direct thrombin inhibitor indicated for stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation. "	( [Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery]. Bachellerie, B; Conil, JM; Crognier, L; Fourcade, O; Georges, B; Ruiz, S; Seguin, T, 2014)	2.11
"Dabigatran is an oral direct thrombin inhibitor; rivaroxaban and apixaban are oral direct Factor Xa inhibitors. "	( Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Barillari, G; Cheng, JW, 2014)	1.85
"Dabigatran is a univalent low-molecular-weight direct thrombin inhibitor that has been developed as an alternative to vitamin K antagonists (VKAs). "	( Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. Atallah, R; Bloom, BJ; Eisenberg, MJ; Filion, KB, 2014)	2.08
"dabigatran (Pradaxa®) is a direct and specific thrombin inhibitor."	( [General characteristics of the new oral anticoagulants]. Berrut, G; Chevalet, P; De Decker, L; Gegu, M; Piloquet, FX, 2013)	1.11
"Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. "	( Increased risk of myocardial infarction with dabigatran: fact or fiction? Basile, E; Di Biase, L; Giglio, AF; Natale, A; Santangeli, P; Trotta, F, 2014)	2.1
"Dabigatran is an oral, reversibly bound, direct thrombin inhibitor currently approved in the United States for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. "	( Management of dabigatran-associated intracerebral and intraventricular hemorrhage: a case report. Faust, AC; Peterson, EJ, 2014)	2.21
"Dabigatran is a novel oral anticoagulant and may be useful during atrial fibrillation (AF) ablation for prevention of thromboembolic events. "	( Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. Aronow, WS; Chatterjee, S; Ghosh, J; Nairooz, R; Sardar, P; Wetterslev, J, 2014)	2.08
"Dabigatran is an oral anticoagulant that is increasingly used for atrial fibrillation (AF). "	( A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Begg, EJ; Chin, PK; Doogue, MP; Patterson, DM; Wright, DF, 2014)	2.12
"Dabigatran is an oral direct thrombin inhibitor that is approved for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. "	( A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience. Henry, BL; Kumar, R; Smith, RE, 2015)	2.08
"Dabigatran is a potent oral anticoagulant. "	( Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation. Clemens, A; Kink-Eiband, M; Schurer, J; van Ryn, J, 2014)	2.22
"Dabigatran is a direct thrombin inhibitor that reduces the risk of systemic embolism in patients with nonvalvular atrial fibrillation. "	( A case of dabigatran-associated acute renal failure. Julius, CJ; Negrete, H; Roy, P; Sarac, E; Shafi, ST, 2013)	2.23
"Dabigatran is an oral anticoagulant from the class of the direct thrombin inhibitors, indicated for prevention of thromboembolic events in patients with non valvular atrial fibrillation. "	( [Hemodialysis to remove anticoagulant dabigatran during emergencies]. Campbell, S; Carrizo, A, 2014)	2.12
"Dabigatran is a novel oral anti-coagulant (NOAC) that reduces risk of stroke in patients with non-valvular atrial fibrillation (NVAF). "	( Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Barón, AE; Bradley, SM; Carey, EP; Cunningham, F; Grunwald, GK; Ho, PM; Jackevicius, CA; Maddox, TM; Marzec, LN; Pilote, L; Rumsfeld, JS; Schneider, PM; Shore, S; Turakhia, MP; Varosy, PD, 2014)	2.21
"Dabigatran is a new oral direct thrombin inhibitor. "	( Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study. Engström, M; Johansson, PI; Nilsson, CU; Ostrowski, SR; Sølbeck, S, 2014)	3.29
"Dabigatran is a direct thrombin (factor IIa) inhibitor; rivaroxaban and apixaban are direct factor Xa inhibitors."	( Newer clinically available antithrombotics and their antidotes. Lévy, S, 2014)	1.12
"Dabigatran is a new non-vitamin K antagonist (VKA) anticoagulant with anti-thrombin action, with supposedly fewer haemorrhagic complications. "	( Epistaxis and dabigatran, a new non-vitamin K antagonist oral anticoagulant. Bécares Martínez, C; Calvo González, J; García Callejo, FJ; Marco Algarra, J; Marco Sanz, M; Martínez Beneyto, P, )	1.93
"Dabigatran is an oral intake thrombin inhibitor for preventive administration against stroke accompanied by atrial fibrillation. "	( Analysis of the influence of dabigatran on coagulation factors and inhibitors. Ito, S; Ohhigashi, H; Shimono, J; Shiratori, S; Teshima, T; Tsutsumi, Y, 2015)	2.15
"Dabigatran is a novel direct thrombin inhibitor that has proven effective in the prevention of vascular events in patients with nonvalvular atrial fibrillation. "	( Use of Extracorporeal Techniques in the Removal of Dabigatran. Muddana, N; Nashar, K; Nayer, A; Ortega, LM; Thuyanh, C, )	1.83
"Dabigatran etexilate is an oral prodrug of dabigatran, a selective, reversible, competitive, direct thrombin inhibitor."	( Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence. Greig, SL; McKeage, K, 2014)	2.57
"Dabigatran is a popular new alternative to warfarin that has no blood monitoring or reversal agent. "	( Spontaneous choroidal hemorrhage in a patient on dabigatran etexilate (Pradaxa). Kang, TS; Kunjukunju, N; Lord, K, 2014)	2.1
"Dabigatran is an anti-aggregation agent used for the treatment of atrial fibrillation."	( Depressive symptoms associated with dabigatran: a case report. Enez Darcin, A; Eryilmaz, G; Gogcegoz Gul, I; Saglam, E, 2015)	1.41
"Dabigatran (DT) is a direct thrombin inhibitor used to prevent venous and arterial thromboembolism due to atrial fibrillation. "	( Generation of an anti-Dabigatran Monoclonal Antibody and Its Use in a Highly Sensitive and Specific Enzyme-Linked Immunosorbent Assay for Serum Dabigatran. Goroku, T; Kariyazono, H; Morinaga, O; Oiso, S; Shoyama, Y; Uto, T, 2015)	2.17
"Dabigatran etexilate is an oral direct thrombin inhibitor. "	( Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis. Gansser, D; Moschetti, V; Schmohl, M; Stangier, J, 2015)	2.21
"Dabigatran is an oral direct inhibitor indicated for stroke prevention in patients with atrial fibrillation. "	( Dabigatran overdose: case report of laboratory coagulation parameters and hemodialysis of an 85-year-old man. Berutti, S; Coglitore, R; Cosseddu, D; Erroi, L; Marangella, M; Migliardi, M; Montaruli, B; Sivera, P; Vitale, C, 2015)	3.3
"Dabigatran is a direct thrombin inhibitor that has been approved for preventing stroke in patients with atrial fibrillation. "	( Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation. Fujino, T; Kuwahara, T; Nakajima, J; Nakashima, E; Okubo, K; Takagi, K; Takahashi, A; Takigawa, M; Tsutsui, H; Watari, Y; Yamao, K, 2015)	2.2
"Dabigatran is a direct thrombin inhibitor that effectively blocks thrombin's catalytic activity but does not preclude thrombin's exosites and binding to fibrinogen."	( Characterization of thrombin-bound dabigatran effects on protease-activated receptor-1 expression and signaling in vitro. Chen, B; Coronel, LJ; Goss, A; Soto, AG; Trejo, J; van Ryn, J, 2015)	1.42
"Dabigatran etexilate is a fixed-dose oral direct thrombin inhibitor available for use in acute and extended treatment of VTE, as well as prophylaxis in high-risk orthopedic surgical patients."	( Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran. Fanola, CL, 2015)	1.35
"Dabigatran is a prodrug that undergoes primarily renal elimination and does not affect cytochrome P450 enzymes."	( Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran. Law, EH; Leung, TS, 2015)	1.36
"Dabigatran etexilate is a novel oral anticoagulant indicated for anticoagulation in the management of atrial fibrillation and venous thromboembolism. "	( Successful hemostasis and reversal of highly elevated PT/INR after dabigatran etexilate use in a patient with acute kidney injury. Jones, JM; Leedahl, DD; Ryan, HM; Tieszen, M, 2016)	2.11
"Dabigatran is a reversible direct thrombin inhibitor and currently approved for the prevention of thromboembolic episodes in non-valvar atrial fibrillation."	( Dabigatran for left ventricular thrombus. Kolekar, S; Munjewar, C; Sharma, S, )	2.3
"Dabigatran etexilate is a direct thrombin inhibitor approved for use in patients with non-valvular atrial fibrillation. "	( The effect of ultrafiltration with cardiopulmonary bypass on the removal of dabigatran from the circulation of adult pigs. Carter, CB; DeNino, WF; Goss, A; Mukherjee, R; Sievert, A; Toole, JM; Uber, WE, 2016)	2.11
"Dabigatran is a novel target specific oral anticoagulant for stroke prevention in non valvular atrial fibrillation. "	( Efficacy and safety of dabigatran in a "real-life" population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry. Bianchi, V; Calabrò, P; Cavallaro, C; D'Onofrio, A; De Vivo, S; Nigro, G; Russo, V; Santangelo, L; Sarubbi, B; Vecchione, F, 2015)	2.17
"Dabigatran is a suitable alternative to warfarin obviating the need for repetitive international normalized ratio monitoring, however, it may need plasma drug monitoring."	( Clinical utility of dabigatran in United Arab Emirates. A pharmacovigilance study. Abu Mandil, M; Al Nuaimi, SK; Al Suwaidi, A; AlShamsi, A; Bhagavathula, A; Elnour, AA; Erkekoglu, P; Hamad, F; Sadik, A; Shehab, A, 2015)	2.18
"Dabigatran is a direct acting (anti-II) oral anticoagulant which does not interfere with CYP and has favourable safety and efficacy profiles compared with VKAs."	( Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. Ajjan, RA; Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Franchi, F; Guzman, LA; King, R; Phoenix, F; Rollini, F; Tello-Montoliu, A; Zenni, MM, 2016)	1.55
"Dabigatran is an oral anticoagulant approved for treatment of non-valvular atrial fibrillation, deep venous thrombosis (DVT), pulmonary embolism and prevention of DVT following orthopedic surgery. "	( Thrombelastography detects dabigatran at therapeutic concentrations in vitro to the same extent as gold-standard tests. Johansson, PI; Ostrowski, SR; Solbeck, S; Stensballe, J, 2016)	2.17
"Dabigatran is a direct thrombin inhibitor shown to be an effective alternative to warfarin in patients with non-valvular atrial fibrillation (AF). "	( Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study. Albuquerque, FP; Aras, R; de Almeida Nunes, B; de Bulhões, FV; de Souza Fernandes, AM; de Souza Roriz, P; Durães, AR, 2016)	3.32
"Dabigatran is a direct thrombin (factor II) inhibitor while rivaroxaban, apixaban and edoxaban are direct inhibitors of factor Xa."	( Bleeding management in patients with new oral anticoagulants. Marra, A; Perrone, A; Servillo, G; Vargas, M, 2016)	1.16
"Dabigatran is an effective oral alternative to enoxaparin for thromboprophylaxis as demonstrated by the RE-NOVATE II study global results. "	( Thromboprophylaxis with dabigatran after total hip arthroplasty in Indian patients: A subanalysis of a double-blind, double-dummy, randomized RE-NOVATE II study. Babhulkar, S; Clemens, A; Dadi, A; Iyer, R; Kamath, S; Malhotra, R; Mody, B; Mutha, S; Reddy, G; Sanjib, KB; Shah, V; Shetty, N; Tapasvi, S; Wadhwa, M, 2017)	2.2
"Dabigatran is an oral direct thrombin inhibitor that can be used with fixed doses, without the need for routine anticoagulation laboratory monitoring and the advantage of few drug or diet interactions."	( Dabigatran in clinical practice: Contemporary overview of the evidence. Ageno, W; Eikelboom, J; Lip, GY, 2016)	2.6
"Dabigatran is a new direct competitive inhibitor of thrombin and is equally effective and safe as warfarin in the prevention of thromboembolism in patients with nonvalvular atrial fibrillation. "	( Left atrial thrombus under dabigatran in a patient with nonvalvular atrial fibrillation. Durian, MF; Janssen, AM; Szabó, B; van de Kerkhof, D; van der Voort, PH, 2016)	2.17
"Dabigatran is a selective direct thrombin inhibitor that reversibly binds to thrombin."	( Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines. Fabris, F; Goss, A; Prandoni, P; Sambado, L; Vianello, F, 2016)	2.6
"Dabigatran etexilate is a direct oral anticoagulant used for the prevention of stroke in atrial fibrillation. "	( Reversal of Anticoagulation With Dabigatran in an 82-Year-Old Patient With Traumatic Retroperitoneal Arterial Bleeding Using the New Antidote Idarucizumab: A Case Report. Brenner, T; Hofer, S; Philipsenburg, C; Weigand, MA, 2016)	2.16
"Dabigatran is a newly commercialized drug that is replacing other anticoagulants in the prevention of venous thromboembolism, stroke and systemic arterial valve embolism. "	( Dabigatran: A new oral anticoagulant. Guidelines to follow in oral surgery procedures. A systematic review of the literature. Casañas-Gil, E; Hernández-Vallejo, G; López-Pintor, RM; Muñoz-Corcuera, M; Ramírez-Martínez-Acitores, L, 2016)	3.32
"Dabigatran is a direct thrombin inhibitor, which is increasingly likely to be encountered in patients presenting for surgery. "	( The effect of dabigatran on the kaolin-activated whole blood thromboelastogram. 'Aho, A; Byrne, K, 2016)	2.24
"Dabigatran is an oral, direct thrombin inhibitor approved by international regulatory agencies for stroke prevention in patients with paroxysmal or persistent non-rheumatic atrial fibrillation (AF). "	( Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. Barcellona, D; Cianchetti, ME; Mameli, A; Marongiu, F; Musu, M; Porru, M; Ruberto, MF; Schirru, P, 2017)	3.34
"Dabigatran is a non-vitamin K antagonist oral anticoagulant that has been approved for atrial fibrillation and prevention of venous thromboembolism. "	( Dabigatran-related leukocytoclastic vasculitis. An, J; Garje, R; Leone, JP; Wanat, KA, 2017)	3.34
"Dabigatran etexilate is a substrate of the P-glycoprotein (adenosine triphosphate-binding cassette subfamily B member 1) transport system and is subject to interactions with medications that induce or inhibit this system. "	( Development of Left Atrial Thrombus After Coadministration of Dabigatran Etexilate and Phenytoin. Albers, L; Bolt, J; Duffy, P; Hager, N; Semchuk, W; Wojcik, W, 2017)	2.14
"Dabigatran etexilate is a prodrug whose absorption is opposed by intestinal P-glycoprotein and which is converted by carboxylesterase to its active form, dabigatran. "	( Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. Antoniou, T; Gomes, T; Hollands, S; Juurlink, DN; Macdonald, EM; Mamdani, MM; Tadrous, M; Yao, Z, 2017)	2.12
"Dabigatran is a feasible alternative to warfarin for shortening the hospitalization period and decreasing delayed bleeding rate, although rivaroxaban has a significantly higher delayed bleeding risk."	( Effect of direct oral anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection. Fujisaki, J; Hirasawa, T; Horiuchi, Y; Igarashi, M; Ishiyama, A; Iwasaki, R; Michitaka, K; Mita, E; Ninomiya, T; Omae, M; Tomida, H; Tsuchida, T; Yamada, T; Yamamoto, Y; Yoshio, T, 2017)	1.18
"Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a potent, concentration-dependent inhibitor of thrombus formation and thrombin-induced platelet aggregation. "	( Dabigatran etexilate. Plosker, GL; Sanford, M, 2008)	3.23
"Dabigatran etexilate is a promising new oral anticoagulant that offers greatly expanded therapeutic options for both patients and physicians."	( New therapeutic option for thromboembolism--dabigatran etexilate. Ieko, M; Nakabayashi, T; Nishio, H, 2008)	2.05
"Dabigatran is an oral direct thrombin inhibitor that has been compared with enoxaparin for prevention of VTE following hip or knee replacement."	( New issues in oral anticoagulants. Francis, CW, 2008)	1.07
"Dabigatran etexilate is a prodrug that is rapidly converted to the active direct thrombin inhibitor dabigatran."	( Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Connolly, S; Ezekowitz, MD; Oldgren, J; Parekh, A; Reilly, PA; Themeles, E; Varrone, J; Wallentin, L; Wang, S; Yusuf, S, 2009)	1.29
"Dabigatran etexilate is a novel, oral reversible direct thrombin inhibitor in the clinical development for the treatment and prevention of thromboembolic diseases. "	( Dabigatran etexilate: future directions in anticoagulant treatment. Reilly, PA; Schulman, S, )	3.02
"Dabigatran etexilate is an oral reversible direct thrombin inhibitor that offers potential practical advantages over existing anticoagulants for the prevention of venous thromboembolism after major joint replacement surgery. "	( Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen. Dahl, OE, )	3.02
"Dabigatran etexilate is a novel, oral reversible direct thrombin inhibitor that is rapidly absorbed and converted to its active form, dabigatran. "	( Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clemens, A; Stangier, J, )	1.82
"Dabigatran is a new oral direct thrombin inhibitor."	( Dabigatran versus warfarin in patients with atrial fibrillation. Alings, M; Connolly, SJ; Darius, H; Diaz, R; Diener, HC; Eikelboom, J; Ezekowitz, MD; Joyner, CD; Lewis, BS; Oldgren, J; Parekh, A; Pogue, J; Reilly, PA; Themeles, E; Varrone, J; Wallentin, L; Wang, S; Xavier, D; Yusuf, S; Zhu, J, 2009)	2.52
"Dabigatran etexilate is a potent, non-peptidic small molecule that specifically and reversibly inhibits both free and clot-bound thrombin by binding to the active site of thrombin molecule."	( New direct thrombin inhibitors. Ageno, W; Dentali, F; Squizzato, A; Steidl, L, 2009)	1.07
"Dabigatran is a direct inhibitor of thrombin and rivaroxaban of factor Xa."	( [New oral anticoagulants. Consequences for perioperative coagulation diagnostics and therapy]. Heindl, B; Spannagl, M, 2009)	1.07
"Dabigatran (Pradaxa) is a new oral, direct, selective and reversible inhibitor of the factor IIa of the coagulation cascade. "	( [Dabigatran: clinical pharmacology]. Laporte, S; Mismetti, P, 2009)	2.71
"Dabigatran is an oral thrombin inhibitor."	( [Oral prevention of thromboembolism with rivaroxaban and dabigatran: are the newly approved drugs innovations in orthopaedic and trauma surgery? ]. Gogarten, W; Pauschert, R; Quante, M, 2010)	1.33
"Dabigatran etexilate is an oral direct thrombin inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. "	( Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Mazur, D; Rathgen, K; Stähle, H; Stangier, J, 2010)	2.03
"Dabigatran etexilate is an oral, reversible direct thrombin inhibitor that is approved in the EU and several other countries for the prevention of venous thromboembolism after elective hip and knee replacement, and is in advanced clinical development for other thromboembolic disorders. "	( Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Clemens, A; Feuring, M; Haertter, S; Liesenfeld, KH; Stangier, J; van Ryn, J; Wienen, W, 2010)	3.25
"Dabigatran is a direct thrombin inhibitor; it has stable, predictable pharmacokinetics and does not require routine monitoring."	( Dabigatran etexilate: a new thrombin inhibitor. Verma, AK, 2010)	2.52
"Dabigatran etexilate is a new, effective, reversible, rapid-acting, oral direct inhibitor of thrombin. "	( Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation. Qureshi, AI; Siddiqui, FM, 2010)	3.25
"Dabigatran is a highly selective, reversible, and potent thrombin inhibitor and is orally available as the prodrug, dabigatran etexilate. "	( Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Clemens, A; Eisert, WG; Hauel, N; Stangier, J; van Ryn, J; Wienen, W, 2010)	3.25
"Dabigatran is a fixed-dose, oral direct thrombin inhibitor with similar or reduced rates of ischemic stroke and intracranial hemorrhage in patients with AF compared with those of warfarin."	( Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP, 2011)	1.41
"Dabigatran is a direct thrombin inhibitor that has undergone clinical trials for VTE prophylaxis and treatment."	( New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors. Morris, TA, 2010)	1.08
"Dabigatran is an oral, reversible thrombin inhibitor that has shown promising results in large clinical trials. "	( Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Baghaei, F; Blixter, IF; Gustafsson, KM; Hillarp, A; Lindahl, TL; Sten-Linder, M; Stigendal, L; Strandberg, K, 2011)	2.07
"Dabigatran (Pradaxa) is a new oral, direct, selective and reversible thrombin inhibitor (factor IIa) acting as anticoagulant. "	( [Medication of the month. Dabigatran etixilate (Pradaxa): an oral anticoagulant acting as a direct selective inhibitor of thrombin]. Lancellotti, P; Scheen, AJ, 2010)	2.1
"Dabigatran is a reasonable alternative to warfarin in patients requiring cardioversion."	( Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Aikens, TH; Brugada, J; Chernick, M; Connolly, SJ; Ezekowitz, MD; Flaker, G; Kamensky, G; Nagarakanti, R; Oldgren, J; Parekh, A; Reilly, PA; Yang, S; Yusuf, S, 2011)	2.53
"Dabigatran is a reversible inhibitor of free thrombin and clot-bound thrombin."	( [Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate]. Meddahi, S; Samama, MM, 2011)	1.33
"Dabigatran etexilate is a promising new option for the prevention of stroke and systemic embolism in patients with atrial fibrillation."	( Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Garnock-Jones, KP, 2011)	2.53
"Dabigatran etexilate is an oral direct thrombin inhibitor that could be administered in fixed doses and does not require laboratory monitoring. "	( A new anticoagulant for a new era: review of recent data on dabigatran etexilate. Faltas, B, 2010)	2.05
"Dabigatran is a direct thrombin inhibitor, which is not metabolized by cytochrome P450, and thus does not require blood coagulation monitoring or vitamin K intake limitation, or produce drug interaction."	( [Dabigatran, a new oral anticoagulant]. Uchiyama, S, 2011)	2
"Dabigatran is an effective and safe alternative to oral vitamin K antagonists for stroke prevention in patients with nonvalvular atrial fibrillation, with fewer drug interactions and monitoring requirements. "	( Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease. Bovio, JA; Gums, JG; Smith, SM, 2011)	3.25
"Dabigatran etexilate is a novel orally administered anticoagulant that exerts its action through reversible direct thrombin inhibition. "	( A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery. Majeed, A; Schulman, S, 2011)	2.1
"Dabigatran is an oral, reversible direct thrombin inhibitor approved in Europe and in several other countries for the prevention of venous thromboembolism after elective knee and hip replacement surgery."	( Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents. Aizawa, Y; Atarashi, H; Inoue, H; Kamakura, S; Koretsune, Y; Kumagai, K; Mitamura, H; Ogawa, S; Okumura, K; Sugi, K; Yamashita, T; Yasaka, M, 2011)	1.09
"Dabigatran etexilate is an oral direct thrombin inhibitor that is approved for use in thromboprophylaxis of atrial fibrillation and deep vein thrombosis. "	( Potential inaccuracy of point-of-care INR in dabigatran-treated patients. Baruch, L; Sherman, O, 2011)	2.07
"Dabigatran is an oral anticoagulant that belongs to the class of direct thrombin inhibitors."	( Dabigatran in atrial fibrillation: pharmacology and clinical trials. Ezekowitz, MD; Nagarakanti, R, 2011)	2.53
"Dabigatran etexilate is an oral, reversible direct thrombin inhibitor and has been recently approved for the prevention of stroke in patients with non-valvular atrial fibrillation. "	( Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment. Qureshi, AI; Siddiqui, FM; Watanabe, M, 2012)	2.04
"Dabigatran is a reversible direct thrombin inhibitor (DTI) that has rapid and predictable anticoagulant effects and does not require the anticoagulation monitoring seen with oral vitamin K antagonists. "	( Dabigatran etexilate: A novel oral direct thrombin inhibitor. Blommel, AL; Blommel, ML, 2011)	3.25
"Dabigatran is a direct thrombin (FIIa) inhibitor, whereas Rivaroxaban and Apixaban are direct factor Xa (FXa) inhibitors."	( [The new Anticoagulants - Relevant Facts for the GP]. Asmis, LM, 2011)	1.09
"Dabigatran etexilate is an oral direct thrombin inhibitor that has been approved by the US Food and Drug Administration for the prevention of stroke and systemic embolization in patients with nonvalvular atrial fibrillation. "	( Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice. Pendleton, RC; Rodgers, GM; Smock, KJ; Wilcox, R, 2011)	2.05
"Dabigatran (Pradaxa) is a competitive direct thrombin inhibitor approved by the US FDA for prevention of embolic stroke in patients with nonvalvular atrial fibrillation. "	( Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. Babu, KM; Boyer, EW; Brown, RS; Ganetsky, M; Salhanick, SD, 2011)	3.25
"Dabigatran is a new anticoagulant and may be useful after AF ablation to prevent thromboembolic events."	( The use of dabigatran immediately after atrial fibrillation ablation. Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA, 2012)	1.49
"Dabigatran appears to be an alternative to warfarin after AF ablation."	( The use of dabigatran immediately after atrial fibrillation ablation. Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA, 2012)	1.49
"Dabigatran is a direct inhibitor of thrombin that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation. "	( Preventing cardioembolic stroke in atrial fibrillation with dabigatran. Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C, 2012)	2.06
"Dabigatran (Pradaxa) is a new oral anticoagulant approved in the United States for the primary prevention of stroke and systemic embolization in patients with nonvalvular atrial fibrillation. "	( Dabigatran: will it change clinical practice? Bartholomew, JR; Wartak, SA, 2011)	3.25
"Dabigatran is an oral direct thrombin inhibitor with a rapid onset. "	( Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor. Augoustides, JG, 2011)	2.08
"Dabigatran etexilate is a specific oral thrombin inhibitor and rivaroxaban and apixaban are oral inhibitors of factor Xa."	( [New anticoagulants. Characteristics, monitoring and management of bleeding]. Heidinger, K; Kemkes-Matthes, B, 2011)	1.09
"Dabigatran is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. "	( Pharmacological basis and clinical evidence of dabigatran therapy. Barez, A; Martínez, MP; Navarro-Dorado, J; Ramajo, M; Redondo, S; Tejerina, T, 2011)	2.07
"Dabigatran is a direct thrombin inhibitor, acting like other members in its class (bivalirudin, argatroban) to impede the clotting process through selective and reversible binding with both free and clot-bound thrombin."	( Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation. Boniface, K; Moore, CH; Scott, J; Snashall, J, 2012)	1.35
"Dabigatran is a direct thrombin inhibitor approved for nonvalvular atrial fibrillation. "	( Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies. Fieland, D; Taylor, M, 2012)	3.26
"Dabigatran is a new oral anticoagulant recently approved for the prevention of stroke or systemic embolism in patients with atrial fibrillation (AF). "	( Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J, 2012)	2.14
"Dabigatran etexilate is an oral, reversible, direct thrombin inhibitor licensed for the prevention of venous thromboembolism and stroke prevention in patients with atrial fibrillation. "	( Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. Clemens, A; Feuring, M; Härtter, S; Sennewald, R; Stangier, J; van Ryn, J; Yamamura, N, 2012)	2.11
"Dabigatran is a direct thrombin inhibitor, does not require blood coagulation monitoring and limitation of vitamin K intake as well as very few drug interactions, and thus expected to be an oral anticoagulant alternative to warfarin. "	( [Expectation to and problems of thrombin inhibitor]. Uchiyama, S, 2011)	1.81
"Dabigatran etexilate is a new oral anticoagulant recently approved in Europe for the prevention of stroke or systemic embolism in adult patients with non-valvular atrial fibrillation (AF) and at least one risk factor for stroke. "	( Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Brueckmann, M; Clemens, A; Diener, HC; Huisman, MV; Lip, GY; van Ryn, J, 2012)	3.26
"Dabigatran is a reversible, direct thrombin inhibitor, which is administered as dabigatran etexilate, the oral prodrug."	( New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders. Dahl, OE, 2012)	1.38
"Dabigatran is an oral direct thrombin-inhibitor recently approved for stroke prevention in atrial fibrillation."	( Warfarin versus dabigatran: comparing the old with the new. Abraham, ME; Marcy, TR, 2012)	1.45
"Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). "	( Dabigatran (Pradaxa). Comin, J; Kallmes, DF, 2012)	3.26
"Dabigatran etexilate is an oral anticoagulant that acts as a direct, competitive thrombin inhibitor. "	( Neurosurgical complications of direct thrombin inhibitors--catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. Garber, ST; Schmidt, RH; Sivakumar, W, 2012)	2.02
"Dabigatran is a direct thrombin (factor IIa) inhibitor that overcomes many of the limitations associated with warfarin."	( Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation. Ibayashi, S; Matsumoto, M; Nagao, T; Nagata, K; Nakagawara, J; Tanahashi, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yasaka, M, 2012)	2.54
"Dabigatran etexilate is a direct thrombin inhibitor that has been in clinical use for the prevention and treatment of venous and arterial thrombosis. "	( Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor. Garza, R; Huo, MH, 2012)	2.07
"Dabigatran is a potent reversible, competitive direct thrombin inhibitor which is available as the prodrug, Dabigatran etexilate."	( Dabigatran: a new chapter in anticoagulation. Ahmed, S; Levin, V; Malacoff, R; Martinez, MW, 2012)	2.54
"Dabigatran etexilate is a new oral anticoagulant used for the prevention of systemic thromboembolism in patients with atrial fibrillation. "	( Hemopericardium in a patient treated with dabigatran etexilate. Barton, CA; Keller, RE; McMillian, WD; Raza, SS, 2012)	2.09
"Dabigatran is an oral direct thrombin inhibitor."	( [Clinical studies, the interests and limits of using dabigatran in atrial fibrillation]. Chatelain, B; Chatelain, C; Dogné, JM; Douxfils, J; Mullier, F; Spinewine, A; Sternotte, A, 2012)	1.35
"Dabigatran etexilate is a new oral direct thrombin inhibitor for prophylaxis of venous thromboembolism (VTE) in patients who have elective surgery for total hip replacement (THR) or total knee replacement (TKR). "	( Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands. Brouwers, JR; Kappelhoff, BS; Postma, MJ; van Hulst, M, 2012)	2.13
"Dabigatran etexilate is an oral prodrug of the potent, rapidly acting, reversible, competitive inhibitor of thrombin, dabigatran."	( Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. Burness, CB; McKeage, K, 2012)	2.54
"Dabigatran is a viable alternative to VKA that provides many advantages over these drugs and is certainly preferred by most patients due to the problems of VKA follow-up."	( [Dabigatran: a new therapeutic alternative in the prevention of stroke]. Gállego, J; Gil Alzueta, MC, 2012)	2.01
"Dabigatran etexelate is a new oral direct thrombin inhibitor that has been approved by the US Food and Drug Administration to prevent stroke in patients with nonvalvular atrial fibrillation. "	( Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization. El Khoury, R; Lopez, G; Misra, V; Sangha, N, 2012)	2.04
"Dabigatran is a cost-effective treatment in Sweden, as its incremental cost-effectiveness ratio is below the normally accepted willingness to pay limit."	( Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. Davidson, T; Husberg, M; Janzon, M; Levin, LÅ; Oldgren, J, 2013)	2.15
"Dabigatran is a novel direct thrombin inhibitor that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation. "	( Dabigatran for stroke prevention in atrial fibrillation. Diener, HC; Hohnloser, SH, 2012)	3.26
"Dabigatran is an oral direct thrombin inhibitor indicated for the prevention of stroke and systemic thromboembolism in patients with nonvalvular AF, at a dose of 150 mg twice daily. "	( Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation. Kim, JJ; Mack, DR, )	1.83
"Dabigatran is an oral direct thrombin inhibitor approved for the reduction of stroke and systemic embolism risk in patients with nonvalvular atrial fibrillation. "	( Hemopericardium and cardiac tamponade associated with dabigatran use. Dy, EA; Shiltz, DL, )	1.82
"Dabigatran (Pradaxa) is a new oral anticoagulant approved by the Food and Drug Administration (FDA), available internationally and indicated as an alternative to warfarin for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. "	( Fatal gastrointestinal hemorrhage after a single dose of dabigatran. Boesen, K; Ito, S; Kernan, L; Shirazi, F, 2012)	2.07
"Dabigatran is an effective thromboprophylactic therapy for normal, pre-obese and obese patients, and outcomes in patients with a BMI >25 kg/m(2) do not differ from the overall population."	( Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. Clemens, A; Dahl, OE; Eriksson, BI; Feuring, M; Friedman, RJ; Hantel, S; Huo, M; Noack, H, 2012)	3.26
"Dabigatran is a novel oral direct thrombin inhibitor that has been shown to have beneficial outcomes in the prevention of thromboembolic stroke in patients with atrial fibrillation. "	( Evaluating and assessing dabigatran drug interactions. Nguyen, T; Wong, E, 2012)	2.13
"Dabigatran is a direct thrombin inhibitor approved for anticoagulation in non-valvular atrial fibrillation and, in some countries, for thromboembolism prophylaxis following select orthopedic surgeries. "	( Hemorrhagic complications associated with dabigatran use. Basciano, P; Chen, BC; Garlich, FM; Hoffman, RS; Howland, MA; Nelson, LS; Smith, SW; Viny, AD, 2012)	2.09
"Dabigatran etexilate is a novel oral direct thrombin inhibitor, which provides stroke risk reduction for patients with nonvalvular atrial fibrillation."	( Dabigatran in clinical practice. Ellis, CR; Nagarakanti, R, 2012)	2.54
"Dabigatran is a recently introduced direct thrombin inhibitor licensed for use as an oral anticoagulant for stroke prevention in non-valvular atrial fibrillation. "	( Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data. Boga, T; Michel, J; Mundell, D; Sasse, A, 2013)	3.28
"Dabigatran etexilate is a new oral anticoagulant for the therapy and prophylaxis of venous thromboembolism and stroke prevention in patients with atrial fibrillation. "	( Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Aspoeck, G; Goebel, G; Griesmacher, A; Halbmayer, WM; Haushofer, AC; Loacker, L; Quehenberger, P; Schnapka-Koepf, M; Tomasits, J; Weigel, G, 2012)	2.08
"Dabigatran is an oral and direct inhibitor of thrombin. "	( Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Aisenberg, J; Bytzer, P; Connolly, SJ; Ezekowitz, M; Formella, S; Reilly, PA; Yang, S, 2013)	2.07
"Dabigatran is an oral direct thrombin inhibitor recently approved for stroke prevention in atrial fibrillation (AF) as an alternative to warfarin. "	( Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong. Chang, AM; Ho, JC; Lam, YY; Lee, VW; Yan, BP; Yu, CM, 2012)	3.26
"Dabigatran etexilate is a competitive, direct thrombin inhibitor that works in the coagulation cascade to ultimately prevent thrombus formation. "	( Treatment of dabigatran-associated bleeding: case report and review of the literature. Harinstein, LM; Morgan, JW; Russo, N, 2013)	2.2
"Dabigatran is a newly available oral direct thrombin inhibitor approved for anticoagulation therapy to prevent strokes in patients with nonvalvular atrial fibrillation. "	( Removal of dabigatran by hemodialysis. Chang, DN; Chin, AI; Dager, WE, 2013)	2.22
"Dabigatran etexilate is a new oral anticoagulant that functions as a direct thrombin inhibitor. "	( The effect of dabigatran on select specialty coagulation assays. Adcock, DM; Dwyre, DM; Gosselin, R; Kitchen, S, 2013)	2.19
"Dabigatran is a new oral anticoagulant that does not require INR monitoring."	( Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland. Eichler, K; Plessow, R; Pletscher, M; Wieser, S, 2013)	1.43
"Dabigatran etexilate is an oral, reversible direct thrombin inhibitor, with predictable and reproducible pharmacodynamic effects and pharmacokinetic characteristics that permit once-daily dosing."	( Dabigatran vs. low molecular weight heparin in preventing venous thromboembolism after elective hip and knee arthroplasty: evaluation of selected clinical parameters. Jackiewicz, A; Krzemiński, M; Mrozik, D, 2012)	2.54
"Dabigatran etexilate is an oral prodrug of dabigatran, a direct thrombin inhibitor, that provides the first available oral anticoagulant alternative to warfarin for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). "	( The pharmacology and therapeutic use of dabigatran etexilate. Sarah, S, 2013)	2.1
"Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery."	( A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. Ahnfelt, L; Bravo, ML; Büller, HR; Dahl, OE; Eriksson, BI; Hettiarachchi, R; Kälebo, P; Piovella, F; Reilly, P; Rosencher, N; Stangier, J, 2005)	2.04
"Dabigatran etexilate is an oral low-molecular-weight direct thrombin inhibitor. "	( Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. Ahnfelt, L; Dahl, OE; Eriksson, BI; Nehmiz, G; Rathgen, K; Stähle, H; Stangier, J; Svärd, R, 2005)	2.01
"Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) undergoing advanced clinical development as its orally active prodrug, dabigatran etexilate. "	( In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Hauel, N; Priepke, H; Ries, UJ; Stassen, JM; Wienen, W, 2007)	2.01
"Dabigatran is a reversible direct, selective thrombin inhibitor, undergoing clinical development as its orally active prodrug, dabigatran etexilate. "	( Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Hauel, N; Priepke, H; Ries, UJ; Stassen, JM; Wienen, W, 2007)	2.05
"Dabigatran etexilate is an orally administered prodrug, which is rapidly absorbed and converted to the active form, dabigatran."	( Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Stangier, J, 2008)	1.29

Effects

Dabigatran has a favorable impact on effectiveness and safety outcomes compared with vitamin K antagonists in real-world populations. It has a wide therapeutic range that allows for fixed-dose administration without the need for routine monitoring, a requirement of standard vitamin K antagonist (VKA) therapy.

Dabigatran has emerged as a promising alternative to vitamin K antagonists (VKAs) in non-valvular atrial fibrillation (NVAF) It has been shown, relative to warfarin, to reduce thromboembolic events without increasing bleeding.

Excerpt	Reference	Relevance
"Dabigatran has a favorable impact on effectiveness and safety outcomes compared with vitamin K antagonists in real-world populations."	( Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis. Amin, AN; Auladell-Rispau, A; Barrios, V; Escobar, C; Lip, GYH; Requeijo, C; Salazar, J; Santero, M, 2021)	2.36
"Dabigatran has a better safety profile and requires less monitoring, but is costlier than warfarin. "	( Cost-Utility Analysis of Dabigatran and Warfarin for Stroke Prevention Among Patients With Nonvalvular Atrial Fibrillation in India. Aggarwal, R; Aghoram, R; Kar, SS; Kumar, SM; Rajasulochana, SR, 2022)	2.47
"Dabigatran also has a favorable safety profile for prevention of VTE, and rivaroxaban has a favorable safety profile for VTE prevention in children with congenital heart disease."	( Just DOAC: Use of direct-acting oral anticoagulants in pediatrics. Cober, MP; Fenn, NE; Hill, C; King, M; Mills, K; Omecene, NE; Pauley, JL; Sierra, CM; Smith, T, 2023)	1.63
"As dabigatran has a favourable benefit-risk profile, it is being increasingly used."	( Dabigatran: patient management in specific clinical settings. Binder, K; Domanovits, H; Eichinger, S; Függer, R; Gollackner, B; Hiesmayr, JM; Huber, K; Kyrle, PA; Lang, W; Perger, P; Quehenberger, P; Roithinger, FX; Schmaldienst, S; Weltermann, A, 2014)	2.36
"Dabigatran etexilate has a wide therapeutic range that allows for fixed-dose administration without the need for routine monitoring, a requirement of standard vitamin K antagonist (VKA) therapy."	( Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence. Greig, SL; McKeage, K, 2014)	2.57
"Dabigatran has a stable pharmacokinetic profile with minimum drug interactions, and requires no routine laboratory evaluation to measure level of anticoagulation."	( Management of dabigatran-induced bleeding with continuous venovenous hemodialysis. Ali, A; Assaly, R; Hamouda, D; Khan, A; Mbaso, C; Paul, S; Prashar, R; Shah, S, 2015)	1.5
"Dabigatran has an impact on a large panel of used coagulation tests."	( Thrombin time and anti-IIa dabigatran's activity: hypothesis of thrombin time's predictive value. Kaabar, M; Le Guyader, M; Lemaire, P; Pineau Vincent, F, )	1.15
"Dabigatran has a low level of plasma protein binding and has been considered dialyzable."	( The effect of ultrafiltration with cardiopulmonary bypass on the removal of dabigatran from the circulation of adult pigs. Carter, CB; DeNino, WF; Goss, A; Mukherjee, R; Sievert, A; Toole, JM; Uber, WE, 2016)	1.39
"Dabigatran has a predictable pharmacokinetic profile, allowing for a fixed-dose regimen without the need for routine coagulation monitoring."	( Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Clemens, A; Feuring, M; Haertter, S; Liesenfeld, KH; Stangier, J; van Ryn, J; Wienen, W, 2010)	2.52
"Dabigatran has a low potential for drug-drug interactions and is predominantly renally excreted."	( Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Clemens, A; Eisert, WG; Hauel, N; Stangier, J; van Ryn, J; Wienen, W, 2010)	2.52
"Dabigatran has a pharmacokinetic profile that produces predictable anticoagulation responses, does not undergo CYP 450 metabolism, has few drug-drug and drug-food interactions, and does not require frequent laboratory monitoring of clotting parameters."	( Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. Babu, KM; Boyer, EW; Brown, RS; Ganetsky, M; Salhanick, SD, 2011)	2.53
"Dabigatran has a favorable impact on effectiveness and safety outcomes compared with vitamin K antagonists in real-world populations."	( Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis. Amin, AN; Auladell-Rispau, A; Barrios, V; Escobar, C; Lip, GYH; Requeijo, C; Salazar, J; Santero, M, 2021)	2.36
"Dabigatran has a better safety profile and requires less monitoring, but is costlier than warfarin. "	( Cost-Utility Analysis of Dabigatran and Warfarin for Stroke Prevention Among Patients With Nonvalvular Atrial Fibrillation in India. Aggarwal, R; Aghoram, R; Kar, SS; Kumar, SM; Rajasulochana, SR, 2022)	2.47
"Dabigatran has been shown to be noninferior to standard of care (SOC) in terms of efficacy, with similar bleeding rates."	( Just DOAC: Use of direct-acting oral anticoagulants in pediatrics. Cober, MP; Fenn, NE; Hill, C; King, M; Mills, K; Omecene, NE; Pauley, JL; Sierra, CM; Smith, T, 2023)	1.63
"Dabigatran has the potential to preserve perfusion and oxygen delivery to the brain, and to prevent parenchymal Aβ-, thrombin- and fibrin-triggered inflammatory and neurodegenerative processes, leading to synapse and neuron death, and cognitive decline."	( Alzheimer's Disease-Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran. Grossmann, K, 2021)	1.57
"Dabigatran has edge over VKAs like warfarin and acenocoumarol including predictable pharmacokinetic and pharmacodynamic profile, minimal drug-drug and no drug-food interactions while no monitoring is needed."	( Dabigatran - the First Approved DTI for SPAF. Hiremath, JS; Trailokya, A, 2018)	2.64
"Dabigatran use has been linked to gastrointestinal complaints, but it is unknown if this leads to more use of proton pump inhibitors (PPI). "	( Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints. Cannegieter, SC; Huisman, MV; Klok, FA; Lijfering, WM; Rosendaal, FR; Teichert, M; Zielinski, GD, 2018)	1.92
"Dabigatran has stricter prescribing advice than rivaroxaban or apixaban for patients with moderate-to-severe renal impairment."	( Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Graff, J; Harder, S, 2013)	1.11
"Dabigatran has demonstrated promising results for the prevention of strokes in patients with non-valvular atrial fibrillation (NVAF). "	( Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice. Hachiya, H; Hirao, K; Isobe, M; Kawabata, M; Nakamura, T; Sasano, T; Sugiyama, K; Suzuki, M; Tanaka, Y; Yagishita, A; Yokoyama, Y, 2013)	2.07
"Dabigatran has been approved by the FDA for stroke and systemic embolism prevention in non-valvular atrial fibrillation as an alternative to warfarin."	( Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey. DeRemer, CE; Elewa, HF; Gujral, J; Joshua, TV; Keller, K, 2014)	1.36
"Dabigatran has similar efficacy and safety compared with warfarin when used for periprocedural anticoagulation during AF ablation."	( Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Camm, AJ; Hohnloser, SH, 2013)	2.14
"Dabigatran has been associated with greater risk of myocardial infarction (MI) than warfarin. "	( Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Artang, R; Nielsen, JD; Rome, E; Vidaillet, HJ, 2013)	1.83
"Dabigatran has been introduced into clinical practice, although issues like laboratory monitoring, its use in elderly patients, drug and food interactions, and an antidote have not been completely clarified."	( Life-threatening epistaxis and red blood cell polyagglutination under dabigatran. Finsterer, J; Krutisch, G; Stöllberger, C, 2014)	1.36
"Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. "	( Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S, 2014)	2.1
"Dabigatran has similar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the treatment of acute VTE."	( Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S, 2014)	2.1
"Dabigatran has several advantages over warfarin including predictable pharmacokinetics and pharmacodynamics which eliminates the need for routine laboratory monitoring, superiority over warfarin in preventing stroke, or systemic embolism without having an increased risk of bleeding."	( A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience. Henry, BL; Kumar, R; Smith, RE, 2015)	1.36
"Dabigatran has advantages over warfarin including predictable pharmacokinetic/pharmacodynamic profile, minimal drug-drug and no drug-food interactions while no monitoring is needed.The 150 mg dose of dabigatran should be considered in younger patients with a low risk of bleeding and good renal function to achieve a superior ischemic stroke reduction, whereas, the 110 mg dose should be considered in elderly patients, those with mild to moderate renal function or those with high risk of bleeding."	( Dabigatran etexilate in atrial fibrillation. Vora, A, 2013)	2.55
"Dabigatran has also been approved for this indication recently."	( The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism. Akwaa, F; Spyropoulos, AC, 2014)	1.12
"As dabigatran has a favourable benefit-risk profile, it is being increasingly used."	( Dabigatran: patient management in specific clinical settings. Binder, K; Domanovits, H; Eichinger, S; Függer, R; Gollackner, B; Hiesmayr, JM; Huber, K; Kyrle, PA; Lang, W; Perger, P; Quehenberger, P; Roithinger, FX; Schmaldienst, S; Weltermann, A, 2014)	2.36
"Dabigatran has emerged as a promising alternative to vitamin K antagonists (VKAs) in non-valvular atrial fibrillation (NVAF)."	( [Eligibility for dabigatran therapy: the real-life experience of a Tuscany general hospital]. Banfi, R; Fallani, F; Palazzi, N; Pugi, A, 2014)	1.46
"Dabigatran etexilate has a wide therapeutic range that allows for fixed-dose administration without the need for routine monitoring, a requirement of standard vitamin K antagonist (VKA) therapy."	( Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence. Greig, SL; McKeage, K, 2014)	2.57
"Dabigatran etexilate has been tested thoroughly in terms of efficacy and safety in clinical trials and studies, involving 'real-world' cohorts."	( Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation. Dzeshka, MS; Lip, GY, 2015)	1.48
"Dabigatran has been approved for prevention of thromboembolic complications in nonvalvular atrial fibrillation. "	( [Thrombosis of a mechanical prosthetic mitral valve during dabigatran treatment]. Hassager, C; Kjaergaard, J; Saust, LT; Thomsen, JH; Wachtell, K, 2014)	2.09
"Dabigatran has a stable pharmacokinetic profile with minimum drug interactions, and requires no routine laboratory evaluation to measure level of anticoagulation."	( Management of dabigatran-induced bleeding with continuous venovenous hemodialysis. Ali, A; Assaly, R; Hamouda, D; Khan, A; Mbaso, C; Paul, S; Prashar, R; Shah, S, 2015)	1.5
"Dabigatran has been shown, relative to warfarin, to reduce thromboembolic events without increasing bleeding."	( Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist. Alonso-Coello, P; Brosa, M; Carles, M; Garcia-Alamino, JM; Guyatt, G; Souto, JC, 2015)	1.42
"Dabigatran has demonstrated similar efficacy and safety to enoxaparin for VTE prevention in patients undergoing hip and knee arthroplasty, and to warfarin for the treatment of VTE. "	( The evolving role of dabigatran etexilate in clinical practice. Drambarean, B; Hellenbart, E; Lee, J; Nutescu, EA, 2015)	2.18
"Dabigatran has significantly less major or clinically relevant bleeds (MCRBE) compared to rivaroxaban in treatment after index DVT and treatment after DVT or PE combined, but was not significantly different from rivaroxaban after index PE or in extended anticoagulation."	( Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting. De Francesco, M; Hösel, V; Jugrin, AV; Lamotte, M; Sunderland, T; Ustyugova, A, 2016)	1.42
"Dabigatran has an impact on a large panel of used coagulation tests."	( Thrombin time and anti-IIa dabigatran's activity: hypothesis of thrombin time's predictive value. Kaabar, M; Le Guyader, M; Lemaire, P; Pineau Vincent, F, )	1.15
"Dabigatran has a low level of plasma protein binding and has been considered dialyzable."	( The effect of ultrafiltration with cardiopulmonary bypass on the removal of dabigatran from the circulation of adult pigs. Carter, CB; DeNino, WF; Goss, A; Mukherjee, R; Sievert, A; Toole, JM; Uber, WE, 2016)	1.39
"Dabigatran has been shown to be superior to warfarin for stroke prevention in nonvalvular atrial fibrillation (NVAF) but with higher out-of-pocket costs for patients. "	( Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial Fibrillation. Barnes, GD; Froehlich, JB; Hutton, DW; Levine, DA; Salata, BM, 2016)	2.19
"Dabigatran has activity in antagonizing all these effects, thereby impairing tumor growth and progression."	( Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines. Fabris, F; Goss, A; Prandoni, P; Sambado, L; Vianello, F, 2016)	2.6
"Dabigatran etexilate has been studied in clinical trials as prophylaxis for venous thromboembolism in patients undergoing total knee replacement or total hip replacement surgeries, as well as for stroke prevention in patients with atrial fibrillation."	( Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Baetz, BE; Spinler, SA, 2008)	2.51
"Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE). "	( Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Caprini, JA; Eriksson, BI; Plumb, JM; Roskell, NS; Wolowacz, SE, 2009)	2.11
"Dabigatran has been shown to be a potent, competitive, and reversible inhibitor of thrombin, inhibiting both thrombin activity and generation."	( Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clemens, A; Stangier, J, )	1.1
"Dabigatran has a predictable pharmacokinetic profile, allowing for a fixed-dose regimen without the need for routine coagulation monitoring."	( Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Clemens, A; Feuring, M; Haertter, S; Liesenfeld, KH; Stangier, J; van Ryn, J; Wienen, W, 2010)	2.52
"Dabigatran has a low potential for drug-drug interactions and is predominantly renally excreted."	( Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Clemens, A; Eisert, WG; Hauel, N; Stangier, J; van Ryn, J; Wienen, W, 2010)	2.52
"Dabigatran has also demonstrated efficacy in the prevention of venous thromboembolism in patients undergoing total hip or knee replacement surgery as well as the prevention of recurrent venous thromboembolism, although these are not current Food and Drug Administration-approved indications."	( Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin. Cheng-Lai, A; Tran, A, )	2.3
"Dabigatran has predictable pharmacokinetics, without significant drug and food interactions, rapid onset, and requires twice-daily administration without the need for monitoring."	( Dabigatran in atrial fibrillation: pharmacology and clinical trials. Ezekowitz, MD; Nagarakanti, R, 2011)	2.53
"Dabigatran etexilate has demonstrated efficacy in several clinical studies in preventing venous thromboembolism (VTE) for patients undergoing total hip or knee replacement, in preventing strokes in patients with nonvalvular atrial fibrillation, and in treating acute VTE."	( Dabigatran etexilate: A novel oral direct thrombin inhibitor. Blommel, AL; Blommel, ML, 2011)	2.53
"Dabigatran has a pharmacokinetic profile that produces predictable anticoagulation responses, does not undergo CYP 450 metabolism, has few drug-drug and drug-food interactions, and does not require frequent laboratory monitoring of clotting parameters."	( Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. Babu, KM; Boyer, EW; Brown, RS; Ganetsky, M; Salhanick, SD, 2011)	2.53
"Dabigatran has been approved in the United States for prevention of stroke in patients with nonvalvular atrial fibrillation and in the European Union and other countries for primary prevention of thromboembolic events after total knee or hip replacement."	( Dabigatran etexilate: what do hospitalists need to know? Faltas, B; Streiff, M; Zeidan, A, 2012)	2.54
"Dabigatran has been granted authorisation by the FDA in non-valvular atrial fibrillation (RE-LY trial) while rivaroxaban is expecting approval in this same indication (ROCKET trial)."	( [Pharmacologic heterogeneity of new anticoagulants]. Combe, S; Conard, J; Flaujac, C; Horellou, MH; Samamaa, MM, 2011)	1.09
"Dabigatran has been investigated for the treatment of established venous thromboembolism and prevention of recurrence in patients undergoing hip or knee replacement, as well as for stroke prevention in atrial fibrillation patients with a moderate and high risk of stroke."	( New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders. Dahl, OE, 2012)	1.38
"As dabigatran (Pradaxa) has recently been approved by the Food and Drug Administration, many spine specialists are not familiar with this agent. "	( Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on Pradaxa (dabigatran). Dieterichs, C; Gaudu, T; Geck, M; Stokes, J; Truumees, E, 2012)	1.22
"Dabigatran has predictable and consistent anticoagulant effects and does not require routine coagulation monitoring or dose titration."	( Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. Burness, CB; McKeage, K, 2012)	2.54
"Dabigatran has been introduced into the prevention of stroke in patients with atrial fibrillation. "	( [Dabigatran and emergency operation on a peritonitis patient]. Ilmakunnas, M; Lassila, R; Louhimo, J, 2012)	2.73
"Dabigatran has the advantage of providing rapid and steady anticoagulation without requiring laboratory monitoring. "	( Dabigatran: a primer for neurosurgeons. Fugate, JE; Lanzino, G; McBane, RD; Rabinstein, AA, 2013)	3.28
"Dabigatran, however, has not been compared to the home-monitoring."	( Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison. Alonso-Coello, P; Guyatt, G; Zhou, Q, 2012)	1.36
"Dabigatran has been rapidly adopted into ambulatory practice in the United States, primarily for treatment of atrial fibrillation, but increasingly for off-label indications. "	( National trends in oral anticoagulant use in the United States, 2007 to 2011. Alexander, GC; Kirley, K; Kornfield, R; Qato, DM; Stafford, RS, 2012)	1.82
"Dabigatran has also been approved in several countries for the prevention of venous thrombosis in patients undergoing total knee or hip replacement."	( [Waiting for the new oral anticoagulants: questions and answers about dabigatran]. Agnelli, G; Verdecchia, P, 2013)	1.35
"Dabigatran has been shown to specifically and reversibly inhibit thrombin, the key enzyme in the coagulation cascade."	( Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Stangier, J, 2008)	1.29

Actions

Dabigatran provides an increase of 0.331 life years and 0.354 quality-adjusted life years for each patient. Dabig atran did not increase the risk of myocardial infarction or major gastrointestinal bleeding in all age groups when compared with warfarin.

Excerpt	Reference	Relevance
"Dabigatran-induced increase in the systolic blood pressure was not affected by PAR-1 modulators."	( Role of protease-activated receptor-1 (PAR-1) in the glomerular filtration barrier integrity. Biederman, L; Brodsky, SV; Ivanov, I; Kerlin, BA; Medipally, A; Parikh, S; Rovin, B; Satoskar, AA; Xiao, M, 2022)	1.44
"Dabigatran had a lower risk of stroke/SE and a similar risk of MB when compared with rivaroxaban."	( Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity. Atreja, N; Dhamane, AD; Di Fusco, M; Emir, B; Ferri, M; Gutierrez, C; Keshishian, A; Russ, C; Yuce, H, 2023)	1.63
"Dabigatran showed lower risk of all-cause mortality than warfarin and of intracranial bleeding than rivaroxaban."	( Efficacy and Safety of Oral Anticoagulants in Older Adult Patients With Atrial Fibrillation: Pairwise and Network Meta-Analyses. Chen, K; Chen, X; Chen, Z; Ju, J; Li, Q; Ma, D; Tian, W; Wang, T; Wang, X; Xu, H; Zhang, J, 2023)	1.63
"Dabigatran users had lower incidence rate for stroke (0.65 vs 1.06) and bleed (1.69 vs 2.20), stroke (0.0006 vs 0.0011, p < 0.001) and bleed-specific hospitalizations (0.002 vs 0.003, p = 0.008), and stroke (0.03 vs 0.04, p < 0.001) and bleed-specific outpatient visits (0.07 vs 0.08, p = 0.018), and significantly lower non-persistence (62.1% vs 66.3%, p < 0.001)."	( Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin. Arora, P; Gandhi, P; Gilligan, AM; Henriques, C; Sander, S; Smith, DM; Song, X; Wang, C, 2019)	1.43
"Dabigatran had lower adherence (PDC = 0.76, 0.64, 0.57) compared with rivaroxaban (PDC = 0.83, 0.73, 0.66; P < 0.001) and apixaban (PDC = 0.82, 0.72, 0.66; P < 0.001) at 3, 6, and 9 months of follow-up and twice the number of switches to either other anticoagulants or antiplatelet therapy. "	( Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data. Brown, JD; Shewale, AR; Talbert, JC, 2017)	2.2
"Dabigatran users had lower hazard of MH compared with warfarin users among patients with low MCC (hazard ratio [HR], 0.62; 95% CI, 0.47-0.83; P < .001; for MCC defined as low CHA2DS2-VASc score), and similar risk in patients with moderate to high MCC."	( Assessment of Outcomes of Treatment With Oral Anticoagulants in Patients With Atrial Fibrillation and Multiple Chronic Conditions: A Comparative Effectiveness Analysis. Chaudhury, P; Mentias, A; Shantha, G; Vaughan Sarrazin, MS, 2018)	1.2
"The dabigatran group had a lower frequency of minor bleeding and number of medical appointments than the warfarin group, without more embolic events or major bleeding."	( Dabigatran and warfarin in nonvalvular atrial fibrillation or atrial flutter in outpatient clinic practice in Brazil. Jesus, P; Monteiro, JMC; Oliveira Filho, J; San-Martin, DL; Silva, BCG; Souza, IFB, 2019)	2.51
"Dabigatran provides an increase of 0.331 life years and 0.354 quality-adjusted life years for each patient. "	( [Economic evaluation of dabigatran for stroke prevention in patients with non-valvular atrial fibrillation]. Ferreira, J; Rocha, E; Silva Miguel, L, )	1.88
"Dabigatran may increase the likelihood of gastrointestinal bleeds."	( Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS, 2014)	2.06
"Dabigatran did not increase the risk of myocardial infarction or major gastrointestinal bleeding in all age groups when compared with warfarin."	( Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation. Chan, YH; Chang, SH; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wu, LS; Yeh, YH; Yen, KC, 2016)	1.41
"Dabigatran did not increase the risk of major gastrointestinal bleeding or myocardial infarction compared with warfarin."	( Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation. Chan, YH; Chang, SH; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wu, LS; Yeh, YH; Yen, KC, 2016)	1.41

Treatment

Dabigatran-treated patients with stroke had significantly lower anti-IIa levels when compared with the trough (40.7 ± 36.9 vs. 40.7) Dabig atran treatment paradoxically increased area under the concentration-time curve and peak values although rivaroxaban decreased peak values (P < 0.01). Dabigsatran treatment had no effect on tyrosine hydroxylase levels.

Excerpt	Reference	Relevance
"Dabigatran-treated patients with stroke had significantly lower anti-IIa levels when compared with the trough (40.7 ± 36.9 vs. "	( Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study. Babálová, L; Bolek, T; Dluhá, J; Hajaš, G; Kubisz, P; Kurča, E; Mokáň, M; Nosáľ, V; Petrovičová, A; Samoš, M; Sivák, Š; Škorňová, I; Stančiaková, L; Staško, J, 2022)	2.16
"Dabigatran treatment paradoxically increased area under the concentration-time curve and peak values although rivaroxaban decreased peak values (P < 0.01)."	( Effects of rivaroxaban and dabigatran on global hemostasis in patients with atrial fibrillation. Al-Khalili, F; Ammar, M; Antovic, A; Antovic, JP; Jakovljevic, V; Malmström, RE; Petkovic, A; Pruner, I; Soutari, N; Vranic, A; Zdravkovic, N, 2020)	1.58
"Dabigatran treatment had no effect on tyrosine hydroxylase levels."	( Inhibiting thrombin improves motor function and decreases oxidative stress in the LRRK2 transgenic Drosophila melanogaster model of Parkinson's disease. Grammas, P; Iannucci, J; Johnson, SL; Seeram, NP, 2020)	1.28
"All dabigatran-treated animals had RBC casts in the kidney regardless of the GFR modification."	( Role of glomerular filtration rate-modifying drugs in the development of anticoagulant-related nephropathy. Brodsky, SV; Ivanov, I; Medipally, AK; Qaisar, S; Rovin, BH; Satoskar, AA; Xiao, M, 2021)	1.1
"Dabigatran-treated patients who bled had significantly higher anti-IIa levels when compared with trough (261.4 ± 163.7 vs."	( Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study. Bolek, T; Galajda, P; Kamenišťáková, A; Kubisz, P; Mokáň, M; Samoš, M; Škorňová, I; Stančiaková, L; Staško, J, 2021)	1.34
"In dabigatran-treated patients (216 on 110 mg bid and 194 on 150 mg bid), the duration of dabigatran interruption was a median of 96 (IQR: 61-158) h."	( Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. Birnie, DH; Connolly, SJ; Coutu, B; Douketis, J; Essebag, V; Ezekowitz, M; Healey, JS; Hohnloser, SH; Lip, GYH; Moriarty, A; Oldgren, J; Parkash, R; Proietti, R; Wang, J, 2017)	1.36
"Dabigatran etexilate treatment led to a significant increase in the duration of wound secretion in both arthroplasty groups when compared to apixaban: wound secretion lasted 1.2 days longer on average in the dabigatran etexilate group than in the apixaban group (4.1 ± 2.1 vs. "	( A comparison of apixaban and dabigatran etexilate for thromboprophylaxis following hip and knee replacement surgery. Fink, B; Mayer, A; Schuster, P, 2017)	2.19
"Dabigatran treatment was as a predictor for lower cardiology costs and lower total hospital care costs in AF patients that initiated oral anticoagulation."	( Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in The Netherlands. Cao, Q; Jacobs, MS; Jansman, FGA; Postma, MJ; Tieleman, RG; van Hulst, M; van Leent, MWJ, 2017)	2.11
"The dabigatran treatment discontinued and warfarin was initiated and, in the follow-ups, the thrombus was observed to shrink, and complete resolution was seen 6 weeks after treatment with warfarin."	( Newly developed left ventricular apical thrombus under dabigatran treatment. Adar, A; Cakan, F; Onalan, O, 2018)	1.21
"Dabigatran treatment was initiated after the confirmation of no change in hematoma size and the follow-up CT revealed a reduction in the hematoma."	( [A Case of Successful Drug Management with Dabigatran and Idarucizumab to Address Embolic and Hemorrhagic Complications for Asymptomatic and Traumatic Subdural Hematoma with Non-valvular Atrial Fibrillation]. Eto, A; Hiraoka, F; Nii, K; Tsutsumi, M, 2018)	1.46
"Dabigatran-treated patients with acute ischemic stroke who received intravenous recombinant tissue plasminogen activator (rt-PA) after idarucizumab reversal were enrolled in the retrospective nationwide study. "	( Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan. Chen, CL; Chen, HM; Chen, LA; Chen, PL; Chou, PC; Fang, CW; Hsieh, CY; Li, YH; Lu, CM; Shih, YS; Sun, MC; Tsai, YT; Tsao, CR; Yeh, JT, 2019)	2.18
"Dabigatran treatment was discontinued in one patient because of undetectable dabigatran levels despite dose escalation."	( Use of dabigatran with antiretrovirals. Holloway, C; O'Dwyer, E; Perram, J, 2019)	1.69
"Dabigatran-treated animals showed increased adipocyte hypertrophy, but reduced numbers of pro-inflammatory M1-polarized macrophages in the adipose tissue. "	( Decreased M1 macrophage polarization in dabigatran-treated Ldlr-deficient mice: Implications for atherosclerosis and adipose tissue inflammation. Feldmann, K; Fender, AC; Fischer, JW; Gerfer, S; Grandoch, M; Hartwig, S; Kohlmorgen, C; Lehr, S; Nagy, N; Valentin, B, 2019)	2.22
"Dabigatran treatment reduces pro-inflammatory M1 macrophages in atherosclerotic lesions, thereby contributing to plaque stabilizing and atheroprotective effects of the thrombin inhibitor. "	( Decreased M1 macrophage polarization in dabigatran-treated Ldlr-deficient mice: Implications for atherosclerosis and adipose tissue inflammation. Feldmann, K; Fender, AC; Fischer, JW; Gerfer, S; Grandoch, M; Hartwig, S; Kohlmorgen, C; Lehr, S; Nagy, N; Valentin, B, 2019)	2.22
"Dabigatran as first-line treatment compared with warfarin for the use of stroke prevention in patients with AF is deemed cost-effective when used in accordance with its registered indication in the SA private sector."	( Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. Bergh, M; Marais, CA; Miller-Jansön, H; Salie, F; Stander, MP, 2013)	2.15
"Dabigatran treatment was discontinued, and bronchial artery embolisation (BAE) was performed twice."	( Massive haemoptysis following dabigatran administration in a patient with bronchiectasis. Hayama, M; Inoue, H; Mio, T; Wada, H, 2014)	1.41
"Dabigatran treatment did not prevent or ameliorate the no-reflow phenomenon, suggesting that fibrin does not play a major role in the development of microvascular obstruction."	( Dabigatran treatment: effects on infarct size and the no-reflow phenomenon in a model of acute myocardial ischemia/reperfusion. Hale, SL; Kloner, RA, 2015)	2.58
"Dabigatran treatment discontinuation occurred in a total of 124 patients during follow-up (25.8 per 100 patient-years in Kaplan Meier analysis)."	( Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Beyer-Westendorf, J; Daschkow, K; Ebertz, F; Endig, H; Förster, K; Gelbricht, V; Köhler, C; Michalski, F; Pannach, S; Sahin, K; Tittl, L; Weiss, N; Werth, S, 2015)	1.43
"Dabigatran treatment within 24 hours of minor stroke is feasible. "	( Dabigatran Therapy in Acute Ischemic Stroke Patients Without Atrial Fibrillation. Buck, B; Butcher, K; Gioia, L; Jeerakathil, T; Kate, M; Shuaib, A; Sivakumar, L, 2015)	3.3
"Dabigatran treatment caused systemic thrombin inhibitory activity corresponding with dabigatran levels reported in human trials."	( Effect of the oral thrombin inhibitor dabigatran on allergic lung inflammation induced by repeated house dust mite administration in mice. Berkhout, LC; de Boer, JD; de Stoppelaar, SF; Meijers, JC; Ottenhoff, R; Roelofs, JJ; van der Poll, T; van't Veer, C; Yang, J, 2015)	1.41
"For dabigatran-treated patients, idarucizumab recently has been approved for clinical use in cases of life-threatening or uncontrolled bleeding or when patients require emergency surgery or urgent procedures, both associated with a high risk of bleeding."	( Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols. Fanikos, J; Huisman, MV, 2016)	0.92
"For dabigatran-treated patients, idarucizumab recently has been approved for clinical use in cases of life-threatening or uncontrolled bleeding or when patients require emergency surgery or urgent procedures, both associated with a high risk of bleeding."	( Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols. Fanikos, J; Huisman, MV, 2016)	0.92
"Dabigatran etexilate treatment exhibited evidence of antitumor activity with a 50% reduction in tumor volume at 4 weeks following orthotopic injection of 4T1 cells in syngeneic Balb/c mice with no weight loss in treated mice."	( Use of dabigatran etexilate to reduce breast cancer progression. Chernick, M; DeFeo, K; Gilmour, SK; Hayes, C; Ryn, JV, 2010)	1.54
"Dabigatran-treated patients had lower acute care and long-term follow-up costs per patient ($52,314 vs."	( Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV, 2012)	2.54
"Dabigatran-treated PVs had slower spontaneous activity (1.1±0.1 Hz; n=10; P=0.0001 versus control)."	( Dabigatran and thrombin modulate electrophysiological characteristics of pulmonary vein and left atrium. Chang, CJ; Chen, SA; Chen, YC; Chen, YJ; Kao, YH; Lin, YK, 2012)	2.54
"Dabigatran treatment (110 mg or 150 mg BID) may not provide sufficient anticoagulation during PCI. "	( A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients. de Maat, MP; Friedman, J; Jones, RL; Leebeek, FW; Lindeboom, W; Regar, E; Reilly, P; Smits, P; ten Berg, JM; Ulmans, VA; Verheugt, FW; Vranckx, P, 2013)	2.15
"Pre-treatment with dabigatran was performed."	( Effects of intermittent hypoxia with thrombin in an in vitro model of human brain endothelial cells and their impact on PAR-1/PAR-3 cleavage. Perek, N; Puech, C; Roche, F; Zolotoff, C, 2022)	1.04
"Treatment with dabigatran, an oral direct thrombin inhibitor, reduces the virulence of Staphylococcus aureus in in vitro and in vivo models. "	( Dabigatran and the Risk of Staphylococcus aureus Bacteremia: A Nationwide Cohort Study. Andersen, PS; Bruun, NE; Bundgaard, H; Butt, JH; Fosbøl, EL; Gerds, TA; Gislason, GH; Iversen, K; Køber, L; Larsen, AR; Olesen, JB; Petersen, A; Skov, RL; Torp-Pedersen, C; Verhamme, P, 2021)	2.42
"Treatment with dabigatran was associated with a significantly lower incidence rate of SAB compared with treatment with factor Xa-inhibitors."	( Dabigatran and the Risk of Staphylococcus aureus Bacteremia: A Nationwide Cohort Study. Andersen, PS; Bruun, NE; Bundgaard, H; Butt, JH; Fosbøl, EL; Gerds, TA; Gislason, GH; Iversen, K; Køber, L; Larsen, AR; Olesen, JB; Petersen, A; Skov, RL; Torp-Pedersen, C; Verhamme, P, 2021)	2.42
"Treatment with dabigatran 150/110 mg BID or rivaroxaban 15/10 mg QD was associated with a significantly lower risk of major bleeding, but not any bleeding, than warfarin."	( Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data. Izumi, N; Katada, J; Kohsaka, S; Murata, T; Terayama, Y; Wang, F, 2017)	1.09
"Treatment with dabigatran significantly inhibited the P65 of nuclear factor κB, tumor necrosis factor α, interleukin (IL)‑1β and IL‑6 activities and significantly enhanced the catalase and superoxide dismutase activities in the AMI rabbits."	( Effects of dabigatran regulates no‑reflow phenomenon in acute myocardial infarction mice through anti‑inflammatory and anti‑oxidative activities and connective tissue growth factor expression. Li, H; Ma, C; Sheng, J; Song, K; Wang, Y, 2018)	1.21
"Treatment with dabigatran in patients with PTD having chronic chronometric hypercoagulation and structural hypocoagulation before the administration of the drug is fraught with excessive anticoagulation and a high risk of clinically significant bleeding."	( Features of Pharmacodynamics of the Anticoagulant Dabigatran in Secondary Thrombophilia. Kairov, GT; Kotlovskaya, LY; Solovev, MA; Udut, VV, 2018)	1.07
"Treatment with dabigatran requires less monitoring than warfarin and may therefore enhance the care of this patient group."	( Use of dabigatran to prevent stroke in patients with atrial fibrillation. Mooney, T, )	0.93
"Treatment with dabigatran (220 mg per day) was initiated because of atrial fibrillation."	( [Successful thrombolysis without hemorrhage in a patient with cardioembolic stroke under dabigatran treatment-a case report and review of literature]. Inaishi, J; Mano, Y; Nogawa, S; Okada, S; Yoshizaki, T, 2014)	0.96
"Treatment with dabigatran and rivaroxaban does not appear to be associated with changes in markers of platelet reactivity or systemic inflammation."	( The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers. Gutstein, A; Haim, M; Kadmon, E; Kornowski, R; Leshem-Lev, D; Lev, EI; Lev, EL; Mager, A; Orvin, KL; Vaduganathan, M; Zemer-Wassercug, N, 2015)	1.12
"Co-treatment with dabigatran etexilate and low dose CP also significantly decreased the number of arginase(+)Gr-1(+)CD11b(+) myeloid derived suppressor cells as well as levels of TGF-β in spleens from tumor bearing mice."	( Thrombin inhibition and cyclophosphamide synergistically block tumor progression and metastasis. Alexander, ET; Gilmour, SK; Goss, A; Hayes, CS; Minton, AR; Van Ryn, J, 2015)	0.74
"Treatment with dabigatran etexilate resulted in a significant reduction of the mean area of atherosclerotic lesions in the aortic sinus in both the young mice (11,176±1,500 μm(2) (control) versus 3,822±836 μm(2) (dabigatran etexilate), P<0.05) and selectively in the older mice at 28 weeks (234,099±13,500 μm(2) (control) versus 175,226±16,132 μm(2) (dabigatran etexilate), P<0.05). "	( Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice. Bea, F; Cabbage, S; Ieronimakis, N; Preusch, MR; Reyes, M; Ricks, J; Rosenfeld, ME; van Ryn, J; Wijelath, ES, 2015)	2.21
"Co-treatment with dabigatran etexilate and cisplatin significantly decreased the number of Gr1+/CD11b+ myeloid derived suppresser cells and CD11b+/CD11c+ dendritic cells in the ascites of ID8 tumor-bearing mice."	( Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment. Alexander, ET; Gilmour, SK; Minton, AR; Peters, MC; van Ryn, J, 2016)	0.76
"Treatment with dabigatran does not require monitoring of haemostasis, whereas vitamin K inhibitors necessitate close INR monitoring."	( Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients. , 2012)	2.16

Toxicity

Dabigatran offers a number of advantages over existing oral and parenteral anticoagulants. Challenges exist for clinicians who must ensure its safe and effective use.

Excerpt	Reference	Relevance
"To determine the safe therapeutic range of dabigatran etexilate following total hip replacement."	( Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. Ahnfelt, L; Dahl, OE; Eriksson, BI; Hermansson, K; Kälebo, P; Kohlbrenner, V; Nehmiz, G; Stangier, J, 2004)	0.82
" New oral anticoagulants that require no monitoring and can be administered in a fixed dose without drug-drug and drug-food interactions would clearly offer practical advantages if shown to be safe and effective."	( [Dabigatran (Pradaxa): efficacy and safety]. Bellamy, L; Rosencher, N, 2009)	1.26
" Although dabigatran offers a number of advantages over existing oral and parenteral anticoagulants, challenges exist for clinicians who must ensure its safe and effective use."	( Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. Dager, WE; Fanikos, J; Gulseth, MP; Nutescu, EA; Spinler, SA; Wittkowsky, AK, 2011)	2.21
" Tolerability was good, with only mild and reversible adverse events during the treatment."	( Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. Clemens, A; Feuring, M; Härtter, S; Sennewald, R; Stangier, J; van Ryn, J; Yamamura, N, 2012)	0.67
" ACS data were tabulated from investigator-reported serious adverse events using ACS-specific Medical Dictionary for Regulatory Authorities (MedDRA) lower-level terms."	( Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials. Barsness, GW; Caprini, J; Clemens, A; Eriksson, BI; Feuring, M; Hantel, S; Schnee, J; Smith, JJ, 2012)	0.62
" Dabigatran at a dose of 110mg twice daily was safe for AF ablation in patients with a relatively low risk of thromboemboli, suggesting that it may become an alternative to warfarin in those patients."	( Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Fuke, E; Hayano, M; Kaseno, K; Kumagai, K; Miki, Y; Naito, S; Nakamura, K; Nishiuchi, S; Oshima, S; Sakamoto, T; Sasaki, T; Tada, H; Tsukada, N; Yamashita, E, 2012)	1.56
"Dabigatran, an oral thrombin inhibitor, and rivaroxaban and apixaban, oral factor Xa inhibitors, have been found to be safe and effective in reducing stroke risk in patients with atrial fibrillation."	( Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S, 2012)	1.82
" We analyzed data from this trial to quantify upper gastrointestinal nonbleeding adverse events (NB-UGI AEs)."	( Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Aisenberg, J; Bytzer, P; Connolly, SJ; Ezekowitz, M; Formella, S; Reilly, PA; Yang, S, 2013)	0.62
"Peri-procedural anticoagulation therapy with dabigatran for RFCA of AF was equally safe and effective compared with warfarin and heparin bridging."	( Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. Fujiwara, R; Fukuzawa, K; Hirata, K; Imamura, K; Itoh, M; Kiuchi, K; Matsumoto, A; Nakanishi, T; Suzuki, A; Takami, K; Takami, M; Takei, A; Yamashita, S; Yoshida, A, 2013)	2.09
"We described the changes in the attitudes of attending physicians toward dabigatran prescription after the blue letter in a specialized hospital for cardiovascular care in Japan, which, we believe, involve useful information for safe use of dabigatran in a real-world clinical setting."	( "Blue letter effects": Changes in physicians' attitudes toward dabigatran after a safety advisory in a specialized hospital for cardiovascular care in Japan. Aizawa, T; Kano, H; Kirigaya, H; Koike, A; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Takai, H; Tanabe, H; Uejima, T; Yajima, J; Yamashita, T, 2013)	0.86
" Orally administered dabigatran after discharge from hospital appears safe for venous thromboembolism prophylaxis after RALP."	( Dabigatran for thromboprophylaxis after robotic assisted laparoscopic prostatectomy: retrospective analysis of safety profile and effect on blood coagulation. Joutsi-Korhonen, L; Lassila, R; Pétas, A; Rannikko, AS; Säily, VM; Taari, K, 2014)	2.16
" Dabigatran appears to be safe and effective for peri-procedural anticoagulation in CA of AF."	( Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Bahmaid, RA; Bin Abdulhak, AA; Garbati, MA; Khan, AR; Sanders, SU; Spertus, JA; Steigerwalt, KE; Tleyjeh, IM; Wimmer, AP, 2013)	1.58
" The rate of occurrences of adverse effects and bleeding were lower than those seen in the RE-LY trial."	( A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation. Hussin, A; Kaur, S; Muhammad, Z; Omar, R; Rusani, BI; Umadevan, D; Yap, LB, 2014)	0.65
"Evaluate dabigatran adverse event reports with a reported bleeding event and/or reported fatal outcome compared with warfarin."	( Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval. Bress, A; McConeghy, KW; Nutescu, EA; Qato, DM; Wing, C, 2014)	1.18
"Retrospective analysis of the FDA Adverse Event Reporting System (FAERS) database."	( Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval. Bress, A; McConeghy, KW; Nutescu, EA; Qato, DM; Wing, C, 2014)	0.76
"Dabigatran was the primary suspected agent in 9029 adverse reports."	( Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval. Bress, A; McConeghy, KW; Nutescu, EA; Qato, DM; Wing, C, 2014)	2.21
"The objective of this study was to analyse spontaneous adverse event (SAE) reports associated with the oral anticoagulant dabigatran from Australia, Canada and USA and to examine concomitant medicine use."	( An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran. Barratt, JD; Caughey, GE; Kalisch Ellett, LM; McDonald, CJ, 2015)	0.83
"Spontaneous adverse event national databases from Australia, Canada and the USA were used to examine all reports of adverse events associated with dabigatran from 1st August 2005 to 31st March 2013."	( An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran. Barratt, JD; Caughey, GE; Kalisch Ellett, LM; McDonald, CJ, 2015)	0.82
" Gastrointestinal (GI) disorders were the most commonly reported adverse event, ranging from 27."	( An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran. Barratt, JD; Caughey, GE; Kalisch Ellett, LM; McDonald, CJ, 2015)	0.62
"A large proportion of adverse events were associated with concomitant therapies, which may have placed the patient at increased risk of harm."	( An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran. Barratt, JD; Caughey, GE; Kalisch Ellett, LM; McDonald, CJ, 2015)	0.62
" Heartburn, the most frequent adverse effect, was reported by 25 patients (22%)."	( Safety of dabigatran in an elderly population: single center experience in Italy. Aita, A; Angeli, F; Bartolini, C; De Filippo, V; di Giacomo, L; Martone, S; Molini, G; Reboldi, G; Valecchi, F; Verdecchia, P, 2015)	0.82
"Compared with warfarin, periprocedural anticoagulation with dabigatran resulted in fewer minor hemorrhages and total adverse events after AF ablation."	( Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD, 2015)	0.66
" Rywaroxaban more frequently causes minor bleeding, whereas treatment with dabigatran is associated with more frequent gastrointestinal adverse symptoms."	( [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation]. Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L, 2014)	0.89
" Overall adverse event (AE) frequency was similar for idarucizumab and placebo, and no relationship with idarucizumab dose was observed."	( A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Glund, S; Lang, B; Moschetti, V; Norris, S; Ramael, S; Reilly, P; Schmohl, M; Stangier, J; van Ryn, J, 2015)	0.62
"Dabigatran could be a safe and potentially more effective alternative to warfarin in patients with atrial fibrillation managed in routine practice settings."	( Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. Brookhart, MA; Fang, G; Farley, JF; Gehi, AK; Lauffenburger, JC; Rhoney, DH, 2015)	2.15
" The objective of this study was to evaluate the interaction between aging and dabigatran- and warfarin-induced gastrointestinal (GI) and nervous system hemorrhage using data available in the FDA Adverse Event Reporting System (FAERS) database."	( Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age. Abe, J; Kato, Y; Kinosada, Y; Nagasawa, H; Nakamura, M; Nakayama, Y; Suzuki, T; Suzuki, Y; Ueda, N; Umetsu, R, 2015)	1.01
"Uninterrupted dabigatran therapy in CA for AF thus may be a safe and effective anticoagulant therapy, and appears to be closely similar to continuous warfarin; however, it is essential to pay close attention to the APTT values when using dabigatran during CA."	( Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation. Fujita, M; Hirai, M; Inden, Y; Ishikawa, S; Kato, H; Miyoshi, A; Murohara, T; Nagao, T; Ohguchi, S; Okumura, S; Shimano, M; Yamamoto, T; Yanagisawa, S; Yoshida, N, 2015)	1.05
"To examine the risk of gastrointestinal adverse effects associated with dabigatran use compared with warfarin among patients with atrial fibrillation (AF)."	( Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study. Bonde, AN; Fosbøl, EL; Gislason, GH; Hansen, ML; Lamberts, M; Lip, GY; Olesen, JB; Staerk, L; Torp-Pedersen, C, 2015)	0.91
" The primary endpoint was incidence of drug-related adverse events, analysed in all randomly assigned participants who received at least one dose of dabigatran etexilate."	( Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Gansser, D; Glund, S; Gruenenfelder, F; Kreuzer, J; Lang, B; Moschetti, V; Norris, S; Ramael, S; Reilly, P; Schmohl, M; Stangier, J; van Ryn, J, 2015)	0.83
" Drug-related adverse events were all of mild intensity and reported in seven participants: one in the 1 g idarucizumab group (infusion site erythema and hot flushes), one in the 5 g plus 2·5 g idarucizumab group (epistaxis); one receiving placebo (infusion site haematoma), and four during dabigatran etexilate pretreatment (three haematuria and one epistaxis)."	( Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Gansser, D; Glund, S; Gruenenfelder, F; Kreuzer, J; Lang, B; Moschetti, V; Norris, S; Ramael, S; Reilly, P; Schmohl, M; Stangier, J; van Ryn, J, 2015)	0.81
" We studied time to cardioversion, risk of adverse events, and risk of readmission with atrial fibrillation after cardioversion according to anticoagulation therapy."	( Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study. Gislason, GH; Hansen, ML; Lindhardt, TB; Olesen, JB; Pallisgaard, JL; Schjerning, AM; Staerk, L; Torp-Pedersen, C, 2015)	0.68
"Anticoagulation treatment with dabigatran allows shorter time to cardioversion for atrial fibrillation than warfarin, and appears to be an effective and safe alternative treatment strategy to warfarin."	( Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study. Gislason, GH; Hansen, ML; Lindhardt, TB; Olesen, JB; Pallisgaard, JL; Schjerning, AM; Staerk, L; Torp-Pedersen, C, 2015)	0.96
"9%) of MonaldiCare population reported adverse effects from treatment with dabigatran, of whom 121 patients (5."	( Efficacy and safety of dabigatran in a "real-life" population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry. Bianchi, V; Calabrò, P; Cavallaro, C; D'Onofrio, A; De Vivo, S; Nigro, G; Russo, V; Santangelo, L; Sarubbi, B; Vecchione, F, 2015)	0.96
"Current methods for prospective drug safety monitoring focus on determining whether and when to generate safety alerts indicating that a new drug may be less safe than a comparator."	( Developing alerting thresholds for prospective drug safety monitoring. Gagne, JJ; Glynn, RJ; Schneeweiss, S; Wangge, G, 2016)	0.43
" Non-vitamin K antagonist oral anticoagulants (NOACs) have emerged as efficacious, safe and convenient stroke prevention agents."	( Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Batson, S; Kachroo, S; Lip, GY; Liu, LZ; Liu, X; Mitchell, SA; Phatak, H, 2016)	0.63
"Anticoagulation with NOAC with a short period of periprocedural interruption without bridging with LMWH seems safe and well-tolerated."	( Safety of novel oral anticoagulants in catheter ablation of atrial fibrillation. Hansen, PS; Sanchez, R; Walfridsson, H, 2016)	0.43
" This study evaluates the total complications and the impact of novel oral anticoagulants (NOACs) compared to phenprocoumon on adverse events in the setting of PVI using CB."	( The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients. Dahmen, A; Gorr, E; Hoppe, C; Horlitz, M; Keskin, K; Koektuerk, B; Schoett, M; Turan, CH; Turan, RG; Yang, A; Yorgun, H, 2016)	0.43
"The incidence of adverse events in PVI using the second-generation CB with the periprocedural administration of NAOCs was not significantly different compared to phenprocoumon."	( The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients. Dahmen, A; Gorr, E; Hoppe, C; Horlitz, M; Keskin, K; Koektuerk, B; Schoett, M; Turan, CH; Turan, RG; Yang, A; Yorgun, H, 2016)	0.43
" All NOACs seem to be safe and effective alternatives to warfarin in a routine care setting."	( Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Kjældgaard, JN; Larsen, TB; Lip, GY; Nielsen, PB; Skjøth, F, 2016)	0.43
" No bleeding events, deaths or drug-related serious adverse events (AEs) were reported; three treatment-emergent AEs, all gastrointestinal-related, occurred in two patients."	( Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study. Belletrutti, M; Cronin, L; Haertter, S; Halton, JM; Lehr, T; Lobmeyer, MT; Mitchell, LG, 2016)	0.69
"Low-dose DE was safe in AF patients with mildly reduced CCr."	( Safety of low-dose dabigatran in patients with atrial fibrillation and mild renal insufficiency. Ako, J; Fujiishi, T; Fukaya, H; Horiguchi, A; Igarashi, T; Ishizue, N; Kishihara, J; Murakami, M; Nakamura, H; Nishinarita, R; Niwano, S; Oikawa, J; Satoh, A; Yoshizawa, T, 2017)	0.78
" In conclusion, DOACs are effective and safe for the extended treatment of VTE, and may reduce the risk of all-cause mortality."	( Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism. Benedetti, R; Fenoglio, L; Imberti, D; Pomero, F, 2016)	0.43
" These findings provide initial evidence that idarucizumab could provide a safe and effective means of reversing anticoagulant activity in patients treated with dabigatran in need of emergency surgery or in emergency bleeding situations."	( Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects. Glund, S; Grottke, O; Reilly, PA; Stangier, J; van Ryn, J, 2016)	0.89
" These findings provide initial evidence that idarucizumab could provide a safe and effective means of reversing anticoagulant activity in patients treated with dabigatran in need of emergency surgery or in emergency bleeding situations."	( Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. Glund, S; Grottke, O; Reilly, PA; Stangier, J; van Ryn, J, 2016)	0.89
" In order to contribute to the debate on their safety profile, we conducted a comparative analysis of the reports of suspected adverse drug reactions (ADRs) associated with DOACs in VigiBase."	( Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. Biagi, C; Conti, V; Donati, M; Melis, M; Monaco, L; Motola, D; Vaccheri, A; Venegoni, M, 2017)	0.46
"Cerebrovascular adverse events collected by the Pharmaceutical and Medical Devices Agency (PMDA) during 2014 were analyzed to describe and compare efficacy and safety among patients prescribed DTI and FXa."	( Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data. Terayama, Y, 2017)	0.46
" In addition, NOACs have been demonstrated to be safe and associated with a significant reduction in major and intracranial bleeding events."	( [New oral anticoagulants in patients with atrial fibrillation: efficacy and safety data from the real world]. Di Pasquale, G; Riva, L, 2017)	0.46
" There were no serious adverse events, bleeding events or recurrent venous thromboembolism."	( Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability. Albisetti, M; Biss, B; Bomgaars, L; Brueckmann, M; Gropper, S; Halton, JML; Harper, R; Huang, F; Luciani, M; Maas, H; Mitchell, LG; Tartakovsky, I, 2017)	0.78
" Safety endpoints included incidence rates of bleeding events and all other adverse events (AEs)."	( Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability. Albisetti, M; Biss, B; Bomgaars, L; Brueckmann, M; Gropper, S; Halton, JML; Harper, R; Huang, F; Luciani, M; Maas, H; Mitchell, LG; Tartakovsky, I, 2017)	0.78
" The secondary efficacy outcome was major adverse cardiovascular events (MACE; composite of myocardial infarction, stroke, and all-cause mortality)."	( Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban, Dabigatran) in Patients With Acute Coronary Syndrome. Arshad, A; Kaluski, E; Khan, SU; Nasir, F; Riaz, IB; Talluri, S, 2018)	0.7
" Newly initiated anticoagulation with dabigatran in patients with nonvalvular AF scheduled for TEE-guided DCC seems to be as effective and safe as uninterrupted VKA therapy, during long-term follow up."	( Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study. D'Onofrio, A; Golino, P; Nigro, G; Papa, AA; Rago, A; Russo, V, 2018)	1.06
"In this cohort of Medicare beneficiaries with VHD (excluding patients with prosthetic valves) and new-onset AF between 2011 and 2013, novel oral non-vitamin K anticoagulants were safe and effective options for prevention of systemic thromboembolism."	( Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease. Akintoye, E; Alvarez, P; Briasoulis, A; Inampudi, C; Panaich, S; Vaughan-Sarrazin, M, 2018)	0.48
" Patients commenced on NOACs should be assessed and followed up in a multidisciplinary AF clinic to ensure safe and effective prescribing and stroke prevention."	( Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke pre Burke, C; Collins, R; Coughlan, T; Egom, EE; McAuliffe, C; McHugh, J; Moore, D; Morrissey, E; O'Brien, J; Pharithi, RB; Ranganathan, D; Ryan, D; Vaughan, M, 2019)	0.51
" These results show dabigatran to be a safe alternative to low-molecular-weight heparin for extended venous thromboembolism prophylaxis with regard to bleeding complications."	( Dabigatran (Pradaxa) Is Safe for Extended Venous Thromboembolism Prophylaxis After Surgery for Pancreatic Cancer. Chabot, JA; Dwyer, FA; Jackson, TL; Kluger, MD; Morgan, JA; Rashid, MF; Schrope, BA, 2019)	2.28
"The safety of the NOACs compared with warfarin was generally favourable across different patient subgroups, including those perceived to be at "high risk" for adverse outcomes."	( The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. Lip, GYH, 2019)	0.51
"Gastrointestinal side effect profiles of these four agents in a real-life setting is consistent with the results obtained from the present study."	( A link between cytotoxicity in cell culture and gastrointestinal side effects of oral anticoagulants: bench-to-bedside. Gurpinar, OA; Karasoy, D; Kubat, E; Onur, MA, )	0.13
"Direct oral anticoagulants (DOACs) are at least as efficacious and safe as warfarin among non-valvular atrial fibrillation (NVAF) patients; limited evidence is available regarding NVAF patients with heart failure (HF)."	( Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. Amin, A; Dhamane, A; Di Fusco, M; Friend, K; Garcia Reeves, AB; Keshishian, A; Li, X; Luo, X; Mardekian, J; Nadkarni, A; Pan, X; Rosenblatt, L; Yuce, H, 2019)	0.51
" Therefore, an effective, safe and convenient new anticoagulant is needed."	( Dabigatran must be used carefully: literature review and recommendations for management of adverse events. Guan, W; Lin, S; Wang, Y; Zhang, L, 2019)	1.96
"This trial found that patients who had CVT anticoagulated with either dabigatran or warfarin had low risk of recurrent VTEs, and the risk of bleeding was similar with both medications, suggesting that both dabigatran and warfarin may be safe and effective for preventing recurrent VTEs in patients with CVT."	( Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial. Alasheev, A; Canhão, P; Caria, J; Coutinho, JM; Dentali, F; Diener, HC; Ferro, JM; Frässdorf, M; Huisman, H; Karpov, D; Kobayashi, A; Nagel, S; Posthuma, L; Reilly, P; Roriz, JM, 2019)	1.06
" The risks of ischemic stroke, intracranial hemorrhage (ICH), major bleeding, mortality, and composite adverse events were compared between NOACs and warfarin in all patients ≥ 65 years of age and, specifically, with different age strata (ie, 65-74, 75-89, ≥ 90 years)."	( Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study. Chao, TF; Chen, SA; Chen, TJ; Chiang, CE; Liao, JN; Lip, GYH, 2020)	0.56
"Compared with warfarin, NOACs were associated with a significantly lower risk of adverse events, with heterogeneity in treatment effects among different age strata."	( Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study. Chao, TF; Chen, SA; Chen, TJ; Chiang, CE; Liao, JN; Lip, GYH, 2020)	0.56
" All adverse events (AEs) were recorded."	( Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects. Duan, J; Harada, A; Li, H; Yamamura, N; Yang, L, 2020)	0.84
" None of the subjects experienced a serious adverse event (SAE) or an AE of moderate or severe intensity."	( Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects. Duan, J; Harada, A; Li, H; Yamamura, N; Yang, L, 2020)	0.84
"Our real-life data study suggests that secondary stroke prevention with DOACs is as effective and safe as primary prevention, both in standard and reduced doses, in a typical group of patients who are older than patients included in RCTs."	( Effectiveness and Safety of Direct Oral Anticoagulants in the Secondary Stroke Prevention of Elderly Patients: Ljubljana Registry of Secondary Stroke Prevention. Frol, S; Hudnik, LK; Oblak, JP; Šabovič, M; Sernec, LP, 2020)	0.56
" Therefore, NOAC is an effective and safe alternative to warfarin in these patients."	( Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation and valvular heart disease. Hung, CS; Li, HJ; Lin, FJ; Lin, SY; Wang, CC, 2021)	0.62
"These results suggest that rivaroxaban is an effective and safe treatment option among NVAF patients with obesity in a commercially-insured US population."	( Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population. Ashton, V; Berger, JS; Jung, Y; Kharat, A; Laliberté, F; Lefebvre, P; Lejeune, D; Moore, KT, 2021)	0.62
" The NOACs seem to be a safe option also in elderly patients."	( Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation. Ghanima, W; Halvorsen, S; Jonasson, C; Rutherford, OW; Söderdahl, F, 2022)	0.72
"Direct oral anticoagulants (DOACs) have been proven to be effective and safe for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)."	( Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study. Dasgupta, K; Godin, R; Nedjar, H; Rahme, E; Tagalakis, V, 2021)	0.62
" Setting FDA Adverse Event Reporting System (FAERS) database."	( Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database. Cui, X; Guo, M; Thai, S; Wang, T; Wei, J; Xu, W; Zhao, Y; Zhou, J, 2021)	0.89
"Oral anticoagulant (OAC)-related adverse events are high post-hospitalization."	( Derivation and validation of predictors of oral anticoagulant-related adverse events in seniors transitioning from hospital to home. Benipal, H; Douketis, J; Foster, G; Holbrook, A; Ma, J; Paterson, JM; Thabane, L, 2021)	0.62
"For a long time, vitamin K antagonists (VKA) were the only oral anticoagulation therapy available to reduce adverse events in atrial fibrillation (AF) patients."	( A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry. Anguita, M; Badimón, L; Bertomeu-Martínez, V; Cequier, Á; Esteve-Pastor, MA; Lip, GYH; López-Gálvez, R; Marín, F; Muñiz, J; Otero, D; Rivera-Caravaca, JM; Roldán-Rabadán, I; Ruiz-Ortiz, M, 2022)	0.72
" Secondary outcomes were major adverse cardiovascular event (MACE), intracranial bleeding, and Major gastrointestinal bleeding."	( Efficacy and Safety of the Non-Vitamin K Antagonist Oral Anticoagulant Among Patients With Nonvalvular Atrial Fibrillation and Cancer: A Systematic Review and Network Meta-analysis. Al Kasasbeh, M; Al-Abdouh, A; Barbarawi, M; Barbarawi, O; Corcoran, J; Mhanna, M; Obeidat, K; Pickett, CC, 2022)	0.72
" It is critical to identify safe and effective anticoagulation therapy for use in this population."	( Anticoagulation and BMI: effect of high body weight on the safety and efficacy of direct oral anticoagulants. Bansal, A; Eisele, CD; Jain, R; Julian, K; Mausteller, KG; Patel, P, 2022)	0.72
" Direct oral anticoagulants are a new, preferred medication option for this, but it is unclear how safe or effective they are in obese people; there is some concern that because of increased body weight, individuals may not get enough medicine to effectively prevent clots from forming, which would ultimately put them at risk for clotting and serious adverse health outcomes such as stroke."	( Anticoagulation and BMI: effect of high body weight on the safety and efficacy of direct oral anticoagulants. Bansal, A; Eisele, CD; Jain, R; Julian, K; Mausteller, KG; Patel, P, 2022)	0.72
" CONCLUSIONS AND RELEVANCE: In our experience, the use of DOAC was safe in selected patients treated with KI, but unclear with bevacizumab."	( Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti-VEGF agents: a retrospective study. Albiges, L; Baudin, E; Besse, B; Boileve, A; Ducreux, M; Hadoux, J; Leary, A; Malka, D; Maulard, A; Mir, O; Rieutord, A; Scotté, F, 2022)	0.72
"The development of an optimal stroke prevention strategy, including the use of oral anticoagulant (OAC) therapy, is particularly important for patients with atrial fibrillation (AF) who are living with dementia, a condition that increases the risk of adverse outcomes."	( Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation. Bessette, LG; Bykov, K; Cervone, A; Kim, DH; Lin, KJ; Mastrorilli, JM; Singer, DE, 2023)	0.91

Pharmacokinetics

Dabigatran is dosed twice daily for stroke prevention in nonvalvular atrial fibrillation (AF) The aim of this study was to build a physiologically based pharmacokinetic (PBPK) model.

Excerpt	Reference	Relevance
" These pharmacokinetic characteristics confirm the suitability of this oral solid dosage form for use in future clinical trials."	( Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. Ahnfelt, L; Dahl, OE; Eriksson, BI; Nehmiz, G; Rathgen, K; Stähle, H; Stangier, J; Svärd, R, 2005)	0.57
" The objective of the analysis was to develop a population pharmacokinetic model characterizing and quantifying the relationship between covariates and model parameters."	( Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. Liesenfeld, KH; Schäfer, HG; Stangier, J; Tillmann, C; Trocóniz, IF, 2007)	0.57
"To investigate the pharmacokinetic and pharmacodynamic profile of dabigatran in healthy elderly subjects; to assess the intra- and interindividual variability of dabigatran pharmacokinetics in order to assess possible gender differences; and to assess the effect of pantoprazole coadministration on the bioavailability of dabigatran."	( Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Fuhr, R; Rathgen, K; Stähle, H; Stangier, J, 2008)	0.81
"The primary pharmacokinetic measurements included the area under the plasma concentration-time curve at steady state (AUC(ss)), maximum (C(max,ss)) and minimum (C(min,ss)) plasma concentrations at steady state, terminal half-life (t((1/2))), time to reach C(max,ss) and renal clearance of dabigatran."	( Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Fuhr, R; Rathgen, K; Stähle, H; Stangier, J, 2008)	0.75
" Intra- and interindividual pharmacokinetic variability in the overall population was low (<30% coefficient of variation), indicating that dabigatran has a predictable pharmacokinetic profile."	( Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Fuhr, R; Rathgen, K; Stähle, H; Stangier, J, 2008)	0.78
"Dabigatran demonstrated reproducible and predictable pharmacokinetic and pharmacodynamic characteristics, together with a good safety profile, when administered to healthy elderly subjects."	( Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Fuhr, R; Rathgen, K; Stähle, H; Stangier, J, 2008)	2.02
" The pharmacodynamic profile of dabigatran demonstrates effective anticoagulation combined with a low risk of bleeding."	( Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Stangier, J, 2008)	0.85
" While the anticoagulant effect of the new thrombin and FXa inhibitors is similar, differences in the pharmacokinetic and pharmacodynamic parameters may influence their use in clinical practice."	( Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Eriksson, BI; Quinlan, DJ; Weitz, JI, 2009)	0.35
" Studies in healthy volunteers and in patients undergoing orthopedic surgery indicate that dabigatran has a predictable pharmacokinetic profile, allowing for a fixed-dose regimen without the need for coagulation monitoring."	( Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clemens, A; Stangier, J, )	0.6
" Its pharmacokinetic characteristics include rapid absorption, high oral availability, high plasma protein binding and a half-life of aprox."	( [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban]. Climent Grana, E; Jover Botella, A; Ordovás Baines, JP; Valero García, I, )	0.37
" Blood and urine samples were collected up to 96 hours after dosing for determination of dabigatran pharmacokinetic and pharmacodynamic parameters."	( Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Mazur, D; Rathgen, K; Stähle, H; Stangier, J, 2010)	0.81
" The pharmacokinetic profile of digoxin also remained unchanged in the presence of dabigatran etexilate."	( Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. Körnicke, T; Rathgen, K; Reseski, K; Roth, W; Stähle, H; Stangier, J, 2012)	0.87
" Simulations were based on a population pharmacokinetic model derived from data from 9522 patients from the pivotal phase III study (RE-LY)."	( Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. Clemens, A; Friedman, J; Haertter, S; Lehr, T; Liesenfeld, KH; Reilly, PA; Staab, A, 2012)	1.82
"To characterize the pharmacokinetics of dabigatran in patients with non-valvular atrial fibrillation (AF) from the Randomized Evaluation of Long-term Anticoagulant Therapy (RE-LY) trial and to quantify the effect of selected factors on pharmacokinetic (PK) model parameters."	( Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. Connolly, SJ; Dansirikul, C; Ezekowitz, MD; Haertter, S; Lehr, T; Liesenfeld, KH; Reilly, PA; Staab, A; Wallentin, L; Yusuf, S, 2011)	0.87
" Various factors, including body weight and renal clearance, may explain these observed pharmacokinetic differences."	( Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate. Clemens, A; Härtter, S; Reilly, PA; Stangier, J; Yamamura, N, 2012)	0.59
" Based on its pharmacokinetic profile, dabigatran is dosed twice daily."	( Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J, 2012)	0.96
"The pharmacokinetic profile of dabigatran was simulated for AF patients given a total daily dose of 300 mg, either once or twice daily."	( Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J, 2012)	0.98
" Pharmacokinetic data collected from a phase II study and RE-LY were consistent with the simulation results."	( Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J, 2012)	0.69
" The aim of this study was to investigate whether, and to what extent, a switch from enoxparin to dabigatran etexilate affects the pharmacokinetic (PK) and pharmacodynamic (PD) parameters and safety profile of dabigatran."	( Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. Clemens, A; Feuring, M; Härtter, S; Sennewald, R; Stangier, J; van Ryn, J; Yamamura, N, 2012)	0.89
"To review the literature regarding the pharmacokinetic (PK) and clinical implications of the use of dabigatran in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation (AF)."	( Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation. Kim, JJ; Mack, DR, )	0.61
"To evaluate the pharmacokinetic and pharmacodynamic effects of concomitant administration of single loading doses of clopidogrel or multiple doses of clopidogrel with multiple doses of dabigatran etexilate."	( Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Baumann, S; Friedman, J; Fritsch, H; Härtter, S; Schepers, C; Sennewald, R, 2013)	0.81
"3-131%), as did its pharmacodynamic effects on the inhibition of platelet aggregation."	( Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Baumann, S; Friedman, J; Fritsch, H; Härtter, S; Schepers, C; Sennewald, R, 2013)	0.62
"When given concomitantly, dabigatran etexilate and clopidogrel at clinically relevant doses did not appear to have significant effects on the pharmacokinetic and pharmacodynamic profiles of either agent."	( Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Baumann, S; Friedman, J; Fritsch, H; Härtter, S; Schepers, C; Sennewald, R, 2013)	0.92
" Though the anticoagulation efficacy of these NOACs has been characterized, differences in their pharmacokinetic and pharmacodynamic profiles have become a significant consideration in terms of drug selection and dosing."	( Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Gong, IY; Kim, RB, 2013)	0.61
"To review pharmacokinetic and pharmacodynamic drug-drug interactions (DDIs) involving new oral anticoagulants for atrial fibrillation."	( Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Gulseth, M; Hellwig, T, 2013)	0.39
"Articles reviewed focused on drugs affecting the permeability glycoprotein (P-gp) efflux transporter protein and/or cytochrome P (CYP) 450 3A4 enzymes, and pharmacodynamic DDIs when drugs are administered concomitantly."	( Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Gulseth, M; Hellwig, T, 2013)	0.39
" In this study, in vivo-based [I]/Ki values were used to predict the DDI risks of a P-gp substrate dabigatran etexilate (DABE) using physiologically based pharmacokinetic (PBPK) modelling."	( Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. Hu, ZY; Zhao, Y, 2014)	0.82
"This approach accurately predicted the effects of five P-gp inhibitors on DABE pharmacokinetics (98-133% and 89-104% for the ratios of AUC and Cmax respectively)."	( Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. Hu, ZY; Zhao, Y, 2014)	0.6
" POCT for aPTT is sensitive to increased concentrations of dabigatran, whereas the PT-POCT assessed with test systems such as the GEM PCL Plus may be helpful to measure the pharmacodynamic anticoagulant effects of rivaroxaban in emergency clinical situations."	( Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. Herrmann, E; Herth, N; Kasper, A; Lindhoff-Last, E; Linnemann, B; Mani, H; Pfeilschifter, W; Schuettfort, G; Weil, Y; Wendt, T, 2014)	0.65
" The mean free dabigatran Cmax was 95."	( An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. Anderson, DR; Goralski, KB; Morrison, M; Mossop, P; Sleno, L; Soroka, SD; Wang, Y; Wilson, JA, 2014)	1.07
" Maximum plasma concentrations were achieved near the end of infusion, followed by a rapid decline, with an initial idarucizumab half-life of ~45 minutes."	( A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Glund, S; Lang, B; Moschetti, V; Norris, S; Ramael, S; Reilly, P; Schmohl, M; Stangier, J; van Ryn, J, 2015)	0.62
" To support the possibility that patients may choose to switch treatment from another nonvitamin K antagonist oral anticoagulant to edoxaban, this clinical study was conducted to evaluate the pharmacokinetic and pharmacodynamic effects of edoxaban after switching from rivaroxaban or dabigatran etexilate to edoxaban."	( Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects. Brown, KS; Dishy, V; Kochan, J; Maa, JF; Parasrampuria, DA; Shi, M; Weilert, D, 2016)	0.81
"Day 4 edoxaban pharmacokinetic parameters were similar for all treatments."	( Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects. Brown, KS; Dishy, V; Kochan, J; Maa, JF; Parasrampuria, DA; Shi, M; Weilert, D, 2016)	0.63
" No impact of age on idarucizumab pharmacokinetics was observed; however, subjects with mild or moderate renal impairment demonstrated increased exposure (up to 84 %), decreased clearance and prolonged (by up to 49 %) initial half-life of idarucizumab compared with healthy middle-aged subjects."	( Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study. De Smet, M; Gansser, D; Glund, S; Haazen, W; Kreuzer, J; Lang, B; Moschetti, V; Norris, S; Reilly, P; Schmohl, M; Stangier, J; van Ryn, J, 2017)	0.67
" The antiretroviral pharmacokinetic enhancers, ritonavir and cobicistat, inhibit both these transporters."	( Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. Alfaro, RM; Brooks, KM; George, JM; Gordon, LA; Hadigan, C; Kellogg, A; Kumar, P; Lozier, J; McManus, M; Nghiem, K; Penzak, SR, 2017)	0.65
" The primary endpoints were pharmacokinetics/pharmacodynamics-related: plasma concentrations of DE and its metabolites; activated partial thromboplastin time (APTT), ecarin clotting time (ECT), and dilute thrombin time (dTT); and pharmacokinetic (PK)-pharmacodynamic (PD) correlation."	( Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability. Albisetti, M; Biss, B; Bomgaars, L; Brueckmann, M; Gropper, S; Halton, JML; Harper, R; Huang, F; Luciani, M; Maas, H; Mitchell, LG; Tartakovsky, I, 2017)	0.78
" The pharmacokinetic characteristics of available DOACs (dabigatran, rivaroxaban, apixaban, edoxaban, betrixaban) differ substantially as regards oral bioavailability, plasma protein binding and the relative involvement of renal and non-renal elimination."	( Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure. Padrini, R, 2019)	0.76
" The pharmacokinetics in patients treated with standard and reduced doses of the four anticoagulants using liquid chromatography-tandem mass spectrometry was compared with the concentration ranges estimated using physiologically based pharmacokinetic modeling."	( Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital. Endo, S; Kishi, H; Kogiku, M; Noda, M; Notsu, Y; Ota, M; Shimizu, M; Takekawa, M; Yamazaki, H; Yamazaki-Nishioka, M, 2019)	0.77
" We conducted virtual drug-drug interactions studies between DABE and the P-glycoprotein inhibitor verapamil in RI populations using physiologically based pharmacokinetic modeling."	( Assessing Potential Drug-Drug Interactions Between Dabigatran Etexilate and a P-Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling. Doki, K; Homma, M; Neuhoff, S; Rostami-Hodjegan, A, 2019)	0.77
" The objective of this study was to build a physiologically based pharmacokinetic (PBPK) model comprising dabigatran etexilate, dabigatran, and dabigatran 1-O-acylglucuronide to describe the pharmacokinetics in healthy adults and renally impaired patients mechanistically."	( A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients. Gómez-Mantilla, JD; Hanke, N; Lehr, T; Maas, H; Moj, D; Schaeftlein, A, 2019)	0.96
" The predicted area under the plasma concentration-time curve, trough concentration, and half-life values of the assessed clinical studies satisfied the two-fold acceptance criterion."	( A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients. Gómez-Mantilla, JD; Hanke, N; Lehr, T; Maas, H; Moj, D; Schaeftlein, A, 2019)	0.74
"Physiologically-based pharmacokinetic (PBPK) modeling is a powerful tool to quantitatively describe drug disposition profiles in vivo, thereby providing an alternative to predict drug-drug interactions (DDIs) that have not been tested clinically."	( Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction. Costales, C; Eatemadpour, S; Kimoto, E; Lazzaro, S; Varma, MV; Yamazaki, S, 2019)	0.51
"A comprehensive and mechanistic PBPK/PD model to study dabigatran reversal has been established, which includes whole-body PBPK modeling of idarucizumab, the idarucizumab-dabigatran interaction, dabigatran hemodialysis, the pharmacodynamic effect of dabigatran on blood coagulation, and the impact of renal function in these different scenarios."	( Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis. Fuhr, LM; Hanke, N; Lehr, T; Meibohm, B, 2020)	1.12
" A plasma trough concentration/dose (C/D) ratio was used as a pharmacokinetic index."	( Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease. Bochkov, P; Fomin, V; Gurinovich, O; Ivashchenko, D; Kogay, V; Krainyaya, A; Krupenin, P; Listratov, A; Napalkov, D; Ryzhikova, K; Shevchenko, R; Skripka, A; Sokolova, A; Sychev, D, 2020)	0.78
" Pharmacokinetic data on this anticoagulant in Chinese subjects are limited."	( Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects. Duan, J; Harada, A; Li, H; Yamamura, N; Yang, L, 2020)	0.84
" Blood samples were collected to analyze the pharmacokinetic profile of dabigatran."	( Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects. Duan, J; Harada, A; Li, H; Yamamura, N; Yang, L, 2020)	1.08
" The plasma concentration of total dabigatran reached its maximum measured concentration at a median time of 3-4 h from the dose of interest (either the initial single dose on day 1 or the final dose on day 10) under fed conditions, and declined with an elimination half-life of 10."	( Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects. Duan, J; Harada, A; Li, H; Yamamura, N; Yang, L, 2020)	1.12
"This study revealed the pharmacokinetic characteristics and good safety profile of dabigatran in healthy Chinese subjects."	( Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects. Duan, J; Harada, A; Li, H; Yamamura, N; Yang, L, 2020)	1.07
" There have been limited studies comparing the potential for pharmacokinetic (PK) drug interactions between different anticoagulants."	( Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy. Anoopkumar-Dukie, S; Badrick, T; Bernaitis, N, 2021)	0.62
" Pharmacokinetic data were available in 94% (132/140) of patients."	( Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. Beyer-Westendorf, J; Birschmann, I; Greinacher, A; Grottke, O; Herrmann, E; Konstantinides, S; Kuhn, J; Lindau, S; Lindhoff-Last, E; Lucks, J; Meybohm, P; Nowak-Göttl, U; Schellong, S; Sümnig, A; von Heymann, C; Zydek, B, 2022)	0.72
" The DOACs' peak and trough plasma levels obtained from our study population were compared with those sourced from pharmacokinetic studies among patients without obesity, defined as a normal reference range in the literature."	( Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity. Atripaldi, U; Bottino, R; Cattaneo, D; Clementi, E; Giannetti, L; Laezza, N; Russo, V, 2021)	0.62
"As one of the key components in model-informed drug discovery and development, physiologically-based pharmacokinetic (PBPK) modeling linked with in vitro-to-in vivo extrapolation (IVIVE) is widely applied to quantitatively predict drug-drug interactions (DDIs) on drug-metabolizing enzymes and transporters."	( Physiologically-based pharmacokinetic modeling to evaluate in vitro-to-in vivo extrapolation for intestinal P-glycoprotein inhibition. De Zwart, L; Evers, R; Yamazaki, S, 2022)	0.72
"We aimed to report outcome and pharmacokinetic parameters in patients who massively ingested DOACs."	( Case series of massive direct oral anticoagulant ingestion-Treatment and pharmacokinetics data. Camoin-Jau, L; Chevillard, L; Delrue, M; Deye, N; Dragoni, A; Gainnier, M; Malissin, I; Mégarbane, B; Siguret, V; Stépanian, A; Voicu, S, 2022)	0.72
" Further studies using physiologically based pharmacokinetic modelling are required to investigate the drug-drug interactions between these drugs."	( Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore. Chan, ECY; Soh, XQ; Tan, DS, 2023)	0.91
" Population pharmacokinetic (PopPK) analyses can help in identifying such factors while providing predictive models."	( Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation. Csajka, C; Daali, Y; Fontana, P; Gaspar, F; Guidi, M; Reny, JL; Terrier, J, 2022)	0.72
" Noncompartmental pharmacokinetic parameters and pharmacodynamic variables were evaluated with geometric mean ratios and 90% confidence intervals of Treatment C1/C2 versus A1/A2."	( Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects. Anliker-Ort, M; Dingemanse, J; Janů, L; Kaufmann, P, 2023)	1.14
"9), respectively, whereas the time to maximum plasma concentration and terminal half-life were comparable between treatments."	( Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects. Anliker-Ort, M; Dingemanse, J; Janů, L; Kaufmann, P, 2023)	1.14

Compound-Compound Interactions

Dabigatran etexilate can be given with verapamil and clarithromycin. Clinical management of DDIs in Chinese older adults can a priori be similar to the EHRA guideline.

Excerpt	Reference	Relevance
"The aim of this study was to develop a PK/PD model to assess drug-drug interactions between dabigatran and P-gp modulators, using the example of clarithromycin, a strong inhibitor of P-gp."	( A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Accassat, S; Basset, T; Bertoletti, L; Delavenne, X; Garcin, A; Laporte, S; Mismetti, P; Ollier, E; Zufferey, P, 2013)	0.84
"The model proposed effectively describes the complex PK of dabigatran and takes into account drug-drug interactions with P-gp activity modulators, such as clarithromycin."	( A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Accassat, S; Basset, T; Bertoletti, L; Delavenne, X; Garcin, A; Laporte, S; Mismetti, P; Ollier, E; Zufferey, P, 2013)	0.86
" Co-prescribed drugs that potentially interact with dabigatran etexilate were present in 75% (154/204) of patients and included strong P-gp inhibitors (16%, 32/204), proton-pump inhibitors (46%, 94/204) and anti-platelet drugs (47%, 95/204)."	( Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. Barclay, ML; Begg, EJ; Chin, PK; Vella-Brincat, JW; Walker, SL, 2013)	1.04
" Most patients were co-prescribed with drugs that potentially interact with dabigatran etexilate."	( Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. Barclay, ML; Begg, EJ; Chin, PK; Vella-Brincat, JW; Walker, SL, 2013)	1.02
" Dabigatran etexilate was proposed as an in vivo probe substrate for intestinal P-gp inhibition in a recent guidance on drug-drug interactions (DDI) from the European Medicines Agency (EMA) and the Food and Drug Administration (FDA)."	( In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold. Ebner, T; Ishiguro, N; Kishimoto, W; Ludwig-Schwellinger, E; Schaefer, O, 2014)	1.53
"To review pharmacokinetic and pharmacodynamic drug-drug interactions (DDIs) involving new oral anticoagulants for atrial fibrillation."	( Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Gulseth, M; Hellwig, T, 2013)	0.39
" Phase I DDI studies have reported pharmacokinetic DDIs mediated by P-gp alone (dabigatran etexilate) or in combination with CYP3A4 enzymes (rivaroxaban and apixaban)."	( Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Gulseth, M; Hellwig, T, 2013)	0.62
"In vitro inhibitory potency (Ki )-based predictions of P-glycoprotein (P-gp)-mediated drug-drug interactions (DDIs) are hampered by the substantial variability in inhibitory potency."	( Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. Hu, ZY; Zhao, Y, 2014)	0.6
"To quantify the drug-drug interactions between dabigatran etexilate (DE) and proton pump inhibitors (PPI) and in particular the role of P-gp activity modulation."	( In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. Accassat, S; Basset, T; Bertoletti, L; Delavenne, X; Hodin, S; Mismetti, P; Ollier, E, 2015)	0.91
" The intraday and interday precision and accuracy of the assays were within acceptable ranges, and the assays were successfully applied to support a study where a microdose cocktail was dosed to healthy human subjects for simultaneous assessment of clinical drug-drug interactions mediated by major drug transporters and CYP3A."	( Microdosing Cocktail Assay Development for Drug-Drug Interaction Studies. Bateman, KP; Chavez-Eng, CM; Goykhman, D; Lutz, RW, 2018)	0.48
"The aim of this study is to assess patterns of potential drug-drug interactions (DDIs) with direct oral anticoagulants (DOACs) in an inpatient hospital setting."	( Evaluation of Potential Drug-Drug Interactions With Direct Oral Anticoagulants in a Large Urban Hospital. Karakas-Torgut, A; Mo, Y; Pham, AQ, 2020)	0.56
" The bleeding risk associated with dabigatran is higher in the setting of renal impairment or drug-drug interactions resulting in supratherapeutic serum concentrations."	( Probable drug-drug interaction between dabigatran and quinidine resulting in thrombin time rebound despite multiple idarucizumab doses. George, S; Lewis, V; Taburyanskaya, M, 2019)	1.06
" NOAC have also been studied in combination with platelet antiaggregation in both patients with coronary and peripheral arterial disease, and reduced doses will presumably emerge as routine treatment also in these conditions."	( [NOAC in combination with platelet antiaggregation in both patients with coronary and peripheral arterial disease]. Gottsäter, A, 2018)	0.48
" Because the combined effects of drug-drug interactions and RI have not been evaluated by means of clinical studies, the decision of DABE dosing for RI patients receiving P-glycoprotein inhibitors is empirical at its best."	( Assessing Potential Drug-Drug Interactions Between Dabigatran Etexilate and a P-Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling. Doki, K; Homma, M; Neuhoff, S; Rostami-Hodjegan, A, 2019)	0.77
"We sought to develop a semiautomated screening approach using electronic healthcare data to identify drug-drug interactions (DDIs) that result in clinical outcomes."	( A Case-Crossover-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data. Bykov, K; Gagne, JJ; Glynn, RJ; Mittleman, MA; Schneeweiss, S, 2019)	0.51
" Accordingly, the drug-drug interaction (DDI) potential of darolutamide was investigated in both nonclinical and clinical studies."	( Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies. Bairlein, M; Denner, K; Fricke, R; Gieschen, H; Graudenz, K; Korjamo, T; Koskinen, M; Prien, O; von Bühler, CJ; Wilkinson, G; Zurth, C, 2019)	0.51
"Self-controlled designs, specifically the case-crossover (CCO) and the self-controlled case series (SCCS), are increasingly utilized to generate real-world evidence (RWE) on drug-drug interactions (DDIs)."	( Drug-Drug Interaction Surveillance Study: Comparing Self-Controlled Designs in Five Empirical Examples in Real-World Data. Bykov, K; Gagne, JJ; Kim, S; Li, H; Lo Re, V; Vine, SM, 2021)	0.62
" Veverimer is not systemically absorbed, so potential drug-drug interactions (DDIs) are limited to effects on the absorption of other oral drugs through binding to veverimer in the gastrointestinal tract or increases in gastric pH caused by veverimer binding to hydrochloric acid."	( Assessment of the Potential for Veverimer Drug-Drug Interactions. Biyani, K; Guttendorf, R; Klaerner, G; Lee, A; Li, E; Mathur, V; Parsell, D; Shao, J; Stasiv, Y; Tabakman, S; Tsao, L; Wu, YS, 2021)	0.62
"Dexamethasone has the potential to interact with the DOACs via CYP3A4 and/or P-gp induction."	( Potential Dexamethasone-Direct Oral Anticoagulant Drug Interaction: Is This a Concern in COVID? Burns, C; Garwood, CL; Liu, Q; Smythe, MA, 2022)	0.72
" The aim of this study was to assess the potential P-gp-mediated drug-drug interactions between 11 tyrosine kinase inhibitors (TKIs) with apixaban and rivaroxaban."	( Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drug-drug interaction mediated by P-glycoprotein. Bertoletti, L; Bin, V; Delavenne, X; Hodin, S; Lafaie, L; Saïb, S, 2022)	0.72
" Both warfarin and direct oral anticoagulants are susceptible to drug-drug interactions (DDIs)."	( Drug Interactions Affecting Oral Anticoagulant Use. Chung, MK; Dukes, J; Ezekowitz, MD; Gengler, BE; Gopinathannair, R; Lakkireddy, D; Lip, GYH; Mar, PL; Miletello, M; Noseworthy, PA; Olshansky, B; Perez, A; Reiffel, J; Tisdale, JE, 2022)	0.72
"Direct oral anticoagulants (DOACs) can be involved in clinical relevant drug-drug interactions (DDIs) which may compromise safe and effective use."	( Drug-drug interactions with direct oral anticoagulants: development of a consensus list for ambulatory care. Boussery, K; Capiau, A; De Backer, T; De Bolle, L; Mehuys, E; Van Tongelen, I, 2023)	0.91
" Clinical management of DDIs in Chinese older adults in the absence of complex polypharmacy can a priori be similar to the EHRA guideline but routine monitoring of bleeding risk is encouraged when dabigatran etexilate given with verapamil and clarithromycin."	( Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults. Cui, C; Lai, X; Li, H; Liu, D; Sia, JEV; Wu, X; Zhang, F, 2023)	1.32
"Whether there are differences in direct oral anticoagulants efficacy and safety in patients with atrial fibrillation (AF) combined with hypertension is unclear."	( Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation Combined With Hypertension: A Multicenter, Retrospective Cohort Study. Chen, X; Dai, H; Du, X; Gu, P; Guan, C; Huang, N; Huang, X; Li, R; Lin, X; Liu, X; Liu, Y; Lv, M; Wu, T; Xu, W; Zhang, J; Zhang, M; Zhang, W; Zheng, Q; Zhu, Z, 2023)	0.91

Bioavailability

Dabigatran may be a viable alternative to enoxaparin for thromboprophylaxis in orthopaedic surgery. The main pharmacokinetic characteristics of dabig atran are a bioavailability of approximately 7.5 h.

Excerpt	Reference	Relevance
"Dabigatran etexilate (BIBR 1048) is an orally bioavailable double prodrug of the active principle dabigatran (BIBR 953 ZW), which exerts potent anticoagulant and antithrombotic activity."	( Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. Liesenfeld, KH; Schäfer, HG; Stangier, J; Tillmann, C; Trocóniz, IF, 2007)	2.02
"To investigate the pharmacokinetic and pharmacodynamic profile of dabigatran in healthy elderly subjects; to assess the intra- and interindividual variability of dabigatran pharmacokinetics in order to assess possible gender differences; and to assess the effect of pantoprazole coadministration on the bioavailability of dabigatran."	( Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Fuhr, R; Rathgen, K; Stähle, H; Stangier, J, 2008)	0.81
" The effects of pantoprazole coadministration on the bioavailability of dabigatran were considered acceptable, and dose adjustment is not considered necessary."	( Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Fuhr, R; Rathgen, K; Stähle, H; Stangier, J, 2008)	0.81
" Its oral bioavailability is low, but shows reduced interindividual variability."	( [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban]. Climent Grana, E; Jover Botella, A; Ordovás Baines, JP; Valero García, I, )	0.37
" Given its safety profile, efficacy, oral bioavailability and stable pharmacokinetic properties, dabigatran may be a viable alternative to enoxaparin for thromboprophylaxis in orthopaedic surgery."	( Dabigatran etexilate: a new thrombin inhibitor. Verma, AK, 2010)	2.02
" Oral bioavailability of dabigatran, together with a rapid onset and offset of action and predictable anticoagulation response, makes this newly available antithrombotic drug an attractive alternative to traditional anticoagulant therapies for numerous thrombosis-related indications."	( New options with dabigatran etexilate in anticoagulant therapy. Azuma, J; Maegdefessel, L; Spin, JM; Tsao, PS, 2010)	1
" In the fasted dog, oral administration of 3 mg kg(-1) S35972 increased TT rapidly and for at least 8 h, and its pharmacologic bioavailability was 75."	( S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy. De Nanteuil, G; Gloanec, P; Marx, I; Mennecier, P; Rupin, A; Vallez, MO; Verbeuren, TJ, 2011)	0.37
"Administration of rifampicin for 7 days resulted in a significant reduction in the bioavailability of dabigatran, which returned almost to baseline after 7 days washout."	( Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Härtter, S; Koenen-Bergmann, M; Lemke, U; Nehmiz, G; Reilly, PA; Sharma, A; Timmer, W, 2012)	0.86
"Dabigatran etexilate is the orally bioavailable pro-drug of dabigatran, a direct thrombin inhibitor."	( A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery. Dansirikul, C; Haertter, S; Lehr, T; Liesenfeld, KH; Staab, A, 2012)	2.09
"Due to low bioavailability and high inter-individual variability, monitoring of dabigatran may be required in specific situations to prevent the risk of bleedings or thrombosis."	( Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Chatelain, B; Chatelain, C; Dogné, JM; Douxfils, J; Mullier, F; Robert, S, 2012)	1.01
" Similarly, clopidogrel bioavailability remained unchanged by chronic administration of dabigatran etexilate (part 3: ratio test/reference for AUC(0-24) was 103%; 90% CI 80."	( Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Baumann, S; Friedman, J; Fritsch, H; Härtter, S; Schepers, C; Sennewald, R, 2013)	0.84
"Concomitant medication with proton pump inhibitors, amiodarone, clarithromycin, and verapamil increased bioavailability whereas rifampicin decreased the bioavailability of dabigatran."	( Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Finsterer, J; Stöllberger, C, 2015)	0.86
"Dronedarone is a strong P-glycoprotein inhibitor with a potential to increase bioavailability of dabigatran."	( Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice. Juhlin, T; Mochalina, N; Platonov, PG; Svensson, PJ; Wieloch, M, 2015)	0.91
"80% relative bioavailability compared with Pradaxa(®) capsules (a commercial DE product)."	( A solid self-nanoemulsifying system of the BCS class IIb drug dabigatran etexilate to improve oral bioavailability. Chai, F; Ding, Y; Liu, X; Sun, L; Webster, TJ; Zhang, Y; Zheng, C, 2016)	0.67
"The developed SNEDDS are promising materials for improving the dissolution and oral bioavailability of BCS class IIb drugs."	( A solid self-nanoemulsifying system of the BCS class IIb drug dabigatran etexilate to improve oral bioavailability. Chai, F; Ding, Y; Liu, X; Sun, L; Webster, TJ; Zhang, Y; Zheng, C, 2016)	0.67
"Anticoagulation in patients with impaired kidney function can be challenging since drugs' pharmacokinetics and bioavailability are altered in this setting."	( Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. Baldovino, S; Fenoglio, R; Radin, M; Roccatello, D; Schreiber, K; Sciascia, S, 2017)	0.46
" In 5-FU-treated rats, the maximum plasma concentration, the area under the concentration-time curve of DAB after the oral administration of DABE, and the oral bioavailability of DABE were significantly decreased to 18."	( 5-Fluororacil-Induced Gastrointestinal Damage Impairs the Absorption and Anticoagulant Effects of Dabigatran Etexilate. Akiyoshi, T; Hattori, T; Imaoka, A; Ohtani, H; Tsujii, K, 2018)	0.7
" This review summarizes the discovery and optimization of representative novel oral anticoagulants with the aim to improve selectivity and bioavailability of compounds."	( The selectivity and bioavailability improvement of novel oral anticoagulants: An overview. Cheng, K; Li, S; Liao, C; Lv, X; Tian, Y; Xiao, X; Xie, Z; Zhan, M, 2018)	0.48
" However, due to altered pharmacokinetics and bioavailability of these drugs in CKD, a significant risk of bleeding exists."	( [The Multimorbid Patient: Use of New Oral Anticoagulants in Patients with Chronic Kidney Disease]. Mohebbi, N, 2018)	0.48
" Consequently, food does not influence its bioavailability and the efficacy and safety of dabigatran are similar with or without concomitant intake of proton pump inhibitors (PPIs)."	( Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran. Earl, KM; Jamali, F; Leblanc, K; Semchuk, W; Weitz, JI, 2018)	0.93
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Dabigatran etexilate (DABE), an oral anticoagulant and substrate of P-glycoprotein (P-gp), is poorly absorbed and exhibits low bioavailability in humans."	( Irinotecan-induced gastrointestinal damage impairs the absorption of dabigatran etexilate. Akiyoshi, T; Hattori, T; Imaoka, A; Ohtani, H, 2019)	1.66
"For weakly basic drugs, the sharp decrease of drug solubility and the following drug precipitation after drugs transferring from the gastric fluid to the intestinal fluid in the gastrointestinal (GI) tract is a main reason for the poor oral bioavailability of drugs."	( A composite nanocarrier to inhibit precipitation of the weakly basic drug in the gastrointestinal tract. Ge, L; He, X; Li, Y; Peng, Z; Sun, Y; Tao, J; Wu, Y; Zheng, C, 2020)	0.56

Dosage Studied

Dabigatran is the first of four direct-acting oral anticoagulants approved to prevent stroke in adult patients with atrial fibrillation. However, dosing based on coagulation parameters can be difficult because available assays may not provide adequate sensitivity and specificity.

Excerpt	Relevance	Reference
" In experimental models of thrombosis, melagatran has been shown to have a shallower dose-response curve than warfarin and, therefore, a better separation between efficacy and bleeding."	( Oral direct thrombin inhibitors in clinical development. Gustafsson, D, 2003)	0.32
" A dose-response was demonstrated for minor bleeding events."	( Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. Ahnfelt, L; Dahl, OE; Eriksson, BI; Hermansson, K; Kälebo, P; Kohlbrenner, V; Nehmiz, G; Stangier, J, 2004)	0.56
" These pharmacokinetic characteristics confirm the suitability of this oral solid dosage form for use in future clinical trials."	( Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. Ahnfelt, L; Dahl, OE; Eriksson, BI; Nehmiz, G; Rathgen, K; Stähle, H; Stangier, J; Svärd, R, 2005)	0.57
" A total of 4604 BIBR 953 ZW plasma concentrations, obtained from 287 patients after once- or twice-daily oral dosing for up to 10 days after surgery in the dose range 12."	( Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. Liesenfeld, KH; Schäfer, HG; Stangier, J; Tillmann, C; Trocóniz, IF, 2007)	0.57
" There are numerous drug/drug and drug/food interactions, and there is difficulty in dosing for one-third of patients."	( The new anticoagulants. Money, SR; Stone, WM; Tonnessen, BH, 2007)	0.34
" It is recommended that the clinician carefully evaluate the elderly patient's creatinine clearance and weight before prescribing anticoagulants, particularly when using fixed dosing regimens."	( Prevention of venous thromboembolism in the geriatric patient. Brotman, DJ; Jaffer, AK, 2008)	0.35
" Dosing stopped at contrast venography, 12 to 15 days after surgery."	( Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. Caprini, JA; Clements, ML; Comp, PC; Davidson, BL; Francis, CW; Friedman, RJ; Ginsberg, JS; Hantel, S; Huo, MH; Lieberman, JR; Muntz, JE; Raskob, GE; Schnee, JM, 2009)	0.66
" Dabigatran etexilate pharmacokinetics were linear across a wide dosage range."	( Dabigatran etexilate. Plosker, GL; Sanford, M, 2008)	2.7
" The use of algorithms for dosing that incorporate pharmacogenomic information perform better than those using clinical data alone."	( New issues in oral anticoagulants. Francis, CW, 2008)	0.35
" It is unique because it includes equal numbers of VKA-experienced and naive patients and evaluates 2 different dosages of dabigatran, which may allow tailoring of dosing to individual patient needs."	( Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Connolly, S; Ezekowitz, MD; Oldgren, J; Parekh, A; Reilly, PA; Themeles, E; Varrone, J; Wallentin, L; Wang, S; Yusuf, S, 2009)	0.77
" Dabigatran is mainly eliminated by renal excretion (a fact which affects the dosage in elderly and in moderate-severe renal failure patients), and no hepatic metabolism by cytochrome P450 isoenzymes has been observed, showing a good interaction profile."	( [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban]. Climent Grana, E; Jover Botella, A; Ordovás Baines, JP; Valero García, I, )	1.28
" These drugs have predictable pharmacokinetics that allow fixed dosing without laboratory monitoring, and are being compared with vitamin K antagonists or aspirin in phase III clinical trials [corrected]."	( New anticoagulants for atrial fibrillation. Eikelboom, J; O'Donnell, M; Sobieraj-Teague, M, 2009)	0.35
"We assessed the efficacy, safety, and dose-response of dabigatran etexilate (DAB) in preventing venous thromboembolism (VTE) in Japanese patients undergoing total knee arthroplasty (TKA)."	( Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with a safety profile comparable to placebo. Fuijita, S; Fuji, T; Sato, T; Ujihira, T, 2010)	2.05
" All of these characteristics can be an obstacle to optimal patient care, particularly when outpatient dosing is required after early discharge."	( [Dabigatran (Pradaxa): efficacy and safety]. Bellamy, L; Rosencher, N, 2009)	1.26
"The RE-LY study compared dabigatran in the dose of 150 mg and 110 mg twice daily, without laboratory monitoring, with the conventional treatment with warfarin dosed according to INR in 18,113 patients with non-valvular atrial fibrillation and high risk of embolisation."	( [The results of the RE-lY study promise more effective, safer and easier prevention of embolic complications in patients with non-valvular atrial fibrillation]. Vojácek, J, 2009)	0.66
" Blood and urine samples were collected up to 96 hours after dosing for determination of dabigatran pharmacokinetic and pharmacodynamic parameters."	( Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Mazur, D; Rathgen, K; Stähle, H; Stangier, J, 2010)	0.81
" Four isomeric acylglucuronides of dabigatran were isolated and purified from urine of dosed rhesus monkeys."	( Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Ebner, T; Wagner, K; Wienen, W, 2010)	2.08
" Depending on its dosage its effectiveness in comparison with vitamin K antagonists is equal or even better without disadvantages in safety."	( [New oral anticoagulants: better than vitamin K antagonists?]. Alban, S; Völler, H; Westermann, D, 2010)	0.36
" Efficacy and safety of oral anticoagulation is limited by a narrow therapeutical range as well as by inter- and intraindividual variability of INR-values due to genetic disposition, differences in alimentation, dosage errors, rare control of INR-levels and drug-interactions."	( [Novel anticoagulants for stroke prevention in atrial fibrillation]. Baumhäkel, M; Böhm, M; Schirmer, SH, 2010)	0.36
" Moreover, the higher dosage was associated with significantly greater efficacy than warfarin in this regard."	( Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Garnock-Jones, KP, 2011)	1.81
" Based on the RE-LY study we investigated the cost-effectiveness of Health Canada approved dabigatran etexilate dosing (150 mg bid for patients <80 years, 110 mg bid for patients ≥80 years) versus warfarin and "real-world" prescribing (i."	( Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Bradley-Kennedy, C; Connolly, S; Kansal, AR; Linnehan, J; Peng, S; Plumb, JM; Sorensen, SV, 2011)	0.9
" Disadvantages of dabigatran may include a higher frequency of dyspepsia compared with warfarin, lack of dosing information in severe renal impairment, possible missed opportunities for periodic health examinations and interventions due to elimination of regular physician's visit for international normalized ratio monitoring, and drug costs."	( Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin. Cheng-Lai, A; Tran, A, )	1.91
" The vitamin K antagonist warfarin has traditionally been used in these patients but presents challenges in dosing and monitoring in these patients."	( Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. Baker, WL; Bendel, SD; Bona, R, 2011)	1.81
" Although dabigatran is not approved for venous thromboembolism (VTE) prevention or treatment, results of the RE-MODEL and RE-NOVATE trials suggest similar efficacy to once-daily dosing of enoxaparin 40 mg but inferior efficacy to the FDA-approved twice-daily dosing of enoxaparin 30 mg in the RE-MOBILIZE trial."	( Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease. Bovio, JA; Gums, JG; Smith, SM, 2011)	2.21
" Additional concerns refer to the dosing-regimens and their practical administration: Fondaparinux, rivaroxaban and dabigatran are dosed to achieve maximum effects very close to their limits of tolerance whereas wide dosing spectra for the low molecular weight herparin (LMWH)'s indicate the potential for dose adaptation and increase."	( Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux. Fareed, J; Hull, R; Welzel, D, 2011)	0.79
"The pharmacology, pharmacokinetics, clinical efficacy, tolerability, dosage and administration, and place in therapy of dabigatran etexilate are reviewed."	( Dabigatran etexilate: A novel oral direct thrombin inhibitor. Blommel, AL; Blommel, ML, 2011)	2.02
" Clinicians are increasingly being challenged with making uncertain anticoagulant dosing decisions, as the optimal dosing strategy for most anticoagulants in the obese patient population remains unknown."	( Anticoagulating obese patients in the modern era. Arya, R; Patel, JP; Roberts, LN, 2011)	0.37
" Exposure to dabigatran was not significantly altered with concomitant digoxin-the maximum concentration (Cmax,ss ) and area under the concentration-time curve at steady state over 1 dosing interval (AUCτ,ss ) of dabigatran with and without digoxin were essentially unchanged."	( Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. Körnicke, T; Rathgen, K; Reseski, K; Roth, W; Stähle, H; Stangier, J, 2012)	1.01
" The aim of this analysis was to derive a modeling and simulation-based dose and dosing regimen for AF patients with severe renal failure who could potentially benefit from the use of DE."	( Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. Clemens, A; Friedman, J; Haertter, S; Lehr, T; Liesenfeld, KH; Reilly, PA; Staab, A, 2012)	1.82
"The objective of this work was to derive a dosing regimen for dabigatran in patients with severe renal impairment by modeling and simulation."	( Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. Hariharan, S; Madabushi, R, 2012)	0.86
" The dosage of 110 mg bid should be preferably used in patients older than 75 years at a higher bleeding risk."	( Preventing cardioembolic stroke in atrial fibrillation with dabigatran. Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C, 2012)	0.62
" Because dabigatran is cleared principally by the kidneys, dosage adjustments are required in the setting of renal dysfunction."	( Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor. Augoustides, JG, 2011)	1.06
" This preliminary evidence, while intriguing, requires confirmation in post-stroke patients receiving orally dosed D in order to determine whether these findings are clinically relevant."	( Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke. Fong, A; Hanley, D; Lynch, D; Sani, Y; Schevchuck, A; Serebruany, V; Svetlov, S; Thevathasan, L, 2012)	0.77
"The labeling of dabigatran etexilate (Pradaxa-Boehringer Ingelheim), an oral direct thrombin inhibitor, has recently been updated to include new dosing and monitoring recommendations and a warning on the risk of bleeding."	( Bleeding with dabigatran (Pradaxa). , 2011)	1.08
"For this paper the authors searched the literature for data on efficacy and bleeding rates with low-molecular-weight heparins and fondaparinux in routine clinical practice; and on the effects of standard or reduced dosing with these anticoagulants or with the oral direct thrombin inhibitor dabigatran etexilate in vulnerable patient groups."	( A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk. Albaladejo, P; Rosencher, N, 2012)	0.78
" Heparin was not used postoperatively and transition dosing from dabigatran to warfarin was started on postoperative day 8, the day of discharge."	( Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies. Fieland, D; Taylor, M, 2012)	2.06
" Based on its pharmacokinetic profile, dabigatran is dosed twice daily."	( Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J, 2012)	0.96
" For patients who miss or delay taking one scheduled dabigatran dose, twice daily dosing maintained adequate minimum trough concentrations better than once daily dosing."	( Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J, 2012)	0.94
" The efficacy and safety of this dosing regimen is supported by clinical data from the RE-LY trial."	( Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J, 2012)	0.69
" However, one study failed to demonstrate noninferiority to subcutaneous enoxaparin dosed BID in the composite end point of VTE, and all-cause mortality."	( Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders. Cheng, JW; Vu, H, 2012)	1.82
" The discussion of clinical trial data focuses on comparative trials with the EU approved dosage regimen of once-daily subcutaneous enoxaparin sodium 40 mg."	( Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. Burness, CB; McKeage, K, 2012)	1.82
" The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option."	( Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. Halperin, JL; Varughese, CJ, 2012)	0.38
" Dosed twice daily, dabigatran offers recipients the ability to forego regular international normalized ratio coagulation monitoring as well as eliminating dietary restrictions (i."	( Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin? Freeman, MK; Hughes, PJ, 2012)	2.15
" These agents promise to be more convenient to administer with fixed dosing but still have equivalent efficacy and improved bleeding risk compared to warfarin."	( Newer oral anticoagulant agents: a new era in medicine. Goel, R; Srivathsan, K, 2012)	0.38
"This study aims to test a new dosing regimen for dabigatran etexilate in patients with a mechanical bileaflet valve."	( A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Brueckmann, M; Connolly, SJ; Eikelboom, JW; Friedman, J; Granger, CB; Harper, R; Härtter, S; Kappetein, AP; Lehr, T; Mack, MJ; Noack, H; Van de Werf, F, 2012)	0.98
" Dabigatran (110 or 150 mg twice daily) demonstrated noninferiority versus adjusted-dose warfarin with regard to the prevention of stroke and systemic embolism (primary endpoint) in patients with AF in the RE-LY trial, and the 150 mg twice-daily dosage was significantly more effective than warfarin for this endpoint, as well as most other efficacy endpoints."	( Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. McKeage, K, 2012)	2.73
" The dosage of 110 mg BID should be preferably used in patients aged 75-80 years or older as the rate of extracranial bleeding events tends to increase with dabigatran 150 mg BID above this age limit."	( Dabigatran for stroke prevention in atrial fibrillation. Diener, HC; Hohnloser, SH, 2012)	2.02
" Genotype-guided warfarin dosing and management may improve patient-time in target range (TTR) and therefore affect the cost-effectiveness of dabigatran compared with warfain."	( Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. Cheng, G; Tsui, KK; Wong, RS; You, JH, 2012)	0.89
" The approved dosing regimen for patients with creatinine clearance 15-30 mL/min (75 mg twice daily) was derived from PK modeling studies, limiting its applicability to the clinical setting."	( Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation. Kim, JJ; Mack, DR, )	0.39
" Steady-state dosing of clopidogrel 75 mg qd and dabigatran etexilate 150 mg bid (part 2) demonstrated minor effects on dabigatran pharmacokinetics (AUC(τ,ss) ratio test/reference: 91."	( Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Baumann, S; Friedman, J; Fritsch, H; Härtter, S; Schepers, C; Sennewald, R, 2013)	0.87
" It is suggested to perform EXCA tests for each individual patient to determine the real drug dosage he needs to reach 10-20% of normal EXCA for therapy or 20-40% of normal EXCA for prophylaxis."	( Determination of the anti-F10a or anti-F2a generation action of rivaroxaban or dabigatran. Stief, TW, 2012)	0.61
" The requirement for a twice-daily dosage regimen, the lack of an anticoagulation monitoring option, the relatively short duration of action and the lack of an antidote may even prove to be crucial disadvantages in clinical practice in comparison to vitamin K antagonists."	( [New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients]. Berthold, HK, 2012)	0.38
" They have a slow onset and offset of action, narrow therapeutic window, marked dose-response variability, and multiple food and drug interactions, and require frequent coagulation monitoring and dose adjustments."	( Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges. Mangiafico, M; Mangiafico, RA, 2012)	0.38
" These data suggest that direct thrombin inhibition in a relevant dosage improved endothelial function and reduced atherosclerotic lesion size, collagen content, and oxidative stress in hypercholesterolemic atherosclerosis."	( The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. Baumhäkel, M; Böhm, M; Kratz, MT; Lee, IO; Schirmer, SH, 2012)	0.64
" Much of the literature associated with dabigatran encourages this view, stressing that dabigatran is a 'game changer' with the advantage of fixed dosing for most patients and no anticoagulation monitoring."	( Dabigatran: rational dose individualisation and monitoring guidance is needed. Al-Sallami, HS; Duffull, SB; Faed, JM; Wright, DF; Zufferey, PJ, 2012)	2.09
" Patients who met at least one caution or contraindication criteria were deemed "non-candidates"; potential dosage reductions of the new oral anticoagulants were not considered."	( Analysis of the projected utility of dabigatran, rivaroxaban, and apixaban and their future impact on existing Hematology and Cardiology Anticoagulation Clinics at The Johns Hopkins Hospital. Carter, KL; Kraus, PS; Ross, PA; Shermock, KM; Streiff, MB; Thomas, ML; Wellman, JC, 2012)	0.65
" Based on the RE-LY and ROCKET AF trial results, we investigated the cost-effectiveness of dabigatran (twice daily dosing of 150 mg or 110 mg based on patient age) versus rivaroxaban from a Canadian payer perspective."	( Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV, 2012)	2.04
" These newer agents possess a highly predictable pharmacokinetic-pharmacodynamic relationship, allowing for fixed dosing and no necessity for routine laboratory monitoring; additionally these agents have minimal drug interactions."	( New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence. Kopecky, S, 2012)	0.38
" However, a delay in dosing could occur for clinical or logistical reasons."	( Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis. Clemens, A; Dahl, OE; Eriksson, BI; Hantel, S; Kurth, AA; Rosencher, N, 2012)	0.64
" Results in patients with dosing delayed more than 4h postsurgery were compared with those of patients without a delay."	( Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis. Clemens, A; Dahl, OE; Eriksson, BI; Hantel, S; Kurth, AA; Rosencher, N, 2012)	0.64
" Linearity of dose-response and responsiveness to increasing dose in addition to standardization are other important issues to consider."	( Laboratory tests and the new oral anticoagulants. Tripodi, A, 2012)	0.38
"This review provides recommendations for clinicians regarding dosing during invasive surgical procedures, transitioning off alternative anticoagulants, and a discussion of storage and handling of the drug."	( Dabigatran in clinical practice. Ellis, CR; Nagarakanti, R, 2012)	1.82
" The first, monitoring, implies laboratory testing to assess the drug's effect and to adjust the dosage to maintain anticoagulation within the therapeutic interval."	( The laboratory and the new oral anticoagulants. Tripodi, A, 2013)	0.39
" The choice of tests is based on such characteristics as availability, linearity of the dose-response curve, standardization, and responsiveness to increasing drug dosage."	( The laboratory and the new oral anticoagulants. Tripodi, A, 2013)	0.39
" Nineteen percent reported some difficulty with twice daily dosing adherence with 13 of 70 reporting missed doses."	( Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data. Boga, T; Michel, J; Mundell, D; Sasse, A, 2013)	1.83
" In addition, dabigatran significantly facilitates management of patients with atrial fibrillation as it does not require laboratory monitoring, has predictable pharmacokinetics, simple dosing regimen that does not require complicated dose adjustments, and does not interact with food."	( [Dabigatran etexilate in clinical practice for prevention of thromboembolic events in patients with atrial fibrillation]. Heinc, P; Hrčková, Y; Táborský, M, 2012)	1.65
" A sequential dosage scheme, in which 150 mg are administered up to the age of 80 years and 110 mg thereafter, resulted in an ICER of CHF 10,215 per QALY."	( Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland. Eichler, K; Plessow, R; Pletscher, M; Wieser, S, 2013)	0.7
" In an open-label, single-centre phase I study with two fixed multiple dosing periods, we investigated the pharmacokinetics, pharmacodynamics and safety of dabigatran before, during and after 4 hour haemodialysis sessions with either 200 or 400 ml/min targeted blood flow in seven end-stage renal disease patients without atrial fibrillation."	( Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Clemens, A; Formella, S; Friedman, J; Härtter, S; Khadzhynov, D; Lehr, T; Liesenfeld, KH; Moschetti, V; Neumayer, HH; Peters, H; Slowinski, T; Wagner, F; Wiegert, E, 2013)	0.89
" DE was indicated by using the same selection criteria and dosing as in the RE-MODEL and RE-NOVATE studies."	( [Dabigatran etexilate use among older adults in a home-care system after hip or knee replacement surgery]. La Valle, RÁ; Saimovici, JM; Silveira, M; Waisman, GD; Zunino, S, )	1.04
" These drugs have predictable pharmacokinetics that allow fixed dosing without routine laboratory monitoring."	( Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. Christory, F; Connolly, SJ; Dan, GA; Hatala, R; Huber, K; Kher, A; Kiss, RG; Klun, NV; Meier, B; Merkely, B; Pieske, B; Potpara, T; Stępińska, J; Vinereanu, D; Widimský, P, 2013)	0.73
"To determine the adherence to dabigatran etexilate renal dosing guidelines, the frequency of co-prescription of potentially interacting drugs in patients on dabigatran, and how these related to dabigatran dosing."	( Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. Barclay, ML; Begg, EJ; Chin, PK; Vella-Brincat, JW; Walker, SL, 2013)	1.08
"Few patients were dosed excessively in relation to creatinine clearance."	( Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. Barclay, ML; Begg, EJ; Chin, PK; Vella-Brincat, JW; Walker, SL, 2013)	0.79
" Rivaroxaban, apixaban, and dabigatran have different pharmacological characteristics, and guidance is needed on optimum doses and dosing intervals and the effects of renal or hepatic impairment, age, food, and other drugs."	( Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Graff, J; Harder, S, 2013)	0.68
" Dabigatran was granted marketing authorisation by the European Medicines Agency for a sequential dosing regimen (DBG sequential), in which patients under 80 years are treated with dabigatran 150 mg twice daily (DBG150) and patients 80 years and over are given dabigatran 110 mg twice daily (DBG110)."	( Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal. Burch, J; Corbacho, B; Faria, R; Palmer, S; Pepper, C; Spackman, E; Todd, D; Woolacott, N, 2013)	2.74
" Consequently, if renal function is impaired, there is a risk of drug accumulation that is highest for dabigatran followed by rivaroxaban and then apixaban and thus dosing recommendations are different."	( Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Böhm, M; Dichgans, M; Diener, HC; Ell, C; Endres, M; Epple, C; Grond, M; Laufs, U; Nickenig, G; Riess, H; Röther, J; Schellinger, PD; Spannagl, M; Steiner, T; Veltkamp, R, 2013)	0.81
" In this review, we outline key pharmacokinetic and pharmacodynamic features of each compound and provide guidance on selection and dosing of the 3 NOACs relative to warfarin when considering OAC therapy for AF patients."	( Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Gong, IY; Kim, RB, 2013)	0.61
" Much remains to be learned about the optimal use of the novel oral anticoagulants in CKD patients; additional studies about optimal dosing of the novel oral anticoagulants and frequency of monitoring renal function in CKD patients with atrial fibrillation are needed."	( Stroke prevention in atrial fibrillation patients with chronic kidney disease. Brimble, KS; Eikelboom, JW; Hart, RG; Ingram, AJ; McMurtry, MS, 2013)	0.39
" If the anticoagulant dosage is not immediately available, worse propositions, based on the usual tests (prothrombin time and activated partial thromboplastin time), are presented."	( Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Albaladejo, P; Blais, N; Cohen, A; de Maistre, E; Fontana, P; Godier, A; Gruel, Y; Llau, JV; Mismetti, P; Pernod, G; Rosencher, N; Samama, CM; Samama, MM; Schved, JF; Sié, P; Susen, S, )	0.13
" However the choice of dosing regimens in different clinical conditions has been different for the various NOACs, and has been established on the basis of widely different considerations, including the clinical setting (venous versus arterial thrombosis), the indications (prophylaxis versus treatment), the likelihood of concomitant antiplatelet drugs, and marketing opportunities; these latter were based on the knowledge that patients' compliance is generally better with once daily than with twice daily dosing."	( The new oral anticoagulants in atrial fibrillation: once daily or twice daily? De Caterina, R; Renda, G, )	0.13
" These new anticoagulants do not require strict and frequent laboratory monitoring, dosing adjustments, or dietary restrictions, and they incur fewer drug-drug interactions than warfarin."	( Novel oral anticoagulants: a review of new agents. Wanat, MA, 2013)	0.39
" If the dosage of the drug is not immediately available, proposals only based on the usual tests, PT and aPTT, also are presented."	( [Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013]. Albaladejo, P; Blais, N; Cohen, A; de Maistre, E; Fontana, P; Godier, A; Gruel, Y; Llau, JV; Mismetti, P; Pernod, G; Rosencher, N; Samama, CM; Samama, MM; Schved, JF; Sié, P; Susen, S, 2013)	0.39
" The authors recommend caution while dosing dabigatran in the Asian population, as the estimates of kidney functioning vary substantially depending on the formula used to estimate GFR, which may in turn lead in some cases of inadequate dosing of dabigatran."	( A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation. Azuma, S; Lum, CJ, 2013)	0.65
"Pharmacogenetics-guided warfarin dosing is an alternative to standard clinical algorithms and new oral anticoagulants for patients with nonvalvular atrial fibrillation."	( Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. Hughes, DA; Lane, S; Pink, J; Pirmohamed, M, 2014)	0.4
" Adjusted dosage of dabigatran to 110 mg/bid according to renal clearance in combination with 150 mg/day aspirin was started."	( [Severe thrombosis of bioprosthesis mitral valve after dabigatran]. Akgüllü, C; Eryılmaz, U; Kurtoğlu, T, 2013)	0.96
" Advantages and disadvantages to using these newer agents are presented, as are dosing adjustments for renal and hepatic impairment."	( Outpatient management of oral anticoagulation in atrial fibrillation. Manning, JA, 2013)	0.39
" These data suggest cautious early uptake of dabigatran, and more careful attention to dosing adjustments is warranted."	( Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Holmes, DN; Hylek, EM; Kowey, PR; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013)	0.98
" These drugs differ in a several important respects from warfarin; most notably they have a reliable dose-response effect which means they can be given without the need for monitoring."	( New oral anticoagulants: their role and future. Laffan, M; Shapiro, S, 2013)	0.39
" The dose of dabigatran was appropriate in 90% of the patients, with the most common cause of inappropriate dosing due to perceived bleeding risk."	( Dabigatran Use in the Real World: A Multihospital System Experience. Davis, M; Kabra, R; Kimmons, LA; Oliphant, CS; Segars, BV, 2014)	2.21
" In contrast to warfarin, most NOACs need dosage adjustments in renal impairment and are contraindicated in severe liver impairment, and there are no specific antidotes for treating NOAC-related over-anticoagulation."	( New oral anticoagulants in practice: pharmacological and practical considerations. Bajorek, B; Wang, Y, 2014)	0.4
" The HTI dosage could help managing the treatment in case of severe bleeding event."	( Impaired renal function and bleeding in elderly treated with dabigatran. Assayag, P; Berthelot, E; Desconclois, C; Lavenu-Bombled, C; Orostegui-Giron, L, 2014)	0.64
" They are at least as effective and as safe as conventional therapy (heparins and vitamin-K inhibitors) and have practical advantages, such as fixed dosing and no need for laboratory monitoring."	( Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. Bounameaux, H; Fontana, P; Goldhaber, SZ, 2014)	0.4
" Dabigatran was given through sequential dosing, where patients<80 years old received 150 mg of dabigatran twice a day and the dosage was reduced to 110 mgs for patients ≥ 80 years old."	( Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan. Chang, CH; Chen, JH; Lin, LJ; Yang, YH, 2014)	1.63
" However, in elderly patients with impaired renal function or considerable bleeding risks, label advice regarding dosing needs strict observation."	( Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation. Harder, S; Meyer Dos Santos, S, 2014)	0.7
"Clinical results of the European Action on Anticoagulation (EAA) computer-assisted dosage study and the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial have been compared."	( Warfarin or dabigatran for treatment of atrial fibrillation. Ibrahim, S; Jespersen, J; Poller, L, 2014)	0.78
" Current dabigatran dosing guidelines use the Cockcroft-Gault (CG) equation to gauge renal function, instead of contemporary equations including the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations employing creatinine (CKD-EPI_Cr), cystatin C (CKD-EPI_Cys) and both renal biomarkers (CKD-EPI_CrCys)."	( Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. Barclay, ML; Begg, EJ; Chin, PK; Jensen, BP; Patterson, DM; Roberts, RL; Wallace, MC; Wright, DF; Zhang, M, 2014)	1.1
" In the studied dosing regimens, these drugs failed to show a net clinical benefit in addition to dual antiplatelet therapy."	( Direct oral anticoagulants in acute coronary syndrome. Ahrens, I; Bode, C, 2014)	0.4
" The results of the 110-mg BID dosage were mainly driven by the RE-LY trial."	( Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. Bruyère, O; Buckinx, F; Dogné, JM; Douxfils, J; Hainaut, P; Minet, V; Mullier, F; Rabenda, V; Reginster, JY, 2014)	1.85
" The most frequent inappropriate criteria were inappropriate choice (28% of patients), wrong dosage (26%), and impractical modalities of administration (26%)."	( Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. Chatelain, C; Devalet, B; Dogné, JM; Douxfils, J; Larock, AS; Mullier, F; Sennesael, AL; Spinewine, A, 2014)	0.69
" Other reasons included dosing frequency (5."	( Continuation of dabigatran therapy in "real-world" practice in Hong Kong. Chan, EW; Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Leung, GK; Siu, CW; Tse, HF, 2014)	0.75
"Compared to Vitamin K antagonists (VKA), novel oral anticoagulants (NOACs) appear to be safer in terms of major bleeding risks with added advantage of having fixed dosing schedules when used in patients with non-valvular atrial fibrillation (AF)."	( Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants. Aryal, MR; Badal, M; Chaudhary, A; Donato, AA; Mege, J, 2015)	0.42
"Ease of dosing and simplicity of monitoring make new oral anticoagulants an attractive therapy in a growing range of clinical conditions."	( Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates. Baumann Kreuziger, LM; Dries, DJ; Keenan, JC; Morton, CT, 2014)	0.4
" Coagulation biomarkers in shed blood were assessed at 3 h after monotherapy with the medicines under study, at 3 h after triple therapy dosing and at steady state trough conditions."	( Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects. Eichinger, S; Gouya, G; Kapiotis, S; Kyrle, PA; Litschauer, B; Mayer, P; Smerda, L; Weisshaar, S; Wolzt, M, 2014)	0.4
"Dabigatran is available on formulary with a dosing and monitoring policy developed by a multidisciplinary subcommittee of the formulary and therapeutics committee."	( Bleeding incidence and real-life prescribing practices with dabigatran use in an acute care setting. Campbell, P; Lam, T; Nguyen, C; Tran, TH, 2014)	2.09
" Practical advantages of NOACs over warfarin include fixed once- or twice-daily oral dosing without the need for coagulation monitoring, and few known or defined drug or food interactions."	( Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Bell, AD; Douketis, J; Eikelboom, J; Liew, A, 2014)	0.4
" This study examines the relative cost-effectiveness of dabigatran (BID dosing of 150 mg or 110 mg based on patient age), rivaroxaban, and apixaban from a UK payer perspective."	( Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. Gonschior, AK; Heinrich-Nols, J; Kansal, AR; Noack, H; Sorensen, SV; Sunderland, T; Zheng, Y, 2014)	0.65
"New oral anticoagulants require dosing adjustment according to renal function."	( Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. Andreu-Cayuelas, JM; Gallego, P; Lip, GY; Manzano-Fernández, S; Marín, F; Orenes-Piñero, E; Roldán, V; Valdés, M; Vicente, V, 2015)	0.42
"Among the overall population, relative to Cockcroft-Gault, discordance in dabigatran dosage was 11."	( Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. Andreu-Cayuelas, JM; Gallego, P; Lip, GY; Manzano-Fernández, S; Marín, F; Orenes-Piñero, E; Roldán, V; Valdés, M; Vicente, V, 2015)	0.65
" It has also been used in patients for other indications as a substitute for warfarin therapy because it requires no monitoring; one group being patients undergoing radiofrequency (RF), ablation for AF, although there have been no consensus guidelines with regards to dosage and timing of dose."	( Left atrial appendage thrombus with resulting stroke post-RF ablation for atrial fibrillation in a patient on dabigatran. Hussaini, A; Kiernan, TJ; Lobo, R; McCann, C; Meany, TB, )	0.34
" Vitamin K antagonists require regular monitoring and dosage adjustment."	( Dabigatran etexilate as second-line therapy in patients with a left ventricular assist device. Charitos, C; Diakos, N; Kaldara, E; Kapelios, CJ; Katsaros, L; Nanas, JN; Ntalianis, A; Terrovitis, JV; Tsamatsoulis, M; Vakrou, S, )	1.57
" The RapidTEG activated clotting time test allowed the creation of a dose-response curve for all 3 NOACs."	( Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants. Dias, JD; Doorneweerd, DD; Norem, K; Omert, LA; Popovsky, MA; Thurer, RL, 2015)	0.42
" The increased incidence of major bleeding (excluding fatal) due to fondaparinux could be perhaps lowered by dosage reduction in patients with a mildly decreased creatinine clearance."	( [Contribution of novel anticoagulants fondaparinux and dabigatran to venous thromboembolism prevention]. Antonijević, N; Apostolović, M; Jovanović, L; Kanjuh, V; Vukčević, M; Živković, I, )	0.38
" The mean dosage of dabigatran was 211."	( Efficacy of Dabigatran for Dissolving Deep Vein Thromboses in Outpatients With a Deteriorated General Condition. Fujino, T; Ikeda, T; Kabuki, T; Kiuchi, S; Kobayashi, K; Yamazaki, A; Yamazaki, J; Yamazaki, Y, 2015)	1.12
"To review current literature for target-specific oral anticoagulants (TSOACs) and provide critical analysis for dosing recommendations in special population groups."	( Dosing of Target-Specific Oral Anticoagulants in Special Populations. Ge, D; Morrill, AM; Willett, KC, 2015)	0.42
" It is valuable to understand the rationale for labeled dosing recommendations in nonvalvular atrial fibrillation and venous thromboembolism treatment and prevention, particularly in patients that fall into special population groups."	( Dosing of Target-Specific Oral Anticoagulants in Special Populations. Ge, D; Morrill, AM; Willett, KC, 2015)	0.42
" In this regard, novel oral anticoagulants (NOACs) have shown promise in the shift toward the "ideal" anticoagulant therapy, in that fixed dosing is the norm, drug interactions are few, food interactions are absent, onset is fairly immediate and offset predictable, and, in the majority of patients, therapeutic monitoring is not required."	( Novel Anticoagulants in Atrial Fibrillation: A Primer for the Primary Physician. Mookadam, F; Mookadam, M; Shamoun, FE, )	0.13
" Rivaroxaban is the only DOAC that has once-daily dosing while apixaban is the only DOAC that has lower risk of overall, major, and gastrointestinal bleeding compared with VKA."	( Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran. Law, EH; Leung, TS, 2015)	0.63
" NOACs overcome these difficulties; however, physicians' hesitation to use NOACs with the optimal dosage may be another limitation in real-world practice."	( A new gap in the novel anticoagulants' era: undertreatment. Bayyigit, A; Belen, E; Canbolat, IP; Helvaci, A; Kilickesmez, K; Pusuroglu, H, 2015)	0.42
"The dabigatran dose-response is predictable; however, it is necessary to measure plasma levels in a variety of clinical conditions."	( Measuring dabigatran with the dilute Russell viper venom confirm assay in an anticoagulation clinic population. Fritsma, GA; McGlasson, DL, 2016)	1.39
"Once daily dosing schedule is associated with increased adherence to and persistence with cardiovascular therapies."	( Adherence to and persistence with non-vitamin K-antagonist oral anticoagulants: does the number of pills per day matter? Rubboli, A, 2015)	0.42
" Thrombin time and anti-IIa activity were dosed for each patient."	( Thrombin time and anti-IIa dabigatran's activity: hypothesis of thrombin time's predictive value. Kaabar, M; Le Guyader, M; Lemaire, P; Pineau Vincent, F, )	0.43
" The patient tolerated the combination, with dabigatran blood levels within the expected range at a standard dosing regimen, without evidence of bleeding or other adverse outcomes."	( Novel oral anticoagulants and HIV: dabigatran use with antiretrovirals. Holloway, C; Joseph, J; Perram, J, 2015)	0.95
" The aim of the present study was to evaluate the hypothetical need for dosage adjustment (based on fluctuations in kidney function) of dabigatran, rivaroxaban and apixaban during the first 6 months after hospital discharge in patients with concomitant atrial fibrillation and heart failure."	( Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure. Andreu-Cayuelas, JM; Flores-Blanco, PJ; García-Alberola, A; Lip, GY; Manzano-Fernández, S; Mateo-Martínez, A; Pastor-Pérez, FJ; Puche, CM; Roldán, V; Valdés, M, 2016)	0.64
" The hypothetical recommended dosage of dabigatran, rivaroxaban and apixaban according to renal function was determined at discharge."	( Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure. Andreu-Cayuelas, JM; Flores-Blanco, PJ; García-Alberola, A; Lip, GY; Manzano-Fernández, S; Mateo-Martínez, A; Pastor-Pérez, FJ; Puche, CM; Roldán, V; Valdés, M, 2016)	0.7
"Among the overall study population, 44% of patients would have needed dabigatran dosage adjustment during follow-up, 35% would have needed rivaroxaban adjustment, and 29% would have needed apixaban dosage adjustment."	( Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure. Andreu-Cayuelas, JM; Flores-Blanco, PJ; García-Alberola, A; Lip, GY; Manzano-Fernández, S; Mateo-Martínez, A; Pastor-Pérez, FJ; Puche, CM; Roldán, V; Valdés, M, 2016)	0.67
"The need for dosage adjustment of nonvitamin K oral anticoagulants during follow-up is frequent in patients with atrial fibrillation after acute decompensated heart failure, especially among older patients and those with renal impairment."	( Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure. Andreu-Cayuelas, JM; Flores-Blanco, PJ; García-Alberola, A; Lip, GY; Manzano-Fernández, S; Mateo-Martínez, A; Pastor-Pérez, FJ; Puche, CM; Roldán, V; Valdés, M, 2016)	0.43
" However, the short half-life of NOAC means that twice-a-day dosing is needed and there is higher risk of a prothrombotic state when doses are missed."	( Novel oral anticoagulants for atrial fibrillation. How, CH, 2015)	0.42
" Dabigatran patients resumed medication 8 h after the procedure, resuming usual dosage (every 12 h) the day after surgery."	( Dental implant surgery in patients in treatment by dabigatran. Aguilar-Salvatierra, A; Calvo-Guirado, JL; de Carlos, F; Delgado-Ruiz, RA; Fernández-Cejas, E; Gómez-Moreno, G, 2018)	1.64
" Normal dosage can be resumed 8 h after implant surgery."	( Dental implant surgery in patients in treatment by dabigatran. Aguilar-Salvatierra, A; Calvo-Guirado, JL; de Carlos, F; Delgado-Ruiz, RA; Fernández-Cejas, E; Gómez-Moreno, G, 2018)	0.73
" If a pericardial effusion is newly diagnosed in a patient during anticoagulant therapy, the pharmacotherapy should be revised concerning potentially interacting drugs, like nonsteroidal anti-inflammatory drugs, and dosage of the anticoagulant drug."	( Hemopericardium under dabigatran for stroke prevention in atrial fibrillation. Finsterer, J; Heger, M; Stöllberger, C, 2017)	0.77
"Following enteric dabigatran dosing in vitro assessment of thrombin clotting times (TCT) was undertaken in rabbit plasma spiked with incremental liposome concentrations."	( Reversal of lipophilic weak bases using pH gradient acidic centre liposomes: demonstration of effect in dabigatran-induced anticoagulation. Cave, G; Chauhan, A; Damitz, R; Harvey, M; Hunter, N; Wu, Z, 2016)	0.98
"All the newer oral anticoagulants compared were more effective than adjusted dosed warfarin."	( Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. Hayes, CJ; Martin, BC; Shah, A; Shewale, A, 2016)	0.43
" However, dosing based on coagulation parameters can be difficult because available assays may not provide adequate sensitivity and specificity for measuring anticoagulation induced by dabigatran or the countering effects of PCCs/aPCCs."	( Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. Aisenberg, J; Bernstein, R; Del Zoppo, GJ; Eikelboom, J; Goldstein, P; Grottke, O; Huisman, MV; Jamieson, DG; Levy, JH; Pollack, CV; Spyropoulos, AC; Steiner, T, 2016)	0.86
" However the peri-procedural dosing protocols used in various studies especially in terms of whether NOAC use is interrupted or uninterrupted during AF ablation, have significant inter-operator and inter-institution variability."	( Are Some Anticoagulants More Equal Than Others? - Evaluating the Role of Novel Oral Anticoagulants in AF Ablation. Fox, DJ; Sankaranarayanan, R, )	0.13
"The standard dabigatran etexilate dosage for prevention of venous thromboembolism (VTE) after elective total hip or knee replacement (THR/TKR) is 220mg once daily (qd), with 150mg qd for patients with moderate renal impairment."	( Observational study of dabigatran etexilate 150mg in patients with moderate renal impairment undergoing elective total hip or knee replacement. Brueckmann, M; Clemens, A; Feuring, M; Frostick, SP; Gullberg, J; Kleine, E; Rosencher, N; Samama, CM, 2016)	1.11
" Susoctocog alfa offers the ability to effectively titrate and monitor dosing based on factor VIII activity levels."	( [Coagulation disorders in the intensive care unit - what is new?]. Hart, C; Schmid, S, 2016)	0.43
"Direct oral anticoagulants (DOACs) offer clinical advantages over warfarin, such as minimal medication and food interactions and fixed dosing without the need for routine monitoring of coagulation status."	( Emergent Bleeding in Patients Receiving Direct Oral Anticoagulants. Sterling, SA; Summers, RL, )	0.13
" In the patients of both groups the product dabigatran etexilate in the standard dosage (220 mg/day) was used for specific prevention."	( [Substantiation of the system of thrombus formation prevention in treatment of patients with hip joint pathology against the background of arterial insufficiency of the lower extremities]. Akhtyamov, IF; Shigaev, ES; Ziatdinov, BG, 2016)	0.7
" Nonetheless, the absence of the ability for clinicians to assess compliance or washout with a simple laboratory test (or to adjust dosing with a similar assessment) and the absence of an antidote to rapidly stop major hemorrhage or to enhance safety in the setting of emergent or urgent surgery/procedures have been limitations to greater non-vitamin K antagonist oral anticoagulant usage and better thromboembolic prevention."	( NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. Kaminskas, E; Reiffel, JA; Reilly, P; Sager, P; Sarich, T; Seltzer, J; Weitz, JI, 2016)	0.43
" Differences in the ACT before ablation and adequate initial heparin dosing in patients receiving non-vitamin K antagonist oral anticoagulants (NOACs) were examined."	( Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants. Higashiya, S; Hina, K; Kamikawa, S; Kawamura, H; Komtasubara, I; Kusachi, S; Murakami, M; Murakami, T; Yamaji, H, 2016)	0.43
" In addition to familiarity with the dosing and monitoring of vitamin K antagonists, clinicians are accustomed to using vitamin K if there is a need to reverse the anticoagulant effect of vitamin K antagonists."	( Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. Antman, EM; Giugliano, RP; Ruff, CT, 2016)	0.43
" If the dosage of the drug is not available, proposals are based on the combination of a PT ≥80% and an aPTT ≤1."	( PT, aPTT, TT and the hemostatic safety threshold of dabigatran and rivaroxaban. Calmette, L; Flaujac, C; Gouin-Thibault, I; Horellou, MH; Ibrahim, F; Layka, A; Mazoyer, É, 2016)	0.68
" We suggest that repeated dosing may lead to higher concentrations, but this should be further explored."	( Vitreous and subretinal fluid concentrations of orally administered dabigatran in patients with rhegmatogenous retinal detachment. Kluft, C; Mulder, VC; van Meurs, JC, 2016)	0.67
" Outcome measures were dosing errors if GFR were to be substituted for CrCL-CG."	( Potential Effect of Substituting Estimated Glomerular Filtration Rate for Estimated Creatinine Clearance for Dosing of Direct Oral Anticoagulants. Schwartz, JB, 2016)	0.43
" At a CrCL-CG of less than 30 mL/min, GFR estimates missed indicated dosage reductions for dabigatran in 18% to 21% of NHANES subjects and 57% to 86% of research subjects."	( Potential Effect of Substituting Estimated Glomerular Filtration Rate for Estimated Creatinine Clearance for Dosing of Direct Oral Anticoagulants. Schwartz, JB, 2016)	0.65
"A recommendation for dosage adjustment of dabigatran etexilate, a prodrug of dabigatran, seems to be desirable based on creatinine clearance to avoid bleeding and stroke."	( Dosage Adjustment of Dabigatran Etexilate Based on Creatinine Clearance in Patients With Cardioembolic Stroke or Atrial Fibrillation. Imazu, T; Kimura, R; Maeda, Y; Matsuda, S; Matsumoto, A; Murakami, T; Nakamura, M, 2016)	1.02
" Since there was no dose-response for bleeding, the switch from VKA to dabigatran in itself was not a risk factor for bleeding."	( Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation. Gislason, GH; Lee, CJ; Lindhardt, TB; Olesen, JB; Pallisgaard, JL; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C, 2016)	0.88
" To our knowledge, this is the first case report to describe the successful use of repeat dosing of idarucizumab with hemodialysis to reverse the anticoagulant effects of dabigatran."	( Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis. Berliner, N; Connell, NT; Connors, JM; Dew, RB; Marino, KK; Santiago, RA; Tucker, JK, 2016)	0.99
" With similar efficacy, better safety, and the convenience of fixed dosing without the need for routine coagulation monitoring, guidelines now recommend DOACs over VKAs for VTE treatment in patients without active cancer."	( Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants. Jaffer, IH; Weitz, JI, 2016)	0.43
" The article addresses some crucial aspects of NOAC therapy such as measurement of anticoagulant effects, transition between different agents, ensuring drug intake compliance, dealing with dosing errors, management of bleeding complications etc based on the guidance offered by the European Heart Rhythm Association in 2013."	( Current Perspective on Use of NOAC in Clinical Practice in India. Bhave, A; Dalal, JJ; Dhall, A, 2016)	0.43
"Compared to enoxaparin (most commonly dosed 40 mg once daily), the relative risk (RR) of VTE was lowest for edoxaban 30 mg once daily (0."	( Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis. Gage, BF; Ganti, BR; Lee, ED; Lin, H; Nunley, RM; Venker, BT, 2017)	0.46
"Direct oral anticoagulants currently have no indication for monitoring even though there are data that imply that individual dosing can improve and add safety to the therapy."	( Development of an UHPLC-UV-Method for Quantification of Direct Oral Anticoagulants: Apixaban, Rivaroxaban, Dabigatran, and its Prodrug Dabigatran Etexilate in Human Serum. Boehr, S; Haen, E, 2017)	0.67
" DOACs have a wide therapeutic range that allows fixed dosing determined based on studies conducted in healthy subjects with normal absorptive capacity."	( Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs). Al-Sanea, N; Hakeam, HA, 2017)	0.46
"Surgical procedures under NOACS can be scheduled at the beginning of next dosing interval or omitted in low/minimal bleeding risk patients, so that only 2-3 NOAC doses are not administered."	( [Management of NOAK administration during invasive or surgical interventions : When and how to pause and when to restart?] Buerke, M; Hoffmeister, HM, 2017)	0.46
" To ensure responsible use of these agents, every hospital needs a bleeding management algorithm that identifies patients eligible for reversal and outlines appropriate dosing regimens."	( Reversal of Direct Oral Anticoagulants: Current Status and Future Directions. Weitz, JI, 2017)	0.46
"Pre-existing and treatment-emergent ADA were present at extremely low levels relative to the idarucizumab dosage under evaluation."	( Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies. Glund, S; Haazen, W; Harada, A; Ikushima, I; Imazu, S; Lang, B; Moschetti, V; Norris, S; Ramael, S; Reilly, PA; Stangier, J, 2017)	0.72
" The fact that the NOACs don't require routine monitoring to assure that patients remain within the therapeutic range and have relatively simple dosing requirements and a safer risk profile makes them attractive substitutes to warfarin in HF patients with atrial fibrillation and other conditions (e."	( Anticoagulation Therapy and NOACs in Heart Failure. EncisoSilva, J; Greenberg, B; Schlueter, M; Thomas, I, 2017)	0.46
" A single 5 g dose is usually sufficient, but higher doses may sometimes be required and optimum dosing has not been defined."	( Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding. Grottke, O; Honickel, M; Rossaint, R; Spronk, HM; Stoppe, C; Ten Cate, H; van Ryn, J, 2017)	0.71
"The superiority of dabigatran has been well proven in the standard dosing regimen in prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and extended venous thromboembolism (VTE) treatment."	( Dabigatran - Metabolism, Pharmacologic Properties and Drug Interactions. Antonijevic, NM; Culafic, MD; Jovanovic, LM; Kanjuh, VI; Kocica, MJ; Matic, DM; Mrdovic, IB; Zivkovic, ID, 2017)	2.23
"We compared NOACs (as a group) to warfarin in non-valvular atrial fibrillation, studying all 12,694 patients starting NOAC treatment within the Swedish clinical register and dosing system Auricula, from July 1, 2011 to December 31, 2014, and matching them to 36,317 patients starting warfarin using propensity scoring."	( Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study. Byström, B; Norrving, B; Oldgren, J; Renlund, H; Själander, A; Sjögren, V; Svensson, PJ, 2017)	0.46
" Therefore, it is likely safe to coadminister ritonavir with DE, while there is a potential need for reduced dosing and prudent clinical monitoring with the coadministration of cobicistat due to the greater net inhibition of intestinal P-gp transport and increased bioavailability."	( Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. Alfaro, RM; Brooks, KM; George, JM; Gordon, LA; Hadigan, C; Kellogg, A; Kumar, P; Lozier, J; McManus, M; Nghiem, K; Penzak, SR, 2017)	0.65
" Off-label indications and dosage too low were the most common not per protocol reasons for apixaban and rivaroxaban prescriptions."	( Comparison of Prescribing Practices with Direct Acting Oral Anticoagulant Protocols. Carley, B; Draper, E; Griesbach, S; Krueger, K; Larson, T; Parkhurst, B, 2017)	0.46
"Once-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) may increase patient adherence to treatment but may also be associated with a higher risk of bleeding."	( Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study. Akyüz, A; Başaran, Ö; Berilgen, R; Çelik, O; Çetin, N; Coşar, S; Dereli, Y; Doğan, T; Doğan, V; Emren, SV; Enhoş, A; Ergene, O; Gürsul, E; İnci, S; Karaca, I; Karaca, Ö; Köseoğlu, C; Levent, F; Onrat, E; Otlu, YÖ; Özdemir, İH; Özmen, Ç; Sümerkan, M; Zoghi, M, 2018)	0.48
" Appropriateness was evaluated based on approved dosing and indications in Canada and the United States."	( Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience. Ali, Z; El-Makaty, H; Elewa, H, 2018)	0.81
"3%) patients, while inappropriate dosing was found in 352 (33."	( Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience. Ali, Z; El-Makaty, H; Elewa, H, 2018)	0.81
" While efficacious, they are difficult to use due to interpatient dose-response variability and the risks of bleeding."	( Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs. Fischer, PM, 2018)	0.48
"The direct oral anticoagulants (DOACs), also referred to as novel (or non-vitamin K antagonist) oral anticoagulants (NOACs), represent a major development in anticoagulation therapy due to their rapid onset of action, predictable dose-response with fixed doses and limited interactions with food and drugs."	( An update on the bleeding risks associated with DOACs. , 2017)	0.46
" However, further prospective randomized trials are needed in order to comprehensively evaluate whether D150 or D110 is the optimal dosage in Asian patients with AF."	( Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation. Ahn, Y; Cho, JG; Cho, JY; Hong, YJ; Hyun, DY; Jeong, MH; Kim, JH; Kim, KH; Kim, MC; Kim, Y; Lee, KH; Lee, N; Oh, SS; Park, HJ; Park, HW; Park, JC; Sim, DS; Won, J; Yoon, HJ; Yoon, NS, 2017)	0.8
"In this review we present comparison of pharmacokinetics of novel oral anticoagulants (NOAC) dabigatran, rivaroxaban, apixaban, and edoxaban, principles of selection of a regimen of their dosing for phase III clinical trials in patients with atrial fibrillation."	( [Clinico-Pharmacological and Clinical Basis of Multiplicity of Intake of Novel Oral Anticoagulants]. Levanov, AN; Sinitsina, II; Sychev, DA; Tsomaya, IV; Vardanyan, AV, 2017)	0.67
"Pradaxa (dabigatrani etexilati mesilas) belongs to a new group of anticoagulants, its pharmacological properties enabling uniform dosage without a need for monitoring the anticoagulant effect."	( [Bleeding during anticoagulant and antiaggregation therapy as a cause of acute abdomen]. Hekerová, M, )	0.55
" Drug dosage changes and serum creatinine determinations were recorded during 1-year follow-up."	( Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation. Albendin Iglesias, H; Andreu Cayuelas, JM; Bailen Lorenzo, JL; Caro Martínez, C; Cerezo Manchado, JJ; Elvira Ruiz, G; Flores Blanco, PJ; García Alberola, A; Januzzi, JL; Manzano-Fernández, S, 2018)	0.48
" Compliance with kidney function monitoring recommendations was associated with adequate NOAC dosage at 1-year follow-up."	( Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation. Albendin Iglesias, H; Andreu Cayuelas, JM; Bailen Lorenzo, JL; Caro Martínez, C; Cerezo Manchado, JJ; Elvira Ruiz, G; Flores Blanco, PJ; García Alberola, A; Januzzi, JL; Manzano-Fernández, S, 2018)	0.48
"There is limited evidence on patients' adherence and the impact of the prescribed dosing regimen in non-vitamin-K oral anticoagulants (NOACs)."	( Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands. de Boer, PT; Hoffmann, M; Jacobs, MS; Levin, LÅ; Postma, MJ; Schouten, JF, 2018)	0.48
" Patients using a consistent dosage for at least 180 consecutive days were included."	( Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands. de Boer, PT; Hoffmann, M; Jacobs, MS; Levin, LÅ; Postma, MJ; Schouten, JF, 2018)	0.48
"Direct acting non-Vitamin K antagonist oral anticoagulants (NOAC) are characterized by a fixed dosing regimen."	( Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119). Beyer-Westendorf, I; Beyer-Westendorf, J; Endig, S; Marten, S; Reitter, A; Tittl, L, 2018)	0.48
" Future directions include identification of clinically relevant SNPs, and change in optimum dosage for patients who are carriers of significant variants."	( Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives. Ašić, A; Marjanović, D; Mirat, J; Primorac, D, 2018)	0.48
" In addition, we have shown that this increase is affected by dabigatran dosage and concomitant treatment with proton-pump inhibitor and digoxin."	( Effect of Bisoprolol on the Level of Dabigatran. Ivankova, J; Mokan, M; Nehaj, F; Sokol, J, )	0.64
"This study demonstrated the interaction between dabigatran and bisoprolol, which is modulated with dabigatran dosage and concomitant treatment with proton-pump inhibitor and digoxin."	( Effect of Bisoprolol on the Level of Dabigatran. Ivankova, J; Mokan, M; Nehaj, F; Sokol, J, )	0.66
" Dosing schedule is dabigatran 150mg BID patients with normal renal function."	( Dabigatran - the First Approved DTI for SPAF. Hiremath, JS; Trailokya, A, 2018)	2.25
" Multivariable adjusted Cox models stratified by dosage estimated hazard ratios (aHR)."	( Dabigatran Versus Rivaroxaban for Secondary Stroke Prevention in Patients with Atrial Fibrillation Rehabilitated in Skilled Nursing Facilities. Alcusky, M; Fisher, M; Goldberg, RJ; Hume, AL; Lapane, KL; McManus, DD; Tjia, J, 2018)	1.92
" The goal of our study was to evaluate the outcomes of our reduced dosing strategy with FEIBA in patients experiencing a DOAC-related bleeding event."	( Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants. Dager, WE; Nishijima, DK; Roberts, AJ, 2019)	0.51
" Monitoring the effects of the targeted anticoagulant demonstrated the need for correction of dosage and discrete use of the drug in prevention and treatment for thrombohemorrhagic complications in this category of patients."	( Features of Pharmacodynamics of the Anticoagulant Dabigatran in Secondary Thrombophilia. Kairov, GT; Kotlovskaya, LY; Solovev, MA; Udut, VV, 2018)	0.73
" The observed effect could be a secondary consequence of dosage control or alternatively a result of different anticoagulant effects among the different medications."	( Higher Incidence of Ischemic Stroke in Patients Taking Novel Oral Anticoagulants. Cowperthwaite, M; Fanale, C; Nadasdy, Z; Ramakrishnan, A; Shpak, M, 2018)	0.48
" The intake of Dabigatran etexilate in fixed dosage does not exclude development of thrombosis of deep veins of lower extremities that substantiates point of view concerning usefulness of individualization of anti-thrombotic prevention in case of application of new oral anti-coagulants."	( [The clotting tests and molecular markers in evaluating of coagulation alterations against the background of anti-thrombotic prevention by Dabigatran after large orthopedic operations]. Antropova, IP; Reino, EV; Yushkov, BG, 2017)	1.01
" Because the combined effects of drug-drug interactions and RI have not been evaluated by means of clinical studies, the decision of DABE dosing for RI patients receiving P-glycoprotein inhibitors is empirical at its best."	( Assessing Potential Drug-Drug Interactions Between Dabigatran Etexilate and a P-Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling. Doki, K; Homma, M; Neuhoff, S; Rostami-Hodjegan, A, 2019)	0.77
"In the past decade, direct-acting oral anticoagulants (DOAC) have been introduced to medical practice for several indications, with a wide range of dosing regimens."	( Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program. Aldouby-Bier, G; Fisher Negev, T; Hirsh-Raccah, B; Hochberg-Klein, S; Horwitz, E; Kalish, Y; Muszkat, M; Perlman, A, 2019)	0.51
" dosing interval) or patient experiences while on treatment."	( Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter? Brown, JD; Pham, PN, 2019)	0.51
"Apixaban users had the highest overall adherence despite twice-daily dosing versus once-daily dosing for rivaroxaban."	( Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter? Brown, JD; Pham, PN, 2019)	0.51
" Benefits of direct oral anticoagulants include a rapid onset of therapeutic effect, fixed dose-response relationships without the need for routine monitoring, a short half-life, and infrequent need for periprocedural bridging with a parenteral agent."	( Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management. Pickett, JD, 2019)	0.51
"To describe heparin dosing requirements in patients who underwent catheter ablation of atrial fibrillation with uninterrupted anticoagulation using dabigatran etexilate (dabigatran) or warfarin to attain therapeutic activated clotting time (ACT) in the RE-CIRCUIT® study."	( Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study. Bis, B; Calkins, H; Gerstenfeld, EP; Hohnloser, SH; Kleine, E; Nordaby, M; Okumura, K; Schilling, R; Verma, A; Willems, S, 2019)	0.96
" Heparin dosing requirement to reach therapeutic ACT was lowest when time from last dose of dabigatran to septal puncture was 0 to <4 h."	( Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study. Bis, B; Calkins, H; Gerstenfeld, EP; Hohnloser, SH; Kleine, E; Nordaby, M; Okumura, K; Schilling, R; Verma, A; Willems, S, 2019)	0.98
"Background The direct oral anticoagulants (DOACs) offer several advantages over warfarin in the management atrial fibrillation, including the provision of fixed dosing without a requirement for regular monitoring."	( The acceptability of a direct oral anticoagulant monitoring regimen among patients with atrial fibrillation: a pilot study. Aslani, P; Brieger, D; D'Souza, M; Mourad, AP, 2019)	0.51
" The prothrombin time (PT) and activated partial thromboplastin time (APTT) were averaged if they were measured more than twice depending on the respective DOAC and dosage across individuals."	( Excessive Prolongation of Coagulation Time During Treatment With Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation. Akiyoshi, K; Goya, M; Hirao, K; Kawabata, M; Koyama, T; Maeda, S; Sekigawa, M; Takahashi, Y; Yagishita, A; Yamamoto, T, 2019)	0.51
"8%), was found to be significantly associated with inappropriately high DOAC dosage and body weight (≤ 60 kg)."	( Excessive Prolongation of Coagulation Time During Treatment With Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation. Akiyoshi, K; Goya, M; Hirao, K; Kawabata, M; Koyama, T; Maeda, S; Sekigawa, M; Takahashi, Y; Yagishita, A; Yamamoto, T, 2019)	0.51
" Patients with the body weight of <60 kg should be considered for dosage reduction or DOAC withdrawal."	( Excessive Prolongation of Coagulation Time During Treatment With Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation. Akiyoshi, K; Goya, M; Hirao, K; Kawabata, M; Koyama, T; Maeda, S; Sekigawa, M; Takahashi, Y; Yagishita, A; Yamamoto, T, 2019)	0.51
"Appropriate dosing of direct oral anticoagulants (DOACs) requires consideration of renal function."	( Renal Function Estimates and Dosing of Direct Oral Anticoagulants in Stroke Patients with Atrial Fibrillation: An Observational Study. Chen, YT; Lin, HJ, 2018)	0.48
"Although substituting eGFR for CrCl carries potential risks of DOAC overdosing in patients with AF, the effect might be offset by clinicians' predilection for lower dosage in this stroke cohort."	( Renal Function Estimates and Dosing of Direct Oral Anticoagulants in Stroke Patients with Atrial Fibrillation: An Observational Study. Chen, YT; Lin, HJ, 2018)	0.48
" Therefore, although dosed as DABE, a P-gp drug-drug interaction (DDI) is reported as a dabigatran plasma concentration ratio (perpetrator versus placebo)."	( Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins. Marathe, P; Rodrigues, AD; Shen, H; Sinz, M; Yao, M; Zhu, M, 2019)	1.06
" There was a low frequency of unapproved dabigatran dosage regimens (3."	( Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program. Butcher, K; Fanikos, J; França, LR; Gruenenfelder, F; Kermer, P; Lane, DA; Murwin, D; Reilly, PA; Tartakovsky, I; Wowern, FV, 2020)	0.82
" Increasing the duration of anticoagulation, determining the optimal dosage of anticoagulants, and switching to another anticoagulant when necessary could be considered to improve treatment effectiveness."	( Outcome of Anticoagulation Therapy of Left Atrial Thrombus or Sludge in Patients With Nonvalvular Atrial Fibrillation or Flutter. Dong, J; Du, X; Ma, C; Yang, Y, 2019)	0.51
"Direct oral anticoagulants (DOACs) especially dabigatran, have gain popularity for their efficacy, fixed dosing and favourable safety profile."	( A national audit on the utilisation and documentation of dabigatran checklist for patients initiated on dabigatran. Devaraj, NK; Doris, G; Noraini, M; Sahimi, M; Shakirin, SR, 2019)	1.02
" Most patients who were taking NOACs had excellent adherence regardless of the dosing frequency."	( NOAC Adherence of Patients with Atrial Fibrillation in the Real World: Dosing Frequency Matters? Bae, HJ; Cho, YK; Choi, SW; Han, S; Hur, SH; Hwang, J; Jun, SW; Kim, H; Kim, IC; Lee, CH; Lee, SH; Nam, CW; Park, HS; Yoon, HJ, 2020)	0.56
" European guidelines criteria 2012 on dabigatran dosing were examined: age ≥80 years, HAS-BLED ≥3, estimated glomerular filtration rate (eGFR)<50 mL/min/1."	( Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose. Bonde, AN; Fosbøl, EL; Gislason, GH; Køber, L; Lee, CJ; Olesen, JB; Rørth, R; Staerk, L; Torp-Pedersen, C; Vinding, NE, 2021)	1.16
" The patient was taking an adequate dosage of dabigatran, thus dabigatran was thought to be overdosed due to its interaction with ranolazine because dabigatran is a p-glycoprotein substrate, whereas ranolazine is the inhibitor of this transporter."	( Possible Interaction between Dabigatran and Ranolazine in Patients with Renal Failure. Damulevičienė, G; Galaunė, V; Gumbrevičius, G; Gumbrevičiūtė, M, 2019)	1.06
"We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF) taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and bleeding risk."	( Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses. Alvarez, P; Asleh, R; Briasoulis, A; Chrischilles, E; Gao, Y; Inampudi, C; Leira, EC; Vaughan-Sarrazin, M, 2020)	0.78
"To review the literature on treatment of venous thromboembolism (VTE) and prevention of cardioembolic stroke with direct-acting oral anticoagulants (DOACs) in low- and high-body-weight patients and to make recommendations regarding agent selection and dosing in these patient populations."	( Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations. Branam, DL; Covert, K, 2020)	0.56
"The selection and optimal dosing of DOACs in low- and high-body-weight patients has not yet been fully elucidated by clinical trials; however, evidence suggests that issues of both safety and efficacy in patients at the extremes of body weight may warrant careful consideration when selecting a DOAC for such patients."	( Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations. Branam, DL; Covert, K, 2020)	0.56
" In elderly, renal dysfunction, co-morbidity, and concomitant intake of different drugs could make the dosage of Dabigatran challenging."	( A Case of Liver Failure Due to Dabigatran Treated with Venovenous Hemodiafiltration and Idarucizumab. Guglielmo, N; Mestroni, R; Montanari, G; Orso, D, 2020)	1.05
"Application of PGT on the carrier of allelic variant rs2244613 of CES1 gene for adjustment of dabigatrane etexilate dosage in patients with non - valve AF may be more cost - effective strategy for prevention of thromboembolic complications in patients with non - valve AF."	( [Comparative clinical and economic evaluation of pharmacogenetic testing application for dabigatran in patients with atrial fibrillation]. Abdullaev, SP; Mirzaev, KB; Sychev, DA, 2019)	0.95
" Mean aPCC dosing was 2974 IU (SD ± 857 IU)."	( Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: Hemostatic and thrombotic outcomes. Buyukdere, H; Carrier, M; Castellucci, LA; Chakraborty, S; Dowlatshahi, D; Shaw, JR; Tokessy, M, 2020)	0.56
" For low-risk procedures, age ≥75 years, female sex, a creatinine clearance (CrCl) <50 mL/min, and an interruption of <36 hours were associated with a greater likelihood of levels ≥30 ng/mL, whereas age ≥75 years, female sex, a CrCl of <50 mL/min, and standard DOAC dosing were associated with levels ≥50 ng/mL."	( Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. Coppens, M; Douketis, JD; Duncan, J; Li, N; Radwi, M; Schulman, S; Shaw, JR; Spyropoulos, AC; Syed, S; Vanassche, T, 2020)	0.56
" They have multiple advantages over vitamin K antagonists including fixed dosing without coagulation lab monitoring, rapid onset and offset of action, and fewer drug and food interactions."	( Direct-Acting Oral Anticoagulants: A Resident-Based Workshop to Improve Knowledge and Confidence. Anderson, I; Arora, VM, 2020)	0.56
" A growing body of evidence shows that once-daily dosing improves adherence and persistence to therapy, without having an impact on bleeding risk."	( Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence. Haas, S; Patti, G, 2020)	0.56
" Only 37% of patients on warfarin had optimal dosing control, and they did not differ significantly in TTB, TTT, and OS from patients on DOACs."	( Patterns of anticoagulation therapy in atrial fibrillation: results from a large real-life single-center registry. Atić, A; Hadžibegović, I; Hulak Karlak, V; Jurin, I; Lucijanić, M; Magličić, A; Šakić, Z; Starčević, B, 2020)	0.56
" Patients receiving warfarin rarely obtain optimal dosing control, and experience significantly shorter survival compared with patients receiving DOACs."	( Patterns of anticoagulation therapy in atrial fibrillation: results from a large real-life single-center registry. Atić, A; Hadžibegović, I; Hulak Karlak, V; Jurin, I; Lucijanić, M; Magličić, A; Šakić, Z; Starčević, B, 2020)	0.56
"The direct oral anticoagulants (DOAC) have similar half-lives, but the dosing regimen varies between once daily (QD) or twice daily (BID)."	( Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis. Bertoletti, L; Cucherat, M; Durieu, I; Grange, C; Grenet, G; Gueyffier, F; Kilo, R; Laporte, S; Lega, JC; Mainbourg, S; Mismetti, P; Nony, P; Provencher, S, 2021)	0.62
" We evaluated the effect of PMT use on questionable DOAC dosing rates within 40 VHA medical centers and whether this effect differed by DOAC indication or agent."	( Working smarter, not harder: evaluating a population health approach to anticoagulation therapy management. Allen, A; Patterson, ME; Rossier, C; Schaefer, M; Spoutz, P, 2021)	0.62
"To evaluate the safety and efficacy of extended-interval dabigatran dosing in older Chinese patients with non-valvular atrial fibrillation."	( Evaluation of Extended-Interval Dabigatran Dosing in Older Patients With Non-Valvular Atrial Fibrillation. Chen, X; Fan, Y; Fu, Z; Liu, M; Ni, L; Sun, D; Zhao, Z, 2021)	1.15
"We conducted an observational study on non-valvular atrial fibrillation patients administered dabigatran at different dosing intervals at the Department of Geriatrics, Peking University First Hospital, China."	( Evaluation of Extended-Interval Dabigatran Dosing in Older Patients With Non-Valvular Atrial Fibrillation. Chen, X; Fan, Y; Fu, Z; Liu, M; Ni, L; Sun, D; Zhao, Z, 2021)	1.12
" Sixty-two patients received extended-interval dosing with dabigatran at a mean dose of 117."	( Evaluation of Extended-Interval Dabigatran Dosing in Older Patients With Non-Valvular Atrial Fibrillation. Chen, X; Fan, Y; Fu, Z; Liu, M; Ni, L; Sun, D; Zhao, Z, 2021)	1.15
"Extended-interval dabigatran dosing in older patients with non-valvular atrial fibrillation and lower creatinine clearance can maintain activated partial thromboplastin time trough and peak values comparable to the conventional low dose."	( Evaluation of Extended-Interval Dabigatran Dosing in Older Patients With Non-Valvular Atrial Fibrillation. Chen, X; Fan, Y; Fu, Z; Liu, M; Ni, L; Sun, D; Zhao, Z, 2021)	1.24
" The aims of this clinical trial were to study the appropriateness of a paediatric dabigatran dosing algorithm, and the efficacy and safety of dabigatran dosed according to that algorithm versus standard of care in treating children with venous thromboembolism."	( Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Albisetti, M; Bomgaars, L; Brandão, LR; Brueckmann, M; Chalmers, E; Gorbatikov, K; Gropper, S; Halton, J; Huang, F; Kreuzer, J; Luciani, M; Mitchell, LG; Nurmeev, I; Reilly, P; Sharathkumar, A; Simetzberger, M; Sun, Z; Svirin, P; Tartakovsky, I, 2021)	2.29
" Standard of care (low-molecular-weight heparins, unfractionated heparin, vitamin K antagonists or fondaparinux) was compared with a paediatric oral dabigatran dosing regimen (an age-adjusted and weight-adjusted nomogram) in children younger than 18 years with acute venous thromboembolism initially treated (5-21 days) with parenteral anticoagulation, requiring anticoagulation therapy for at least 3 months."	( Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Albisetti, M; Bomgaars, L; Brandão, LR; Brueckmann, M; Chalmers, E; Gorbatikov, K; Gropper, S; Halton, J; Huang, F; Kreuzer, J; Luciani, M; Mitchell, LG; Nurmeev, I; Reilly, P; Sharathkumar, A; Simetzberger, M; Sun, Z; Svirin, P; Tartakovsky, I, 2021)	2.26
"An age-adjusted and weight-adjusted dabigatran dosing algorithm was appropriate in children aged birth to less than 18 years with venous thromboembolism."	( Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Albisetti, M; Bomgaars, L; Brandão, LR; Brueckmann, M; Chalmers, E; Gorbatikov, K; Gropper, S; Halton, J; Huang, F; Kreuzer, J; Luciani, M; Mitchell, LG; Nurmeev, I; Reilly, P; Sharathkumar, A; Simetzberger, M; Sun, Z; Svirin, P; Tartakovsky, I, 2021)	2.34
"This study evaluated DE pharmacokinetics (PK) in children with VTE and the appropriateness of a DE pediatric age- and weight-based dosing algorithm."	( Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism. Albisetti, M; Bergstrand, M; Bomgaars, L; Brandão, LR; Brueckmann, M; Chalmers, E; Gropper, S; Halton, J; Huang, F; Ibrahim, MMA; Joseph, D; Luciani, M; Mitchell, LG; Röshammar, D; Tartakovsky, I, 2021)	0.84
" The final model was used to evaluate the pediatric dosing algorithm, with simulations comparing pediatric trough exposure with reference exposure defined for the pediatric studies."	( Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism. Albisetti, M; Bergstrand, M; Bomgaars, L; Brandão, LR; Brueckmann, M; Chalmers, E; Gropper, S; Halton, J; Huang, F; Ibrahim, MMA; Joseph, D; Luciani, M; Mitchell, LG; Röshammar, D; Tartakovsky, I, 2021)	0.84
" Simulations confirmed that for all DE formulations, the final pediatric dosing algorithms achieved reference exposure without dose adjustment."	( Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism. Albisetti, M; Bergstrand, M; Bomgaars, L; Brandão, LR; Brueckmann, M; Chalmers, E; Gropper, S; Halton, J; Huang, F; Ibrahim, MMA; Joseph, D; Luciani, M; Mitchell, LG; Röshammar, D; Tartakovsky, I, 2021)	0.84
"Using a population PK model of DE for children with VTE, simulations showed that the final dosing algorithms were appropriate for all DE formulations; no dose titration was needed."	( Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism. Albisetti, M; Bergstrand, M; Bomgaars, L; Brandão, LR; Brueckmann, M; Chalmers, E; Gropper, S; Halton, J; Huang, F; Ibrahim, MMA; Joseph, D; Luciani, M; Mitchell, LG; Röshammar, D; Tartakovsky, I, 2021)	0.84
"To clarify the appropriate initial dosage of heparin during radiofrequency catheter ablation (RFCA) in patients with atrial fibrillation (AF) receiving uninterrupted nonvitamin K antagonist oral anticoagulant (NOAC) treatment."	( Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment. Dong, YX; Gao, LJ; Li, WW; Ma, CM; Wang, N; Xia, YL; Xiao, XJ; Yang, MH; Yin, XM; Yu, XH; Zhang, RF, 2021)	0.62
"For patients with AF receiving uninterrupted NOAC treatment who underwent RFCA, an initial heparin dosage of 120 U/kg or 130 U/kg can provide an adequate intraprocedural anticoagulant effect, and 130 U/kg allowed ACT to reach the target earlier."	( Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment. Dong, YX; Gao, LJ; Li, WW; Ma, CM; Wang, N; Xia, YL; Xiao, XJ; Yang, MH; Yin, XM; Yu, XH; Zhang, RF, 2021)	0.62
" These differences between DOACs with almost equal half-life are probably partly due to the differences in dosing interval: twice a day (BID) versus once a day (QD)."	( [Is one DOAC better than another?] Pos, L, 2021)	0.62
" However, suboptimal adherence, variable dosing and use in patient populations that otherwise would have been excluded from clinical trials may impact the efficacy and safety profile of DOACs in a routine care setting."	( Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study. Dasgupta, K; Godin, R; Nedjar, H; Rahme, E; Tagalakis, V, 2021)	0.62
" US Food and Drug Administration-approved dosing was used in 91."	( Evaluation of Prescribing Practices and Outcomes Using Direct-acting Oral Anticoagulants After Cardiac Surgery. Cook, BM; Kanaan, DM; Kelly, J; Malloy, R, 2021)	0.62
"We aimed to assess differences in ACT values and UFH dosage during PVI in patients on different oral anticoagulants."	( Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy. Anic, A; Bakotic, Z; Benko, I; Bojko, A; Brusich, S; Jan, M; Manola, S; Pavlovic, N; Pernat, A; Pezo Nikolic, B; Radeljic, V; Scherr, D; Szavits Nossan, J; Traykov, V; Velagic, V; Zeljkovic, I, 2021)	0.62
" There is a paucity of data for rates of inappropriate inpatient DOAC dosing in Australia."	( Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation. Caughey, GE; Li, RJ; Shakib, S, 2022)	0.72
" Results of clinical trials and real clinical practice studies have confirmed that rivaroxaban may provide a comprehensive protection for a senile patient with AF due to favorable indexes of efficiency and safety, beneficial effect on the risk of coronary events and impairment оf renal function, whereas once a day dosing of rivaroxaban improves the compliance with this treatment and its constancy."	( [Atrial fibrillation in old age: risk management and features of the use of direct oral anticoagulants]. Kanorskii, SG, 2021)	0.62
"To analyse the appropriateness of direct oral anticoagulant (DOAC) dosing and determinants for under-and overdosing as well as acceptance and implementation rates of pharmacists' interventions."	( Determinants for under- and overdosing of direct oral anticoagulants and physicians' implementation of clinical pharmacists' recommendations. Cornu, P; Dupont, A; Moudallel, S; Steurbaut, S, 2022)	0.72
" In patients aged 80 years and over, however, the fear of DOAC-associated bleeding and the complexity of DOAC dosing regimes may prompt physicians to prescribe inappropriate dose levels."	( Direct Oral Anticoagulants and Non-valvular Atrial Fibrillation: Compliance with Dose Level Guidelines in Patients Aged 80 Years and Over. Cavillon Decaestecker, M; Decaestecker, K; Ferret, L; Gautier, S; Tsogli, ES; Verdun, S, 2021)	0.62
" In contrast, initial management in a neurology department was associated with appropriate dosing (p = 0."	( Direct Oral Anticoagulants and Non-valvular Atrial Fibrillation: Compliance with Dose Level Guidelines in Patients Aged 80 Years and Over. Cavillon Decaestecker, M; Decaestecker, K; Ferret, L; Gautier, S; Tsogli, ES; Verdun, S, 2021)	0.62
" It might be possible to reduce inappropriate dosing by raising awareness among hospital-based and private-practice prescribers, providing prescription support tools for DOACs, and performing medication reconciliations and reviews at hospital and in private practice."	( Direct Oral Anticoagulants and Non-valvular Atrial Fibrillation: Compliance with Dose Level Guidelines in Patients Aged 80 Years and Over. Cavillon Decaestecker, M; Decaestecker, K; Ferret, L; Gautier, S; Tsogli, ES; Verdun, S, 2021)	0.62
" Anticoagulant dosing may differ under special considerations."	( An Update of the Efficacy and Comparative Characteristics of Direct (New) Oral Anticoagulants (DOACs). Abuşka, D; Afacan, G; Ersan, E; Hosseinzadeh, M; Karcioglu, O; Ozkaya, B; Yeniocak, S; Yilmaz, S; Zengin, S, 2022)	0.72
"Ciraparantag provides a dose-related reversal of anticoagulation induced by steady-state dosing of apixaban or rivaroxaban."	( Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects. Ansell, J; Bakhru, S; Freedman, D; Laulicht, BE; Tracey, G; Villano, S, 2022)	0.72
"Dabigatran, a novel oral anticoagulant, is a direct thrombin inhibitor and is being increasingly used owing to the advantage of dosing without the need for laboratory monitoring."	( Extensive skin necrosis in an elderly woman on dabigatran. Ahuja, N; Ashraf, R; Bharati, J; Rajarajen, AP, 2021)	2.32
" To what extent the observed increases in DOAC exposure in the older patients is the cause of their increased risk of bleeding, which could potentially be ameliorated by dosing titration, requires further investigation."	( Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients. Avery, P; Biss, T; Kamali, F; Kampouraki, E; Wynne, H, 2021)	0.62
" Previous VKA dosage and creatinine clearance were inversely associated with DOAC trough concentrations."	( Inter- and intra-individual concentrations of direct oral anticoagulants: The KIDOAC study. Cannegieter, SC; Huisman, MV; Lijfering, WM; Nierman, MC; Toorop, MMA; van der Meer, FJM; van Rein, N; Vermaas, HW, 2022)	0.72
" Lower previous VKA dosage and creatinine clearance were associated with higher DOAC trough concentrations."	( Inter- and intra-individual concentrations of direct oral anticoagulants: The KIDOAC study. Cannegieter, SC; Huisman, MV; Lijfering, WM; Nierman, MC; Toorop, MMA; van der Meer, FJM; van Rein, N; Vermaas, HW, 2022)	0.72
" In these situations, the type, dosage or the time of last intake of anticoagulants is often unknown and single substance analysis by functional tests is only possible if the substance contained in the sample is known."	( Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC-MS/MS. Beyer-Westendorf, J; Brückner, L; Pietsch, J; Tiebel, O, 2022)	0.72
"Clear guidelines exist to guide the dosing of direct-acting oral anticoagulants (DOACs)."	( Guideline-discordant dosing of direct-acting oral anticoagulants in the veterans health administration. Berlowitz, DR; Lee, JS; Liu, W; Mitra, A; Rose, AJ; Yu, H, 2021)	0.62
" We examined how often patient dosing was concordant with these recommendations."	( Guideline-discordant dosing of direct-acting oral anticoagulants in the veterans health administration. Berlowitz, DR; Lee, JS; Liu, W; Mitra, A; Rose, AJ; Yu, H, 2021)	0.62
"A substantial portion of DOAC prescriptions in the VA system are dosed contrary to clinical guidelines."	( Guideline-discordant dosing of direct-acting oral anticoagulants in the veterans health administration. Berlowitz, DR; Lee, JS; Liu, W; Mitra, A; Rose, AJ; Yu, H, 2021)	0.62
" Child-appropriate formulations have been developed, age-specific dosing information generated, and safety and efficacy evaluated in ongoing phase 3 trials."	( Anticoagulation in Pediatric Patients. Male, C, 2022)	0.72
" Peak and trough drug plasma concentrations were collected based on the dosing interval and pharmacokinetics of the drugs and quantified using high performance liquid chromatography."	( Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore. Chan, ECY; Soh, XQ; Tan, DS, 2023)	0.91
" As the overall effect of accumulation of several covariates could be difficult to apprehend for the clinicians, PopPK modeling could represent an interesting approach for informed precision dosing and to improve personalized prescription of DOACs."	( Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation. Csajka, C; Daali, Y; Fontana, P; Gaspar, F; Guidi, M; Reny, JL; Terrier, J, 2022)	0.72
"3 mL dosage of CFA into the rat's hind leg planter surface resulted in articular surface deformities, reduced cartilage thickness, loss of intercellular matrix, and inflammatory cell infiltration."	( Ameliorative Effect of Dabigatran on CFA-Induced Rheumatoid Arthritis via Modulating Kallikrein-Kinin System in Rats. Abdel-Reheim, MA; Ahmed Gaafar, AG; Atwa, GMK; Cavalu, S; El-Daly, M; Morsy, MA; Saber, S; Yahya, G; Youssef, ME, 2022)	1.03
" The dosage of dabigatran etexilate was 110 mg twice daily for adults and 55 mg twice daily for children."	( Dabigatran etexilate is efficacious in consumptive coagulopathy and pain associated with venous malformations. Chen, H; Gu, H; Hu, L; Lin, X; Liu, H; Xu, Z; Yang, X, 2023)	2.71
" However, there remain gaps in our understanding of dosage and disparities in use."	( Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014-2019). Arora, J; de Lusignan, S; Delanerolle, G; Emanuel, S; Fan, X; Feher, M; Field, BC; Heiss, C; Hobbs, FR; Joy, M; Kar, D; Pollock, KG; Sandler, B; Sheppard, JP; Williams, J, 2023)	0.91
" Eventually, standard dosing regimens of DABE and digoxin were assessed in Chinese old-elderly patients with chronic heart failure (CHF) with different stages of renal impairment."	( Assessment of Aging-Related Function Variations of P-gp Transporter in Old-Elderly Chinese CHF Patients Based on Modeling and Simulation. Cui, C; Jiang, Y; Li, H; Ling, J; Liu, D; Pan, J; Qu, Y; Sia, JEV; Wang, Y; Zhu, Z, 2022)	0.72
"Per-label dosing of direct oral anticoagulants (DOACs) is important for the prevention of stroke and systemic embolism among patients with non-valvular atrial fibrillation (NVAF), especially those with poor renal function, advanced age, low body weight or concomitant P-glycoprotein inhibitors."	( Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database. Anastassopoulou, A; Doobaree, IU; Fay, M; Gusto, G; Khachatryan, A; Manu, M; Mughal, F; Spentzouris, G; Zawaneh, Y, 2023)	0.91
"Although most patients received per-label dosing, ~ one in five patients was incorrectly dosed with DOAC, which may lead to serious clinical consequences and increased healthcare burden."	( Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database. Anastassopoulou, A; Doobaree, IU; Fay, M; Gusto, G; Khachatryan, A; Manu, M; Mughal, F; Spentzouris, G; Zawaneh, Y, 2023)	0.91
" Hypothetically, an increased glomerular filtration rate (GFR) may lead to suboptimal dosing and a higher thromboembolic events incidence."	( Impact of increased kidney function on clinical and biological outcomes in real-world patients treated with Direct Oral Anticoagulants. Acosta-Isaac, R; Corrochano, M; Mojal, S; Moret, C; Muñoz, R; Plaza, M; Souto, JC, 2022)	0.72
" Importantly, no study has adequately accounted for warfarin dosing being continuously modified based on INR values while dosing of DOACs is fixed."	( Comparison of medication adherence to different oral anticoagulants: population-based cohort study. Ágústsson, AS; Björnsson, ES; Guðmundsdóttir, BR; Hreinsson, JP; Ingason, AB; Lund, SH; Önundarson, PT; Pálsson, DA; Reynisson, IE; Rumba, E, 2023)	0.91
" Additional data on safety, efficacy, and dosing strategies for reversal agents are also necessary, especially as the use of DOACs becomes more common in the pediatric population."	( Just DOAC: Use of direct-acting oral anticoagulants in pediatrics. Cober, MP; Fenn, NE; Hill, C; King, M; Mills, K; Omecene, NE; Pauley, JL; Sierra, CM; Smith, T, 2023)	0.91
" Our simulation results revealed that recommended reduced dosing regimen of dabigatran etexilate during comedication with verapamil and clarithromycin (110 and 75 mg BID for Chinese young and old older adults) will result in exposure (trough concentration) that was either slightly higher or similar to the trough concentration of patients with any bleeding events."	( Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults. Cui, C; Lai, X; Li, H; Liu, D; Sia, JEV; Wu, X; Zhang, F, 2023)	1.36
" Nevertheless, high interindividual variability in DOAC exposure in older adults was noted, which can be explained by distinctive older patient characteristics, such as kidney function, changes in body composition (especially reduced muscle mass), and co-medication with P-gp inhibitors, which is in line with the current dosing reduction criteria of apixaban, edoxaban, and rivaroxaban."	( Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review. Dia, N; Dreesen, E; Edwina, AE; Spriet, I; Tournoy, J; Van der Linden, L; Vanassche, T; Verhamme, P, 2023)	0.91
" Dosing was considered inappropriate when use of eGFR resulted in a lower (undertreatment) or higher (overtreatment) dose than that recommended by the eCrCl."	( Variability in Nonvitamin K Oral Anticoagulant Dose Eligibility and Adjustment According to Renal Formulae and Clinical Outcomes in Patients With Atrial Fibrillation With and Without Chronic Kidney Disease: Insights From ORBIT-AF II. Andrade, JG; Fordyce, CB; Holmes, DN; Levin, A; Piccini, JP; Yao, RJR, 2023)	0.91
"Twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) may reduce drug adherence compared with once-daily dosing of NOACs in patients with atrial fibrillation (AF), thus worsening clinical outcomes."	( Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important? Bae, YJ; Hwang, HJ; Jin, ES; Sohn, IS, 2023)	0.91
" The proportion of patients with high adherence to NOACs was 95%, which did not significantly differ according to the dosing regimen."	( Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important? Bae, YJ; Hwang, HJ; Jin, ES; Sohn, IS, 2023)	0.91
"Adherence between once- and twice-daily dosing NOACs in patients with AF was high and similar among both dosing regimens."	( Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important? Bae, YJ; Hwang, HJ; Jin, ES; Sohn, IS, 2023)	0.91
"Dabigatran is the first of four direct-acting oral anticoagulants approved to prevent stroke in adult patients with atrial fibrillation using a fixed two-dose scheme compared with warfarin dosing adjusted to a prothrombin time range associated with optimal risk reduction in stroke and serious bleeding."	( Dabigatran Dosing Proposal for Adults With Atrial Fibrillation: Stress-Testing Renal Function Range in Real World Patients. Al Qaraghuli, F; Fiedler-Kelly, J; Gonzalez, D; Powell, JR; Weiner, D, 2023)	3.8
"26)), once daily DOAC dosing (OR = 3."	( Impact of Direct Oral Anticoagulant Concentration on Clinical Outcomes in Asian Patients with Atrial Fibrillation. Ho, LT; Huang, CF; Jeng, JS; Kuo, CH; Lin, SY; Liu, YB; Peng, YF; Tang, SC; Tsai, LK, 2023)	0.91
" The objectives of this study were to evaluate DOAC dosing discordance and to determine whether discordance based on various estimates of kidney function is associated with bleeding or thromboembolism."	( DOAC Dosing Discordance Using Different Estimates of Kidney Function and Outcomes. Achanta, A; Bhalodia, NJ; Cheng, J; Coons, JC; Deri, CR; Heiney, H; Iasella, CJ; Marchionda, O; Stahl, K; White, EM, 2023)	0.91
"Lower risks for bleed and mortality associated with reduced- versus standard-dose dabigatran in patients with AF and a high bleeding risk suggest a better dosing strategy."	( Effectiveness and safety of Dabigatran 110 mg versus 150 mg for Stroke Prevention in Patients with Atrial Fibrillation at High Bleeding Risk. An, J; Cheetham, TC; Lang, DT; Lee, MS; Luong, T; Reynolds, K, 2023)	1.43
" Inappropriate dosing was noted in 18% of the population."	( Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF. Assouline, S; Cohen, C; Cohen, S; Dhanjal, TS; Dib, JC; Dievart, F; Durand, P; Garban, T; Guedj-Meynier, D; Guenoun, M; Hoffman, O; Lellouche, N; Lequeux, B; Ouazana, L; Parrens, E; Pradeau, V; Sabouret, P; Schwartz, J; Sharareh, A; Villaceque, M, 2023)	0.91
"Within this large registry, DOACs were associated with inappropriate dosing in 18% of cases."	( Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF. Assouline, S; Cohen, C; Cohen, S; Dhanjal, TS; Dib, JC; Dievart, F; Durand, P; Garban, T; Guedj-Meynier, D; Guenoun, M; Hoffman, O; Lellouche, N; Lequeux, B; Ouazana, L; Parrens, E; Pradeau, V; Sabouret, P; Schwartz, J; Sharareh, A; Villaceque, M, 2023)	0.91
"This single-center, open-label, fixed-sequence study enrolled 24 healthy male subjects who were dosed orally with dabigatran etexilate 75 mg on days 1 (Treatment A1) and 9 (Treatment C1) as well as rosuvastatin 10 mg on days 3 (Treatment A2) and 11 (Treatment C2)."	( Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects. Anliker-Ort, M; Dingemanse, J; Janů, L; Kaufmann, P, 2023)	1.35

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

Role	Description
anticoagulant	An agent that prevents blood clotting.
EC 3.4.21.5 (thrombin) inhibitor	An EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of thrombin (EC 3.4.21.5).
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor	An EC 1.10.99.* (oxidoreductases acting on diphenols and related substances as donors, other acceptors) inhibitor that interferes with the action of ribosyldihydronicotinamide dehydrogenase (quinone), EC 1.10.99.2.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

Class	Description
aromatic amide	An amide in which the amide linkage is bonded directly to an aromatic system.
benzimidazoles	An organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
carboxamidine	Compounds having the structure RC(=NR)NR2. The term is used as a suffix in systematic nomenclature to denote the -C(=NH)NH2 group including its carbon atom.
pyridines	Any organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
beta-alanine derivative
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (23)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	10.6840	0.0123	7.9835	43.2770	AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	0.1795	0.0013	10.1577	42.8575	AID1259253; AID1259256
G	Vesicular stomatitis virus	Potency	10.6840	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	37.9083	0.0010	8.3798	61.1304	AID1645840
Interferon beta	Homo sapiens (human)	Potency	10.6840	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	10.6840	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	10.6840	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	10.6840	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 22 member 2	Homo sapiens (human)	IC50 (µMol)	4.7000	0.4000	3.1000	9.7000	AID721751
Prothrombin	Homo sapiens (human)	IC50 (µMol)	0.0046	0.0000	0.7107	10.0000	AID1202328; AID1254403; AID1266251; AID1299221; AID1315499; AID1332061; AID1381646; AID1436084; AID1681853; AID1871814; AID228064; AID719849
Prothrombin	Homo sapiens (human)	Ki	0.0050	0.0000	0.7846	9.0000	AID1057658; AID1393315; AID1681853; AID228213; AID645253; AID683501; AID753177
Coagulation factor X	Homo sapiens (human)	Ki	2.8533	0.0000	0.4708	9.0000	AID1057659; AID1681852; AID52166
Plasminogen	Homo sapiens (human)	Ki	1.6950	0.0170	1.1560	4.4000	AID225426
Coagulation factor XII	Homo sapiens (human)	IC50 (µMol)	33.0000	0.0104	3.8890	10.9666	AID1681854
Tissue-type plasminogen activator	Homo sapiens (human)	Ki	45.3600	0.0170	3.7196	8.6000	AID210579
Vitamin K-dependent protein C	Homo sapiens (human)	Ki	20.9300	1.8000	2.1000	2.4000	AID30726
Serine protease hepsin	Homo sapiens (human)	Ki	0.8350	0.0005	0.1917	0.8350	AID1195363
Trypsin-1	Homo sapiens (human)	Ki	0.0501	0.0000	1.7676	8.9000	AID1393316; AID228436
Trypsin-2	Homo sapiens (human)	Ki	0.0501	0.0043	0.9487	3.2900	AID1393316; AID228436
Muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	IC50 (µMol)	10.0000	0.0005	2.7739	25.1700	AID719847
Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)	IC50 (µMol)	10.5000	0.0027	1.6287	9.9000	AID719845; AID719847
Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)	Ki	60.0000	0.0065	0.0436	0.0880	AID719846
Trypsin-3	Homo sapiens (human)	Ki	0.0501	0.0043	0.9487	3.2900	AID1393316; AID228436
Multidrug and toxin extrusion protein 2	Homo sapiens (human)	IC50 (µMol)	25.3000	0.1600	3.9571	8.6000	AID721752
Multidrug and toxin extrusion protein 1	Homo sapiens (human)	IC50 (µMol)	8.1000	0.0100	2.7656	10.0000	AID721754
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (169)

Process	via Protein(s)	Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic process	Solute carrier family 22 member 2	Homo sapiens (human)
positive regulation of gene expression	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
monoatomic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 2	Homo sapiens (human)
body fluid secretion	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 2	Homo sapiens (human)
amine transport	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 2	Homo sapiens (human)
choline transport	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 2	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
histamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 2	Homo sapiens (human)
histamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
amino acid import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
export across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
L-alpha-amino acid transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
positive regulation of protein phosphorylation	Prothrombin	Homo sapiens (human)
proteolysis	Prothrombin	Homo sapiens (human)
acute-phase response	Prothrombin	Homo sapiens (human)
cell surface receptor signaling pathway	Prothrombin	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Prothrombin	Homo sapiens (human)
blood coagulation	Prothrombin	Homo sapiens (human)
positive regulation of cell population proliferation	Prothrombin	Homo sapiens (human)
regulation of cell shape	Prothrombin	Homo sapiens (human)
response to wounding	Prothrombin	Homo sapiens (human)
negative regulation of platelet activation	Prothrombin	Homo sapiens (human)
platelet activation	Prothrombin	Homo sapiens (human)
regulation of blood coagulation	Prothrombin	Homo sapiens (human)
positive regulation of blood coagulation	Prothrombin	Homo sapiens (human)
positive regulation of cell growth	Prothrombin	Homo sapiens (human)
positive regulation of insulin secretion	Prothrombin	Homo sapiens (human)
positive regulation of collagen biosynthetic process	Prothrombin	Homo sapiens (human)
fibrinolysis	Prothrombin	Homo sapiens (human)
negative regulation of proteolysis	Prothrombin	Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STAT	Prothrombin	Homo sapiens (human)
negative regulation of astrocyte differentiation	Prothrombin	Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol	Prothrombin	Homo sapiens (human)
regulation of cytosolic calcium ion concentration	Prothrombin	Homo sapiens (human)
cytolysis by host of symbiont cells	Prothrombin	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Prothrombin	Homo sapiens (human)
negative regulation of fibrinolysis	Prothrombin	Homo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptide	Prothrombin	Homo sapiens (human)
neutrophil-mediated killing of gram-negative bacterium	Prothrombin	Homo sapiens (human)
positive regulation of lipid kinase activity	Prothrombin	Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory response	Prothrombin	Homo sapiens (human)
positive regulation of protein localization to nucleus	Prothrombin	Homo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway	Prothrombin	Homo sapiens (human)
ligand-gated ion channel signaling pathway	Prothrombin	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Prothrombin	Homo sapiens (human)
proteolysis	Coagulation factor X	Homo sapiens (human)
blood coagulation	Coagulation factor X	Homo sapiens (human)
positive regulation of cell migration	Coagulation factor X	Homo sapiens (human)
positive regulation of TOR signaling	Coagulation factor X	Homo sapiens (human)
proteolysis	Plasminogen	Homo sapiens (human)
blood coagulation	Plasminogen	Homo sapiens (human)
negative regulation of cell population proliferation	Plasminogen	Homo sapiens (human)
negative regulation of cell-substrate adhesion	Plasminogen	Homo sapiens (human)
extracellular matrix disassembly	Plasminogen	Homo sapiens (human)
tissue regeneration	Plasminogen	Homo sapiens (human)
fibrinolysis	Plasminogen	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	Plasminogen	Homo sapiens (human)
myoblast differentiation	Plasminogen	Homo sapiens (human)
muscle cell cellular homeostasis	Plasminogen	Homo sapiens (human)
tissue remodeling	Plasminogen	Homo sapiens (human)
biological process involved in interaction with symbiont	Plasminogen	Homo sapiens (human)
negative regulation of fibrinolysis	Plasminogen	Homo sapiens (human)
positive regulation of fibrinolysis	Plasminogen	Homo sapiens (human)
trophoblast giant cell differentiation	Plasminogen	Homo sapiens (human)
labyrinthine layer blood vessel development	Plasminogen	Homo sapiens (human)
mononuclear cell migration	Plasminogen	Homo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmission	Plasminogen	Homo sapiens (human)
negative regulation of cell-cell adhesion mediated by cadherin	Plasminogen	Homo sapiens (human)
plasma kallikrein-kinin cascade	Coagulation factor XII	Homo sapiens (human)
Factor XII activation	Coagulation factor XII	Homo sapiens (human)
blood coagulation, intrinsic pathway	Coagulation factor XII	Homo sapiens (human)
positive regulation of plasminogen activation	Coagulation factor XII	Homo sapiens (human)
protein processing	Coagulation factor XII	Homo sapiens (human)
protein autoprocessing	Coagulation factor XII	Homo sapiens (human)
positive regulation of blood coagulation	Coagulation factor XII	Homo sapiens (human)
zymogen activation	Coagulation factor XII	Homo sapiens (human)
fibrinolysis	Coagulation factor XII	Homo sapiens (human)
innate immune response	Coagulation factor XII	Homo sapiens (human)
response to misfolded protein	Coagulation factor XII	Homo sapiens (human)
positive regulation of fibrinolysis	Coagulation factor XII	Homo sapiens (human)
blood coagulation	Coagulation factor XII	Homo sapiens (human)
response to hypoxia	Tissue-type plasminogen activator	Homo sapiens (human)
proteolysis	Tissue-type plasminogen activator	Homo sapiens (human)
blood coagulation	Tissue-type plasminogen activator	Homo sapiens (human)
negative regulation of plasminogen activation	Tissue-type plasminogen activator	Homo sapiens (human)
plasminogen activation	Tissue-type plasminogen activator	Homo sapiens (human)
protein modification process	Tissue-type plasminogen activator	Homo sapiens (human)
fibrinolysis	Tissue-type plasminogen activator	Homo sapiens (human)
negative regulation of proteolysis	Tissue-type plasminogen activator	Homo sapiens (human)
negative regulation of fibrinolysis	Tissue-type plasminogen activator	Homo sapiens (human)
prevention of polyspermy	Tissue-type plasminogen activator	Homo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmission	Tissue-type plasminogen activator	Homo sapiens (human)
platelet-derived growth factor receptor signaling pathway	Tissue-type plasminogen activator	Homo sapiens (human)
smooth muscle cell migration	Tissue-type plasminogen activator	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
proteolysis	Vitamin K-dependent protein C	Homo sapiens (human)
blood coagulation	Vitamin K-dependent protein C	Homo sapiens (human)
negative regulation of blood coagulation	Vitamin K-dependent protein C	Homo sapiens (human)
negative regulation of apoptotic process	Vitamin K-dependent protein C	Homo sapiens (human)
negative regulation of inflammatory response	Vitamin K-dependent protein C	Homo sapiens (human)
negative regulation of coagulation	Vitamin K-dependent protein C	Homo sapiens (human)
positive regulation of establishment of endothelial barrier	Vitamin K-dependent protein C	Homo sapiens (human)
proteolysis	Serine protease hepsin	Homo sapiens (human)
regulation of cell shape	Serine protease hepsin	Homo sapiens (human)
positive regulation of gene expression	Serine protease hepsin	Homo sapiens (human)
negative regulation of epithelial to mesenchymal transition	Serine protease hepsin	Homo sapiens (human)
positive regulation of plasminogen activation	Serine protease hepsin	Homo sapiens (human)
positive regulation of cell growth	Serine protease hepsin	Homo sapiens (human)
basement membrane disassembly	Serine protease hepsin	Homo sapiens (human)
negative regulation of apoptotic process	Serine protease hepsin	Homo sapiens (human)
positive regulation by host of viral transcription	Serine protease hepsin	Homo sapiens (human)
negative regulation of epithelial cell proliferation	Serine protease hepsin	Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of sound	Serine protease hepsin	Homo sapiens (human)
potassium ion transmembrane transport	Serine protease hepsin	Homo sapiens (human)
cochlea morphogenesis	Serine protease hepsin	Homo sapiens (human)
response to thyroid hormone	Serine protease hepsin	Homo sapiens (human)
pilomotor reflex	Serine protease hepsin	Homo sapiens (human)
positive regulation of hepatocyte proliferation	Serine protease hepsin	Homo sapiens (human)
positive regulation of thyroid hormone generation	Serine protease hepsin	Homo sapiens (human)
digestion	Trypsin-1	Homo sapiens (human)
extracellular matrix disassembly	Trypsin-1	Homo sapiens (human)
proteolysis	Trypsin-1	Homo sapiens (human)
proteolysis	Trypsin-2	Homo sapiens (human)
digestion	Trypsin-2	Homo sapiens (human)
antimicrobial humoral response	Trypsin-2	Homo sapiens (human)
extracellular matrix disassembly	Trypsin-2	Homo sapiens (human)
positive regulation of cell growth	Trypsin-2	Homo sapiens (human)
collagen catabolic process	Trypsin-2	Homo sapiens (human)
positive regulation of cell adhesion	Trypsin-2	Homo sapiens (human)
quinone catabolic process	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
proteolysis	Trypsin-3	Homo sapiens (human)
digestion	Trypsin-3	Homo sapiens (human)
antimicrobial humoral response	Trypsin-3	Homo sapiens (human)
zymogen activation	Trypsin-3	Homo sapiens (human)
endothelial cell migration	Trypsin-3	Homo sapiens (human)
organic cation transport	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
transmembrane transport	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
proton transmembrane transport	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
amino acid import across plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine import across plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-alpha-amino acid transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
proton transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (71)

Process	via Protein(s)	Taxonomy
amine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
choline transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
efflux transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
lipopolysaccharide binding	Prothrombin	Homo sapiens (human)
serine-type endopeptidase activity	Prothrombin	Homo sapiens (human)
signaling receptor binding	Prothrombin	Homo sapiens (human)
calcium ion binding	Prothrombin	Homo sapiens (human)
protein binding	Prothrombin	Homo sapiens (human)
growth factor activity	Prothrombin	Homo sapiens (human)
heparin binding	Prothrombin	Homo sapiens (human)
thrombospondin receptor activity	Prothrombin	Homo sapiens (human)
serine-type endopeptidase activity	Coagulation factor X	Homo sapiens (human)
calcium ion binding	Coagulation factor X	Homo sapiens (human)
protein binding	Coagulation factor X	Homo sapiens (human)
phospholipid binding	Coagulation factor X	Homo sapiens (human)
protease binding	Plasminogen	Homo sapiens (human)
endopeptidase activity	Plasminogen	Homo sapiens (human)
serine-type endopeptidase activity	Plasminogen	Homo sapiens (human)
signaling receptor binding	Plasminogen	Homo sapiens (human)
protein binding	Plasminogen	Homo sapiens (human)
serine-type peptidase activity	Plasminogen	Homo sapiens (human)
enzyme binding	Plasminogen	Homo sapiens (human)
kinase binding	Plasminogen	Homo sapiens (human)
protein domain specific binding	Plasminogen	Homo sapiens (human)
apolipoprotein binding	Plasminogen	Homo sapiens (human)
protein-folding chaperone binding	Plasminogen	Homo sapiens (human)
protein antigen binding	Plasminogen	Homo sapiens (human)
serine-type endopeptidase activity	Coagulation factor XII	Homo sapiens (human)
calcium ion binding	Coagulation factor XII	Homo sapiens (human)
protein binding	Coagulation factor XII	Homo sapiens (human)
misfolded protein binding	Coagulation factor XII	Homo sapiens (human)
serine-type endopeptidase activity	Tissue-type plasminogen activator	Homo sapiens (human)
signaling receptor binding	Tissue-type plasminogen activator	Homo sapiens (human)
protein binding	Tissue-type plasminogen activator	Homo sapiens (human)
phosphoprotein binding	Tissue-type plasminogen activator	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
serine-type endopeptidase activity	Vitamin K-dependent protein C	Homo sapiens (human)
calcium ion binding	Vitamin K-dependent protein C	Homo sapiens (human)
protein binding	Vitamin K-dependent protein C	Homo sapiens (human)
serine-type endopeptidase activity	Serine protease hepsin	Homo sapiens (human)
protein binding	Serine protease hepsin	Homo sapiens (human)
peptidase activity	Serine protease hepsin	Homo sapiens (human)
serine-type peptidase activity	Serine protease hepsin	Homo sapiens (human)
serine-type exopeptidase activity	Serine protease hepsin	Homo sapiens (human)
serine-type endopeptidase activity	Trypsin-1	Homo sapiens (human)
metal ion binding	Trypsin-1	Homo sapiens (human)
metalloendopeptidase activity	Trypsin-2	Homo sapiens (human)
serine-type endopeptidase activity	Trypsin-2	Homo sapiens (human)
calcium ion binding	Trypsin-2	Homo sapiens (human)
protein binding	Trypsin-2	Homo sapiens (human)
serine-type peptidase activity	Trypsin-2	Homo sapiens (human)
dihydronicotinamide riboside quinone reductase activity	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
protein binding	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
zinc ion binding	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
electron transfer activity	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
oxidoreductase activity	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
oxidoreductase activity, acting on other nitrogenous compounds as donors	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
chloride ion binding	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
protein homodimerization activity	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
FAD binding	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
melatonin binding	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
resveratrol binding	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
NAD(P)H dehydrogenase (quinone) activity	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
serine-type endopeptidase activity	Trypsin-3	Homo sapiens (human)
calcium ion binding	Trypsin-3	Homo sapiens (human)
protein binding	Trypsin-3	Homo sapiens (human)
serine-type peptidase activity	Trypsin-3	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (44)

Process	via Protein(s)	Taxonomy
plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
extracellular exosome	Solute carrier family 22 member 2	Homo sapiens (human)
presynapse	Solute carrier family 22 member 2	Homo sapiens (human)
external side of plasma membrane	Prothrombin	Homo sapiens (human)
collagen-containing extracellular matrix	Prothrombin	Homo sapiens (human)
extracellular region	Prothrombin	Homo sapiens (human)
extracellular space	Prothrombin	Homo sapiens (human)
endoplasmic reticulum lumen	Prothrombin	Homo sapiens (human)
Golgi lumen	Prothrombin	Homo sapiens (human)
plasma membrane	Prothrombin	Homo sapiens (human)
extracellular exosome	Prothrombin	Homo sapiens (human)
blood microparticle	Prothrombin	Homo sapiens (human)
collagen-containing extracellular matrix	Prothrombin	Homo sapiens (human)
extracellular space	Prothrombin	Homo sapiens (human)
extracellular region	Coagulation factor X	Homo sapiens (human)
endoplasmic reticulum lumen	Coagulation factor X	Homo sapiens (human)
Golgi lumen	Coagulation factor X	Homo sapiens (human)
plasma membrane	Coagulation factor X	Homo sapiens (human)
external side of plasma membrane	Coagulation factor X	Homo sapiens (human)
extracellular space	Coagulation factor X	Homo sapiens (human)
extracellular region	Plasminogen	Homo sapiens (human)
extracellular space	Plasminogen	Homo sapiens (human)
plasma membrane	Plasminogen	Homo sapiens (human)
external side of plasma membrane	Plasminogen	Homo sapiens (human)
cell surface	Plasminogen	Homo sapiens (human)
platelet alpha granule lumen	Plasminogen	Homo sapiens (human)
collagen-containing extracellular matrix	Plasminogen	Homo sapiens (human)
extracellular exosome	Plasminogen	Homo sapiens (human)
blood microparticle	Plasminogen	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Plasminogen	Homo sapiens (human)
glutamatergic synapse	Plasminogen	Homo sapiens (human)
extracellular space	Plasminogen	Homo sapiens (human)
extracellular region	Coagulation factor XII	Homo sapiens (human)
extracellular space	Coagulation factor XII	Homo sapiens (human)
plasma membrane	Coagulation factor XII	Homo sapiens (human)
collagen-containing extracellular matrix	Coagulation factor XII	Homo sapiens (human)
extracellular exosome	Coagulation factor XII	Homo sapiens (human)
extracellular space	Coagulation factor XII	Homo sapiens (human)
rough endoplasmic reticulum	Coagulation factor XII	Homo sapiens (human)
collagen-containing extracellular matrix	Tissue-type plasminogen activator	Homo sapiens (human)
extracellular region	Tissue-type plasminogen activator	Homo sapiens (human)
cytoplasm	Tissue-type plasminogen activator	Homo sapiens (human)
cell surface	Tissue-type plasminogen activator	Homo sapiens (human)
secretory granule	Tissue-type plasminogen activator	Homo sapiens (human)
apical part of cell	Tissue-type plasminogen activator	Homo sapiens (human)
extracellular exosome	Tissue-type plasminogen activator	Homo sapiens (human)
serine protease inhibitor complex	Tissue-type plasminogen activator	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Tissue-type plasminogen activator	Homo sapiens (human)
glutamatergic synapse	Tissue-type plasminogen activator	Homo sapiens (human)
extracellular space	Tissue-type plasminogen activator	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular region	Vitamin K-dependent protein C	Homo sapiens (human)
endoplasmic reticulum	Vitamin K-dependent protein C	Homo sapiens (human)
endoplasmic reticulum lumen	Vitamin K-dependent protein C	Homo sapiens (human)
Golgi apparatus	Vitamin K-dependent protein C	Homo sapiens (human)
Golgi lumen	Vitamin K-dependent protein C	Homo sapiens (human)
extracellular space	Vitamin K-dependent protein C	Homo sapiens (human)
nuclear membrane	Serine protease hepsin	Homo sapiens (human)
endoplasmic reticulum membrane	Serine protease hepsin	Homo sapiens (human)
plasma membrane	Serine protease hepsin	Homo sapiens (human)
cell-cell junction	Serine protease hepsin	Homo sapiens (human)
cell surface	Serine protease hepsin	Homo sapiens (human)
membrane	Serine protease hepsin	Homo sapiens (human)
apical plasma membrane	Serine protease hepsin	Homo sapiens (human)
neuronal cell body	Serine protease hepsin	Homo sapiens (human)
extracellular exosome	Serine protease hepsin	Homo sapiens (human)
extracellular region	Trypsin-1	Homo sapiens (human)
collagen-containing extracellular matrix	Trypsin-1	Homo sapiens (human)
blood microparticle	Trypsin-1	Homo sapiens (human)
extracellular space	Trypsin-1	Homo sapiens (human)
extracellular region	Trypsin-2	Homo sapiens (human)
extracellular space	Trypsin-2	Homo sapiens (human)
extracellular matrix	Trypsin-2	Homo sapiens (human)
azurophil granule lumen	Trypsin-2	Homo sapiens (human)
extracellular space	Trypsin-2	Homo sapiens (human)
nucleoplasm	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
cytosol	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
extracellular exosome	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
cytosol	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
extracellular region	Trypsin-3	Homo sapiens (human)
extracellular space	Trypsin-3	Homo sapiens (human)
tertiary granule lumen	Trypsin-3	Homo sapiens (human)
extracellular space	Trypsin-3	Homo sapiens (human)
plasma membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (105)

Assay ID	Title	Year	Journal	Article
AID1436084	Inhibition of human thrombin preincubated for 10 mins followed by Ac-FVR-AMC substrate addition measured every 20s for 10 mins by fluorescence assay	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Novel dabigatran derivatives with a fluorine atom at the C-2 position of the terminal benzene ring: Design, synthesis and anticoagulant activity evaluation.
AID1681805	Anticoagulant activity in human platelet-rich plasma assessed as reduction in TF-induced thrombin generation by measuring Tmax of clotting time at 1 uM preincubated for 15 mins followed by TF addition by Z-Gly-Gly-Arg-AMC substrate based calibrated automa	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Acylated 1
AID1681839	Inhibition of human coagulation factor XIIA in presence of Boc-Gln-Gly-Arg-AMC as fluorogenic substrate at 1 uM measured at 1 min interval for 1 hr by fluorometric assay relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Acylated 1
AID1681830	Inhibition of porcine trypsin using Z-Gly-Gly-Arg-AMC as fluorogenic substrate at 5 uM measured at 1 min interval for 1 hr by fluorometric assay relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Acylated 1
AID1266251	Inhibition of thrombin (unknown origin)	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Molecular modeling studies, synthesis and biological evaluation of dabigatran analogues as thrombin inhibitors.
AID719844	Displacement of (S)-N4-(2-(4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-yl)ethyl)-N1-(15-oxo-19-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-trioxa-14-azanonadecyl)-2-(4-(3-(trifluoromethyl	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID719848	Inhibition of human alpha thrombin using Boc-Val-Pro-Arg-AMC as substrate after 2 hrs by fluorometric analysis	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID228213	Inhibitory constant (Ki) was determined against human thrombin	2002	Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9	Structure-based design of novel potent nonpeptide thrombin inhibitors.
AID1681852	Inhibition of human coagulation factor Xa using Boc-Ile-Glu-Gly-Arg-AMC as fluorogenic substrate measured at 1 min interval for 1 hr by fluorometric assay	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Acylated 1
AID1681853	Inhibition of human coagulation factor alpha-thrombin using Boc-Val-Pro-Arg-AMC as fluorogenic substrate measured at 1 min interval for 1 hr by fluorometric assay	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Acylated 1
AID721752	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID753175	Displacement of biotinylated fibrinogen from human glycoprotein 2b/3a receptor after 2 hrs by chemiluminescence assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.
AID1681831	Inhibition of human coagulation factor Xa using Boc-Ile-Glu-Gly-Arg-AMC as fluorogenic substrate at 1 uM measured at 1 min interval for 1 hr by fluorometric assay relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Acylated 1
AID1871814	Inhibition of thrombin in human blood using fluorogenic Ac-FVR-AMC as substrate by chromogenic assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.
AID1057646	Reduction of thrombin generation time in human platelet-rich plasma by spectrophotometer analysis	2013	Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23	5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor.
AID210579	Inhibitory constant (Ki) was determined against human Tissue plasminogen activator (tissue plasminogen activator)	2002	Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9	Structure-based design of novel potent nonpeptide thrombin inhibitors.
AID719843	Displacement of 3-(1-methyl-N-(pyridin-2-yl)-2-((4-(N-((S)-6,9,25-trioxo-29-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-8-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzamido)-14,17,20-trioxa-5,10,24-triazanonacosyl)carbamimidoyl)phenylamino	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID1299221	Inhibition of human thrombin preincubated for 10 mins followed by Ac-FVR-AMC substrate addition measured within 10 mins by fluorescence assay	2016	Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12	Molecular design, synthesis and anticoagulant activity evaluation of fluorinated dabigatran analogues.
AID228436	Inhibitory constant (Ki) was determined against human trypsin	2002	Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9	Structure-based design of novel potent nonpeptide thrombin inhibitors.
AID1681851	Inhibition of porcine trypsin using Z-Gly-Gly-Arg-AMC as fluorogenic substrate measured at 1 min interval for 1 hr by fluorometric assay	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Acylated 1
AID721751	Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1393316	Inhibition of human trypsin	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs.
AID1195363	Inhibition of hepsin (unknown origin) using Boc-QAR-AMC as substrate after 30 mins prior to substrate addition by fluorescence assay	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
AID1681804	Anticoagulant activity in human platelet-rich plasma assessed as reduction in TF-induced thrombin generation by measuring endogenous thrombin potential at 1 uM preincubated for 15 mins followed by TF addition by Z-Gly-Gly-Arg-AMC substrate based calibrate	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Acylated 1
AID1315500	Anticoagulant activity in rat assessed as inhibition of arteriovenous thrombosis at 0.5 mg/ml after 15 mins relative to control	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Design, synthesis, anticoagulant activity evaluation and molecular docking studies of a class of N-ethyl dabigatran derivatives.
AID1254403	Inhibition of human thrombin using tosyl-glycyl-prolyl-arginine-4-nitranilide acetate as substrate preincubated for 10 mins by spectrophotometer analysis	2015	Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23	Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors.
AID1202328	Inhibition of human thrombin using Ac-FVR-AMC as substrate incubated for 10 mins prior to substrate addition measured for 10 min by fluorescence assay	2015	European journal of medicinal chemistry, , Volume: 96	Design, synthesis and structural exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors.
AID1381646	Inhibition of human thrombin using tosyl-glycyl-prolyl-arginine-4-nitranilide acetate as substrate preincubated for 10 mins followed by substrate addition by spectrophotometric method	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	The selectivity and bioavailability improvement of novel oral anticoagulants: An overview.
AID753176	Inhibition of trypsin (unknown origin) using S-2222 as substrate incubated for 15 mins prior to substrate addition measured every 10 secs by spectrophotometric analysis	2013	European journal of medicinal chemistry, Jun, Volume: 64	Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.
AID645253	Inhibition of thrombin using S-2238 as substrate preincubated for 15 mins prior substrate addition measured for every 10 secs by spectrophotometry	2012	European journal of medicinal chemistry, Apr, Volume: 50	Fluorinated dual antithrombotic compounds based on 1,4-benzoxazine scaffold.
AID719845	Displacement of (S)-N4-(4-(3-(2-((4-carbamimidoylphenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanamido)butyl)-N1-(15-oxo-19-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-trioxa-14-azanonadecyl)-2	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID1681806	Anticoagulant activity in human platelet-rich plasma assessed as reduction in TF-induced thrombin generation by measuring half life of clotting time at 1 uM preincubated for 15 mins followed by TF addition by Z-Gly-Gly-Arg-AMC substrate based calibrated a	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Acylated 1
AID228064	Inhibition of human thrombin by chromogenic assay	2002	Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9	Structure-based design of novel potent nonpeptide thrombin inhibitors.
AID52166	Inhibitory constant (Ki) was determined against human Coagulation factor Xa (fXa)	2002	Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9	Structure-based design of novel potent nonpeptide thrombin inhibitors.
AID719841	Displacement of 3-(1-methyl-N-(pyridin-2-yl)-2-((4-(N-((S)-6,9,25-trioxo-29-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-8-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzamido)-14,17,20-trioxa-5,10,24-triazanonacosyl)carbamimidoyl)phenylamino	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID1393315	Inhibition of human thrombin using tosyl-glycyl-prolyl-arginine-4-nitranilide acetate as substrate preincubated for 10 mins followed by substrate addition by spectrophotometer	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs.
AID719820	Displacement of (S)-N4-(3-(3-(2-((4-carbamimidoylphenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanamido)propyl)-N1-(15-oxo-19-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-trioxa-14-azanonadecyl)-	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID1436086	Oral bioavailability in human at 10 to 400 mg administered as single dose measured after 24 hrs	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Novel dabigatran derivatives with a fluorine atom at the C-2 position of the terminal benzene ring: Design, synthesis and anticoagulant activity evaluation.
AID1436085	Anti-thrombotic activity in Sprague-Dawley rat assessed as inhibition of arteriovenous thrombosis weight at 0.5 mg/ml relative to control	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Novel dabigatran derivatives with a fluorine atom at the C-2 position of the terminal benzene ring: Design, synthesis and anticoagulant activity evaluation.
AID721754	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID719836	Displacement of (S)-N4-(4-(3-(2-((4-carbamimidoylphenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanamido)butyl)-N1-(15-oxo-19-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-trioxa-14-azanonadecyl)-2	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID1332061	Inhibition of human thrombin assessed as reduction in release of free nitroaniline using tosyl-glycyl-prolyl-arginine-4-nitranilide acetate as substrate preincubated for 10 mins followed by substrate addition by spectrophotometer	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Design, synthesis and antithrombotic evaluation of novel non-peptide thrombin inhibitors.
AID1871825	Anticoagulant activity in mouse plasma assessed inhibition of thrombin-induced platelet aggregation	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.
AID1681838	Inhibition of human coagulation factor alpha thrombin in presence of Boc-Val-Pro-Arg-AMC as fluorogenic substrate at 1 uM measured at 1 min interval for 1 hr by fluorometric assay relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Acylated 1
AID1299222	Anticoagulant activity in Sprague-Dawley rat assessed as inhibition of arteriovenous thrombosis at 0.5 mg/ml administered 3 days prior to testing measured on day 4 relative to control	2016	Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12	Molecular design, synthesis and anticoagulant activity evaluation of fluorinated dabigatran analogues.
AID719834	Displacement of (S)-N4-(4-(3-(2-((4-carbamimidoylphenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanamido)butyl)-N1-(15-oxo-19-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-trioxa-14-azanonadecyl)-2	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID1681826	Non-covalent inhibition of human coagulation factor XIIA using Boc-Gln-Gly-Arg-AMC as fluorogenic substrate measured every 87 sec for 180 mins by time-dependent fluorescence assay	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Acylated 1
AID719822	Displacement of 3-(1-methyl-N-(pyridin-2-yl)-2-((4-(N-((S)-6,9,25-trioxo-29-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-8-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzamido)-14,17,20-trioxa-5,10,24-triazanonacosyl)carbamimidoyl)phenylamino	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID1681854	Inhibition of human coagulation factor XIIA using Boc-Gln-Gly-Arg-AMC as fluorogenic substrate measured at 1 min interval for 1 hr by fluorometric assay	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Acylated 1
AID719824	Displacement of 3-(1-methyl-N-(pyridin-2-yl)-2-((4-(N-((S)-6,9,25-trioxo-29-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-8-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzamido)-14,17,20-trioxa-5,10,24-triazanonacosyl)carbamimidoyl)phenylamino	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID753178	Inhibition of F10a (unknown origin) using S-2222 as substrate incubated for 15 mins prior to substrate addition measured every 10 secs by spectrophotometric analysis	2013	European journal of medicinal chemistry, Jun, Volume: 64	Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.
AID719838	Displacement of (S)-N4-(4-(3-(2-((4-carbamimidoylphenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanamido)butyl)-N1-(15-oxo-19-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-trioxa-14-azanonadecyl)-2	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID719821	Displacement of 3-(1-methyl-N-(pyridin-2-yl)-2-((4-(N-((S)-6,9,25-trioxo-29-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-8-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzamido)-14,17,20-trioxa-5,10,24-triazanonacosyl)carbamimidoyl)phenylamino	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID719847	Competitive inhibition of human recombinant NQO2-mediated mitomycin C metabolism using NADH as cosubstrate incubated for 5 mins prior to NADH addition measured after 30 mins by Michaelis-Menten plot analysis	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID89068	Effective dose was determined against human plasma using PTT reagent	2002	Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9	Structure-based design of novel potent nonpeptide thrombin inhibitors.
AID683501	Binding affinity to human thrombin	2012	European journal of medicinal chemistry, Nov, Volume: 57	Synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing a cleavable moiety with anti-platelet activity.
AID1057649	Reduction of thrombin generation time in human platelet-poor plasma by spectrophotometer analysis	2013	Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23	5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor.
AID719840	Displacement of (S)-N4-(4-(3-(2-((4-carbamimidoylphenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanamido)butyl)-N1-(15-oxo-19-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-trioxa-14-azanonadecyl)-2	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID1057650	Reduction of thrombin generation time in rat platelet-poor plasma by spectrophotometer analysis	2013	Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23	5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor.
AID1315499	Inhibition of human thrombin pre-incubated for 10 mins before Ac-FVR-AMC substrate addition and measured after 10 mins by fluorescence based assay	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Design, synthesis, anticoagulant activity evaluation and molecular docking studies of a class of N-ethyl dabigatran derivatives.
AID30726	Inhibitory constant (Ki) was determined against human Activated protein C	2002	Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9	Structure-based design of novel potent nonpeptide thrombin inhibitors.
AID719842	Displacement of (S)-N4-(4-(3-(2-((4-carbamimidoylphenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanamido)butyl)-N1-(15-oxo-19-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-trioxa-14-azanonadecyl)-2	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID719849	Inhibition of human thrombin-mediated platelet aggregation in cell-based assay	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID225426	Inhibitory constant (Ki) was determined against human plasmin	2002	Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9	Structure-based design of novel potent nonpeptide thrombin inhibitors.
AID1681850	Effect on blood coagulation in human blood assessed as increase in prothrombin time at 300 uM incubated for 3 mins followed by CaCl2 addition by PT reagent based assay relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Acylated 1
AID1681807	Anticoagulant activity in human platelet-rich plasma assessed as reduction in TF-induced thrombin generation by measuring amplitude of thrombin peak at 1 uM preincubated for 15 mins followed by TF addition by Z-Gly-Gly-Arg-AMC substrate based calibrated a	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Acylated 1
AID753177	Inhibition of thrombin (unknown origin) using S-2238 as substrate incubated for 15 mins prior to substrate addition measured every 10 secs by spectrophotometric analysis	2013	European journal of medicinal chemistry, Jun, Volume: 64	Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.
AID719846	Inhibition of human recombinant NQO2-mediated mitomycin C metabolism using NADH as cosubstrate incubated for 5 mins prior to NADH addition measured after 30 mins by spectrophotometric analysis	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID1057658	Inhibition of thrombin (unknown origin)	2013	Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23	5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor.
AID719823	Displacement of 3-(1-methyl-N-(pyridin-2-yl)-2-((4-(N-((S)-6,9,25-trioxo-29-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-8-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzamido)-14,17,20-trioxa-5,10,24-triazanonacosyl)carbamimidoyl)phenylamino	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
AID1057659	Inhibition of factor-10a (unknown origin)	2013	Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23	5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor.
AID1681849	Anticoagulant activity in human blood assessed as increase in activated partial thromboplastin time at 300 uM incubated for 1 min by aPTT reagent based assay relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Acylated 1
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1345816	Human coagulation factor II, thrombin (S1: Chymotrypsin)	2002	Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9	Structure-based design of novel potent nonpeptide thrombin inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,685)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	98 (2.66)	29.6817
2010's	2819 (76.50)	24.3611
2020's	768 (20.84)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 103.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	103.76 (24.57)
Research Supply Index	8.33 (2.92)
Research Growth Index	6.05 (4.65)
Search Engine Demand Index	191.05 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (103.76)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	261 (6.71%)	5.53%
Reviews	976 (25.11%)	6.00%
Case Studies	458 (11.78%)	4.05%
Observational	192 (4.94%)	0.25%
Other	2,000 (51.45%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (268)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Assessment of Electrophysiological Effects of 150 mg and 600 mg of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind Three-way Crossover Study With an Open Label Posi [NCT02170987]	Phase 1	40 participants (Actual)	Interventional	2006-03-31	Completed
Safety, Pharmacodynamics and Pharmacokinetics After Single Oral Administration of 600 mg, 750 mg and 900 mg Dabigatran Etexilate as Capsule in Healthy Subjects. A Randomised, Placebo-controlled Study, Double Blind at Each Dose Level [NCT02171455]	Phase 1	10 participants (Actual)	Interventional	2006-01-31	Completed
Safety, Tolerability and Pharmacokinetics Study After Single and Multiple Oral Doses of Dabigatran Etexilate Capsule (110mg,150 mg b.i.d., 7 Days) in Healthy Chinese Subjects (Open Label Study) [NCT02171572]	Phase 1	28 participants (Actual)	Interventional	2009-10-31	Completed
Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 4 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days, in Healthy Subjects. Intraindividual Comparison (5-wa [NCT02170636]	Phase 1	15 participants (Actual)	Interventional	2002-01-31	Completed
Comparative Effectiveness and Safety Between Warfarin and Dabigatran Using Real World Claims Data of Japanese Non-valvular Atrial Fibrillation Patients [NCT03254134]		22,490 participants (Actual)	Observational	2017-10-20	Completed
Post-Marketing Surveillance on the Use of Prazaxa® Capsules in Japanese Patients With Nonvalvular Atrial Fibrillation After the Availability of Idarucizumab [NCT03175198]		5,660 participants (Actual)	Observational	2017-07-05	Completed
A 24-month, Randomized-control, Double-blind, Multi-center, Delayed-start, Pilot Study Evaluating Thrombin Inhibitions Alzheimer's Disease Using 150mg Dabigatran Daily: A Novel Therapeutic Target for Alzheimer's Disease [NCT03752294]	Phase 1	40 participants (Anticipated)	Interventional	2018-11-30	Not yet recruiting
Safety of Dabigatran Etexilate (DE) for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Paediatric Patients From Birth to Less Than 2 Years of Age: a Prospective European Non-interventional Cohort Study Based on New Data Colle [NCT05536791]		50 participants (Anticipated)	Observational	2022-11-24	Recruiting
Treatment Patterns and Clinical Outcomes Among Venous Thromboembolism Patients Treated With Anticoagulants After the Entry of Non-vitamin K Antagonist Oral Anticoagulants in Korea [NCT05022563]		55,759 participants (Actual)	Observational	2021-08-31	Completed
Identification of Clinical and Pharmacogenetic Factors Predictive of Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation. [NCT04297150]		700 participants (Anticipated)	Observational	2020-06-18	Active, not recruiting
Reversion of the Anticoagulant Effect of the New Antithrombotic Agents Anti-Xa and Anti IIa by Specific and Non-specific Haemostatic Drugs,: an Ex-Vivo Study in Healthy Volunteers [NCT01210755]	Phase 4	10 participants (Anticipated)	Interventional	2010-11-30	Completed
"RE-ELECT Study: Randomized Evaluation of Changing Kidney Function Over a Time in Patients With Atrial Fibrillation (AF), Concomitant T2DM and Existing Chronic Kidney Disease (CKD) Treated With Dabigatran or Warfarin for Stroke Prevention" [NCT03789695]	Phase 4	200 participants (Anticipated)	Interventional	2018-11-14	Recruiting
A Single-center, Open-label, Three-period, Fixed-sequence Design Study to Investigate the Effect of Daridorexant on the Pharmacokinetics of Dabigatran and Rosuvastatin in Healthy Male Subjects [NCT05480475]	Phase 1	24 participants (Actual)	Interventional	2022-09-03	Completed
Pattern of Use of Direct Oral Anticoagulants in Non-valvular Atrial Fibrillation Patients in UK General Practices [NCT03119116]		31,336 participants (Actual)	Observational	2017-05-15	Completed
Phase II, Randomized, Crossover, Single Blind, Safety Trial of DABIGATRAN Versus ASA for Preventing Ischaemic Brain Lesions in Patients Affected by CADASIL [NCT01361763]	Phase 2	50 participants (Anticipated)	Interventional	2011-06-30	Recruiting
RE-SPECT CVT: a Randomised, Open-label, Exploratory Trial With Blinded Endpoint Adjudication (PROBE), Comparing Efficacy and Safety of Oral Dabigatran Etexilate Versus Oral Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis Over a 24-wee [NCT02913326]	Phase 3	120 participants (Actual)	Interventional	2016-12-13	Completed
Prospective Study of the Assessment of the Dental Protocol for Tooth Extraction in Patients With Atrial Fibrillation in Continuous Use of New Oral Anticoagulants: A Pilot Study [NCT03181386]	Phase 3	60 participants (Actual)	Interventional	2017-05-03	Completed
Effects of LMWH Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease [NCT02389582]	Phase 4	29 participants (Actual)	Interventional	2014-05-31	Completed
A Phase 1, Multi-center, Open-label, 3-arm, Fixed Sequence Study to Assess the Effect of Co-administration of AZD9833 on the Pharmacokinetics of Midazolam (CYP3A4/5 Substrate), of Omeprazole (CYP2C19 Substrate), of Celecoxib (CYP2C9 Substrate) and of Dabi [NCT05438303]	Phase 1	59 participants (Actual)	Interventional	2022-06-13	Completed
Intracerebral Hemorrhage Due to Oral Anticoagulants in the Secondary Prevention of Ischemic Stroke: Prediction of the Risk by the Detection of Leukoaraiosis and Microbleeding With Magnetic Resonance [NCT02238470]		1,000 participants (Actual)	Observational [Patient Registry]	2012-04-30	Completed
Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation [NCT01339819]	Phase 4	70 participants (Actual)	Interventional	2011-04-30	Completed
Open-label, Fixed Sequence Crossover Study to Determine the Effects of a Single Dose of Elinzanetant (BAY 3427080) on the Pharmacokinetics of Dabigatran Etexilate in Healthy Participants [NCT05471817]	Phase 1	20 participants (Actual)	Interventional	2022-08-05	Completed
Evaluation of Non-Vitamin K Antagonist Oral Anticoagulants Concentration Among Patients With Acute Stroke (The Direct Oral AntiCoagulant Registry in Taiwan-Emergent Department, DOACT-ED) [NCT06144866]		1,000 participants (Anticipated)	Observational [Patient Registry]	2020-05-01	Recruiting
Safety and Effectiveness of Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation: a Multi-database Cohort Study With Meta-analysis (DOACs vs DOACs) [NCT03568916]		227,579 participants (Actual)	Observational	2016-11-30	Completed
Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban. [NCT02085824]		60 participants (Anticipated)	Interventional	2012-07-31	Recruiting
A Phase 1, 2-part, Open-label, Fixed-sequence Study Evaluating Potential Drug-drug Interactions Between Gemfibrozil (Part 1) or Dabigatran Etexilate (Part 2) and Camlipixant (BLU-5937) 50 mg Tablet in Healthy Participants Under Fasting Conditions [NCT05959447]	Phase 1	36 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of 50, 150 and 350 mg BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin. Double-blind at Each Dose Level, Placebo-controlled, Randomised Study [NCT02170844]	Phase 1	40 participants (Actual)	Interventional	2004-06-30	Completed
Relative Bioavailability of 200 mg Film Coated Tablets of BIBR 1048 MS With or Without Food Compared to 200 mg Solution of BIBR 1048 MS Given as Single Oral Administrations to Healthy Subjects. A 3-way Crossover, Open, Partly Randomized Study. [NCT02170922]	Phase 1	6 participants (Actual)	Interventional	1999-07-31	Completed
Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule (150 mg b.i.d., 7 Days) in Healthy Japanese Male Subjects (Open Label Study) [NCT02171000]	Phase 1	7 participants (Actual)	Interventional	2005-04-30	Completed
Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule (110 mg and 150 mg b.i.d., 7 Days) in Healthy Japanese and Caucasian Male Subjects (Open Label Study) [NCT02171468]	Phase 1	48 participants (Actual)	Interventional	2006-05-31	Completed
A Two-part Study to Determine the Relative Bioavailability of Dabigatran Etexilate 150 mg Bid (Capsules) With and Without 600 mg Quinidine Sulfate Tablets (Part 1) and to Measure the Effect of Quinidine as a Probe Inhibitor of P-glycoprotein on the Absorp [NCT02171546]	Phase 1	42 participants (Actual)	Interventional	2007-11-30	Terminated
A Two-way Crossover Study to Evaluate the Safety and Pharmacokinetics of Quinidine Sulfate Alone (200 mg Orally q2h to a Maximum of 1,000 mg), Dabigatran Etexilate Alone (150 mg BID for Three Days), and the Co-administration of Dabigatran Etexilate (150 m [NCT02171624]	Phase 1	42 participants (Actual)	Interventional	2009-03-31	Completed
Bioavailability of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953) Administered as Capsule With and Without Coadministration of Pantoprazole as Well as Under the Influence of Food in Healthy Subjects. A Threeway Crossover, Randomised, Op [NCT02170610]	Phase 1	18 participants (Actual)	Interventional	2002-03-31	Completed
Bioavailability of BIBR 953 ZW After Single Oral Doses of 12.5, 25, 50 or 100 mg BIBR 1048 MS Film-coated Tablet With and Without Pre-treatment With Pantoprazole to Healthy Subjects. Four Groups, 2-way Crossover, Randomised, Open Trial. [NCT02170766]	Phase 1	48 participants (Actual)	Interventional	2000-10-31	Completed
Pharmacokinetics of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953) Administered as Capsule Twice Daily Over Seven Days With or Without Pantoprazole Co-treatment to Healthy Male and Female Elderly Subjects [NCT02173730]	Phase 1	36 participants (Actual)	Interventional	2002-11-30	Completed
Effect of Inhibitors of the Proton Pump on Intestinal Transporters and Their Impact on the Pharmacokinetics of Dabigatran - Mechanistic and Clinical Approach -BIPP Study [NCT02524210]	Phase 1	12 participants (Actual)	Interventional	2014-05-31	Completed
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Patients With Venous Thromboembolism. [NCT03129555]	Phase 4	5,000 participants (Anticipated)	Interventional	2023-04-01	Recruiting
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Atrial Fibrillation (DANNOAC-AF). [NCT03129490]	Phase 4	11,000 participants (Anticipated)	Interventional	2023-04-01	Recruiting
Multicenter, Open-label-study to Assess PK Profile of a Single Oral Dose of 150 mg BIBR 1048 (Capsule) in Patients Shortly After Primary Elective Total Hip Replacement Surgery. [NCT02170935]	Phase 2	62 participants (Actual)	Interventional	2002-04-30	Completed
Bioequivalence of Two Different Drug Product Batches of 150 mg of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers (Double Blind, Randomised, Single-dose, Replicate Design in a Two-treatments, Four Periods Crossover [NCT02171013]	Phase 1	66 participants (Actual)	Interventional	2006-04-30	Completed
Bioequivalence of Two Different Polymorphs of 150 mg Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers (Double-blind, Randomised, Single Dose, Replicate Design in a Two Treatments, Four Periods Crossover Phase I Stud [NCT02171481]	Phase 1	66 participants (Actual)	Interventional	2008-05-31	Completed
Relative Bioavailability and Pharmacodynamics of Dabigatran After a Single Dose of 220 mg Dabigatran Etexilate and After 40 mg Enoxaparin s.c. for 3 Days Followed by a Single Dose of 220 mg Dabigatran Etexilate in Healthy Male and Female Volunteers (an Op [NCT02171559]	Phase 1	29 participants (Actual)	Interventional	2008-08-31	Completed
Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 2 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days in Healthy Subjects. Intraindividual Comparison (3-way [NCT02170623]	Phase 1	12 participants (Actual)	Interventional	2002-02-28	Completed
Multicenter, Open-label, Ascending Dose Study of BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery. Bistro I [NCT02170701]	Phase 2	289 participants (Actual)	Interventional	2000-10-31	Completed
A Phase I, Non-randomized, Open-label, Fixed-sequence Study to Investigate the Effect of Darolutamide (ODM-201) on the Pharmacokinetics of a Probe Substrate of CYP3A4 and P-gp in Healthy Male Volunteers [NCT03237416]	Phase 1	15 participants (Actual)	Interventional	2017-08-02	Completed
Association Between Socioeconomic Factors and Use of Direct Oral Anticoagulants Versus Standard of Care (Warfarin) in Patients With Non-valvular Atrial Fibrillation in Sweden [NCT03684395]		68,056 participants (Actual)	Observational	2016-06-15	Completed
Validation of Predictors for Oral Anticoagulant Medication Choice Using EMR Data [NCT03006341]		140,187 participants (Actual)	Observational	2017-02-28	Completed
Development of Precision Medicine Platform for Pharmacogenomics of Novel Oral Anticoagulants (NOACs) [NCT04056143]		500 participants (Anticipated)	Observational	2019-01-02	Recruiting
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation at High Risk of Stroke and Bleeding Compared to Medical Therapy: a Prospective Randomized Clinical Trial [NCT03463317]	Phase 4	1,512 participants (Anticipated)	Interventional	2018-02-28	Recruiting
RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-centre, Prospective, Placebo Controll [NCT00621855]	Phase 2	1,878 participants (Actual)	Interventional	2008-03-31	Completed
Comparison of Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran in Patients With Non-valvular Atrial Fibrillation (RIVAL-AF Study) -Multicenter Randomized Study- [NCT02331602]	Phase 4	200 participants (Anticipated)	Interventional	2013-07-31	Recruiting
SIFNOS STUDY: RETROSPECTIVE STUDY IN PATIENTS WITH ATRIAL FIBRILLATION (AF) EXPOSED AND UNEXPOSED TO AN ORAL ANTICOAGULANT THERAPY BETWEEN 2014-2020 IN FRANCE [NCT05838664]		1 participants (Anticipated)	Observational	2023-07-07	Active, not recruiting
Anticoagulant Treatment Patterns and Outcomes Among Non-valvular Atrial Fibrillation Patients With High Risk of Gastrointestinal Bleeding in France: a Retrospective Cohort Analysis Using SNDS Database [NCT05038228]		1 participants (Actual)	Observational	2022-08-01	Active, not recruiting
Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Replicate Design in a Two-treatment, Four-period, Two-s [NCT03070171]	Phase 1	160 participants (Actual)	Interventional	2017-03-21	Completed
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI) [NCT04695106]	Phase 4	2,230 participants (Anticipated)	Interventional	2021-10-25	Recruiting
[NCT02313584]	Phase 3	464 participants (Anticipated)	Interventional	2014-12-31	Not yet recruiting
Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 4 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days, in Healthy Subjects. Intraindividual Comparison (5-wa [NCT02170896]	Phase 1	16 participants (Actual)	Interventional	2001-10-31	Completed
Bioavailability of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as HPMC Polymorph II Capsule Relative to 150 mg HPMC Polymorph I Capsule in Healthy Subjects. A Two-way Crossover, Randomised, Open Trial [NCT02170974]	Phase 1	28 participants (Actual)	Interventional	2004-07-31	Completed
Relative Bioavailability of Dabigatran and Digoxin After 150 mg BID Dabigatran Etexilate and Digoxin at 0.25 mg QD Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers (an Open Label, Randomised, Multiple-dose [NCT02171052]	Phase 1	24 participants (Actual)	Interventional	2006-06-30	Completed
Pharmacodynamics, Safety and Pharmacokinetics After Single Oral Administration of 10, 30, 100, 200 and 400 mg BIBR 1048 MS as Drinking Solution in Healthy Subjects. An Open Study, Placebo Randomized Double Blind at Each Dose Level. [NCT02170116]	Phase 1	40 participants (Actual)	Interventional	1998-11-30	Completed
Metabolism and Pharmacokinetics of [14C]-BIBR 953 ZW After Administration of Single Doses of 5 mg [14C]-BIBR 953 ZW Intravenously or 200 mg [14C]-BIBR 1048 Oral Solution in a Group Comparison Design in 12 Healthy Male Volunteers. [NCT02171442]	Phase 1	10 participants (Actual)	Interventional	2002-04-30	Completed
Tolerability of Single Rising Doses of 0.1 mg, 1 mg, and 5 mg BIBR 953 ZW IV (Placebo-controlled in Each Dose Group; Substudy 1) and Absolute and Relative Bioavailability of 100mg BIBR 1048 Tablet and of Solution and of 1 mg or 5 mg BIBR 953 ZW IV (Random [NCT02170584]	Phase 1	30 participants (Actual)	Interventional	2001-01-31	Completed
Bioequivalence of Two Different Generations of Drug Product of 150 mg Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers (Double-blind, Randomised, Single Dose, Replicate Design in a Two Treatments, Four Periods Cross [NCT02171520]	Phase 1	66 participants (Actual)	Interventional	2008-05-31	Completed
Bioavailability of BIBR 953 ZW After Multiple Oral Doses of 50 and 200 mg BIBR 1048 MS Film-coated Tablet Administered BIDfor 3 Days or 200 mg BIBR 1048 MS With and Without Pre-treatment With Pantoprazole to Healthy Volunteer Subjects. Two Groups, 2-way C [NCT02170740]	Phase 1	26 participants (Actual)	Interventional	1999-11-30	Completed
Randomised, Open Label, 3-way Cross Over Phase I Study to Investigate the Impact of Concomitant Use of Multiple Doses of Clopidogrel (75 mg qd After a Loading Dose of 300 mg) With Multiple Doses of Dabigatran Etexilate (150 mg Bid) on the Pharmacokinetic [NCT02171598]	Phase 1	44 participants (Actual)	Interventional	2009-02-28	Completed
Safety and Efficacy of Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk (HBR) Patients With History of Paroxysmal Atrial Fibrillation [NCT04151680]		100 participants (Anticipated)	Observational [Patient Registry]	2019-12-01	Recruiting
Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF Trial) [NCT03061006]	Phase 4	101 participants (Actual)	Interventional	2017-04-03	Completed
Long-term, Open-label Follow-up Treatment of Patients With Atrial Fibrillation Who Have Been Previously Treated With BIBR 1048 in the PETRO Trial (Trial 1160.20 - NCT01227629). (PETRO Extension Trial: PETRO-Ex) [NCT00157248]	Phase 2	361 participants (Actual)	Interventional	2003-12-31	Terminated
[NCT02309970]		90 participants (Anticipated)	Observational	2014-12-31	Not yet recruiting
A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With Half Dose (75 [NCT00168818]	Phase 3	3,494 participants (Actual)	Interventional	2004-11-30	Completed
Bioavailability of BIBR 953 ZW After Single Oral Doses of 12.5, 50 or 200 mg BIBR 1048 MS Film-coated Tablet Over 2 Days With and Without Coadministration of Ranitidine to Healthy Subjects. Three Groups, 2-way Crossover, Randomised, Open Trial. [NCT02170792]	Phase 1	30 participants (Actual)	Interventional	2001-02-28	Completed
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of 150 mg Dabigatran Etexilate p.o. in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open, Parallel-group Trial [NCT02182024]	Phase 1	35 participants (Actual)	Interventional	2005-04-30	Completed
Novel Oral Anticoagulants in Oral and Maxillofacial Surgery: Impact on Bleeding Tendency, Surgical Difficulty and Post-operative Complications [NCT04662515]		300 participants (Anticipated)	Observational	2016-06-01	Recruiting
Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation. A Multicenter Randomized Clinical Trial. (Occlusion-AF) [NCT03642509]		750 participants (Anticipated)	Interventional	2019-01-01	Recruiting
Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation [NCT01352702]	Phase 4	46 participants (Actual)	Interventional	2011-05-31	Terminated(stopped due to Slow recruitment; Study was terminated for futility reasons)
Dabigatran Following Transient Ischemic Attack and Minor Stroke [NCT02295826]	Phase 2	300 participants (Actual)	Interventional	2015-01-31	Completed
A PHASE 1, OPEN-LABEL, 3-TREATMENT, 6-SEQUENCE, 3-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF PF-07321332/RITONAVIR AND RITONAVIR ON THE PHARMACOKINETICS OF DABIGATRAN IN HEALTHY PARTICIPANTS [NCT05064800]	Phase 1	24 participants (Actual)	Interventional	2021-09-21	Completed
A Post-marketing Retrospective Non-interventional Study Using Nationwide Registries and Electronic Medical Records to Investigate the Real-life Effectiveness and Major Bleeding Complications of Oral Anticoagulants in Norwegian Non-valvular Atrial Fibrilla [NCT03715725]		70,000 participants (Actual)	Observational	2018-10-31	Terminated(stopped due to After feasibility assessment and due to delays in data receipt study was terminated)
A Study to Assess the Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin Administered as Microdoses in Subjects With Varying Degrees of Renal Insufficiency in the Presence and Absence of Rifampin [NCT03311841]	Phase 1	32 participants (Actual)	Interventional	2018-03-01	Completed
A Randomized Clinical Trial to Validate Novel Biomarker Approaches After Single Doses of Anticoagulants in Healthy Young Male Subjects and in Healthy Elderly Subjects [NCT01379300]	Phase 1	42 participants (Actual)	Interventional	2011-05-31	Completed
Patients Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation Impact of Conventional Oral Anticoagulant (OAC) Compared With Novel Oral Anticoagulant (NOAC) [NCT03187197]		1,315 participants (Actual)	Observational	2017-06-20	Completed
A Clinical Trial to Evaluate the Effect of Simvastatin on the Pharmacokinetics and Pharmacodynamics of Dabigatran in Healthy Male Adults [NCT03728101]	Phase 1	12 participants (Actual)	Interventional	2018-11-16	Completed
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) [NCT02744092]		811 participants (Actual)	Interventional	2016-12-13	Completed
Observational Cohort Study to Evaluate the Safety and Efficacy of Switching From Lovenox (Enoxaparin) 40mg to Pradaxa (Dabigatran Etexilate) 220mg in Patients Undergoing Elective Total Hip or Knee Replacement Surgery [NCT01153698]		167 participants (Actual)	Observational	2010-08-31	Terminated(stopped due to This trial was prematurely discontinued due to low enrolment.)
Relative Bioavailability of Tablet Formulation of Dabigatran Etexilate With and Without Co-administration of Rabeprazole in Healthy Male Subjects (an Open-label, Single-dose, Two-period, Single-arm Study) [NCT03143166]	Phase 1	36 participants (Actual)	Interventional	2017-05-22	Completed
Relative Bioavailability of Rosuvastatin (Part 1) and Dabigatran (Part 2) Given Alone and Together With BI 1358894 in Healthy Male Subjects (Open, Single-dose, Fixed Sequence, Two-period Crossover Design in Each Trial Part) [NCT04099732]	Phase 1	26 participants (Actual)	Interventional	2019-10-07	Completed
Pilot-Trial: Dabigatran as an Alternative Anticoagulant in Patients With Left Ventricular Assist Device [NCT02872649]	Phase 2	16 participants (Actual)	Interventional	2013-01-31	Terminated(stopped due to safety reasons)
A Phase 1, 2-Panel, Fixed-Sequence, Open-Label Single-Center Study to Assess the Effect of Single and Multiple Doses of Darunavir in Combination With Cobicistat or Ritonavir on the Pharmacokinetics of Single Dose Dabigatran Etexilate in Healthy Subjects [NCT04208061]	Phase 1	28 participants (Actual)	Interventional	2019-12-18	Completed
Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study) [NCT02666157]	Phase 4	3,672 participants (Anticipated)	Interventional	2016-01-31	Recruiting
The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation [NCT02646267]	Phase 4	210 participants (Anticipated)	Interventional	2016-03-31	Enrolling by invitation
Relative Bioavailability of Rosuvastatin (Part 1) and Dabigatran (Part 2) Given Alone and Together With BI 1323495 in Healthy Male Subjects (Open, Single-dose, Randomised, Two-period Crossover Design in Each Trial Part) [NCT04257032]	Phase 1	28 participants (Actual)	Interventional	2020-02-13	Completed
Rationale and Design of Dabigatran for Mitral Stenosis Atrial Fibrillation Trial [NCT04045093]	Phase 4	686 participants (Anticipated)	Interventional	2020-10-22	Recruiting
Relationship of Advanced Holding Education and ADherence on Antithrombotic in Younger SPAF Patients [NCT04532528]		898 participants (Actual)	Observational	2020-08-27	Completed
AF Patient Preferences Towards NOAC Versus VKA Treatment: a Patient Preference Study. [NCT02611635]		382 participants (Actual)	Observational	2016-02-02	Completed
Phase I, Open-label, Single Sequence, Two-Period Study to Evaluate the Effect of Tepotinib on P-gp by Investigating the PK of the P-gp Probe Substrate Dabigatran Etexilate in Healthy Subjects [NCT03492437]	Phase 1	20 participants (Actual)	Interventional	2018-05-17	Completed
Study on the Pharmacokinetics and Point of Care Testing After a Single Dose of 150 mg Dabigatran, 20 mg Rivaroxaban, 5 mg Apixaban, and 60 mg Edoxaban in Healthy Male Subjects [NCT05491460]	Phase 1	24 participants (Anticipated)	Interventional	2022-07-01	Active, not recruiting
An Open-label, Single-center, Three-part Study in Healthy Subjects to Investigate the Effect of Givinostat on the Pharmacokinetics of Midazolam and Dabigatran, the Effect of Clarithromycin on the Pharmacokinetics of Givinostat and the Pharmacokinetics of [NCT05492318]	Phase 1	54 participants (Actual)	Interventional	2022-03-21	Completed
A Phase III, Randomized, Parallel-group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens (75mg Day 1 Followed by 150 mg Day 2-completion, and 110 mg Day 1 Followed by 220 mg Day 2-completion) of [NCT00152971]	Phase 3	2,615 participants (Actual)	Interventional	2004-11-30	Completed
OBServaToire INternational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs [NCT04262492]		500 participants (Anticipated)	Observational [Patient Registry]	2020-10-21	Recruiting
Relative Bioavailability of Dabigatran and Atorvastatin After 150 mg BID Dabigatran Etexilate and Atorvastatin at 80 mg QD Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers (an Open-label, Randomised, Multi [NCT02171039]	Phase 1	24 participants (Actual)	Interventional	2006-06-30	Completed
Relative Bioavailability of Dabigatran and Diclofenac After 150 mg b.i.d. Dabigatran Etexilate and Diclofenac at 50 mg Single Dose Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers (an Open Label, Randomise [NCT02171507]	Phase 1	24 participants (Actual)	Interventional	2006-05-31	Completed
Relative Bioavailability of Dabigatran After Single Oral Administration of 150 mg Dabigatran Etexilate (Capsule) With or Without Multiple Oral Administration of 500 mg Clarithromycin (Tablet) Bid in Healthy Male and Female Volunteers (an Open Label, Fixed [NCT02171585]	Phase 1	20 participants (Actual)	Interventional	2008-06-30	Completed
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of 150 mg Dabigatran Etexilate p.o. in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function in a Monocentric, Open, Parallel-group Design [NCT02170571]	Phase 1	24 participants (Actual)	Interventional	2005-07-31	Completed
Bioavailability of BIBR 953 ZW After Single Oral Doses of Two Different 50 mg Capsules of BIBR 1048 MS With and Without Coadministration of Pantoprazole to Healthy Subjects Relative to Solution. Two Groups, 3-way Crossover, Randomised, Open Trial [NCT02170805]	Phase 1	24 participants (Actual)	Interventional	2001-04-30	Completed
Effects of Dabigatran in Patients With AF - A Prospective, Randomized, Open-label, Explorative, Blinded-endpoint Trial to Compare the Efficacy of Dabigatran With Phenprocoumon for the Resolution of LAA Thrombus in Patients With AF [NCT02256683]	Phase 2	64 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to Recruiting problems)
Non-interventional Study Describing Patients' Perception on Anticoagulant Treatment and Treatment Convenience When Treated With Pradaxa or Vitamin K Antagonist for Stroke Prophylaxis in Atrial Fibrillation. [NCT02849509]		1,313 participants (Actual)	Observational	2016-06-20	Completed
The Role of D-dimer in Patients With Atrial Fibrillation Receiving Anticoagulation Therapy [NCT03280641]		1,194 participants (Actual)	Observational	2015-08-09	Completed
An Open-Label, Randomized, 2-Period Crossover Study To Evaluate The Effect Of A Single Oral Dose Of Bosutinib On The Pharmacokinetics Of Dabigatran Etexilate Mesylate Administered Orally To Healthy Subjects [NCT02102633]	Phase 1	27 participants (Actual)	Interventional	2014-05-31	Completed
Real-World Comparisons of Bleeding Among Novel Oral Anticoagulant (NOAC)-Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage, Who Newly Initiated Novel Oral Anticoagulation Therapies or Were Treated With Warfarin [NCT03189069]		36,000 participants (Actual)	Observational	2016-10-06	Completed
The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement [NCT03183843]	Phase 4	40 participants (Actual)	Interventional	2016-06-29	Enrolling by invitation
Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma [NCT02426229]	Phase 1	15 participants (Actual)	Interventional	2016-02-29	Completed
Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of LT3001 Drug Product and Drug-Drug Interaction in Healthy Adult Subjects [NCT04809818]	Phase 1	64 participants (Anticipated)	Interventional	2021-03-21	Recruiting
Safety, Pharmacokinetics and Pharmacodynamics After Single (150 mg, 220 mg and 300 mg) and Multiple (150 mg and 220 mg q.d. and 150 mg b.i.d.) Rising Oral Doses of BIBR 1048 MS/Capsules in Healthy Male Subjects of Japanese and Caucasian Origin. (Open Labe [NCT02170909]	Phase 1	42 participants (Actual)	Interventional	2004-12-31	Completed
Relative Bioavailability of Single Oral Doses of 150 mg Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages (240 mg and 480 mg Daily) (Open-label, Fixed-sequence Design), and Relative Bioavailability of Single Or [NCT02171533]	Phase 1	40 participants (Actual)	Interventional	2008-06-30	Completed
Bioavailability of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as HPMC Capsule Relative to a Gelatine Capsule, and Bioavailability of the HPMC Capsule Under the Influence of Food in Healthy Subjects. A Three-way Cross [NCT02170597]	Phase 1	12 participants (Actual)	Interventional	2003-08-31	Completed
Relative Bioavailability of Single Doses of 150 mg Dabigatran Etexilate (Capsule) When Administered Alone or in Combination With a Single Dose of 400 mg Ketoconazole (Tablet) or in Combination With 400 mg q.d. Ketoconazole (Tablet) at Steady State in Heal [NCT02170675]	Phase 1	24 participants (Actual)	Interventional	2009-06-30	Completed
Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Oral Doses of 50, 100, 200, and 400 mg BIBR 1048 MS Solution Administered TID for 7 Days to Healthy Volunteer Subjects. An Open Study, Placebo-controlled Randomised Double Blind at Each Dose Le [NCT02170831]	Phase 1	40 participants (Actual)	Interventional	1999-05-31	Completed
Relative Bioavailability of Single Doses of 150 mg Dabigatran Etexilate (Capsule)When Administered Alone, After Seven Days of Dosing With 600 mg Rifampicin(Tablet), and Seven Days and Fourteen Days After Last Administration of Rifampicin in Healthy Male a [NCT02173717]	Phase 1	24 participants (Actual)	Interventional	2009-06-30	Completed
A Randomized Study Comparing Dabigatran Etexilate Versus Warfarin in Chinese Patients With Nonvalvular Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention With Stenting (DES) [NCT03536611]	Phase 4	1,120 participants (Anticipated)	Interventional	2018-09-01	Recruiting
RE-MODEL (Thromboembolism Prevention After Knee Surgery). Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With a Half Dose (i.e.75 or 110 mg) on the Day of Surgery] Compared to Subcutaneo [NCT00168805]	Phase 3	2,101 participants (Actual)	Interventional	2004-11-30	Completed
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) - a Multi-centre Assessor-blind Randomised-controlled Trial [NCT05735639]	Phase 4	6,660 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
"Prospective Open Label Randomized Evaluation of Abbreviated Course of Dabigatran Etexilate With tranSesophageal echOcardiography (TEE) Control vs Conventional 3-week coUrse With dabigatraN Etexilate Before Cardioversion: Analysis of MRI-detecteD Cerebral [NCT03975062]	Phase 4	400 participants (Anticipated)	Interventional	2017-12-28	Recruiting
Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S [NCT02769078]		14,201 participants (Actual)	Observational	2014-11-30	Completed
Dabigatran Study in the Early Phase of Stroke. New Neuroimaging Markers and Biomarkers Study (SEDMAN STUDY) [NCT02742480]		500 participants (Anticipated)	Observational	2016-06-28	Recruiting
AN INTERVENTIONAL, PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY TO EVALUATE THE EFFECT OF A SINGLE ORAL DOSE OF ARV-471 (PF-07850327) ON THE PHARMACOKINETICS OF DABIGATRAN IN HEALTHY PARTICIPANTS [NCT05673889]	Phase 1	24 participants (Actual)	Interventional	2023-01-27	Completed
A PHASE 1, RANDOMIZED, 2-WAY CROSSOVER, SINGLE DOSE, OPEN LABEL STUDY TO ESTIMATE THE EFFECT OF PF-04965842 ON DABIGATRAN PHARMACOKINETICS IN HEALTHY PARTICIPANTS [NCT03742336]	Phase 1	20 participants (Actual)	Interventional	2018-11-21	Completed
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES Trial [NCT03568890]	Phase 4	510 participants (Anticipated)	Interventional	2018-09-01	Recruiting
Clinical Application Model of Direct Oral Anticoagulants (MACACOD). Comprehensive Management of ACOD From a Specialized Center in Antithrombotic Therapy and Its Area of Influence [NCT04042155]		1,600 participants (Anticipated)	Observational [Patient Registry]	2019-07-29	Recruiting
Relative Bioavailability of Dabigatran and Amiodarone After Multiple Oral Administrations of 150 mg Dabigatran Etexilate b.i.d. With or Without 600 mg Amiodarone as Single Dose in Healthy Male and Female Volunteers (an Open-Label, Multiple-Dose, Group-Com [NCT02171026]	Phase 1	24 participants (Actual)	Interventional	2006-04-30	Completed
Real-world Comparative Effectiveness of Dabigatran Versus VKA [NCT02687867]		56,039 participants (Actual)	Observational	2016-02-12	Completed
Open-label Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given for 3 Days at the End of Standard Anticoagulant Therapy in Children Aged 12 Years to Less Than 18 Years [NCT00844415]	Phase 2	9 participants (Actual)	Interventional	2009-06-30	Completed
The Safety and Pharmacodynamics of Two Doses of Dabigatran Etexilate in Patients Undergoing Cardiac Catheterization [NCT00818753]	Phase 2	53 participants (Actual)	Interventional	2009-01-31	Completed
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative Atrial Fibrillation After Noncardiac Surgery - The ASPIRE-AF Trial [NCT03968393]	Phase 4	2,800 participants (Anticipated)	Interventional	2019-06-14	Recruiting
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes [NCT00808067]	Phase 3	5,897 participants (Actual)	Interventional	2008-11-30	Completed
AF Patient Preferences Towards NOAC Versus VKA Treatment: a Patient Preference Study [NCT02607371]		198 participants (Actual)	Observational	2015-08-27	Completed
Burden of Ischemic Stroke and Adherence to Oral Anticoagulants in Atrial Fibrillation in the UK Primary Care [NCT04099238]		3,739 participants (Actual)	Observational	2019-10-01	Completed
Investigation Drug-drug Interaction Between Dabigatran and Clarithromycin [NCT01385683]	Phase 1	10 participants (Actual)	Interventional	2011-06-30	Completed
Evaluation of the Potential Action of Coagulation Factors Concentrates in the Reversal of the Antithrombotic Action of New Oral Anticoagulants: Studies ex Vivo in Blood Samples From Healthy Volunteers [NCT01478282]	Phase 4	10 participants (Anticipated)	Interventional	2012-01-31	Recruiting
Open Label, Randomised Exploratory Dose Response Study in Pharmacodynamics and Safety of BIBR 1048 (110 mg Twice Daily (b.i.d.) and 150 mg b.i.d.) for 12 Weeks in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin [NCT01136408]	Phase 2	174 participants (Actual)	Interventional	2005-11-30	Completed
APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study [NCT02640222]		321,501 participants (Actual)	Observational	2014-01-01	Completed
A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial Treatm [NCT00680186]	Phase 3	2,589 participants (Actual)	Interventional	2008-04-30	Completed
A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Comp [NCT00657150]	Phase 3	2,055 participants (Actual)	Interventional	2008-03-31	Completed
The Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Extended Treatment of Venous Thromboembolism [NCT03292666]		39,603 participants (Actual)	Observational	2010-01-01	Completed
The Effect of Dicloxacillin on Oral Absorption of Drugs [NCT05073627]	Phase 1	12 participants (Actual)	Interventional	2022-02-07	Completed
A Phase 1, Open-label, Sequential Study to Investigate the Pharmacokinetic Interaction Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Subjects [NCT02945020]	Phase 1	15 participants (Actual)	Interventional	2016-11-10	Completed
Efficacy and Safety of Non-vitamin K Oral Anticoagulants and Vitamin K Oral Anticoagulants on Some Metabolic and Coagulation Parameters in Diabetic and Nondiabetic Patients With First Diagnosis of Non-valvular Atrial Fibrillation [NCT02935855]	Phase 4	300 participants (Actual)	Interventional	2015-09-30	Completed
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria [NCT00262600]	Phase 3	18,113 participants (Actual)	Interventional	2005-12-31	Completed
Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in the Treatment of Non Valvular Atrial Fibrillation in Patients Aged 80 Years and Over, Living at Home or in Nursing Home. A Prospective Cohort Study [NCT02286414]		159 participants (Actual)	Observational	2015-02-28	Completed
A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembo [NCT00329238]	Phase 3	2,867 participants (Actual)	Interventional	2006-05-31	Completed
A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate 150 mg Twice Daily Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (VTE), Following In [NCT00291330]	Phase 3	2,564 participants (Actual)	Interventional	2006-02-28	Completed
Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia. A Prospective Randomized Controlled Academic Single-centre Feasibility Study. [NCT01911624]	Phase 2	94 participants (Actual)	Interventional	2013-01-31	Completed
Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study). [NCT03539055]	Phase 4	100 participants (Anticipated)	Interventional	2018-09-01	Active, not recruiting
Randomized Clinical Trial for the Prevention of Cognitive Impairment in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin [NCT01994265]	Phase 4	200 participants (Actual)	Interventional	2014-11-07	Completed
Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data [NCT04735523]		5,350 participants (Actual)	Observational	2020-09-22	Completed
Investigating the Role of the Coagulation Cascade in Idiopathic Pulmonary Fibrosis [NCT02885961]		12 participants (Anticipated)	Interventional	2016-08-31	Not yet recruiting
Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism [NCT02596555]	Phase 4	400 participants (Actual)	Interventional	2016-01-31	Terminated(stopped due to "Interim results suggested a reduction of sample size.~Anticipated length of enrolment period with resulting funding issues to pose a threat to the study.")
Closure of Patent Foramen Ovale or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence [NCT00562289]	Phase 3	664 participants (Actual)	Interventional	2007-12-31	Completed
A Single Dose, Randomized, Open Label, Two-Treatment, Two-Sequence, Two-Period, Crossover Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition [NCT04592822]	Phase 1	20 participants (Anticipated)	Interventional	2021-01-06	Not yet recruiting
Prospective, Multi-centre, Randomized, Parallel Comparison to Evaluate the Safety and Efficacy of the Abluminal Sirolimus Coated Bio-engineered Stent (COMBO Stent) in Association With Short-term Single Antiplatelet Therapy in Patients With Coronary Artery [NCT02723981]	Phase 4	0 participants (Actual)	Interventional	2016-04-30	Withdrawn(stopped due to Regulatory authority approval for the initial study design could not be obtained)
The Comparative Safety of Direct Oral Anticoagulants Versus Warfarin for the Treatment of Venous Thromboembolism [NCT02833987]		59,525 participants (Actual)	Observational	2015-03-31	Completed
Dose Exploration in Patients With Atrial Fibrillation [NCT01227629]	Phase 2	502 participants (Actual)	Interventional	2003-09-30	Completed
Oral Anticoagulant Bleeding Rate and Discontinuation and Adherence Patterns in Non-Valvular Atrial Fibrillation (NVAF) Patients [NCT02792335]		28,000 participants (Actual)	Observational	2012-01-31	Completed
A Randomized Pilot Study Comparing the Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery [NCT01431456]	Phase 3	148 participants (Actual)	Interventional	2013-09-30	Completed
Use of Public Health Surveillance Models in the French National Health System Database: A Tool for an Ongoing Monitoring of Adverse Drug Reaction? The Case of Dabigatran [NCT02904499]		814,446 participants (Actual)	Observational	2013-12-31	Completed
MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention: The MOSES-study. An International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial [NCT03961334]	Phase 3	620 participants (Anticipated)	Interventional	2019-12-05	Recruiting
Prospective Randomized Study for Evaluating Vascular Protective Effects of New Oral Anticoagulants in High Risk Patients With Atrial Fibrillation [NCT02544932]	Phase 3	55 participants (Anticipated)	Interventional	2015-10-31	Not yet recruiting
Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation Using Healthcare Data for Pragmatic Research: A Randomised Controlled Trial [NCT04700826]	Phase 4	3,000 participants (Anticipated)	Interventional	2021-06-01	Recruiting
RE-DUAL PCI Real Life Registry Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI [NCT04688723]	Phase 4	1,000 participants (Anticipated)	Interventional	2020-12-23	Recruiting
A Phase 1, Open-Label, Fixed Sequence Drug Interaction Study to Evaluate the Potential Intestinal Inhibitory Effect of Quizartinib on the Pharmacokinetics of a Pgp Substrate Dabigatran Etexilate in Healthy Subjects [NCT04459585]	Early Phase 1	20 participants (Actual)	Interventional	2020-08-28	Completed
Start or STop Anticoagulants Randomised Trial (SoSTART) After Spontaneous Intracranial Haemorrhage [NCT03153150]	Phase 3	203 participants (Actual)	Interventional	2018-03-28	Completed
Bioequivalence of Two Different Capsule Types of 150 mg Dabigatran Etexilate Made From Two Different Drug Product Batches, Following Oral Administration in Healthy Male and Female Volunteers (Open-label, Randomised, Single Dose, Replicate Design in a Two [NCT01290757]	Phase 1	180 participants (Actual)	Interventional	2011-01-31	Completed
BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery [NCT01225822]	Phase 2	1,973 participants (Actual)	Interventional	2002-11-30	Completed
An Open Label, Non-comparative, Pharmacokinetic and Pharmacodynamic Study to Evaluate the Effect of Dabigatran Etexilate on Coagulation Parameters Including a Calibrated Thrombin Time Test in Patients With Moderate Renal Impairment (Creatinine Clearance 3 [NCT01184989]	Phase 4	142 participants (Actual)	Interventional	2010-08-31	Completed
A Phase 1, Open-label, 2-part, 2-period Fixed-sequence Study to Evaluate the Effect of Fruquintinib on the Pharmacokinetics of Dabigatran Etexilate (A P-GP Substrate) and Rosuvastatin (A BCRP Substrate) in Healthy Subjects [NCT05368805]	Phase 1	32 participants (Actual)	Interventional	2022-03-02	Completed
Safety and Effectiveness Study Comparing Dabigatran, Rivaroxaban & Apixaban in Non-valvular Atrial Fibrillation Patients Enrolled in the US Department of Defense Military Health System [NCT03026556]		42,534 participants (Actual)	Observational	2016-12-29	Completed
PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation (PRESTIGE-AF) [NCT03996772]	Phase 3	350 participants (Anticipated)	Interventional	2019-06-03	Recruiting
The Dabigatran, Apixaban, Rivaroxaban, Edoxaban, Warfarin Comparative Effectiveness Research Study [NCT03271450]		416,000 participants (Anticipated)	Observational	2017-07-01	Enrolling by invitation
Oral Anticoagulation After Cardiac Surgery in the Era of Direct Oral Anticoagulants: is Large Use of Vitamin K Antagonists Still Justified? [NCT04002011]	Phase 2	0 participants (Actual)	Interventional	2022-03-09	Withdrawn(stopped due to Submission process abandoned. No patient enrolled.)
Single Dose Open-label PK/PD, Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given at the End of Standard Anticoagulant Therapy in Successive Groups of Children Aged 2 Years to Less Than 12 Years Followed by 1 Year to Less Than 2 Years [NCT01083732]	Phase 2	18 participants (Actual)	Interventional	2010-03-31	Completed
Relative Bioavailability of a Single Dose of 150 mg Dabigatran Etexilate (Capsule) When Administered Alone or in Combination With a Single Dose of 400 mg Dronedarone Tablet) or in Combination With 400 mg Bid Dronedarone (Tablet) at Steady State in Healthy [NCT01306162]	Phase 1	36 participants (Actual)	Interventional	2011-02-28	Completed
A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of RDG-17012(Dabigatran Etexilate Tosylate) With Pradaxa® Capsule(Dabigatran Etexilate Mesylate) in Healthy Male Volunteers [NCT03495739]	Phase 1	64 participants (Actual)	Interventional	2018-02-01	Active, not recruiting
OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke: a Randomised Controlled Trial [NCT03759938]		3,478 participants (Anticipated)	Interventional	2019-06-18	Recruiting
Relative Bioavailability of Dabigatran After Administration of Different Dosage Forms of Multiple Doses of 150 mg Dabigatran Etexilate (Hard Capsule, Granules Resolved in Reconstitution Solution, Pellets on Food) in Healthy Male Volunteers (an Open-label, [NCT02044367]	Phase 1	54 participants (Actual)	Interventional	2014-01-31	Completed
An Open-Label, Drug-Drug Interaction Study Designed to Evaluate the Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Subjects [NCT05347979]	Phase 1	30 participants (Actual)	Interventional	2022-05-25	Completed
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms [NCT04192916]		442 participants (Actual)	Observational	2019-09-01	Completed
A Randomized Controlled Trial to Investigate Whether a Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at the Time of Device Surgery, in Patients With Moderate to High Risk of Arterial Thrombo-embolic Events, Leads to a Reduction in the [NCT01675076]	Phase 3	663 participants (Actual)	Interventional	2013-01-31	Completed
A Retrospective Cohort Study With Chart Review to Assess the Management of Major Bleeding Events in NVAF Patients Treated With Dabigatran Etexilate [NCT02149303]		191 participants (Actual)	Observational	2014-06-30	Completed
A Cohort (Follow Up) Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax (Tablet) Post Discharge for Ten Days, Without the Need for Routine Coagulation Monitoring and Dose Adjustment [NCT00868179]	Phase 4	0 participants (Actual)	Interventional	2009-04-30	Withdrawn(stopped due to study never started)
Relative Bioavailability of Dabigatran After Single Oral Administration of Five Different Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Six-period, [NCT02710630]	Phase 1	35 participants (Actual)	Interventional	2016-03-22	Completed
Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy [NCT01810237]		0 participants (Actual)	Interventional	2013-03-31	Withdrawn(stopped due to No patients recruited)
Randomised, Double-blind Within Dose Groups, Placebo-controlled Phase I Trial in Healthy Japanese Male Volunteers to Investigate Safety, Tolerability and Pharmacokinetics of Different Doses of BI 655075 (Part 1) and to Explore the Effective Dose of BI 655 [NCT02028780]	Phase 1	80 participants (Actual)	Interventional	2014-01-31	Completed
Relative Bioavailability of Dabigatran After Administration of Different Application Forms of a Single Oral Dose of 150 mg Dabigatran Etexilate (Capsule, Powder for Reconstitution Into Solution, Pellets on Food) in Healthy Male and Female Volunteers (an O [NCT02171611]	Phase 1	30 participants (Actual)	Interventional	2009-03-31	Completed
AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS) [NCT02701062]	Phase 4	562 participants (Actual)	Interventional	2016-02-29	Completed
A Randomised, Parallel-group, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Knee Replacement Surgery [NCT00246025]	Phase 2	512 participants (Actual)	Interventional	2005-10-31	Completed
APIXABAN DRUG UTILIZATION STUDY IN STROKE PREVENTION IN ATRIAL FIBRILLATION (SPAF) [NCT03441633]		51,690 participants (Actual)	Observational	2016-02-18	Completed
Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants [NCT02754154]		321,182 participants (Actual)	Observational	2014-12-31	Completed
Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study [NCT04684212]		2,931 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
A Large, International, Randomized, Placebo-controlled Trial to Assess the Impact of Dabigatran (a Direct Thrombin Inhibitor) and Omeprazole (a Proton-pump Inhibitor) in Patients Suffering Myocardial Injury After Noncardiac Surgery [NCT01661101]	Phase 3	1,754 participants (Actual)	Interventional	2013-01-31	Completed
Impact of Rabeprazole-induced Elevated Gastric pH on APO-Dabigatran Exposure in Healthy Volunteers [NCT04157881]	Phase 4	46 participants (Actual)	Interventional	2020-01-03	Completed
Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients [NCT01727427]		695 participants (Actual)	Observational	2012-11-30	Completed
Dabigatran Treatment Following Transient Ischemic Attack and Minor Stroke [NCT01769703]	Phase 2	53 participants (Actual)	Interventional	2012-02-29	Completed
Single Dose Open-label PK/PD, Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given at the End of Standard Anticoagulant Therapy in Children Aged 1 Year to Less Than 2 Years in Conjunction With Study 1160.89 [NCT01773174]	Phase 2	0 participants (Actual)	Interventional	2013-01-31	Withdrawn
A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Pradaxa (Dabigatran Etexilate Mesilate, 110 mg or 150 mg b.i.d.) in Korean Patients With Non-valvular Atrial Fibrillation(SPARK: Safety Study of Pradaxa in AF Pat [NCT01774370]		3,182 participants (Actual)	Observational	2013-01-14	Completed
Treating Acute Pancreatitis With Dabigatran, a Pilot Study [NCT03807856]	Phase 1	2 participants (Actual)	Interventional	2019-06-24	Terminated(stopped due to Difficult recruitment)
A Prospective, Randomized, Controlled, Analyst-blinded, Parallel Group Study to Investigate the Effect of Antithrombotic Triple Therapy With Ticagrelor and Acetylsalicylic Acid in Combination With Dabigatran or Rivaroxaban or Phenprocoumon on Markers of C [NCT01812200]	Phase 4	60 participants (Actual)	Interventional	2012-10-31	Completed
Comparison of the Length of Stay in Patients Hospitalized and Initiated With Dabigatran or Warfarin for a Concomitant Non-Valvular Atrial Fibrillation in Real-world Japanese Therapeutic Practice (SHORT-J) [NCT02631057]		4,313 participants (Actual)	Observational	2016-09-01	Completed
Open-label, Single Dose, Tolerability, Pharmacokinetic/Pharmacodynamics and Safety Study of Dabigatran Etexilate Given at the End of Standard Anticoagulant Therapy in Children Aged Less Than 1 Year Old [NCT02223260]	Phase 2	8 participants (Actual)	Interventional	2014-09-30	Completed
Pradaxa Initiation Post-Stroke Study: SITS-Pradaxa 1. A Retrospective Analysis From the SITS-AF Registry on Treatment Initiation of Dabigatran Etexilate in Non-valvular Atrial Fibrillation Patients Hospitalized With Acute Ischemic Stroke [NCT03258645]		1,489 participants (Actual)	Observational	2018-11-15	Completed
A Clinical Study to Evaluate the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Healthy Volunteers and Renal Impairment Patients [NCT05747768]	Phase 4	60 participants (Anticipated)	Interventional	2022-07-15	Recruiting
Efficacy and Safety of Vascular Boot Warming Program After Acute DVT±PE for Earlier Resolution of Venous Thromboembolism (VTE) and Prevention of Post Thrombotic Syndrome: A Pilot Study. [NCT03465735]		15 participants (Actual)	Interventional	2017-01-13	Terminated(stopped due to Due to lack of recruitment of eligible participants)
Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation [NCT02067182]	Phase 4	200 participants (Actual)	Interventional	2015-08-31	Completed
Replication of the RELY Anticoagulant Trial in Healthcare Claims Data [NCT04593043]		78,140 participants (Actual)	Observational	2020-01-01	Completed
Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation [NCT01468155]	Phase 4	50 participants (Actual)	Interventional	2011-07-13	Completed
A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO ESTIMATE THE EFFECT OF PF-07081532 ADMINISTRATION ON THE SINGLE-DOSE PHARMACOKINETICS OF DABIGATRAN AND ROSUVASTATIN IN OVERWEIGHT OR OBESE ADULT PARTICIPANTS [NCT05788328]	Phase 1	16 participants (Actual)	Interventional	2023-03-27	Terminated(stopped due to The decision to terminate clinical development of lotiglipron is based on pharmacokinetic data from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these Phase 1 studies as well as a Phase 2 study.)
Stroke/Systemic Embolism and Major Bleeding in Patients Newly Treated With Oral Anticoagulants: a Real World Study From Portuguese Administrative Claims Data [NCT04808934]		0 participants (Actual)	Observational	2020-06-01	Withdrawn(stopped due to Withdrawn due to COVID19 pandemic. Several delays affected this study, therefore company decided to not conduct the study. It was cancelled prior to any enrollment.)
Open Label Phase I Trial in Healthy Chinese Male and Female Volunteers to Investigate Pharmacokinetics and Pharmacodynamics of Idarucizumab to Reverse Dabigatran Anticoagulant Activity [NCT03086356]	Phase 1	12 participants (Actual)	Interventional	2017-05-10	Completed
Open Label, Non Randomized, Multiple Dose Phase I Study to Investigate the Elimination, Pharmacokinetics, Pharmacodynamics and Safety of Dabigatran Etexilate (Pradaxa) Under Steady State Conditions Before, During and After Haemodialysis in Patients With E [NCT01241539]	Phase 1	7 participants (Actual)	Interventional	2010-11-30	Completed
Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial [NCT03148457]		2,013 participants (Actual)	Interventional	2017-11-06	Completed
A Prospective Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism [NCT03240120]	Phase 3	99 participants (Anticipated)	Interventional	2017-09-01	Recruiting
Drug Persistence/Adherence in Patients Being Treated With Dabigatran Etexilate or VKA for Stroke Prevention in Non-valvular Atrial Fibrillation (SPAF) [NCT02240667]		1,506 participants (Actual)	Observational	2014-09-18	Completed
The Direct Oral Anticoagulation Versus Warfarin After Cardiac Surgery Trial [NCT04284839]	Phase 3	6,215 participants (Anticipated)	Interventional	2021-07-18	Recruiting
Dabigatran Versus Warfarin After Mitral and Aortic Bioprosthesis Replacement for the Management of Atrial Fibrillation Postoperatively: Pilot Study [NCT01868243]	Phase 2/Phase 3	27 participants (Actual)	Interventional	2013-08-31	Terminated(stopped due to because a significant decrease of viable candidates for the study.)
A Pilot Trial of Restarting Direct Oral Anticoagulants After Traumatic Intracranial Hemorrhage [NCT04891861]	Phase 3	100 participants (Anticipated)	Interventional	2021-07-01	Not yet recruiting
Phase 1 Study of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients [NCT01590823]	Phase 1	10 participants (Actual)	Interventional	2012-07-31	Completed
Early Versus Late DC-cardioversion of Persistent Atrial Fibrillation. Effect on Atrial Remodeling,Inflammatory and Neurohumoral Markers and Recurrence of Atrial Fibrillation. [NCT01593150]		141 participants (Actual)	Interventional	2011-11-30	Completed
SafeTy and Efficacy of Direct Oral Anticoagulant Versus Aspirin for Reduction Of RisK of CErebrovascular Events in Patients Undergoing Ventricular Tachycardia Ablation (STROKE-VT) [NCT02666742]	Phase 4	246 participants (Actual)	Interventional	2017-02-16	Completed
VICTORIE (VTE In Cancer - Treatment, Outcomes and Resource Use In Europe) [NCT04618913]		1 participants (Anticipated)	Observational	2020-12-14	Active, not recruiting
Pharmacodynamic Effects of Dabigatran in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel [NCT01852162]		35 participants (Actual)	Interventional	2012-02-29	Completed
Pilot Study of Post-thrombotic Syndrome & Predictors of Recurrence in Cancer Patients With Catheter-related Thrombosis [NCT01999179]		27 participants (Actual)	Interventional	2014-06-30	Completed
Registration of Idarucizumab for Patients With IntraCranial Hemorrhage (RIC-ICH) [NCT04062097]		104 participants (Actual)	Observational	2019-09-19	Completed
Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor (Part 1 and 2, Open, Non-randomised, 2 Parallel Groups) and Assessment of Ticagrelor Interaction Potential With Dabigatran (Part 3, Open, Randomised, Two-period Cross-over) in Healthy M [NCT01595854]	Phase 1	36 participants (Actual)	Interventional	2012-05-31	Completed
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism. [NCT00558259]	Phase 3	1,353 participants (Actual)	Interventional	2007-11-30	Completed
Randomised, Double-blind, Placebo-controlled Phase I Study in Healthy Male Volunteers. to Investigate Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BI 655075 (Part 1) and to Explore the Dose of BI 655075 Effective to Reverse Dabigatr [NCT01688830]	Phase 1	157 participants (Actual)	Interventional	2012-09-30	Completed
A Prospective Randomised Controlled Study to Evaluate Outcomes of the Treatment With Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism Undergoing Endovascular Mechanical Fragme [NCT02979561]	Phase 4	200 participants (Anticipated)	Interventional	2016-10-31	Recruiting
Medical Need of Oral Anti-coagulant Reversal in Japan: Epidemiological Assessment of Head Trauma, Fracture, and Emergency Surgery Using Large Scale Claims Database (Please Note That This Study Contains no Patients Treated With Idarucizumab Although the St [NCT03254147]		53,969 participants (Actual)	Observational	2017-10-15	Completed
Prospective, Observational, Non-interventional Open-label Multicenter Registry Regarding the Incidence of Heavy Menstrual Bleeding in Women of Reproductive Age Treated With Direct Oral Anticoagulants Because of Venous Thromboembolism [NCT04477837]		150 participants (Anticipated)	Observational [Patient Registry]	2020-10-15	Recruiting
Open Label, Single Arm Safety Prospective Cohort Study of Dabigatran Etexilate for Secondary Prevention of Venous Thromboembolism in Children From 0 to Less Than 18 Years [NCT02197416]	Phase 3	214 participants (Actual)	Interventional	2014-09-29	Completed
THE REAL WORLD EVIDENCE ON TREATMENT PATTERNS, EFFECTIVENESS, AND SAFETY OF DRUGS FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS IN KOREA [NCT03572972]		64,684 participants (Actual)	Observational	2018-01-31	Completed
Dabigatran-related Effect on Progression of Atrial Fibrosis in Patients With Atrial Fibrillation [NCT01546883]	Phase 4	14 participants (Actual)	Interventional	2012-02-29	Terminated(stopped due to Not enough patients in time period allotted for study)
Evaluation of the Long Term Safety of the Use of Dabigatran Etexilate in Patients With a Bileaflet Mechanical Heart Valve [NCT01505881]	Phase 2	158 participants (Actual)	Interventional	2011-12-31	Terminated
A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt [NCT01452347]	Phase 2	328 participants (Actual)	Interventional	2011-10-31	Terminated
A Prospective, Open Label Study Evaluating the Efficacy of Two Management Strategies (Pantoprazole 40 mg q.a.m. and Taking Pradaxa® With Food (Within 30 Minutes After a Meal) on Gastrointestinal Symptoms (GIS) in Patients Newly on Treatment With Pradaxa® [NCT01493557]	Phase 4	1,067 participants (Actual)	Interventional	2011-12-31	Completed
Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty [NCT04878497]		1,000,000 participants (Anticipated)	Observational	2021-03-30	Active, not recruiting
Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis-A Randomized Placebo Controlled Trial [NCT04433481]		84 participants (Anticipated)	Interventional	2020-06-20	Recruiting
Effect of LY3314814 on the Pharmacokinetics of Dabigatran in Healthy Subjects [NCT02568397]	Phase 1	60 participants (Actual)	Interventional	2015-10-31	Completed
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in Daily Clinical Practice - A French Cohort Within the Nationwide Claims and Hospital Database [NCT02864758]		99,999 participants (Actual)	Observational	2016-09-08	Completed
Prostate Cancer VTE in Sweden: Epidemiology and Anticoagulation Treatment of VTE [NCT03965741]		97,765 participants (Actual)	Observational	2019-05-30	Completed
An Open-label Crossover Trial Assessing the Value of Dabigatran in a Drug Interaction Cocktail in Healthy Young Volunteers [NCT02361619]	Phase 1	16 participants (Actual)	Interventional	2015-02-28	Completed
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of EDP-938 on the Pharmacokinetics of Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects [NCT04498741]	Phase 1	89 participants (Actual)	Interventional	2020-07-08	Completed
The Efficacy and Safety of Dabigatran Etexilate Comparing With Warfarin for the Anticoagulation Treatment of Cerebral Venous Thrombosis :a Pilot Study [NCT03217448]	Phase 3	80 participants (Anticipated)	Interventional	2017-10-30	Recruiting
Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor Under Steady State Conditions in Healthy Male Subjects [NCT01734772]	Phase 1	48 participants (Actual)	Interventional	2012-11-30	Completed
Canadian Pradaxa Acute Stroke Safety Study [NCT02415855]		101 participants (Actual)	Observational [Patient Registry]	2015-03-31	Completed
Randomized Evaluation of Dabigatran Etexilate Compared to warfarIn in pulmonaRy Vein Ablation: Assessment of an Uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial) [NCT02348723]	Phase 4	678 participants (Actual)	Interventional	2015-04-28	Completed
A Prospective Observational Cohort Study of Predictive Factors Related to Prognosis of In-hosiptal Patients With Ischemic Stroke Due to Large-artery Atherosclerosis [NCT04847752]		1,000 participants (Anticipated)	Observational	2021-03-01	Recruiting
An Open-Label Study to Investigate the Effect of Selpercatinib on the Pharmacokinetics of Dabigatran in Healthy Volunteers [NCT04782076]	Phase 1	36 participants (Actual)	Interventional	2021-03-05	Completed
Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism in Patients Undergoing Left Atrial Catheter Ablation Procedures for Paroxysmal or Persistent (Non-permanent) Atrial Fibrillation and Left Atrial Flutter [NCT01976507]	Phase 4	101 participants (Actual)	Interventional	2013-10-31	Completed
Effectiveness of Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Aortic and Mitral Valvular Atrial Fibrillation Patients [NCT02982850]	Phase 4	120 participants (Actual)	Interventional	2016-12-31	Completed
Open-label, Randomized, Parallel-group, Active-controlled, Multi-centre Non-inferiority Study of Dabigatran Etexilate Versus Standard of Care for Venous Thromboembolism Treatment in Children From Birth to Less Than 18 Years of Age [NCT01895777]	Phase 3	267 participants (Actual)	Interventional	2013-09-25	Completed
A Randomized Trial of the Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery: a Pilot Study [NCT05006287]	Phase 2	100 participants (Anticipated)	Interventional	2021-10-01	Not yet recruiting
An Open-Label, 2-Part Study to Investigate the Effect of Lasmiditan on the Pharmacokinetics of Dabigatran and Rosuvastatin in Healthy Volunteers [NCT04749914]	Phase 1	96 participants (Actual)	Interventional	2021-02-15	Completed
Real-world Evidence for Non-valvular Atrial Fibrillation Patients Treated With Oral Anticoagulation in the Nordics [NCT04249401]		134,897 participants (Actual)	Observational	2020-03-01	Completed
International Registry on the Use of the Direct Oral Anticoagulants for the Treatment of Unusual Site Venous Thromboembolism [NCT03778502]		300 participants (Anticipated)	Observational [Patient Registry]	2019-10-01	Recruiting
Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embol [NCT02239120]	Phase 3	5,390 participants (Actual)	Interventional	2014-11-27	Completed
A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus C [NCT02164864]	Phase 3	2,725 participants (Actual)	Interventional	2014-07-22	Completed
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy [NCT01896297]	Phase 4	63 participants (Actual)	Interventional	2013-07-31	Completed
An Exploratory Study to Investigate the Pharmacokinetics and Effects of DABIgatran Etexilate in Patients With Stable Severe RENAL Disease: DabiRenal [NCT01711853]	Phase 1	19 participants (Actual)	Interventional	2012-10-31	Completed
A Study Evaluating the Pharmacokinetics of Dabigatran Etexilate in Adult Healthy Subjects, Elderly Healthy Subjects, and Elderly Patients With Atrial Fibrillation [NCT05715658]		36 participants (Anticipated)	Interventional	2022-08-15	Recruiting
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring [NCT01706146]	Phase 4	59 participants (Actual)	Interventional	2012-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00152971 (9) [back to overview]	Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period
NCT00152971 (9) [back to overview]	Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period
NCT00152971 (9) [back to overview]	Number of Participants With Total Deep Vein Thrombosis During Treatment Period
NCT00152971 (9) [back to overview]	Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period
NCT00152971 (9) [back to overview]	Number of Participants Who Died During Treatment Period
NCT00152971 (9) [back to overview]	Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period
NCT00152971 (9) [back to overview]	Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period
NCT00152971 (9) [back to overview]	Number of Participants With Pulmonary Embolism During Treatment Period
NCT00152971 (9) [back to overview]	Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period
NCT00157248 (16) [back to overview]	Severe Adverse Event
NCT00157248 (16) [back to overview]	Yearly Event Rate of Haemorrhagic Stroke
NCT00157248 (16) [back to overview]	Yearly Event Rate of Death
NCT00157248 (16) [back to overview]	Yearly Event Rate for Transient Ischaemic Attacks
NCT00157248 (16) [back to overview]	Yearly Event Rate for Systemic Thromboembolism
NCT00157248 (16) [back to overview]	Yearly Event Rate for Stroke
NCT00157248 (16) [back to overview]	Yearly Event Rate for Major Bleeding
NCT00157248 (16) [back to overview]	Yearly Event Rate for Major + Minor/Relevant Bleeding
NCT00157248 (16) [back to overview]	Yearly Event Rate for Composite Secondary Endpoint of Ischaemic Stroke, Transient Ischaemic Attacks, Non-central Nervous System Systemic Thromboembolism, Myocardial Infarction, Other Major Adverse Cardiac Events and All-cause Mortality
NCT00157248 (16) [back to overview]	Yearly Event Rate for Minor Bleeding
NCT00157248 (16) [back to overview]	Laboratory Analyses
NCT00157248 (16) [back to overview]	Yearly Event Rate of Other Major Adverse Cardiac Events
NCT00157248 (16) [back to overview]	Yearly Event Rate of Myocardial Infarction
NCT00157248 (16) [back to overview]	Yearly Event Rate of Ischaemic Stroke
NCT00157248 (16) [back to overview]	Yearly Event Rate for Composite Endpoint of Stroke, Transient Ischaemic Attacks, System Thromboembolism, Myocardial Infarction, Other Major Adverse Cardiac Events and Mortality.
NCT00157248 (16) [back to overview]	Yearly Event Rate for Any Bleeding
NCT00168805 (12) [back to overview]	Blood Transfusion
NCT00168805 (12) [back to overview]	Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period
NCT00168805 (12) [back to overview]	Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period
NCT00168805 (12) [back to overview]	Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period
NCT00168805 (12) [back to overview]	Number of Participants Who Died During Treatment Period
NCT00168805 (12) [back to overview]	Laboratory Analyses
NCT00168805 (12) [back to overview]	Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period
NCT00168805 (12) [back to overview]	Number of Participants With Pulmonary Embolism During Treatment Period
NCT00168805 (12) [back to overview]	Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period
NCT00168805 (12) [back to overview]	Number of Participants With Total Deep Vein Thrombosis During Treatment Period
NCT00168805 (12) [back to overview]	Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period
NCT00168805 (12) [back to overview]	Volume of Blood Loss
NCT00168818 (12) [back to overview]	Laboratory Analyses
NCT00168818 (12) [back to overview]	Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period
NCT00168818 (12) [back to overview]	Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period
NCT00168818 (12) [back to overview]	Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period
NCT00168818 (12) [back to overview]	Symptomatic Deep Vein Thrombosis During Treatment Period
NCT00168818 (12) [back to overview]	Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period
NCT00168818 (12) [back to overview]	Total Deep Vein Thrombosis During Treatment Period
NCT00168818 (12) [back to overview]	Proximal Deep Vein Thrombosis During Treatment Period
NCT00168818 (12) [back to overview]	Pulmonary Embolism During Treatment Period
NCT00168818 (12) [back to overview]	Volume of Blood Loss
NCT00168818 (12) [back to overview]	Blood Transfusion
NCT00168818 (12) [back to overview]	Death During Treatment Period
NCT00246025 (11) [back to overview]	Number of Participants With Bleeding Events During Treatment Period
NCT00246025 (11) [back to overview]	Laboratory Analyses
NCT00246025 (11) [back to overview]	Blood Transfusion
NCT00246025 (11) [back to overview]	Volume of Blood Loss
NCT00246025 (11) [back to overview]	Percentage of Participants With Symptomatic DVT (Deep Vein Thrombosis)
NCT00246025 (11) [back to overview]	Percentage of Participants Who Have Total DVT (Deep Vein Thrombosis) During Treatment Period
NCT00246025 (11) [back to overview]	Percentage of Participants Who Have Proximal DVT (Deep Vein Thrombosis) During Treatment Period
NCT00246025 (11) [back to overview]	Percentage of Participants Who Have a Composite of Major VTE (Defined as Proximal DVT and PE) and VTE Related Mortality
NCT00246025 (11) [back to overview]	Percentage of Participants Who Have a Composite Endpoint Consisting of Total Venous Thromboembolic Event (VTE) and All Cause Mortality During the Treatment Period.
NCT00246025 (11) [back to overview]	Number of Participants With Pulmonary Embolism During Treatment Period
NCT00246025 (11) [back to overview]	Number of Participants Who Died During Treatment Period
NCT00262600 (6) [back to overview]	Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death
NCT00262600 (6) [back to overview]	Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death
NCT00262600 (6) [back to overview]	Bleeding Events (Major and Minor)
NCT00262600 (6) [back to overview]	Abnormal Liver Function Test
NCT00262600 (6) [back to overview]	Yearly Event Rate for Composite Endpoint of Stroke/SEE
NCT00262600 (6) [back to overview]	Clinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH)
NCT00291330 (9) [back to overview]	Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE
NCT00291330 (9) [back to overview]	Number of Participants With Bleeding Events
NCT00291330 (9) [back to overview]	Laboratory Analyses
NCT00291330 (9) [back to overview]	Number of Participants Who Died (Any Cause)
NCT00291330 (9) [back to overview]	Number of Participants Who Died Due to VTE
NCT00291330 (9) [back to overview]	Number of Participants With Acute Coronary Syndrome (ACS)
NCT00291330 (9) [back to overview]	Number of Participants With Recurrent Symptomatic DVT
NCT00291330 (9) [back to overview]	Number of Participants With Recurrent Symptomatic Non-fatal PE
NCT00291330 (9) [back to overview]	Number of Participants With Recurrent Symptomatic VTE and All Deaths
NCT00329238 (15) [back to overview]	DVT at 18 Months
NCT00329238 (15) [back to overview]	Deep Vein Thrombosis (DVT) at 36 Months
NCT00329238 (15) [back to overview]	Symptomatic Pulmonary Embolism (PE) at 18 Months
NCT00329238 (15) [back to overview]	Number of Participants With Definite Acute Coronary Syndrome (ACS)
NCT00329238 (15) [back to overview]	Number of Participants With Bleeding Events
NCT00329238 (15) [back to overview]	Laboratory Analysis
NCT00329238 (15) [back to overview]	Deaths Related to VTE at 18 Months
NCT00329238 (15) [back to overview]	Deaths of All Causes at 36 Months
NCT00329238 (15) [back to overview]	Deaths of All Causes at 18 Months
NCT00329238 (15) [back to overview]	Composite of Recurrent VTE or VTE Death at 36 Months
NCT00329238 (15) [back to overview]	Composite of Recurrent VTE or VTE Death at 18 Months
NCT00329238 (15) [back to overview]	Composite of Recurrent VTE or All Cause Death at 36 Months
NCT00329238 (15) [back to overview]	Composite of Recurrent VTE or All Cause Death at 18 Months
NCT00329238 (15) [back to overview]	Deaths Related to VTE at 36 Months
NCT00329238 (15) [back to overview]	Symptomatic Pulmonary Embolism (PE) at 36 Months
NCT00558259 (8) [back to overview]	Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Including Unexplained Death During the Intended Treatment Period
NCT00558259 (8) [back to overview]	Centrally Confirmed Unexplained Deaths During the Intended Treatment Period
NCT00558259 (8) [back to overview]	Centrally Confirmed Symptomatic Pulmonary Embolism (PE) Events During the Intended Treatment Period
NCT00558259 (8) [back to overview]	Centrally Confirmed Bleeding Event During the Treatment Period
NCT00558259 (8) [back to overview]	Laboratory Measures, Especially Liver Function Tests (LFTs)
NCT00558259 (8) [back to overview]	Centrally Confirmed Cardiovascular Events During the Treatment Period
NCT00558259 (8) [back to overview]	Centrally Confirmed Symptomatic Recurrent Deep Venous Thrombotic (DVT) Events During the Intended Treatment Period
NCT00558259 (8) [back to overview]	Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Excluding Unexplained Death During the Intended Treatment Period
NCT00621855 (7) [back to overview]	Laboratory Analyses
NCT00621855 (7) [back to overview]	Number of Participants Displaying the Composite of Major and Clinically Relevant Minor Bleeding Events During Total Observation Time
NCT00621855 (7) [back to overview]	Composite of Cardiovascular Death (CVD) With Non Fatal Myocardial Infarction (MI) and Non Haemorrhagic Stroke and All Cause Death (ACD), Non Fatal MI, Severe Recurrent Ischaemia (SRI) and Non Haemorrhagic Stroke During Six Months Treatment
NCT00621855 (7) [back to overview]	Number of Participants With Bleeding Events During Total Observation Time
NCT00621855 (7) [back to overview]	Change From Baseline in log10 D-dimer After 1 and 4 Weeks
NCT00621855 (7) [back to overview]	Number of Participants With Any Reduction of D-dimer Concentration
NCT00621855 (7) [back to overview]	Individual Occurrence of Death (Cardiovascular and All-cause), Non-fatal MI, Severe Recurrent Ischaemia and Non-haemorrhagic Stroke During Six Months of Treatment
NCT00657150 (12) [back to overview]	Volume of Blood Loss
NCT00657150 (12) [back to overview]	Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period
NCT00657150 (12) [back to overview]	Number of Participants With Total Deep Vein Thrombosis During Treatment Period
NCT00657150 (12) [back to overview]	Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period
NCT00657150 (12) [back to overview]	Number of Participants With Pulmonary Embolism During Treatment Period
NCT00657150 (12) [back to overview]	Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period
NCT00657150 (12) [back to overview]	Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period
NCT00657150 (12) [back to overview]	Number of Participants Who Died During Treatment Period
NCT00657150 (12) [back to overview]	Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period
NCT00657150 (12) [back to overview]	Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period
NCT00657150 (12) [back to overview]	Laboratory Analyses
NCT00657150 (12) [back to overview]	Blood Transfusion
NCT00680186 (10) [back to overview]	Number of Participants With Recurrent Symptomatic VTE and All Deaths
NCT00680186 (10) [back to overview]	Number of Participants With MBE, MBE and/or CRBE, and Any Bleeding Events
NCT00680186 (10) [back to overview]	Number of Participants With Acute Coronary Syndrome (ACS)
NCT00680186 (10) [back to overview]	Number of Participants Who Died Due to VTE
NCT00680186 (10) [back to overview]	Number of Participants Who Died (Any Cause)
NCT00680186 (10) [back to overview]	Laboratory Analyses
NCT00680186 (10) [back to overview]	Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE
NCT00680186 (10) [back to overview]	Number of Participants With Recurrent Symptomatic Non-fatal PE
NCT00680186 (10) [back to overview]	Number of Participants With Recurrent Symptomatic Fatal and Non-fatal PE
NCT00680186 (10) [back to overview]	Number of Participants With Recurrent Symptomatic DVT
NCT00808067 (14) [back to overview]	Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE) and All Cause Death
NCT00808067 (14) [back to overview]	Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction (MI), All Cause Death and Major Bleed
NCT00808067 (14) [back to overview]	Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction, Vascular Death
NCT00808067 (14) [back to overview]	Annualized Rate of Subjects With Minor Bleeds
NCT00808067 (14) [back to overview]	Annualized Rate of Subjects With Intra-Cranial Hemorrhage (ICH)
NCT00808067 (14) [back to overview]	Pulmonary Embolism (PE), Annualized Rate of Subjects With PE
NCT00808067 (14) [back to overview]	Stroke, Annualized Rate of Subjects With Stroke
NCT00808067 (14) [back to overview]	Non CNS Systemic Embolism (SEE), Annualized Rate of Subjects With Non-CNS SEE
NCT00808067 (14) [back to overview]	Major Bleeding, Annualized Rate of Subjects With Major Bleeds
NCT00808067 (14) [back to overview]	Deep Vein Thrombosis, Annualized Rate of Subjects With DVT
NCT00808067 (14) [back to overview]	Death, Annualized Rate of Subject Death
NCT00808067 (14) [back to overview]	Acute Myocardial Infarction (MI), Annualized Rate of Subjects With MI
NCT00808067 (14) [back to overview]	Annualized Rate of Subjects With Any Bleeds (Major Plus Minor)
NCT00808067 (14) [back to overview]	Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE)
NCT00818753 (5) [back to overview]	Percentage of Participants Who Experienced Abrupt Vessel Closure, New Thrombus With Reduced Reflow or no Reflow
NCT00818753 (5) [back to overview]	Number of Participants With Bleeding Events
NCT00818753 (5) [back to overview]	Percentage of Participants Who Experienced Catheter Related Thrombi Requiring Rescue Anticoagulation Therapy
NCT00818753 (5) [back to overview]	Percentage of Participants Who Require Anticoagulation and/or Have Clinical Signs of Catheter Related Thrombosis
NCT00818753 (5) [back to overview]	Percentage of Participants Who Experienced Catheter Related Thrombi Not Resulting in Clinical Complications Including Guide-catheter (Wire) Thrombosis
NCT00844415 (11) [back to overview]	TT Locally Measured
NCT00844415 (11) [back to overview]	Thrombin Time (TT) Centrally Measured
NCT00844415 (11) [back to overview]	Number of Patients With Bleeding Events (Major and Minor)
NCT00844415 (11) [back to overview]	Plasma Concentration of Total Dabigatran
NCT00844415 (11) [back to overview]	Ecarin Clotting Time (ECT)
NCT00844415 (11) [back to overview]	Plasma Concentration of Free Dabigatran
NCT00844415 (11) [back to overview]	Occurences of Clinical Outcome
NCT00844415 (11) [back to overview]	Number of Patients With Adverse Events
NCT00844415 (11) [back to overview]	Patients With Clinically Relevant Changes in Any Laboratory Parameter, Electrocardiogram (ECG) or Vital Signs
NCT00844415 (11) [back to overview]	Activated Partial Thromboplastin Time (aPTT) Centrally Measured
NCT00844415 (11) [back to overview]	aPTT Locally Measured
NCT01083732 (19) [back to overview]	Tmax (Time From Dosing to Maximum Measured Concentration of Total Dabigatran in Plasma)
NCT01083732 (19) [back to overview]	Tmax (Time From Dosing to Maximum Measured Concentration of Free Dabigatran in Plasma)
NCT01083732 (19) [back to overview]	Percentage of Patients With Incidence of Any Bleeding Events (Major, Clinically Relevant Non-major (CRNM) and Minor) During the Treatment Period.
NCT01083732 (19) [back to overview]	Percentage of Patients With Changes in Laboratory and Clinical Parameters Such as Liver Enzymes and Physical Examination
NCT01083732 (19) [back to overview]	Cmax (Maximum Measured Concentration of Total Dabigatran in Plasma)
NCT01083732 (19) [back to overview]	AUC0-tz (Area Under the Concentration Time Curve of the Total Dabigatran in Plasma Over the Time Interval 0 up to the Last Quantifiable Data Point)
NCT01083732 (19) [back to overview]	AUC0-tz (Area Under the Concentration Time Curve of the Free Dabigatran in Plasma Over the Time Interval 0 up to the Last Quantifiable Data Point)
NCT01083732 (19) [back to overview]	Central Measurement of Ecarin Clotting Time (ECT) at Predose and 2 and 10 h After Intake of Study Medication.
NCT01083732 (19) [back to overview]	Central Measurement of Diluted Thrombin Time (dTT) at Predose and 2 and 10 h After Intake of Study Medication.
NCT01083732 (19) [back to overview]	Central Measurement of Activated Partial Thromboplastin Time (aPTT) at Predose and 2 and 10 h After Intake of Study Medication.
NCT01083732 (19) [back to overview]	Cmax (Maximum Measured Concentration of Free Dabigatran in Plasma)
NCT01083732 (19) [back to overview]	Plasma Concentration of Unchanged Dabigatran Etexilate (BIBR 1048 BS)
NCT01083732 (19) [back to overview]	Plasma Concentration of Total Dabigatran (SUM BIBR 953 ZW)
NCT01083732 (19) [back to overview]	Plasma Concentration of Metabolite BIBR 951 BS
NCT01083732 (19) [back to overview]	Plasma Concentration of Metabolite BIBR 1087 SE
NCT01083732 (19) [back to overview]	Plasma Concentration of Free Dabigatran (BIBR 953 ZW).
NCT01083732 (19) [back to overview]	Global Assessment of Tolerability of Study Medication- Taste Assessment
NCT01083732 (19) [back to overview]	Percentage of Patients With Any Adverse Events During the Treatment Period
NCT01083732 (19) [back to overview]	Global Assessment of Tolerability of Study Medication
NCT01136408 (18) [back to overview]	Discontinuation of the Study Drug Due to Adverse Events
NCT01136408 (18) [back to overview]	Frequency (Occurrence Rates) of a Composite Clinical Endpoint.
NCT01136408 (18) [back to overview]	Frequency (Occurrence Rates) of Clinically Relevant Bleeding Event
NCT01136408 (18) [back to overview]	Changes in Laboratory Test Values
NCT01136408 (18) [back to overview]	Anticoagulation Effects Trough INR (International Normalised Ratio)
NCT01136408 (18) [back to overview]	Frequency (Occurrence Rates) of Major Bleeding Event
NCT01136408 (18) [back to overview]	Anticoagulation Effects Trough aPTT (Activated Partial Thromboplastin Time)
NCT01136408 (18) [back to overview]	Anticoagulation Effects Trough 11-dehydrothromboxane B2
NCT01136408 (18) [back to overview]	Frequency (Occurrence Rates) of Transient Ischemic Attack
NCT01136408 (18) [back to overview]	Frequency (Occurrence Rates) of Ischemic or Haemorrhagic Stroke (Fatal or Non-fatal)
NCT01136408 (18) [back to overview]	Frequency (Occurrence Rates) of Systemic Embolism
NCT01136408 (18) [back to overview]	Anticoagulation Effects Trough ECT (Ecarin Clotting Time)
NCT01136408 (18) [back to overview]	Frequency (Occurrence Rates) of Nuisance Bleeding Event
NCT01136408 (18) [back to overview]	Frequency (Occurrence Rates) of Myocardial Infarction (Fatal or Non-fatal)
NCT01136408 (18) [back to overview]	Frequency (Occurrence Rates) of Death
NCT01136408 (18) [back to overview]	Steady-state Pharmacokinetics of Total Dabigatran Trough Plasma Concentration
NCT01136408 (18) [back to overview]	Incidence and Severity of Adverse Events
NCT01136408 (18) [back to overview]	Frequency (Occurrence Rates) of Other Major Adverse Cardiac Events
NCT01153698 (10) [back to overview]	Percentage of Patients With Symptomatic Venous Thromboembolic Events (sVTE) and All-cause Mortality Events During the Switch-/ Post-switch Treatment Period
NCT01153698 (10) [back to overview]	Percentage of Patients With Single Components of Composite of sVTE and All-cause Mortality Events During Total Treatment Period
NCT01153698 (10) [back to overview]	Volume of Wound Drainage (Post-operative)
NCT01153698 (10) [back to overview]	Percentage of Patients With Major Bleeding Events (MBE) During the Switch-/ Post-switch Treatment Period
NCT01153698 (10) [back to overview]	Percentage of Patients With Major Extra-surgical Site Bleedings During Total Treatment Period
NCT01153698 (10) [back to overview]	Percentage of Patients With MBE During Pre-switch Treatment Period
NCT01153698 (10) [back to overview]	Percentage of Patients With MBE During Total Treatment Period
NCT01153698 (10) [back to overview]	Percentage of Patients With sVTE and All-cause Mortality Events During Pre-switch Treatment Period
NCT01153698 (10) [back to overview]	Percentage of Patients With sVTE and All-cause Mortality Events During Switch Treatment Period
NCT01153698 (10) [back to overview]	Percentage of Patients With sVTE and All-cause Mortality Events During Total Treatment Period
NCT01184989 (3) [back to overview]	Dabigatran Concentration in Plasma, Estimated From Local Hemoclot®
NCT01184989 (3) [back to overview]	Dabigatran Concentration in Plasma, Estimated From Central Hemoclot®
NCT01184989 (3) [back to overview]	Dabigatran Concentration in Plasma, Measured With HPLC-MS/MS
NCT01225822 (11) [back to overview]	Plasma Concentration (Cmax) of Dabigatran
NCT01225822 (11) [back to overview]	Number of Participants With Clinically Significant, Minor or Any Bleeding Events
NCT01225822 (11) [back to overview]	Laboratory Analyses
NCT01225822 (11) [back to overview]	Area Under the Plasma Concentration-time Curve During a Dosing Interval
NCT01225822 (11) [back to overview]	Number of Participants With Major Bleeding Events (MBE)
NCT01225822 (11) [back to overview]	Rate of Transfusions Due to Bleedings
NCT01225822 (11) [back to overview]	Number of Participants With VTE Events and All Cause Mortality
NCT01225822 (11) [back to overview]	Number of Participants With Venous Thromboembolic (VTE) Events
NCT01225822 (11) [back to overview]	Volume of Blood Loss
NCT01225822 (11) [back to overview]	Number of Participants With Proximal DVT, PE (Pulmonary Embolism) and VTE Related Mortality
NCT01225822 (11) [back to overview]	Number of Participants With Proximal DVT
NCT01227629 (21) [back to overview]	Number of Participants With Thromboembolic Events: Ischemic Stroke
NCT01227629 (21) [back to overview]	Thromboembolic Events: Number of Participants With Myocardial Infarction
NCT01227629 (21) [back to overview]	Number of Participants With Increase of Bilirubin to >2*Baseline
NCT01227629 (21) [back to overview]	Number of Participants With Increase of Aspartat-Aminotransferase (AST) to >2*Baseline
NCT01227629 (21) [back to overview]	Number of Participants With Increase of Alkaline Phosphatase (AP) to >2*Baseline
NCT01227629 (21) [back to overview]	Number of Participants With Increase of Alanine-Aminotransferase (ALT) to >2*Baseline
NCT01227629 (21) [back to overview]	Trough Plasma Concentration of Dabigatran (BIBR 953)
NCT01227629 (21) [back to overview]	Thromboembolic Events: Number of Participants With Transient Ischemic Attack
NCT01227629 (21) [back to overview]	Thromboembolic Events: Number of Participants With Systemic Thromboembolism
NCT01227629 (21) [back to overview]	Thromboembolic Events: Number of Participants With Other Major Cardiac Events
NCT01227629 (21) [back to overview]	Thromboembolic Events: Number of Participants Who Died
NCT01227629 (21) [back to overview]	Soluble Fibrin: Difference From Baseline
NCT01227629 (21) [back to overview]	Number of Participants With Thromboembolic Events: Composite Endpoint
NCT01227629 (21) [back to overview]	D-dimer: Difference From Baseline
NCT01227629 (21) [back to overview]	Ecarin Clotting Time (ECT): Difference From Baseline
NCT01227629 (21) [back to overview]	Severity of Adverse Events
NCT01227629 (21) [back to overview]	Number of Participants With Minor/Relevant Bleeding Events
NCT01227629 (21) [back to overview]	Number of Participants With Minor/Nuisance Bleeding Events
NCT01227629 (21) [back to overview]	11-dehydrothromboxane B2 (TXB2): Difference From Baseline
NCT01227629 (21) [back to overview]	Activated Partial Thromboplastin Time (aPTT): Difference From Baseline
NCT01227629 (21) [back to overview]	Number of Participants With Fatal or Life-threatening Major Bleeding Events
NCT01241539 (9) [back to overview]	Safety and Tolerability
NCT01241539 (9) [back to overview]	Additional Safety Parameters
NCT01241539 (9) [back to overview]	Area Under the Curve Exposure to Dabigatran During the First 8 Hours Post Dose (AUC0-8h)
NCT01241539 (9) [back to overview]	Coagulation Parameters
NCT01241539 (9) [back to overview]	Dialysis Clearance of Dabigatran
NCT01241539 (9) [back to overview]	Extent Cleared From Circulation (Plasma) During 1 Complete Cycle of Dialysis
NCT01241539 (9) [back to overview]	Maximum Plasma Concentrations of Dabigatran (Cmax)
NCT01241539 (9) [back to overview]	Plasma Concentration Extraction Ratio
NCT01241539 (9) [back to overview]	Time to Maximum Plasma Concentration (Tmax)
NCT01290757 (6) [back to overview]	Cmax of Free Dabigatran in Plasma.
NCT01290757 (6) [back to overview]	Area Under the Curve 0 to Infinity (AUC0-∞) of Total Dabigatran.
NCT01290757 (6) [back to overview]	AUC0-∞ of Free Dabigatran.
NCT01290757 (6) [back to overview]	AUC0-tz of Free Dabigatran.
NCT01290757 (6) [back to overview]	Area Under the Curve 0 to tz (AUC0-tz) of Total Dabigatran
NCT01290757 (6) [back to overview]	Maximum Measured Concentration (Cmax) of Total Dabigatran in Plasma
NCT01306162 (4) [back to overview]	Free Dabigatran: Maximum Measured Concentration (Cmax)
NCT01306162 (4) [back to overview]	Free Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01306162 (4) [back to overview]	Total Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01306162 (4) [back to overview]	Total Dabigatran: Maximum Measured Concentration (Cmax)
NCT01452347 (8) [back to overview]	Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at End of Trial (EoT) at Week 12
NCT01452347 (8) [back to overview]	Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 4
NCT01452347 (8) [back to overview]	Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 2
NCT01452347 (8) [back to overview]	Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 1
NCT01452347 (8) [back to overview]	Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at End of Trial (EoT) Week 12
NCT01452347 (8) [back to overview]	Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations at Steady State (C Trough,ss) at Week 1
NCT01452347 (8) [back to overview]	Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 4
NCT01452347 (8) [back to overview]	Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 2
NCT01493557 (10) [back to overview]	Rate of Partial Effectiveness of Combined GIS Management Strategies
NCT01493557 (10) [back to overview]	Time Between Symptom Onset and First Observed Complete or Partial Effectiveness and Between Symptom Onset and Last Observed Symptom
NCT01493557 (10) [back to overview]	Combined Rate of Complete or Partial Effectiveness of Initial GIS Management Strategies
NCT01493557 (10) [back to overview]	Rates of Complete Effectiveness of GIS at Each Visit.
NCT01493557 (10) [back to overview]	Rate of Complete Effectiveness of Combined GIS Management Strategies
NCT01493557 (10) [back to overview]	The Rate of Complete Effectiveness of Initial GIS Management Strategy
NCT01493557 (10) [back to overview]	Rate of Partial Effectiveness of Initial GIS Management Strategies
NCT01493557 (10) [back to overview]	Rates of Complete or Partial Effectiveness of GIS at Each Visit.
NCT01493557 (10) [back to overview]	Rates of Partial Effectiveness of GIS at Each Visit.
NCT01493557 (10) [back to overview]	Combined Rate of Complete or Partial Effectiveness of Combined GIS Management Strategies
NCT01505881 (4) [back to overview]	Percentage of Patients With Serious AEs
NCT01505881 (4) [back to overview]	Percentage of Patients With Any Adverse Event (AE)
NCT01505881 (4) [back to overview]	Percentage of Patients With AEs Leading to Discontinuation of Trial Drug
NCT01505881 (4) [back to overview]	Percentage of Deaths, Venous Thromboembolism (VTE), Myocardial Infarction (MI), Transient Ischaemic Attacks (TIA), Strokes, Systemic Embolism, and Valve Thrombosis.
NCT01595854 (3) [back to overview]	Total Dabigatran: Maximum Measured Concentration (Cmax)
NCT01595854 (3) [back to overview]	Number of Participants With Drug Related Adverse Events
NCT01595854 (3) [back to overview]	Total Dabigatran (Dabi): Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01688830 (10) [back to overview]	AUCt1-t2,ss (Area Under the Concentration-time Curve for the Unbound Sum Dabigatran in Plasma From Time Point t1 to Time Point t2, at Steady State) on Day 3 and Day 4
NCT01688830 (10) [back to overview]	Number of Subjects With Drug Related Adverse Events (AE)
NCT01688830 (10) [back to overview]	AUECt1-t2 (Area Under the Effect Curve From Time Point t1 to Time Point t2) on Day 3 and Day 4 (Determined Under Consideration of the Baseline Value) for Part 3 of the Study
NCT01688830 (10) [back to overview]	AUC0-inf (Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity) for Idarucizumab
NCT01688830 (10) [back to overview]	Aet1-t2,ss (Amount of Dabigatran Etexilate Eliminated in Urine From Time Point t1 to Time Point t2, at Steady State) on Day 3 and Day 4 for Sum Dabigatran
NCT01688830 (10) [back to overview]	Tmax (Time From Dosing to Maximum Measured Concentration) for Idarucizumab
NCT01688830 (10) [back to overview]	Aet1-t2 (Amount of Idarucizumab Eliminated in Urine From Time Point t1 to Time Point t2)
NCT01688830 (10) [back to overview]	AUECt1-t2 (Area Under the Effect Curve From Time Point t1 to Time Point t2) on Day 3 and Day 4 (Determined Under Consideration of the Baseline Value) for Part 2 of the Study
NCT01688830 (10) [back to overview]	C1.92,ss, C2,ss, C2.5,ss, C6,ss, and C12,ss (Concentration of the Unbound Sum Dabigatran in Plasma at Steady State)
NCT01688830 (10) [back to overview]	Cmax (Maximum Measured Concentration) for Idarucizumab
NCT01706146 (2) [back to overview]	Number of Days on Anticoagulation
NCT01706146 (2) [back to overview]	Bleeding Incidence
NCT01711853 (2) [back to overview]	Cmax,ss
NCT01711853 (2) [back to overview]	AUCtau,ss
NCT01734772 (2) [back to overview]	Total Dabigatran: Maximum Measured Concentration at Steady State (Cmax,ss)
NCT01734772 (2) [back to overview]	Total Dabigatran: Area Under the Concentration-time Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)
NCT01774370 (3) [back to overview]	Percentage of Participants With Stroke
NCT01774370 (3) [back to overview]	Occurrence of Adverse Events(Including Unexpected Adverse Events, Serious Adverse Events, Drug-related Adverse Events, Adverse Events Leading to Discontinuation and Adverse Events by Intensity, Outcome of the Event, Causality)
NCT01774370 (3) [back to overview]	Percentage of Participants With Systemic Embolism
NCT01852162 (5) [back to overview]	TRAP-induced Platelet Aggregation
NCT01852162 (5) [back to overview]	Clot Kinetic: Clot Stength
NCT01852162 (5) [back to overview]	Clot Kinetic: Thrombin Activity
NCT01852162 (5) [back to overview]	Platelet Reactivity Measured by Multiple Electrode Aggregometry.
NCT01852162 (5) [back to overview]	Platelet Reactivity Measured by LTA
NCT01868243 (2) [back to overview]	Spontaneous Echo Contrast
NCT01868243 (2) [back to overview]	Intracardiac Thrombus
NCT01895777 (13) [back to overview]	Frequency of Dose Adjustment During the Treatment Phase
NCT01895777 (13) [back to overview]	Composite Primary Endpoint
NCT01895777 (13) [back to overview]	Assessment of the Acceptability of an Age-appropriate Formulation at End of Therapy (Pellets)
NCT01895777 (13) [back to overview]	Assessment of the Acceptability of an Age-appropriate Formulation at End of Therapy (Oral Liquid Formulation - OLF)
NCT01895777 (13) [back to overview]	Assessment of the Acceptability of an Age-appropriate Formulation at End of Therapy (Capsules)
NCT01895777 (13) [back to overview]	All Components of the Primary Efficacy Endpoint
NCT01895777 (13) [back to overview]	All Bleeding Events
NCT01895777 (13) [back to overview]	Steady State Plasma Concentrations of Total Dabigatran at Visit 3
NCT01895777 (13) [back to overview]	Frequency of Patients Switching the Type of Anti-coagulation Therapy Including Dabigatran Etexilate to Standard of Care Treatment and Switching From One Standard of Care Treatment to Another
NCT01895777 (13) [back to overview]	Freedom From Thrombus Progression at End of Therapy Compared With Baseline
NCT01895777 (13) [back to overview]	Freedom From Major Bleeding Events (MBEs)
NCT01895777 (13) [back to overview]	All-cause Mortality
NCT01895777 (13) [back to overview]	Steady State Plasma Concentrations After at Least 3 Days Following Any Dabigatran Etexilate Dose Adjustment
NCT01896297 (2) [back to overview]	Concentration of Analyte in Plasma at Steady State at 2 Hours After Administration of the Last Dose
NCT01896297 (2) [back to overview]	Pre-dose Concentration of the Analyte in Plasma at Steady State Immediately Before Administration of the Next Dose
NCT01976507 (3) [back to overview]	Number of Participants With Minor Bleeding Events
NCT01976507 (3) [back to overview]	Frequency of Major Thrombo-embolic Events in Patients Administered Dabigatran Following RF Ablation.
NCT01976507 (3) [back to overview]	Frequency of Major Bleeding Complications in Patients Administered Dabigatran Following RF Ablation.
NCT01999179 (5) [back to overview]	PTS Assessment Completion
NCT01999179 (5) [back to overview]	Biomarker Sample Collection
NCT01999179 (5) [back to overview]	Number of Participants With Major Bleeding
NCT01999179 (5) [back to overview]	Number of Participants With Recurrent Thrombosis
NCT01999179 (5) [back to overview]	Number of Participants With Post-thrombotic Syndrome
NCT02028780 (8) [back to overview]	AUEC2-12
NCT02028780 (8) [back to overview]	AUC2-12,ss on Days 4 and 11 for Unbound Sum Dabigatran (Part II).
NCT02028780 (8) [back to overview]	Ae0-74,ss on Days 4 and 11 for Sum Dabigatran (Part II)
NCT02028780 (8) [back to overview]	Percentage of Subjects With Drug-related Adverse Events in Part 1 and Part 2
NCT02028780 (8) [back to overview]	Ae0-73 for the Dose Group 4 in the Part I
NCT02028780 (8) [back to overview]	Ae0-72 for Idarucizumab in the Part I & Part II.
NCT02028780 (8) [back to overview]	Cmax for Idarucizumab in the Part I & Part II.
NCT02028780 (8) [back to overview]	AUC0-inf for Idarucizumab in the Part I & Part II.
NCT02044367 (6) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Free Dabigatran.
NCT02044367 (6) [back to overview]	Palatability Rating for Pellets (on Food) and Oral Solution Will be Assessed by Asking the Subjects 1 Multiple Choice Verbal Question.
NCT02044367 (6) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran.
NCT02044367 (6) [back to overview]	Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Free Dabigatran.
NCT02044367 (6) [back to overview]	Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran.
NCT02044367 (6) [back to overview]	Acceptability Rating for Pellets (on Food) and Oral Solution Will be Assessed by Asking the Subjects 1 Multiple Choice Verbal Question.
NCT02149303 (3) [back to overview]	Proportion of Subjects With Index Event Safety Outcomes (Resolved / Recovery Ongoing / Deceased) at the Time of Their Hospital Discharge / Release.
NCT02149303 (3) [back to overview]	Proportion of Subjects Receiving Different Types of Interventions (i.e., Medication / Procedure and Surgery) to Manage the Index Events Until Their Hospital Discharge / Release
NCT02149303 (3) [back to overview]	Index Event Characteristics (i.e. Type of Bleeding and Anatomic Locations of the Index Event) at the Time of the ED / ER Presentation or Hospitalization
NCT02164864 (13) [back to overview]	Time to Adjudicated Non-CV
NCT02164864 (13) [back to overview]	Time to Adjudicated All Cause Death
NCT02164864 (13) [back to overview]	Time to Composite Endpoint of Death or First Thrombotic Event
NCT02164864 (13) [back to overview]	Time to Adjudicated Undetermined Cause of Death
NCT02164864 (13) [back to overview]	Time to Composite Endpoint of Death + MI + Stroke
NCT02164864 (13) [back to overview]	Time to Death or First Thrombotic Event or Unplanned Revascularisation by PCI/CABG
NCT02164864 (13) [back to overview]	Time to First Adjudicated ISTH MBE or CRNMBE
NCT02164864 (13) [back to overview]	Time to First Adjudicated MI
NCT02164864 (13) [back to overview]	Time to First Adjudicated SE
NCT02164864 (13) [back to overview]	Time to First Adjudicated ST
NCT02164864 (13) [back to overview]	Time to First Adjudicated Stroke
NCT02164864 (13) [back to overview]	Time to First Adjudicated Unplanned Revascularisation by PCI/CABG
NCT02164864 (13) [back to overview]	Time to Adjudicated CV
NCT02171611 (21) [back to overview]	MRTpo for Free Dabigatran
NCT02171611 (21) [back to overview]	Cmax for Total Dabigatran
NCT02171611 (21) [back to overview]	Cmax for Free Dabigatran
NCT02171611 (21) [back to overview]	CL/F for Free Dabigatran
NCT02171611 (21) [back to overview]	AUC0-tz for Total Dabigatran
NCT02171611 (21) [back to overview]	AUC0-tz for Free Dabigatran
NCT02171611 (21) [back to overview]	AUC0-inf for Total Dabigatran
NCT02171611 (21) [back to overview]	λz for Total Dabigatran
NCT02171611 (21) [back to overview]	Percentage of Participants With Drug-related Adverse Events
NCT02171611 (21) [back to overview]	Tmax for Total Dabigatran
NCT02171611 (21) [back to overview]	Assessment of Tolerability by Investigator.
NCT02171611 (21) [back to overview]	λz for Free Dabigatran
NCT02171611 (21) [back to overview]	Vz/F for Total Dabigatran
NCT02171611 (21) [back to overview]	Vz/F for Free Dabigatran
NCT02171611 (21) [back to overview]	Tmax for Free Dabigatran
NCT02171611 (21) [back to overview]	t1/2 for Total Dabigatran
NCT02171611 (21) [back to overview]	t1/2 for Free Dabigatran
NCT02171611 (21) [back to overview]	Percentage of Participants With Findings in Physical Examination, Vital Signs , Pulse Rate (PR)), 12-lead ECG, Clinical Laboratory Tests.
NCT02171611 (21) [back to overview]	CL/F for Total Dabigatran
NCT02171611 (21) [back to overview]	AUC0-inf for Free Dabigatran
NCT02171611 (21) [back to overview]	MRTpo for Total Dabigatran
NCT02197416 (11) [back to overview]	Central Measurement of Diluted Thrombin Time (dTT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)
NCT02197416 (11) [back to overview]	Central Measurement of Activated Partial Thromboplastin Time (aPTT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)
NCT02197416 (11) [back to overview]	Event-free Probability of Major or Minor (Including Clinically Relevant Non-major (CRNM)) Bleeding Events at 6 and 12 Months
NCT02197416 (11) [back to overview]	Central Measurement of Activated Partial Thromboplastin Time (aPTT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)
NCT02197416 (11) [back to overview]	Central Measurement of Ecarin Clotting Time (ECT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)
NCT02197416 (11) [back to overview]	Central Measurement of Ecarin Clotting Time (ECT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)
NCT02197416 (11) [back to overview]	Percentage of Participants With Dabigatran Etexilate (DE) Dose Adjustments During on Treatment Period
NCT02197416 (11) [back to overview]	Event-free Probability of Mortality Overall and Related to Thrombotic or Thromboembolic Events at 6 and 12 Months
NCT02197416 (11) [back to overview]	Event-free Probability of Occurrence of Post-thrombotic Syndrome (PTS) at 6 and 12 Months
NCT02197416 (11) [back to overview]	Event-free Probability of Recurrence of Venous Thromboembolism (VTE) at 6 and 12 Months
NCT02197416 (11) [back to overview]	Central Measurement of Diluted Thrombin Time (dTT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)
NCT02223260 (13) [back to overview]	Central Measurement: The Mean of dTT Ratio at 2h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
NCT02223260 (13) [back to overview]	Central Measurement: The Mean of ECT Coagulation Time at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
NCT02223260 (13) [back to overview]	Central Measurement: The Mean of Diluted Thrombin Time (dTT) Coagulation Time at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
NCT02223260 (13) [back to overview]	Central Measurement: The Mean ECT Ratio at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
NCT02223260 (13) [back to overview]	Incidence of All AEs During the Treatment Period
NCT02223260 (13) [back to overview]	Incidence of All Bleeding Events (Major, CRNM and Minor) During the Treatment Period.
NCT02223260 (13) [back to overview]	PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters APTT Values.
NCT02223260 (13) [back to overview]	PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters dTT Values.
NCT02223260 (13) [back to overview]	PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters ECT Values.
NCT02223260 (13) [back to overview]	Global Assessment of Acceptability and Tolerability of Study Medication
NCT02223260 (13) [back to overview]	Central Measurement: The Mean aPTT Coagulation Time at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
NCT02223260 (13) [back to overview]	Plasma Concentrations of Total Dabigatran, 2h and 12 h (+/-2h) Post Administration of Dabigatran Etexilate
NCT02223260 (13) [back to overview]	Central Measurement: The Mean aPTT Ratio at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
NCT02239120 (10) [back to overview]	Adjudicated Ischaemic Stroke
NCT02239120 (10) [back to overview]	Adjudicated Recurrent Stroke
NCT02239120 (10) [back to overview]	All-cause Death
NCT02239120 (10) [back to overview]	Disabling Stroke
NCT02239120 (10) [back to overview]	First Major Bleed (Adjudicated)
NCT02239120 (10) [back to overview]	Adjudicated Life-threatening Bleed
NCT02239120 (10) [back to overview]	Any Bleed (Investigator-reported)
NCT02239120 (10) [back to overview]	Adjudicated Composite of Non-fatal Stroke, Non-fatal Myocardial Infarction, or Cardiovascular Death
NCT02239120 (10) [back to overview]	Adjudicated Fatal Bleed
NCT02239120 (10) [back to overview]	Adjudicated Intracranial Hemorrhage
NCT02240667 (3) [back to overview]	Percentage of Patients With Low, Medium or High Adherence at the Timepoint of 6 Months-visit.
NCT02240667 (3) [back to overview]	Percentage of Patients Treated With Anticoagulation Initially Started at the 12 Month
NCT02240667 (3) [back to overview]	Number of Patients With the Reason for Definitive Treatment Discontinuation
NCT02348723 (4) [back to overview]	Incidence of ISTH MBE, Stroke, Systemic Embolism, or TIA (Composite Endpoint Combining Safety and Efficacy
NCT02348723 (4) [back to overview]	Incidence of Minor Bleeding Events
NCT02348723 (4) [back to overview]	Incidence of the Composite of Stroke, Systemic Embolism, or Transient Ischemic Attack (TIA)
NCT02348723 (4) [back to overview]	Incidence of Major Bleeding Events (MBEs), as Defined by the International Society on Thrombosis and Haemostasis (ISTH)
NCT02415855 (5) [back to overview]	Any Parenchymal Haemorrhage (PH1 or PH2)
NCT02415855 (5) [back to overview]	Recurrent TIA/Ischemic Stroke
NCT02415855 (5) [back to overview]	Symptomatic Hemorrhagic Transformation Rate
NCT02415855 (5) [back to overview]	Symptomatic Hemorrhagic Transformation Rate (PH2)
NCT02415855 (5) [back to overview]	Systemic Hemorrhagic Complication Rate
NCT02568397 (6) [back to overview]	Pharmacodynamics: Area Under the Effect Versus Time Curve (AUEC) of Thrombin Time
NCT02568397 (6) [back to overview]	Pharmacokinetics (PK) : Maximum Concentration (Cmax) of Dabigatran
NCT02568397 (6) [back to overview]	Pharmacokinetics: Area Under The Dabigatran Pharmacokinetic (PK) Concentration Versus Time Curve From Zero to Infinity (AUC[0-infinity)
NCT02568397 (6) [back to overview]	Pharmacokinetics: Area Under the Lanabecestat Pharmacokinetic (PK) Concentration Versus Time Curve During One Dosing Interval (24 Hours) (AUCtau)
NCT02568397 (6) [back to overview]	Pharmacokinetics: Maximum Concentration (Cmax) of Lanabecestat
NCT02568397 (6) [back to overview]	Pharmacodynamics: Ratio of Maximum Effect to Baseline Effect (ERmax) of Thrombin Time
NCT02631057 (1) [back to overview]	Length of Stay (LoS) From Treatment of Oral Anticoagulant Initiation to Hospital Discharge Without Consideration of Baseline
NCT02666742 (12) [back to overview]	Number of Participants With Transient Ischemic Attack
NCT02666742 (12) [back to overview]	Number of Participants With Asymptomatic Cerebral Event on MRI - 24 Hours
NCT02666742 (12) [back to overview]	Number of Participants With Stroke
NCT02666742 (12) [back to overview]	Number of Participants With Retroperitoneal Bleed
NCT02666742 (12) [back to overview]	Number of Participants With Progressive Heart Failure and Electromechanical Dissociation (EMD)
NCT02666742 (12) [back to overview]	Number of Participants With In-hospital Mortality
NCT02666742 (12) [back to overview]	Number of Participants With Heart Block
NCT02666742 (12) [back to overview]	Number of Participants With Groin Hematoma
NCT02666742 (12) [back to overview]	Number of Participants With Fatal Pulmonary Embolism
NCT02666742 (12) [back to overview]	Number of Participants With Cardiac Tamponade
NCT02666742 (12) [back to overview]	Number of Participants With Asymptomatic Cerebral Event on MRI - 30 Days
NCT02666742 (12) [back to overview]	Number of Participants With Acute Procedure Related Complications
NCT02701062 (8) [back to overview]	Healthcare Resource Utilization Variance Between Groups as Related to the Composite Events Above (Event Rates)
NCT02701062 (8) [back to overview]	Number of Perioperative Complications Associated With AtriClip Placement
NCT02701062 (8) [back to overview]	Composite Event Rates for ALL Subjects Regardless of POAF Through 365 Days
NCT02701062 (8) [back to overview]	Composite Event Rates Between Subjects Not Diagnosed With POAF (Through 30 Days)
NCT02701062 (8) [back to overview]	Composite Event Rates Between Subjects Diagnosed With Post-operative Atrial Fibrillation (POAF) (Through 365 Days)
NCT02701062 (8) [back to overview]	Number of Subjects With Intraoperative Successful Exclusion of LAA.
NCT02701062 (8) [back to overview]	Healthcare Resource Utilization Variance Between Groups as Related to the Composite Events Above (Median Values)
NCT02701062 (8) [back to overview]	Healthcare Resource Utilization Variance Between Groups as Related to the Composite Events Above (Mean Values)
NCT02710630 (6) [back to overview]	Cmax (Maximum Plasma Concentration of Total Dabigatran)
NCT02710630 (6) [back to overview]	Cmax (Maximum Concentration of Free Dabigatran)
NCT02710630 (6) [back to overview]	AUC0-tz (Area Under the Concentration-time Curve of Total Dabigatran in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)
NCT02710630 (6) [back to overview]	AUC0-tz (Area Under the Concentration-time Curve of Free Dabigatran in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)
NCT02710630 (6) [back to overview]	AUC0-infinity (Area Under the Concentration-time Curve of Total Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity) (if Applicable)
NCT02710630 (6) [back to overview]	AUC0-infinity (Area Under the Concentration-time Curve of Free Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity) (if Applicable)
NCT02744092 (11) [back to overview]	Burden of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire
NCT02744092 (11) [back to overview]	Burden of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire
NCT02744092 (11) [back to overview]	Cumulative Non-Fatal VTE Recurrence at 6 Months (%)
NCT02744092 (11) [back to overview]	Cumulative Rates of Major Bleeding
NCT02744092 (11) [back to overview]	Health Related Quality of Life (Mental Health) Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire at 3-months
NCT02744092 (11) [back to overview]	Health Related Quality of Life (Mental Health) Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire at 6-months
NCT02744092 (11) [back to overview]	Health Related Quality of Life Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire
NCT02744092 (11) [back to overview]	Health Related Quality of Life Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire
NCT02744092 (11) [back to overview]	Mortality Reported by Participants' Surrogates (Via Study-specific Questionnaire) or Clinicians (Via Study-specific Case Report Form)
NCT02744092 (11) [back to overview]	Benefit of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire
NCT02744092 (11) [back to overview]	Benefit of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire
NCT02849509 (12) [back to overview]	Description of Perception of Anticoagulant Treatment Questionnaire, Part 1 (PACT-Q1) Items at Baseline for Cohort B
NCT02849509 (12) [back to overview]	Mean PACT-Q2 Scores, for Patients in Cohort B, at Last Assessment Compared Between Treatment Groups
NCT02849509 (12) [back to overview]	Mean PACT-Q2 Scores, for Patients in Cohort B, at Second Assessment Compared Between Treatment Groups
NCT02849509 (12) [back to overview]	Mean Perception of Anticoagulant Treatment Questionnaire, Part 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second Assessment Compared to Baseline Assessment
NCT02849509 (12) [back to overview]	Patient Characterization at Baseline - Categorical Parameters
NCT02849509 (12) [back to overview]	Patient Characterization at Baseline - Categorical Parameters
NCT02849509 (12) [back to overview]	Patient Characteristics at Baseline - CHA2DS2-VASc Stroke Risk Score
NCT02849509 (12) [back to overview]	Mean PACT-Q2 Scores, for Patients in Cohort A, at Last Assessment Compared to Second Assessment
NCT02849509 (12) [back to overview]	Mean PACT-Q2 Scores, for Patients in Cohort A, at Last Assessment Compared to Baseline Assessment
NCT02849509 (12) [back to overview]	Patient Characteristics at Baseline - Duration of Previous VKA Treatment for Cohort A
NCT02849509 (12) [back to overview]	Patient Characteristics at Baseline - HAS-BLED Bleeding Risk Score
NCT02849509 (12) [back to overview]	Patient Characteristics at Baseline - Creatinine Clearance
NCT02913326 (8) [back to overview]	Cerebral Venous Recanalisation as Measured by the Change in Number of Occluded Cerebral Veins and Sinuses at Week 24
NCT02913326 (8) [back to overview]	Percentage of Participants With Clinically Relevant Non-major Bleeding Events in Full Observation Period.
NCT02913326 (8) [back to overview]	Percentage of Participants With Composite of Venous Thrombotic Event (VTE) or Major Bleeding Event (MBE) According to International Society on Thrombosis and Haemostasis (ISTH) Criteria in Full Observation Period.
NCT02913326 (8) [back to overview]	Percentage of Participants With Major Bleeding According to ISTH Criteria in Full Observation Period
NCT02913326 (8) [back to overview]	Percentage of Participants With Major Bleeding According to ISTH Criteria or CRNMBEs After up to 24 Weeks
NCT02913326 (8) [back to overview]	Percentage of Participants With Recurring Cerebral Venous and Dural Sinus Thrombosis; DVT of Any Limb, PE or Splanchnic Vein Thrombosis in Full Observation Period
NCT02913326 (8) [back to overview]	Percentage of Participants With Any Bleeding Event After up to 24 Weeks
NCT02913326 (8) [back to overview]	Composite Endpoint of Percentage of Participants With New Intracranial Haemorrhage or Worsening of the Haemorrhagic Component of a Previous Lesion After up to 24 Weeks
NCT03006341 (17) [back to overview]	Percentage of Patients With Obesity
NCT03006341 (17) [back to overview]	Percentage of Patients With Uncontrolled Hypertension
NCT03006341 (17) [back to overview]	Percentage of Patients With Use of Antiplatelets or Non-steroidal Anti-inflammatory Drugs
NCT03006341 (17) [back to overview]	Percentage of Patients With Prior Transient Ischemic Attack
NCT03006341 (17) [back to overview]	EMR Characteristic: Duration of Atrial Fibrillation
NCT03006341 (17) [back to overview]	EMR Characteristic: History/Duration of Congestive Heart Failure (CHF)
NCT03006341 (17) [back to overview]	EMR Characteristic: History/Duration of Hypertension
NCT03006341 (17) [back to overview]	EMR Characteristic: Hypertension, Abnormal Liver/Renal Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol Usage (HAS-BLED) Score
NCT03006341 (17) [back to overview]	EMR Characteristic: Renal Function - Glomerular Filtration Rate (GFR)
NCT03006341 (17) [back to overview]	EMR Characteristic: Serum Creatinine
NCT03006341 (17) [back to overview]	Percentage of Patients Smoking
NCT03006341 (17) [back to overview]	Percentage of Patients With Abnormal Liver Function
NCT03006341 (17) [back to overview]	Percentage of Patients With Abnormal Renal Function
NCT03006341 (17) [back to overview]	Percentage of Patients With Alcohol Consumption
NCT03006341 (17) [back to overview]	Percentage of Patients With Bleeding History or Predisposition
NCT03006341 (17) [back to overview]	Percentage of Patients With Diabetes
NCT03006341 (17) [back to overview]	Percentage of Patients With Hyperlipidemia
NCT03026556 (13) [back to overview]	Hemorrhagic Stroke
NCT03026556 (13) [back to overview]	Major Urogenital Bleeding
NCT03026556 (13) [back to overview]	Major GI Bleeding
NCT03026556 (13) [back to overview]	All-cause Mortality
NCT03026556 (13) [back to overview]	Major Intracranial Bleeding
NCT03026556 (13) [back to overview]	Ischemic Stroke
NCT03026556 (13) [back to overview]	Lower GI Bleeding
NCT03026556 (13) [back to overview]	Major Extracranial Bleeding
NCT03026556 (13) [back to overview]	Major Other Bleeding
NCT03026556 (13) [back to overview]	TIA
NCT03026556 (13) [back to overview]	Overall Major Bleeding
NCT03026556 (13) [back to overview]	Stroke Overall (Hemorrhagic, Ischemic, Uncertain)
NCT03026556 (13) [back to overview]	Upper GI Bleeding
NCT03070171 (6) [back to overview]	Cmax of Total Dabigatran
NCT03070171 (6) [back to overview]	AUC0-∞ of Free Dabigatran
NCT03070171 (6) [back to overview]	AUC0-∞ of Total Dabigatran
NCT03070171 (6) [back to overview]	AUC0-tz of Free Dabigatran
NCT03070171 (6) [back to overview]	AUC0-tz of Total Dabigatran
NCT03070171 (6) [back to overview]	Cmax of Free Dabigatran
NCT03086356 (6) [back to overview]	Amount of Idarucizumab Eliminated in Urine Over the Time Interval From 0 to 72 Hours (h) (Ae0-72)
NCT03086356 (6) [back to overview]	Area Under the Concentration-time Curve of Idarucizumab in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT03086356 (6) [back to overview]	Maximum Measured Concentration of Idarucizumab in Plasma (Cmax)
NCT03086356 (6) [back to overview]	For Diluted Thrombin Time: Area After Subtraction of Baseline Area From Area Under the Effect Curve Over the Time Interval From 2 - 12 Hours (AUEC Above,2-12) on Day 4 and Day 11
NCT03086356 (6) [back to overview]	For Sum Dabigatran: Amount of the Analyte Excreted in Urine at Steady State Over the Time Interval 0-74 Hours (Ae0-74,ss ) on Day 4 and Day 11
NCT03086356 (6) [back to overview]	For Unbound Sum Dabigatran: Area Under the Concentration-time Curve of the Dabigatran in Plasma at Steady State Over the Time Interval 2 Hours-12 Hours
NCT03143166 (6) [back to overview]	Area Under the Concentration-time Curve of Free Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).
NCT03143166 (6) [back to overview]	Maximum Concentration of Total Dabigatran in Plasma (Cmax).
NCT03143166 (6) [back to overview]	Maximum Concentration of Free Dabigatran in Plasma (Cmax).
NCT03143166 (6) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Total Dabigatran (AUC0-tz).
NCT03143166 (6) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Free Dabigatran (AUC0-tz).
NCT03143166 (6) [back to overview]	Area Under the Concentration-time Curve of Total Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).
NCT03175198 (1) [back to overview]	Percentage of Patients With Suspected Adverse Drug Reactions (ADRs)
NCT03187197 (4) [back to overview]	Mean Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second and Last Assessment Compared to Baseline Assessment
NCT03187197 (4) [back to overview]	Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment Groups
NCT03187197 (4) [back to overview]	Mean PACT-Q2 Scores, for Patients in Cohort A, at Last Assessment Compared to Second Assessment
NCT03187197 (4) [back to overview]	Description of PACT-Q1 Items for Patients in Cohort B at Baseline
NCT03254134 (2) [back to overview]	Incidence Rate of Major Bleeding
NCT03254134 (2) [back to overview]	Incidence Rate of Stroke and Systemic Embolism (SE)
NCT03254147 (2) [back to overview]	The Number of Patients With Cardiac Tamponade and Pericardiocentesis.
NCT03254147 (2) [back to overview]	The Number of Patients With Emergency Surgery and Major Bleeding Due to Fracture or Trauma.
NCT03258645 (12) [back to overview]	Percentage of Patients With Non-Valvular Atrial Fibrillation (NVAF) According to the Timing of Dabigatran Initiation After the First Ever Ischaemic Stroke (the Index Event)
NCT03258645 (12) [back to overview]	Number of Times of Reason to Delay Oral Anticoagulation (OAC) Entered by Physicians.
NCT03258645 (12) [back to overview]	Age of Patients According to Dabigatran Initiation Time Period
NCT03258645 (12) [back to overview]	CHA2DS2-VASc of Patients According to Dabigatran Initiation Time Period
NCT03258645 (12) [back to overview]	Diastolic Blood Pressure (DBP) of Patients According to Dabigatran Initiation Time Period
NCT03258645 (12) [back to overview]	HAS-BLED of Patients According to Dabigatran Initiation Time Period
NCT03258645 (12) [back to overview]	National Institute of Health Stroke Scale (NIHSS) at First Ever Ischaemic Stroke According to Dabigatran Initiation Time Period
NCT03258645 (12) [back to overview]	Percentage of Patients With History of or Predisposition to Bleeding According to Dabigatran Initiation Time Period
NCT03258645 (12) [back to overview]	Previous Modified Rankin Scale (mRS) at First Ever Ischaemic Stroke According to Dabigatran Initiation Time Period
NCT03258645 (12) [back to overview]	Number of Times of Reason to Chose Daily Dosage of 220 Milligram of Dabigatran Entered by Physicians
NCT03258645 (12) [back to overview]	Number of Times of Reason to Chose Daily Dosage of 300 Milligram of Dabigatran Entered by Physicians
NCT03258645 (12) [back to overview]	Number of Times of Reason to Delay Dabigatran Initiation Entered by Physicians According to Dabigatran Initiation Time Period
NCT03311841 (18) [back to overview]	Apparent Volume of Distribution During the Terminal Phase (Vz/F) Post-dose Period 1
NCT03311841 (18) [back to overview]	Apparent Plasma Terminal Half-life (t1/2) Post-dose Period 1
NCT03311841 (18) [back to overview]	Apparent Clearance After Extravascular Administration (CL/F) Post-dose Period 1
NCT03311841 (18) [back to overview]	Time to Maximum Plasma Concentration (Tmax) Post-dose Period 1
NCT03311841 (18) [back to overview]	Plasma Concentration at 24 Hours (C24) Post-dose Period 1
NCT03311841 (18) [back to overview]	Maximum Plasma Concentration (Cmax) Post-dose Period 1
NCT03311841 (18) [back to overview]	Effect of Rifampin on Vz/F Post-dose Period 2
NCT03311841 (18) [back to overview]	Effect of Rifampin on Tmax Post-dose Period 2
NCT03311841 (18) [back to overview]	Effect of Rifampin on t1/2 Post-dose Period 2
NCT03311841 (18) [back to overview]	Effect of Rifampin on Cmax Post-dose Period 2
NCT03311841 (18) [back to overview]	Effect of Rifampin on CL/F Post-dose Period 2
NCT03311841 (18) [back to overview]	Effect of Rifampin on C24 Post-dose Period 2
NCT03311841 (18) [back to overview]	Effect of Rifampin on AUC0-last Post-dose Period 2
NCT03311841 (18) [back to overview]	Effect of Rifampin on AUC0-inf Post-dose Period 2
NCT03311841 (18) [back to overview]	Effect of Rifampin on AUC0-24 Post-dose Period 2
NCT03311841 (18) [back to overview]	Area Under the Plasma Concentration-time Curve From Time 0 to Last (AUC0-last) Post-dose Period 1
NCT03311841 (18) [back to overview]	Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) Post-dose Period 1
NCT03311841 (18) [back to overview]	Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) Post-dose Period 1
NCT03441633 (10) [back to overview]	International Normalized Ratio (INR) Values During the Last 12 Months Values in Participants Previously Treated With VKA
NCT03441633 (10) [back to overview]	Apixaban Adherence With VKA, Dabigatran and Rivaroxaban by Number of Defined Daily Dose (NDDD)
NCT03441633 (10) [back to overview]	Time in Therapeutic Range (TTR) Values During the Last 12 Months Values in Participants Previously Treated With VKA
NCT03441633 (10) [back to overview]	Number of Participants by Their Sociodemographic Characteristics: Body Mass Index (BMI)
NCT03441633 (10) [back to overview]	Risk of Thromboembolic Events: CHADS2 Score
NCT03441633 (10) [back to overview]	Risk of Thromboembolic Events: CHA2DS2Vasc Score
NCT03441633 (10) [back to overview]	Risk of Bleeding Events: HAS-BLED Score
NCT03441633 (10) [back to overview]	Number of Participants With Apixaban Adherence With VKA, Dabigatran and Rivaroxaban as Assessed by Discontinuation Throughout the Year
NCT03441633 (10) [back to overview]	Number of Participants by Comorbidity
NCT03441633 (10) [back to overview]	Number of Participants by Comedications
NCT03492437 (12) [back to overview]	Apparent Volume of Distribution During Terminal Phase (Vz/f) of Total Dabigatran
NCT03492437 (12) [back to overview]	Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Total Dabigatran
NCT03492437 (12) [back to overview]	Number of Participants With Clinically Significant Changes in Laboratory Values
NCT03492437 (12) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Total Dabigatran
NCT03492437 (12) [back to overview]	Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Total Dabigatran
NCT03492437 (12) [back to overview]	Elimination Half Life (t1/2) of Total Dabigatran
NCT03492437 (12) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
NCT03492437 (12) [back to overview]	Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG) Findings
NCT03492437 (12) [back to overview]	Apparent Clearance (CL/f) of Total Dabigatran
NCT03492437 (12) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax) of Total Dabigatran
NCT03492437 (12) [back to overview]	Percentage of Area Under the Plasma Concentration-Time Curve From Time Tlast Extrapolated to Infinity (AUC0-inf) Obtained by Extrapolation (AUCextra%) of Total Dabigatran
NCT03492437 (12) [back to overview]	Number of Participants With Clinically Significant Changes in Vital Signs
NCT03572972 (16) [back to overview]	Event Rate of Systemic Embolism Requiring Hospitalization: NOAC Versus NOAC Analysis
NCT03572972 (16) [back to overview]	Event Rate of Systemic Embolism Requiring Hospitalization: NOAC Versus Warfarin Analysis
NCT03572972 (16) [back to overview]	Event Rate of Stroke/Systemic Embolism Requiring Hospitalization: NOAC Versus Warfarin Analysis
NCT03572972 (16) [back to overview]	Event Rate of Stroke/Systemic Embolism Requiring Hospitalization: NOAC Versus NOAC Analysis
NCT03572972 (16) [back to overview]	Event Rate of Gastrointestinal (GI) Bleeding Requiring Hospitalization: NOAC Versus NOAC Analysis
NCT03572972 (16) [back to overview]	Event Rate of Gastrointestinal (GI) Bleeding Requiring Hospitalization: NOAC Versus Warfarin Analysis
NCT03572972 (16) [back to overview]	Event Rate of Hemorrhagic Stroke Requiring Hospitalization: NOAC Versus NOAC Analysis
NCT03572972 (16) [back to overview]	Event Rate of Hemorrhagic Stroke Requiring Hospitalization: NOAC Versus Warfarin Analysis
NCT03572972 (16) [back to overview]	Event Rate of Intracranial Hemorrhage Requiring Hospitalization: NOAC Versus Warfarin Analysis
NCT03572972 (16) [back to overview]	Event Rate of Ischemic Stroke Requiring Hospitalization: NOAC Versus NOAC Analysis
NCT03572972 (16) [back to overview]	Event Rate of Ischemic Stroke Requiring Hospitalization: NOAC Versus Warfarin Analysis
NCT03572972 (16) [back to overview]	Event Rate of Major Bleeding Requiring Hospitalization: NOAC Versus NOAC Analysis
NCT03572972 (16) [back to overview]	Event Rate of Major Bleeding Requiring Hospitalization: NOAC Versus Warfarin Analysis
NCT03572972 (16) [back to overview]	Event Rate of Other Bleeding Requiring Hospitalization: NOAC Versus NOAC Analysis
NCT03572972 (16) [back to overview]	Event Rate of Other Bleeding Requiring Hospitalization: NOAC Versus Warfarin Analysis
NCT03572972 (16) [back to overview]	Event Rate of Intracranial Hemorrhage Requiring Hospitalization: NOAC Versus NOAC Analysis
NCT04459585 (9) [back to overview]	Time of Maximum Plasma Concentration (Tmax) of Quizartinib and the Metabolite ACC886 Following Single Dose of Dabigatran With Quizartinib in Participants
NCT04459585 (9) [back to overview]	Time of Maximum Plasma Concentration (Tmax) of Total Dabigatran and of Free Dabigatran Following a Single Dose in Participants Without and With Concomitant Quizartinib
NCT04459585 (9) [back to overview]	Maximum Plasma Concentration (Cmax) of Quizartinib and the Metabolite ACC886 Following Single Dose of Dabigatran With Quizartinib in Participants
NCT04459585 (9) [back to overview]	Area Under the Plasma Concentration-Time Curve From Time 0 to 74 Hours (AUClast,74) of Quizartinib and the Metabolite ACC886 Following Single Dose of Dabigatran With Quizartinib in Participants
NCT04459585 (9) [back to overview]	Area Under the Plasma Concentration-Time Curve up to Infinity (AUCinf) of Total Dabigatran and of Free Dabigatran Following a Single Dose in Participants Without and With Concomitant Quizartinib
NCT04459585 (9) [back to overview]	Area Under the Plasma Concentration-Time Curve up to the Last Quantifiable Concentration Post-Dose (AUClast) of Total Dabigatran and of Free Dabigatran Following a Single Dose in Participants Without and With Concomitant Quizartinib
NCT04459585 (9) [back to overview]	Maximum Plasma Concentration (Cmax) of Total Dabigatran and of Free Dabigatran Following a Single Dose in Participants Without and With Concomitant Quizartinib
NCT04459585 (9) [back to overview]	Number of Participants Reporting Treatment-Emergent Adverse Events (TEAE) Relatedness to Study Medication Following Single Dose of Dabigatran Without and With Quizartinib in Participants
NCT04459585 (9) [back to overview]	Terminal Elimination Half-Life (T1/2) of Total Dabigatran and of Free Dabigatran Following a Single Dose in Participants Without and With Concomitant Quizartinib
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation
NCT05022563 (60) [back to overview]	Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months
NCT05022563 (60) [back to overview]	Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months
NCT05022563 (60) [back to overview]	Number of Participants Who Switched to Another Anticoagulant Therapy
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]	Number of Participants With Interruption in Index Anticoagulant Treatment
NCT05022563 (60) [back to overview]	Time to Treatment Discontinuation
NCT05022563 (60) [back to overview]	Time to Treatment Interruption
NCT05022563 (60) [back to overview]	Time to Treatment Switch
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]	Number of Participants Who Completely Discontinued Index Anticoagulant Treatment
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]	Overall Index Anticoagulant Treatment Duration
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]	Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event

Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period

"Major bleeding events were defined as~fatal~clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected~clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected~symptomatic retroperitoneal, intracranial, intraocular or intraspinal~requiring treatment cessation~leading to re-operation~Clinically-relevant was defined as~spontaneous skin hematoma greater than or equal to 25 cm²~wound hematoma greater than or equal to 100 cm²~spontaneous nose bleed lasting longer than 5 min~macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention~spontaneous rectal bleeding (more than a spot on toilet paper)~gingival bleeding lasting longer than 5 min~any other bleeding event considered clinically relevant by the investigator~Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00152971)
Timeframe: First administration until 12-15 days

Intervention	Participants (Number)
	Major	Clinically relevant	Minor	None
Dabigatran 150mg	5	22	45	799
Dabigatran 220mg	5	23	46	783
Enoxaparin	12	21	51	784

Intervention	Participants (Number)
	Total VTE and all-cause mortality	asymptotic Deep Vein Thrombosis	symptotic Deep Vein Thrombosis	Pulmonary Embolism	death
Dabigatran 150mg	7	1	4	0	2
Dabigatran 220mg	7	2	2	2	1
Enoxaparin	10	4	2	2	2

Intervention	participants (Number)
50 mg Once Daily	0
50 mg Twice Daily	5
150 mg Once Daily	13
150 mg Twice Daily	96
300 mg Once Daily	28
300 mg Twice Daily	16

Intervention	yearly event rate (percentage) (Number)
50 mg Once Daily	0.0
50 mg Twice Daily	17.0
150 mg Once Daily	5.0
150 mg Twice Daily	5.5
300 mg Once Daily	4.5
300 mg Twice Daily	2.4

Intervention	yearly event rate (percentage) (Number)
	Clinically relevant	Nuisance only
150 mg Once Daily	5.0	9.9
150 mg Twice Daily	4.5	7.1
300 mg Once Daily	5.8	8.3
300 mg Twice Daily	19.5	31.7
50 mg Once Daily	0.0	0.0
50 mg Twice Daily	8.5	17.0

Intervention	participants (Number)
	AST > 3*ULN	ALT > 3*ULN	Bilirubin > 2*ULN
150 mg Once Daily	0	0	0
150 mg Twice Daily	10	9	5
300 mg Once Daily	3	4	2
300 mg Twice Daily	1	2	0
50 mg Once Daily	0	0	0
50 mg Twice Daily	0	0	0

Intervention	yearly event rate (percentage) (Number)
50 mg Once Daily	0.0
50 mg Twice Daily	25.5
150 mg Once Daily	21.5
150 mg Twice Daily	14.7
300 mg Once Daily	14.9
300 mg Twice Daily	58.5

Intervention	participants (Number)
	Patients with >=1 transfusions	Patients with >=1 non-autologous transfusions
Dabigatran 150mg	253	86
Dabigatran 220mg	242	87
Enoxaparin	265	120

Intervention	participants (Number)
	AST increase N=(620;645;636)	AST decrease N=(620;645;636)	ALT increase N=(621;645;637)	ALT decrease N=(621;645;637)	Bilirubin increase N=(619;644;635)	Bilirubin decrease N=(619;644;635)
Dabigatran 150mg	6	0	21	0	23	0
Dabigatran 220mg	9	0	16	0	19	0
Enoxaparin	9	0	24	0	14	0

Intervention	participants (Number)
	AST increase N=(1103;1097;1103)	AST decrease N=(1103;1097;1103)	ALT increase N=(1103;1098;1103)	ALT decrease N=(1103;1098;1103)	Bilirubin increase N=(1102;1094;1102)	Bilirubin decrease N=(1102;1094;1102)
Dabigatran 150mg	16	0	29	0	24	0
Dabigatran 220mg	11	0	28	0	25	0
Enoxaparin	29	0	59	0	34	0

Intervention	Participants (Number)
	Major	Clinical relevant	Minor	None
Dabigatran 150mg	15	55	72	1021
Dabigatran 220mg	23	48	70	1005
Enoxaparin	18	40	74	1022

Intervention	participants (Number)
	Major bleeding events	Major and clinically relevant bleeding events	Any bleeding events
Dabigatran Etexilate 110 mg	1	1	13
Dabigatran Etexilate 150 mg	0	1	13
Dabigatran Etexilate 220 mg	3	5	14
Treatment Group With Placebo	1	4	10

Intervention	participants (Number)
	AST increase N=(120;131;122;126)	AST decrease N=(120;131;122;126)	ALT increase N=(120;131;122;126)	ALT decrease N=(120;131;122;126)	Bilirubin increase N=(120;130;122;127)	Bilirubin decrease N=(120;130;122;127)
Dabigatran Etexilate 110 mg	1	0	0	0	1	0
Dabigatran Etexilate 150 mg	0	0	1	0	0	0
Dabigatran Etexilate 220 mg	0	0	0	0	0	0
Treatment Group With Placebo	2	0	2	0	0	0

Intervention	participants (Number)
	Autologous	Homologous	Autologous and homologous
Dabigatran Etexilate 110 mg	82	4	0
Dabigatran Etexilate 150 mg	77	4	0
Dabigatran Etexilate 220 mg	76	2	3
Treatment Group With Placebo	75	5	0

Intervention	mL (Mean)
Treatment Group With Placebo	82.8
Dabigatran Etexilate 110 mg	90.5
Dabigatran Etexilate 150 mg	67.5
Dabigatran Etexilate 220 mg	77.3

Intervention	percentage of participants (Number)
Treatment Group With Placebo	56.4
Dabigatran Etexilate 110 mg	39.6
Dabigatran Etexilate 150 mg	32.7
Dabigatran Etexilate 220 mg	24.0

Intervention	yearly event rate (percentage) (Number)
	Major bleeds	Minor bleeds
Dabigatran 110 mg	2.99	13.16
Dabigatran 150 mg	3.55	14.85
Warfarin	3.81	16.37

Intervention	yearly event rate (percentage)] (Number)
	intracerebral hemorrhage	intracranial hemorrhage (ICH)
Dabigatran 110 mg	0.12	0.23
Dabigatran 150 mg	0.10	0.32
Warfarin	0.38	0.76

Intervention	Participants (Number)
	Participants with event (up to day 180)	Participants with event (up to end of ptp)
Dabigatran 150 mg	30	34
Warfarin	27	32

Intervention	participants (Number)
	Major bleeding events	MBE and/or CRBE	Any bleeding events
Dabigatran 150 mg	20	71	207
Warfarin	24	111	280

Intervention	participants (Number)
	AST increase	AST decrease	ALT increase	ALT decrease	Bilirubin increase	Bilirubin decrease
Dabigatran 150 mg	21	0	26	0	7	0
Warfarin	22	0	38	0	13	0

chemdatabank.com

dabigatran

Description

Cross-References

Synonyms (90)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (5)

Protein Targets (23)

Potency Measurements

Inhibition Measurements

Biological Processes (169)

Molecular Functions (71)

Ceullar Components (44)

Bioassays (105)

Research

Studies (3,685)

Market Indicators

Research Demand Index: 103.76

Study Types

Clinical Trials (268)

Trial Overview

Trial Outcomes

Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period

Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period

Number of Participants With Total Deep Vein Thrombosis During Treatment Period

Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period

Number of Participants Who Died During Treatment Period

Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period

Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period

Number of Participants With Pulmonary Embolism During Treatment Period

Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period

Severe Adverse Event

Yearly Event Rate of Haemorrhagic Stroke

Yearly Event Rate of Death

Yearly Event Rate for Transient Ischaemic Attacks

Yearly Event Rate for Systemic Thromboembolism

Yearly Event Rate for Stroke

Yearly Event Rate for Major Bleeding

Yearly Event Rate for Major + Minor/Relevant Bleeding

Yearly Event Rate for Composite Secondary Endpoint of Ischaemic Stroke, Transient Ischaemic Attacks, Non-central Nervous System Systemic Thromboembolism, Myocardial Infarction, Other Major Adverse Cardiac Events and All-cause Mortality

Yearly Event Rate for Minor Bleeding

Laboratory Analyses

Yearly Event Rate of Other Major Adverse Cardiac Events

Yearly Event Rate of Myocardial Infarction

Yearly Event Rate of Ischaemic Stroke

Yearly Event Rate for Composite Endpoint of Stroke, Transient Ischaemic Attacks, System Thromboembolism, Myocardial Infarction, Other Major Adverse Cardiac Events and Mortality.

Yearly Event Rate for Any Bleeding

Blood Transfusion

Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period

Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period

Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period

Number of Participants Who Died During Treatment Period

Laboratory Analyses

Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period

Number of Participants With Pulmonary Embolism During Treatment Period

Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period

Number of Participants With Total Deep Vein Thrombosis During Treatment Period

Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period

Volume of Blood Loss

Laboratory Analyses

Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period

Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period

Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period

Symptomatic Deep Vein Thrombosis During Treatment Period

Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period

Total Deep Vein Thrombosis During Treatment Period

Proximal Deep Vein Thrombosis During Treatment Period

Pulmonary Embolism During Treatment Period

Volume of Blood Loss

Blood Transfusion

Intervention	participants (Number)
	During intake of active study drug	After stopping active study drug	Before/without intake of active study drug
Dabigatran 150 mg	5	4	2
Warfarin	3	2	0

Intervention	Participants (Number)
	Number of participants with event	Number of participants with no event
Dabigatran	15	1415
Warfarin	12	1414

Intervention	participants (Number)
	During intake of study drug, N=1430 , N=1415	After stopping study drug, N=1426, N=1400
Dabigatran	12	1
Warfarin	2	5

Intervention	participants (Number)
	patients with MBE	patients with MBE and /or CRBE	patients with any bleeding event
Dabigatran	13	80	277
Warfarin	25	145	373

Intervention	participants (Number)
	ALT increase	AST increase	Alkaline phosphatase	Total bilirubin
Dabigatran	26	23	9	9
Warfarin	30	23	14	8

Intervention	participants (Number)
	AST increase (N=655, 629)	ALT increase (N=655, 629)	Alkaline phosphatase increase (N=658, 629)	Total bilirubin increase (N=658, 628)
Dabigatran	2	3	0	1
Placebo	2	5	0	1

Intervention	participants (Number)
	AST increase N=(359;359;388;329;356)	AST decrease N=(359;359;388;329;356)	ALT increase N=(359;359;388;329;356)	ALT decrease N=(359;359;388;329;356)	Bilirubin increase N=(359;360;388;329;355)	Bilirubin decrease N=(359;360;388;329;355)
110mg Dabigatran Etexilate	5	0	4	0	2	0
150mg Dabigatran Etexilate	2	0	7	0	0	0
50mg Dabigatran Etexilate	8	0	10	0	1	0
75mg Dabigatran Etexilate	5	0	4	0	1	0
Placebo	4	0	4	0	0	0

Intervention	participants (Number)
	Major and clinically relevant minor bleed events	No major or clinically relevant minor bleed events
110mg Dabigatran Etexilate	32	374
150mg Dabigatran Etexilate	27	320
50mg Dabigatran Etexilate	13	356
75mg Dabigatran Etexilate	16	352
Placebo	8	363

Intervention	participants (Number)
	CVD, non-fatal MI, non-haemorrhagic stroke	ACD, non-fatal MI, SRI, non-haemorrhagic stroke
110mg Dabigatran Etexilate	12	21
150mg Dabigatran Etexilate	12	25
50mg Dabigatran Etexilate	17	25
75mg Dabigatran Etexilate	18	27
Placebo	14	26

Intervention	participants (Number)
	Major bleeding events	Clinically relevant bleeding events	Not clinically relevant bleeding events	Any bleeding events
110mg Dabigatran Etexilate	8	24	35	60
150mg Dabigatran Etexilate	4	23	20	42
50mg Dabigatran Etexilate	3	10	32	42
75mg Dabigatran Etexilate	1	16	29	45
Placebo	2	6	17	25